US20130260438A1 - Compositions and methods comprising serine protease variants (as amended) - Google Patents

Compositions and methods comprising serine protease variants (as amended) Download PDF

Info

Publication number
US20130260438A1
US20130260438A1 US13/696,512 US201113696512A US2013260438A1 US 20130260438 A1 US20130260438 A1 US 20130260438A1 US 201113696512 A US201113696512 A US 201113696512A US 2013260438 A1 US2013260438 A1 US 2013260438A1
Authority
US
United States
Prior art keywords
amino acid
subtilisin
variant
protease
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/696,512
Other languages
English (en)
Inventor
Viktor Yuryevich Alekseyev
Neelam A Amin
Katherine Auguslyn
Luis Gustavo Cascao-Pereira
Katherine D. Collier
David A. Estell
James T. Kellis, Jr.
Ayrookaran J. Poulose
Philip Frank Souter
Glenn Steven Ward
Jian Yao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Danisco US Inc
Original Assignee
Danisco US Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Danisco US Inc filed Critical Danisco US Inc
Priority to US13/696,512 priority Critical patent/US20130260438A1/en
Assigned to DANISCO US INC. reassignment DANISCO US INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: YAO, JIAN, ALEKSEYEV, VIKTOR YURYEVICH, AMIN, NEELAM S., POULOSE, AYROOKARAN J., CASCAO-PEREIRA, LUIS GUSTAVO, ESTELL, DAVID A., KELLIS, JAMES T., JR., AUGUSTYN, KATHERINE, COLLIER, KATHERINE D.
Assigned to DANISCO US INC. reassignment DANISCO US INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AMIN, NEELAM S., KELLIS, JAMES T., JR., CASCAO-PEREIRA, LUIS GUSTAVO, POULOSE, AYROOKARAN J., AUGUSTYN, KATHERINE, COLLIER, KATHERINE D., ESTELL, DAVID A., YAO, JIAN, YURYEVICH, ALEKSEYEV VIKTOR
Assigned to DANISCO US INC. reassignment DANISCO US INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: THE PROCTER AND GAMBLE COMPANY
Publication of US20130260438A1 publication Critical patent/US20130260438A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/38—Products with no well-defined composition, e.g. natural products
    • C11D3/386—Preparations containing enzymes, e.g. protease or amylase
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/38—Products with no well-defined composition, e.g. natural products
    • C11D3/386—Preparations containing enzymes, e.g. protease or amylase
    • C11D3/38681—Chemically modified or immobilised enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C12N9/54—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea bacteria being Bacillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21062—Subtilisin (3.4.21.62)

Definitions

  • the present invention provides serine protease variants. Specifically, the present invention provides serine protease variants having one or more substitutions as compared to a reference serine protease. In addition, the present invention provides compositions comprising these serine protease variants. In some embodiments, the present invention provides cleaning compositions comprising at least one of these serine protease variants.
  • proteases Although serine proteases have long been known in the art of industrial enzymes, there remains a need for engineered proteases that are suitable for particular conditions and uses.
  • the present invention provides serine protease variants. Specifically, the present invention provides serine protease variants having one or more substitutions as compared to a reference serine protease. In addition, the present invention provides compositions comprising these serine protease variants. In some embodiments, the present invention provides cleaning compositions comprising at least one of these serine protease variants.
  • subtilisin variants wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X1R, X2W, X2M, X2R, X2A, X2S, X3R, X4R, X4C, X4S, X8A, X9F, X9W, X9A, X10S, X10M, X10H, X10A, X12R, X12F, X14K, X14F, X14Q, X15R, X15F, X16S, X17R, X17M, X17F, X18R, X18K, X20F, X20R, X20K, X22Y, X22A, X22R, X22V, X22Q, X22W, X22L, X23F
  • the present invention also provides isolated subtilisin variants wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X16S, X18R, X20R, X22A, X24R, X43R/D, X45T, X76D, X101A, X103G, X104L, X111V, X128N, X1481, X230E, X242R, and X249R, wherein the amino acid positions of the subtilisin variant are numbered by correspondence with the amino acid sequence of B. amyloliquefaciens subtilisin BPN′ set forth as SEQ ID NO:1.
  • the present invention further provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X1R, X230E, X271L, X115R, X20R, X249R, X235F, X27V/F/L, X75E, X82R, X18R, X269R, X43D, X43R, X76D, X45T, X212F, X242R, X24R, X78R, X9A, X22R, X121E, X244R, X28E, X30E, X4R, and X241R, wherein the amino acid positions of the subtilisin variant are numbered by correspondence with the amino acid sequence of B. amyloliquefaciens subtilisin BPN′ set forth as SEQ ID NO:1.
  • subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X062E-X158E, X103G-X158E, X128N-X158E, X016S-X158E, X104L-X158E, X089P-X158E, X111V-X158E, X022A-X158E, X101A-X158E, X1481-X158E, X129E-X158E, X022A-X089P, X016S-X089P, X062E-X089P, X062E-X271F, X158E-X271F, X186H-X271F, X129E-X271F, X111V-X271F, X209E-X271F, X016S-X271F, X016S-X271
  • subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X018R-X241R, X020R-X241R, X024R-X241R, X009A-X241R, X020R-X241R, X004R-X241R, X043R-X241R, X078R-X241R, X022R-X241R, X115R-X241R, X001R-X241R, X212F-X241R, X082R-X241R, X018R-X244R, X024R-X244R, X078R-X244R, X020R-X244R, X212F-X244R, X009A-X244R, X08
  • subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X020R-X-43R, X020K-X062E, X024F-X116L, X020K-X024F, X024R-X174T, X024R-X118R, X024R-X235F, X024R-X086R, X024R-X086W, X078R-X118R, X033S-X118R, X033S-X235F, X209A-X241R, X020R-X076D, X018R-X245R, X024R-X045T, X232V-X245R, X118R-X172V, X118R-X194T, X008T-X024R
  • subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X020R-X076D, X024R-X045T, X230E-X249R, X018R-X045T, X018R-X245R, X101G-X232V, X024R-X232V, X232V-X245R, X024R-X101G, X018R-X104I, X018R-X103A, X101G-X249R, X232V-X249R, X103A-X232V, X076D-X245R, X101G-X104I, X104I-X232V, X076D-X249R, X024R-X076D, X024F-X116L, X020K
  • subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X004R-X009A-X020R-X242R, X020R-X043R-X241R, X020R-X242R-X269R, X004R-X009A-X020R-X043R, X004R-X020R-X249R, X018R-X024R-X244R, X009A-X022R-X212F-X241R, X020R-X043R-X269R, X018R-X024R-X242R, X004R-X009A-X043R-X241R, X020R-X043R-X244R, X020R-X022R-X24
  • subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X018R-X020R-X043D-X045T-X230E, X018R-X043R-X045T-X242R-X249R, X024R-X043D-X249R, X018R-X020R-X045T, X020R-X024R-X076D-X249R, X024R-X043R-X230E-X242R, X018R-X024R-X043D-X230E, X020R-X076D, X018R-X024R-X043D-X076D-X249R, X024R-X043R-X076D-X249R, X024R-X043R-X076D-X249R
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X101G-X103A-X104I-X232V-X236H-X245R-X252K, X101G-X103A-X104I-X232V-X245R-X248R, X101G-X103A-X104I-X159R-X232V-X245R-X248D, X101G-X103A-X104I-X159D-X232V-X245R-X248R, X101G-X103A-X104I-X232V-X245R, X101G-X103A-X104I-X232V-X245R, X101G-X103A-X104I-X159D-X232V-X245R, and X101G-X103A-X104I-X232
  • subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X101G-X103A-X104I-X129E-X188D-X232V-X238R-X245R-X248D, X024R-X101G-X103A-X104I-X129E-X158E-X188D-X232V-X245R-X248D-X249R, X022A-X101G-X103A-X104I-X129E-X158E-X188D-X232V-X245R-X248D-X249R, X022A-X024R-X101G-X103A-X104I-X129E-X158E-X188D-X232V-X245R-X248D-X249R, X024R-X101G-X103A-X104I-X129E-X158E-X188D-
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X022A-X024R-X101G-X103A-X104I-X158E-X232V-X245R-X248D-X249R, X022A-X024R-X101G-X103A-X104I-X129E-X232V-X245R-X248D-X249R, X024R-X101G-X103A-X104I-X158E-X159E-X232V-X238R-X245R-X248D, X024R-X101G-X103A-X104I-X232V-X245R-X248D-X249R, X101G-X103A-X104I-X158E-X232V-X245R-X248D-X2
  • subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X104L-X128N-X158E-X186H-X249R, X128N-X158E-X188D-X249R, X062E-X128N-X158E-X159E-X271F, X062E-X158E-X188D-X249R-X271F, X062E-X158E-X186H-X249R-X271F, X128N-X158E-X188D-X209E-X271F, X062E-X159E-X188D-X249R, X0165-X062E-X158E-X186H-X249R, X062E-X158E-X159E-X249R, X101A-X128N
  • subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X001R-X101G-X103A-X104I-X232V-X245R, X004R-X101G-X103A-X104I-X232V-X245R, X043R-X101G-X103A-X104I-X232V-X245R-X271L, X078R-X101G-X103A-X104I-X232V-X245R, X004R-X043R-X101G-X103A-X104I-X232V-X245R, X018R-X043R-X101G-X103A-X104I-X232V-X245R, X020R-X101G-X103A-X104I-X232V-X245R, X101G-
  • subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X020R-X022W-X078R-X101A-X103A-X104I-X116S-X213A-X215F-X232V-X245R, X018R-X078R-X101G-X103A-X104I-X232V-X245R, X024R-X045T-X101G-X103A-X104I-X232V-X245R-X269R, X020R-X022W-X078R-X101G-X103A-X104I-X116A-X232V-X245R, X020R-X22W-X101G-X103A-X104I-X232V-X245R, X018R-X043R-X101G-X
  • subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X018R-X024R-X043R-X076D-X249R-X269R, X018R-X022R-X024R-X043R-X076D-X249R, X018R-X043D-X101G-X103A-X104I-X232V-X245R, X020R-X043D-X101G-X103A-X104I-X232V-X245R, X043D-X101G-X103A-X104I-X232V-X245R, X043D-X101G-X103A-X104I-X232V-X245R-X269R, X043D-X078R-X101G-X103A-X104I-X232V-X245R, X043R
  • subtilisin variants wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X020R-X101A-X103A-X104I-X118R-X232V-X245R, X020R-X024R-X116A-X213A, X043R-X101A-X116A-X215F-X269R, X024R-X043R-X101A-X116A, X024R-X043R-X101A-X116A-X215F-X269R, X020R-X101G-X103A-X104I-X215F-X232V-X245R, X043R-X101A-X269R, X024R-X043R-X116A-X213A-X269R, X020R-X024R-X0024R-X0
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X043R-X076D-X101A-X103A-X104I-X158E-X188D-X232V-X245R-X248D-X249R-X271F, X024R-X043R-X076D-X101A-X103A-X104I-X158E-X188D-X217E-X232V-X245R-X248D-X249R, X101A-X103A-X104I-X158E-X188D-X232V-X245R-X248D-X249R, X101A-X103A-X104I-X158E-X188D-X232V-X245R-X248D-X249R-X271F-X271F, X
  • subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X022A-X101G-X103A-X104I-X159D-X217E-X232V-X245R-X248D-X271F, X022A-X043R-X101G-X103A-X104I-X159D-X188D-X217E-X232V-X245R-X248D-X271F, X022A-X101G-X103A-X104I-X159D-X188D-X232V-X245R-X248D-X271F, X043R-X101A-X103A-X104I-X158E-X188D-X217E-X232V-X245R-X248D-X249R, X043R-X076D-X
  • subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X017R-X022A-X076D-X101G-X103A-X104I-X159D-X188D-X232V-X245R-X248D-X271F, X022A-X043R-X101G-X103A-X104I-X159D-X232V-X245R-X248D-X271F, X022A-X101G-X103A-X104I-X159D-X188D-X232V-X245R-X248D-X249R-X271F, X017R-X022A-X076D-X101G-X103A-X104I-X159D-X232V-X245R-X248D-X271F, X022A-X076D-X101G-X103A-X
  • subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X101S-X103A-X104I-X158E-X188D-X232V-X245R-X248D-X249R, X101S-X103G-X104V-X158E-X188D-X232V-X245R-X248D-X249R, X101G-X103S-X104I-X158E-X188D-X232V-X245R-X248D-X249R, X101A-X103A-X104I-X158E-X188D-X232V-X245R-X248D-X249R, X101A-X103A-X104I-X158E-X188D-X232V-X245R-X248D-X249R, X101A-X103A-X104L-X158E-X188D-X
  • subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X026F-X051W-X104L-X106E, X026F-X031F-X078N-X102A-X160D, X020K-X100S-X116L-X158E-X166D-X243F, X033S-X043W-X218D-X239G-X243F, X022L-X038F-X048R-X062E-X100S-X186K, X101D-X103N-X116L-X144R-X215D, X104L-X105T-X213A-X217E-X256N, X043W-X101D-X212M-X243F, X026F-X048R-X105T-X213A-X213A-X213A-X2213A-
  • subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X022A-X024R-X101D-X103A-X104I-X118R-X159D-X188D-X232V-X248D-X271F, X022A-X024R-X103A-X104I-X129E-X159D-X188D-X232V-X248D-X271F, X022A-X024R-X103A-X104I-X118R-X159D-X188D-X217D-X232V-X248D, X022A-X024R-X101D-X103A-X104I-X118R-X129E-X159D-X188D-X232V-X245R-X248D, X022A-X024R-X101D-X-X103A-X104I-X118R-X
  • subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X020K-X024F-X062E-X188D-X239G, X024F-X062E-X116L-X239G, X020K-X023A-X062E-X188D, X020K-X023A-X024F-X062E-X118R-X188D-X213A, X020K-X043W-X062E-X116L-X188D-X213A-X239G, X023A-X062E-X116L-X118R, X023A-X024F-X062E-X116L-X118R, X024F-X116L, X024F-X062E-X188D-X213A, X020K-X043W-X062E-
  • subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X020K-X023A-X043W-X118R-X1281-X129E-X159D-X188D, X024F-X118R-X1281-X129E-X159D, X020K-X024F-X062E-X116L-X118R-X188D, X020K-X062E-X116L-X118R-X188D, X062E-X116L-X118R-X213A, X020K-X023A-X062E-X116L-X188D, X062E-X116L-X118R-X188D, X020K-X062E-X116L-X213A, X020K-X023A-X062E-X116L-X188D, X062E-X116
  • subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X087R-X101G-X103A-X104I-X109R-X212P-X232V-X245R-X271V, X101G-X103A-X104I-X109R-X232V-X245R, X101G-X103A-X104I-X109R-X212P-X232V-X245R-X271V, X101G-X103A-X104I-X109R-X212P-X232V-X245R, X076D-587R-X103A-X104I-X212P-X271V, X076D-X103A-X104I-X109R, X076D-X103A-X104I-X109R, X076D-X103A-X104I-X212P-X271V, X076D-
  • subtilisin variants wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X024R-X086W-X118R, X024R-X078R-X086W-X243F, X024R-X033S-X086S-X087N-X209A, X033S-X118R, X024R-X078R-X086W-X118R-X270T, X024R-X033S-X086W-X118R, X078R-X086W-X243F, X033S-X078R-X086W-X118R-X209A, X033S-X078R-X209A, X086W-X118R-X243F, X024R-X086W, X078R-X086W-X243F, X0
  • subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X020R-X087D-X101G-X103A-X104I-X232V-X245R, X020R-X101G-X103A-X104I-X150L-X232V-X245R, X018R-X020R-X024R-X076D-X087D-X249R, X018R-X020R-X024R-X076D-X150L-X249R, X018R-X024R-X043R-X076D-X087D-X249R, X018R-X024R-X043R-X076D-X087D-X249R, X018R-X024R-X043R-X076D-X150L-X249R, X018R-
  • subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X024R-X101G-X103A-X104I-X129Q-X158E-X188D-X217E-X232V-X245R-X248D-X249R, X024R-X101G-X103A-X104I-X130A-X158E-X183D-X188D-X232V-X245R-X248D-X249R, X024R-X101G-X103A-X104I-X129Q-X158E-X183D-X188D-X232V-X245R-X248D-X249R, X101G-X103A-X104I-X130A-X158E-X188D-X232V-X245R-X248D-X249R, X101G-X103A-X104I-X130A-X
  • subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X101G-X103A-X104I-X232V-X222Q-X245R, X101G-X103A-X104I-X158E-X188D-X2225-X232V-X245R-X248D-X249R, X101G-X103A-X104I-X158E-X188D-X222Q-X232V-X245R-X248D-X249R, X076D-X101G-X103A-X104I-X232V-X222Q-X245R, X101G-X103A-X104I-X232V-X2225-X245R, X076D-X101G-X103A-X104I-X232V-X222S-X245R, and X076D
  • subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X024R-X101G-X103A-X104I-X128L-X129Q-X158E-X188D-X232V-X245R-X248D-X249R, X101G-X103A-X104I-X130A-X158E-X188D-X232V-X245R-X248D-X249R, X024R-X101G-X103A-X104I-X158E-X188D-X232V-X245R-X248D-X249R, X101G-X103A-X104I-X128L-X129Q-X158E-X188D-X232V-X245R-X248D-X249R, X101G-X103A-X104I-X129Q, X158E-X188D-X232V-
  • subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X101G-X103A-X104I, X22A-X101A-X209E, S103G-L111V-G159E, X22A-X103G-X159E, X22A-X111V-X159E, X22A-X128N-X271F-X209E, X22A-X103G-X111V, X62E-X111V-X128N, X22A-X111V-X128N, X22A-X62E-X111V, X101A-X103G-X104L-X188D, X101G-X103A-X104I-X159D, X101A-X103G-X104L-X128N, X22A-X101A-X159E, X101A
  • subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X103A-X104I-X159D-X232V-X236H-X245R-X248D-X252K, X101G-X104I-X159D-X232V-X236H-X245R-X248D-X252K, X101G-X103A-X159D-X232V-X236H-X245R-X248D-X252K, X101G-X103A-X104L-X232V-X236H-X245R-X248D-X252K, X101G-X103A-X104L-X159D-X236H-X245R-X248D-X252K, X101G-X103A-X104L-X159D-X236H-X245R-X248D-X252K,
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X101G-X103A-X104I-X159D-X232V-X245R-X248D, X101G-X103A-X104I-X159D-X232V-X245R-X248D-X271F, X101G-X103A-X104I-X159D-X232V-X245R-X248D-X238R, X101G-X103A-X104I-X159D-X232V-X245R-X248D-X248R, X101G-X103A-X104I-X159D-X232V-X245R-X248D-X248R, X101G-X103A-X104I-X159D-X232V-X245R-X248D-X
  • subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X20R-X43R-X249R, X20R-X22R-X43R, X20R-X43R-X242R, X20R-X43R-X271L, X20R-X43R-X244R, X20R-X24R-X43R-X242R, X9A-X22R-X78R-X212F-X241R, X9A-X20R-X43R-X212F, X9A-X43R-X212F, X20R-X43R-X212F, X20R-X22R-X43R-X212F, X24R-X78R-X212F, X9A-X43R-X78R, X9A-X43R-X78R, X9A-X43R-X78R,
  • subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X101G-X103A-X104I-X232V-X245R-X248D, X101G-X103A-X104I-X159D-X232V-X245R, X101G-X103A-X104I-X159R-X232V-X245R-X248D, X101G-X103A-X104I-X159D-X232V-X245R-X248R, X101G-X103A-X104I-X232V-X245R, X101G-X103A-X104I-X232V-X245R, X101G-X103A-X104I-X232V-X245R-X248R, X101G-X103A-X104I-X232V-X245R-X248R, X101G-X103A-
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X16S, X22A, X24R, X62E, X76D, X89P, X101A/G, X103G/A, X104L/I, X111V, X128N, X129E, X232V, X1481, X158E, X159D/E, X166D, X186H, X188D, X209E, X236H, X238R, X245R, X248D/R, X249R, X252K/R, X253R, and X271F, wherein the amino acid positions of the subtilisin variant are numbered by correspondence with the amino acid sequence of B. amyloliquefaciens subtilisin BPN′ set forth as SEQ
  • subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: N062E-A158E, S103G-A158E, S128N-A158E, A016S-A158E, V104L-A158E, E089P-A158E, L111V-A158E, T022A-A158E, S101A-A158E, L148I-A158E, P129E-A158E, T022A-E089P, A016S-E089P, N062E-E089P, N062E-E271F, A158E-E271F, R186H-E271F, P129E-E271F, L111V-E271F, Y209E-E271F, A016S-E271F, S188D-E271F, T022A-E271F
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: N018R-W241R, G020R-W241R, S024R-W241R, S009A-W241R, G020R-W241R, V004R-W241R, N043R-W241R, S078R-W241R, T022R-W241R, G115R-W241R, A001R-W241R, S212F-W241R, L082R-W241R, N018R-V244R, S024R-V244R, S078R-V244R, G020R-V244R, S212F-V244R, S009A-V244R, L082R-V244R, A001R-V244R, N0
  • subtilisin variants wherein said subtilisin variant is a mature form having proteolytic activity and comprises an amino acid sequence comprising a combination of amino acid substitutions selected from: G020R-N043R, N062E-A158E, S103G-A158E, S128N-A158E, A016S-A158E, V104L-A158E, E089P-A158E, L111V-A158E, T022A-A158E, S101A-A158E, L148I-A158E, P129E-A158E, T022A-E089P, A016S-E089P, N062E-E089P, N062E-E271F, A158E-E271F, R186H-E271F, P129E-E271F, L111V-E271F, Y209E-E271F, A016S-E271F, S188D-E271
  • said protease variant comprises:
  • said protease variant comprises:
  • the present invention further provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: G020R-N043R, G020K-N062E, S024F-N116L, G020K-S024F, S024R-A174T, S024R-G118R, S024R-K235F, S024R-P086R, S024R-P086W, S078R-G118R, T033S-G118R, T033S-K235F, Y209A-W241R, G020R-N076D, N018R-Q245R, S024R-R045T, A232V-Q245R, G118R-A172V, G118R-A194T, 1008T-S024R, K235F-N243F, N018R-S103A, N
  • the present invention further provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: G020R-N076D, S024R-R045T, A230E-H249R, N018R-R045T, N018R-Q245R, S101G-A232V, S024R-A232V, A232V-Q245R, S024R-S101G, N018R-V104I, N018R-S103A, S101G-H249R, A232V-H249R, S103A-A232V, N076D-Q245R, S101G-V104I, V104I-A232V, N076D-H249R, S024R-N076D, S024F-N116L, G020K-S024F, G020K-N062E, T033S
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: V004R-S009A-G020R-S242R, G020R-N043R-W241R, G020R-S242R-N269R, V004R-S009A-G020R-N043R, V004R-G020R-H249R, N018R-S024R-V244R, S009A-T022R-S212F-W241R, G020R-N043R-N269R, N018R-S024R-S242R, V004R-S009A-N043R-W241R, G020R-N043R-V244R, G020R-T022R-S242R, V004R-G020
  • subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: N018R-G020R-N043D-R045T-A230E, N018R-N043R-R045T-S242R-H249R, S024R-N043D-H249R, N018R-G020R-R045T, G020R-S024R-N076D-H249R, S024R-N043R-A230E-S242R, N018R-S024R-N043D-A230E, G020R-N076D, N018R-S024R-N043D-N076D-H249R, S024R-N043R-N076D-H249R, N018R-S024R-R045T-S
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: S101G-S103A-V104I-A232V-Q236H-Q245R-N252K, S101G-S103A-V104I-A232V-Q245R-N248R, S101G-S103A-V104I-G159R-A232V-Q245R-N248D, S101G-S103A-V104I-G159D-A232V-Q245R-N248R, S101G-S103A-V104I-A232V-Q245R, S101G-S103A-V104I-G159D-A232V-Q245R, and S101G-S103A-V104I-A232V-Q245R-N248D, wherein the amino acid positions of the subtilisin variant are numbered by correspondence
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: S101G-S103A-V104I-P129E-S188D-A232V-N238R-Q245R-N248D, S024R-S101G-S103A-V104I-P129E-A158E-S188D-A232V-Q245R-N248D-H249R, T022A-S101G-S103A-V104I-P129E-A158E-S188D-A232V-Q245R-N248D-H249R, T022A-S024R-S101G-S103A-V104I-P129E-A158E-S188D-A232V-Q245R-N248D-H249R, S024R-S101G-S103A-V104I-P129
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: T022A-S024R-S101G-S103A-V104I-A158E-A232V-Q245R-N248D-H249R, T022A-S024R-S101G-S103A-V104I-P129E-A232V-Q245R-N248D-H249R, S024R-S101G-S103A-V104I-A158E-G159E-A232V-N238R-Q245R-N248D, S024R-S101G-S103A-V104I-A232V-Q245R-N248D-H249R, S101G-S103A-V104I-A158E-A232V-Q245R-N248D-H249R, S101
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: V104L-S128N-A158E-R186H-H249R, S128N-A158E-S188D-H249R, N062E-S128N-A158E-G159E-E271F, N062E-A158E-S188D-H249R-E271F, N062E-A158E-R186H-H249R-E271F, S128N-A158E-S188D-Y209E-E271F, N062E-G159E-S188D-H249R, A016S-N062E-A158E-R186H-H249R, N062E-A158E-G159E-H249R, S101A-S128N-A158E-Y209
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: A001R-S101G-S103A-V104I-A232V-Q245R, V004R-S101G-S103A-V104I-A232V-Q245R, N043R-S101G-S103A-V104I-A232V-Q245R-E271L, S078R-S101G-S103A-V104I-A232V-Q245R, V004R-N043R-S101G-S103A-V104I-A232V-Q245R, N018R-N043R-S101G-S103A-V104I-A232V-Q245R, G020R-S101G-S103A-V104I-A232V-Q245R, S101G-S103A-V104I
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: G020R-T022W-S078R-S101A-S103A-V104I-N116S-T213A-A215F-A232V-Q245R, N018R-S078R-S101G-S103A-V104I-A232V-Q245R, S024R-R045T-S101G-S103A-V104I-A232V-Q245R-N269R, G020R-T022W-S078R-S101G-S103A-V104I-N116A-A232V-Q245R, G020R-T22W-S101G-S103A-V104I-A232V-Q245R, N018R-N043R-S101G-S103A-V104
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: N018R-S024R-N043R-N076D-H249R-N269R, N018R-T022R-S024R-N043R-N076D-H249R, N018R-N043D-S101G-S103A-V104I-A232V-Q245R, G020R-N043D-S101G-S103A-V104I-A232V-Q245R, N043D-S101G-S103A-V104I-A232V-Q245R, N043D-S101G-S103A-V104I-A232V-Q245R-N269R, N043D-S078R-S101G-S103A-V104I-A232V-Q2
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: G020R-S101A-S103A-V104I-G118R-A232V-Q245R, G020R-S024R-N116A-T213A, N043R-S101A-N116A-A215F-N269R, S024R-N043R-S101A-N116A, S024R-N043R-S101A-N116A-A215F-N269R, G020R-S101G-S103A-V104I-A215F-A232V-Q245R, N043R-S101A-N269R, S024R-N043R-N116A-T213A-N269R, G020R-S024R-N043R-R045T-
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: N043R-N076D-S101A-S103A-V104I-A158E-S188D-A232V-Q245R-N248D-H249R-E271F, S024R-N043R-N076D-S101A-S103A-V104I-A158E-S188D-L217E-A232V-Q245R-N248D-H249R, S101A-S103A-V104I-A158E-S188D-A232V-Q245R-N248D-H249R-E271F-E271F, S101A-S103A-V104I-A158E-S188D-L217E-A232V-Q245R-N248D-H249R-E
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: T022A-S101G-S103A-V104I-G159D-L217E-A232V-Q245R-N248D-E271F, T022A-N043R-S101G-S103A-V104I-G159D-S188D-L217E-A232V-Q245R-N248D-E271F, T022A-S101G-S103A-V104I-G159D-S188D-A232V-Q245R-N248D-E271F, N043R-S101A-S103A-V104I-A158E-S188D-L217E-A232V-Q245R-N248D-H249R, N043R-N076D-S101A-S
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: H017R-T022A-N076D-S101G-S103A-V104I-G159D-S188D-A232V-Q245R-N248D-E271F, T022A-N043R-S101G-S103A-V104I-G159D-A232V-Q245R-N248D-E271F, T022A-S101G-S103A-V104I-G159D-S188D-A232V-Q245R-N248D-H249R-E271F, H017R-T022A-N076D-S101G-S103A-V104I-G159D-A232V-Q245R-N248D-E271F, T022A-N076D
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: S101S-S103A-V104I-A158E-S188D-A232V-Q245R-N248D-H249R, S101S-S103G-V104V-A158E-S188D-A232V-Q245R-N248D-H249R, S101G-S103S-V104I-A158E-S188D-A232V-Q245R-N248D-H249R, S101A-S103A-V104I-A158E-S188D-A232V-Q245R-N248D-H249R, S101A-S103A-V104I-A158E-S188D-A232V-Q245R-N248D-H249R, S101A-S103A-V104L-
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: V026F-V051W-V104L-S106E, V026F-L031F-S078N-G102A-S160D, G020K-G100S-N116L-A158E-S166D-N243F, T033S-N043W-N218D-P239G-N243F, T022L-T038F-A048R-N062E-G100S-R186K, S101D-S103N-N116L-S144R-A215D, V104L-S105T-T213A-L217E-S256N, N043W-S101D-S212M-N243F, V026F-A048R-S105T-T213A-N218D-T224A, S
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: T022A-S024R-S101D-S103A-V104I-G118R-G159D-S188D-A232V-N248D-E271F, T022A-S024R-S103A-V104I-P129E-G159D-S188D-A232V-N248D-E271F, T022A-S024R-S103A-V104I-G118R-G159D-S188D-L217D-A232V-N248D, T022A-S024R-S101D-S103A-V104I-G118R-P129E-G159D-S188D-A232V-Q245R-N248D, T022A-S024R-S101D-S103A-V
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: G020K-S024F-N062E-S188D-P239G, S024F-N062E-N116L-P239G, G020K-G023A-N062E-S188D, G020K-G023A-S024F-N062E-G118R-S188D-T213A, G020K-N043W-N062E-N116L-S188D-T213A-P239G, G023A-N062E-N116L-G118R, G023A-S024F-N062E-N116L-G118R, S024F-N116L, S024F-N062E-S188D-T213A, G023A-N062E-
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: G020K-G023A-N043W-G118R-S1281-P129E-G159D-S188D, S024F-G118R-S1281-P129E-G159D, G020K-S024F-N062E-N116L-G118R-S188D, G020K-N062E-N116L-S188D, N062E-N116L-G118R-T213A, G020K-G023A-N062E-N116L-S188D, N062E-N116L-G118R-S188D, G020K-N062E-N116L-T213A, G020K-G023A-N062E-N116L-S188D, N062E-N
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: S087R-S101G-S103A-V104I-Q109R-S212P-A232V-Q245R-E271V, S101G-S103A-V104I-Q109R-A232V-Q245R, S101G-S103A-V104I-Q109R-S212P-A232V-Q245R-E271V, S101G-S103A-V104I-Q109R-S212P-A232V-Q245R, N076D-S87R-S103A-V104I-S212P-E271V, N076D-S103A-V104I-Q109R, N076D-S103A-V104I-S212P-E271V, N076D-S103A-V104I-Q109
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: S024R-P086W-G118R, S024R-S078R-P086W-N243F, S024R-T033S-P086S-S087N-Y209A, T033S-G118R, S024R-S078R-P086W-G118R-A270T, S024R-T033S-P086W-G118R, S078R-P086W-N243F, T033S-S078R-P086W-G118R-Y209A, T033S-S078R-Y209A, P086W-G118R-N243F, S024R-P086W, S078R-P086W-K235F, S024R-G118R
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: G020R-S087D-S101G-S103A-V104I-A232V-Q245R, G020R-S101G-S103A-V104I-V150L-A232V-Q245R, N018R-G020R-S024R-N076D-S087D-H249R, N018R-G020R-S024R-N076D-V150L-H249R, N018R-S024R-N043R-N076D-S087D-H249R, N018R-S024R-N043R-N076D-S087D-H249R, N018R-S024R-N043R-N076D-V150L-H249
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: S024R-S101G-S103A-V104I-P129Q-A158E-S188D-L217E-A232V-Q245R-N248D-H249R, S024R-S101G-S103A-V104I-S130A-A158E-N183D-S188D-A232V-Q245R-N248D-H249R, S024R-S101G-S103A-V104I-P129Q-A158E-N183D-S188D-A232V-Q245R-N248D-H249R, S101G-S103A-V104I-S130A-A158E-S188D-A232V-Q245R-N248D-H249R, S101G-S103A
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: S101G-S103A-V104I-A232V-M222Q-Q245R, S101G-S103A-V104I-A158E-S188D-M222S-A232V-Q245R-N248D-H249R, S101G-S103A-V104I-A158E-S188D-M222Q-A232V-Q245R-N248D-H249R, N076D-S101G-S103A-V104I-A232V-M222Q-Q245R, S101G-S103A-V104I-A232V-M222S-Q245R, N076D-S101G-S103A-V104I-A232V-M222S-Q245R, N076D-S101G-S103
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: S024R-S101G-S103A-V104I-S128L-P129Q-A158E-S188D-A232V-Q245R-N248D-H249R, S101G-S103A-V104I-S130A-A158E-S188D-A232V-Q245R-N248D-H249R, S024R-S101G-S103A-V104I-A158E-S188D-A232V-Q245R-N248D-H249R, S101G-S103A-V104I-S128L-P129Q-A158E-S188D-A232V-Q245R-N248D-H249R, S101G-S103A-V104I-S128L-P129
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: S101G-S103A-V104I, T22A-S101A-Y209E, S103G-L111V-G159E, T22A-S103G-G159E, T22A-L111V-G159E, T22A-S128N-E271F-Y209E, T22A-S103G-L111V, N62E-L111V-S128N, T22A-L111V-S128N, T22A-N62E-L111V, S101A-S103G-V104L-S188D, S101G-S103A-V104I-G159D, S101A-S103G-V104L-S128N, T22A-S101A-G159E, S101A-S103G-V104L, S101A-
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: S103A-V104I-G159D-A232V-Q236H-Q245R-N248D-N252K, S101G-V104I-G159D-A232V-Q236H-Q245R-N248D-N252K, S101G-S103A-G159D-A232V-Q236H-Q245R-N248D-N252K, S101G-S103A-V104L-A232V-Q236H-Q245R-N248D-N252K, S101G-S103A-V104L-G159D-Q236H-Q245R-N248D-N252K, S101G-S103A-V104L-G159D-Q236H-Q245R-N
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: S101G-S103A-V104I-G159D-A232V-Q245R-N248D, S101G-S103A-V104I-G159D-A232V-Q245R-N248D-E271F, S101G-S103A-V104I-G159D-A232V-Q245R-N248D-N238R, S101G-S103A-V104I-G159D-A232V-Q245R-N248D-N248R, S101G-S103A-V104I-G159D-A232V-Q245R-N248D-N248R, S101G-S103A-V104I-G159D-A232V-Q245R-N248D-T253R, S101
  • subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: A1R, A230E, E271L, G115R, G20R, H249R, K235F, K27V/F/L, L75E, L82R, N18R, N269R, N43D, N43R, N76D, R45T, S212F, S242R, S24R, S78R, S9A, T22R, V121E, V244R, V28E, V30E, V4R, W241R, G20R-N43R-H249R, G20R-T22R-N43R, G20R-N43R-S242R, G20R-N43R-E271L, G20R-N43R-V244R, G20R-S24R-N43R-S242R, S9A-T
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: S101G-S103A-V104I-A232V-Q245R-N248D, S101G-S103A-V104I-G159D-A232V-Q245R, S101G-S103A-V104I-G159R-A232V-Q245R-N248D, S101G-S103A-V104I-G159D-A232V-Q245R-N248R, S101G-S103A-V104I-A232V-Q245R, S101G-S103A-V104I-A232V-Q245R, S101G-S103A-V104I-A232V-Q245R-N248R, S101G-S103A-V104I-G159R-A232V-Q245R-N248
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: A16S, T22A, S24R, N62E, N76D, E89P, S101A/G, S103G/A, V104L/I, L111V, S128N, P129E, A232V, L148I, A158E, G159D/E, R186H, S188D, Y209E, Q236H, Q245R, N248D/R, H249R, N252K/R, T253R, and E271F wherein amino acid positions of the subtilisin variant are numbered by correspondence with the amino acid sequence of B. amyloliquefaciens subtilisin BPN′ set forth as SEQ ID NO:1.
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: A1R, Q2S, Q2M, Q2A, Q2R, Q2W, S3R, V4R, V4S, V4C, I8A, S9A, S9F, S9W, R10S, R10A, R10H, R10M, Q12F, Q12R, P14K, P14F, P14Q, A15R, A15F, A16S, H17R, H17M, H17F, N18R, N18K, G20F, G20K, G20R, T22A, T22R, T22Y, T22V, T22Q, T22L, T22W, G23A, G23S, G23F, S24R, S24F, S24W, S24Q, S24H, S24L, G25V, G25F
  • the present invention also provides protease variants of Bacillus lentus subtilisin GG36 protease, wherein the Bacillus lentus subtilisin GG36 protease comprises the amino acid sequence shown in SEQ ID NO:2, wherein the protease variant comprises an amino acid sequence which differs from the amino acid sequence of SEQ ID NO:2 in no more than two, three, four, five, six, seven, eight, nine, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 mutations at amino acid positions selected from amino acid 1, 2, 3, 4, 8, 9, 10, 12, 14, 15, 16, 17, 18, 20, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 33, 34, 35, 36, 38, 40, 42, 43, 45, 46, 48, 50, 51, 52, 55, 57, 59, 60, 62, 63, 64, 68, 69, 71, 72, 74, 75, 76, 78, 79, 81, 82, 85, 86, 89, 91, 92, 94,
  • amyloliquefaciens subtilisin BPN′ set forth as SEQ ID NO:1, wherein amino acid positions of the protease variant are numbered according to the numbering of corresponding amino acid positions in the amino acid sequence of Bacillus amyloliquefaciens subtilisin BPN′ shown in SEQ ID NO:1 as determined by alignment of the variant protease amino acid sequence with the Bacillus amyloliquefaciens subtilisin BPN′ amino acid sequence.
  • the present invention also provides protease variants of Bacillus lentus subtilisin GG36 protease, wherein the Bacillus lentus subtilisin GG36 protease comprises the amino acid sequence shown in SEQ ID NO:2, wherein the protease variant comprises an amino acid sequence which differs from the amino acid sequence of SEQ ID NO:2, in no more than two, three, four, five, six, seven, eight, nine, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 mutations selected from the group of A1R, Q2S, Q2M, Q2A, Q2R, Q2W, S3R, V4R, V4S, V4C, I8A, S9A, S9F, S9W, R10S, R10A, R10H, R10M, Q12F, Q12R, P14K, P14F, P14Q, A15R, A15F, A16S, H17R, H17M, H17F, N18R, N
  • the present invention also provides protease variants of Bacillus lentus subtilisin GG36 protease, wherein the Bacillus lentus subtilisin GG36 protease comprises the amino acid sequence shown in SEQ ID NO:2, wherein the protease variant comprises an amino acid sequence which differs from the amino acid sequence of SEQ ID NO:2 in no more than two, three, four, five, six, seven, eight, nine, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 mutations selected from the group of A1R, Q2S, V4R, V4S, S9A, R105, P14K, A16S, H17R, N18R, G20R, T22A, T22R, S24R, S24W, G25R, G25V, V26F, L42I, N43R, N43A, G46R, P52F, P52E, P52N, T57R, Q59A, N62E, N62Q, V68A, V68
  • the present invention also provides protease variants of Bacillus lentus subtilisin GG36 protease, wherein the Bacillus lentus subtilisin GG36 protease comprises the amino acid sequence shown in SEQ ID NO:2, wherein the protease variant comprises an amino acid sequence which differs from the amino acid sequence of SEQ ID NO:2 in no more than two, three, four, five, six, seven, eight, nine, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 mutations selected from the group of A16S, T22A, S24R, N62E, N76D, E89P, S101A/G, S103G/A, V104L/I, L111V, S128N, P129E, A232V, L148I, A158E, G159D/E, R186H, S188D, Y209E, Q236H, Q245R, N248D/R, H249R, N252K/R, T253R,
  • the present invention also provides protease variants of Bacillus lentus subtilisin GG36 protease, wherein the Bacillus lentus subtilisin GG36 protease comprises the amino acid sequence shown in SEQ ID NO:2, wherein the protease variant comprises an amino acid sequence which differs from the amino acid sequence of SEQ ID NO:2 in no more than two, three, four, five, six, seven, eight, nine, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 mutations selected from the group of G20K, G20R, G23A, S24F, S24R, N43R, N43W, R45T, N62E, N76D, S101A, N116A, N116L, G118R, S128I, P129E, S166D, S188D, T213A, A215F, L217E, P239G, and N269R, wherein amino acid positions of the protease variant are numbered according to the numbering of
  • the present invention also provides protease variants of Bacillus lentus subtilisin GG36 protease, wherein the Bacillus lentus subtilisin GG36 protease comprises the amino acid sequence shown in SEQ ID NO:2, wherein the protease variant comprises an amino acid sequence which differs from the amino acid sequence of SEQ ID NO:2 in no more than two, three, four, five, six, seven, eight, nine, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 mutations selected from the group of A1R, A230E, E271L, G115R, G20R, H249R, K235F, K27V/F/L, L75E, L82R, N18R, N269R, N43D, N43R, N76D, R45T, S212F, S242R, S24R, S78R, S9A, T22R, V121E, V244R, V28E, V30E, V4R, and W241
  • the present invention also provides protease variants of Bacillus lentus subtilisin GG36 protease, wherein the Bacillus lentus subtilisin GG36 protease comprises the amino acid sequence shown in SEQ ID NO:2, wherein the protease variant comprises an amino acid sequence which differs from the amino acid sequence of SEQ ID NO:2 in no more than two, three, four, five, six, seven, eight, nine, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 mutations selected from the group of A1R, A230E, E271L, G115R, G20R, H249R, K235F, K27V/F/L, L75E, L82R, N18R, N269R, N43D, N43R, N76D, R45T, S212F, S242R, S24R, S78R, S9A, T22R, V121E, V244R, V28E, V30E, V4R, and W241
  • the present invention also provides protease variants comprising amino acid sequence which differs from the amino acid sequence of SEQ ID NO:2, and wherein the total net charge of the protease variant is 0, +1, +2, +3, +4, +5, ⁇ 1, ⁇ 2, ⁇ 3, ⁇ 4, or ⁇ 5 relative to the total net charge of the Bacillus lentus subtilisin GG36 protease, and wherein amino acid positions of the protease variant are numbered according to the numbering of corresponding amino acid positions in the amino acid sequence of Bacillus amyloliquefaciens subtilisin BPN′ shown in SEQ ID NO:1 as determined by alignment of the protease variant amino acid sequence with the Bacillus amyloliquefaciens subtilisin BPN′ amino acid sequence.
  • the total net charge of the protease variant is 0 relative to the total net charge of the Bacillus lentus subtilisin GG36 protease. In some instances, the total net charge of the protease variant is ⁇ 5 relative to the total net charge of the Bacillus lentus subtilisin GG36 protease. In some instances, the total net charge of the protease variant is ⁇ 4 relative to the total net charge of the Bacillus lentus subtilisin GG36 protease. In some instances, the total net charge of the protease variant is ⁇ 3 relative to the total net charge of the Bacillus lentus subtilisin GG36 protease.
  • the total net charge of the protease variant is ⁇ 2 relative to the total net charge of the Bacillus lentus subtilisin GG36 protease. In some instances, the total net charge of the protease variant is ⁇ 1 relative to the total net charge of the Bacillus lentus subtilisin GG36 protease. In some instances, the total net charge of the protease variant is +1 relative to the total net charge of the Bacillus lentus subtilisin GG36 protease. In some instances, the total net charge of the protease variant is +2 relative to the total net charge of the Bacillus lentus subtilisin GG36 protease.
  • the total net charge of the protease variant is +3 relative to the total net charge of the Bacillus lentus subtilisin GG36 protease. In some instances, the total net charge of the protease variant is +4 relative to the total net charge of the Bacillus lentus subtilisin GG36 protease. In some instances, the total net charge of the protease variant is +5 relative to the total net charge of the Bacillus lentus subtilisin GG36 protease. In some instances, the total net charge of the protease variant differs from 0 (i.e, the total net charge of the protease is not neutral).
  • the present invention also provides protease variants having one or more of the following characteristics: a) a Test Method 2 performance index of at least 1.1, at least 1.2, at least 1.3, at least 1.4, at least 1.5, at least 1.6, at least 1.7, at least 1.8, at least 1.9, at least 2, from 1.1 to about 10, from 1.1 to about 8, or even from 1.1 to about 5; b) a Test Method 3 performance index of at least 1.1, at least 1.2, at least 1.3, at least 1.4, at least 1.5, at least 1.6, at least 1.7, at least 1.8, at least 1.9, at least 2, from 1.1 to about 10, from 1.1 to about 8, or even from 1.1 to about 5; c) a Test Method 4 performance index of at least 1.0, at least 1.1, at least 1.2, at least 1.3, at least 1.4, at least 1.5, at least 1.6, at least 1.7, at least 1.8, at least 1.9, at least 2, from 1.0 to about 10, from 1.0 to about 8, or
  • the present invention also provides isolated nucleic acids comprising polynucleotide sequences that encode the subtilisin variants provided herein.
  • the present invention further provides expression vectors comprising the nucleic acid sequences encoding the subtilisin variants provided herein.
  • the nucleic acid in the expression vector operably linked to a promoter.
  • the present invention also provides host cells comprising the expression vectors provided herein.
  • the host cells are Bacillus host cells.
  • the host cells are B. subtilis host cells.
  • the present invention also provides methods for producing at least one subtilisin variant, comprising: transforming a host cell with an expression vector comprising at least one nucleic acid encoding at least one subtilisin variant provided herein to produce a transformed host cell; and cultivating the transformed host cell under conditions suitable for the production of at least one subtilisin variant, to produce at least one subtilisin variant.
  • the methods further comprise harvesting the produced subtilisin variant.
  • the present invention also provides host cells comprising the expression vectors provided herein.
  • the host cells are Bacillus host cells.
  • the host cells are B. subtilis host cells.
  • the protease variants of the present invention can also be used in fabric and home care products comprising at least one subtilisin variant provided herein.
  • the fabric and home care product is a cleaning composition.
  • the cleaning composition is a granular, powder, solid, bar, liquid, tablet, gel, or paste composition.
  • the cleaning composition is a detergent composition.
  • the cleaning composition is a cold water detergent composition, a low pH detergent composition, or a compact detergent composition.
  • the cleaning composition is a laundry detergent composition, a dish detergent composition and/or a hard surface cleaning composition.
  • the dish detergent composition is a hand dishwashing detergent composition or an automatic dishwashing detergent composition.
  • the fabric and home care product further comprises at least one bleaching agent.
  • the cleaning composition is phosphate-free, while in other embodiments, the cleaning composition contains phosphate.
  • the fabric and home care product further comprises at least one additional enzyme.
  • the at least one additional enzyme is selected from hemicellulases, cellulases, peroxidases, proteases, metalloproteases, xylanases, lipases, phospholipases, esterases, perhydrolases, cutinases, pectinases, pectate lyases, mannanases, keratinases, reductases, oxidases, phenoloxidases, lipoxygenases, ligninases, pullulanases, tannases, pentosanases, malanases, ⁇ -glucanases, arabinosidases, hyaluronidases, chondroitinases, laccases, and amylases, or any combination thereof.
  • the fabric and home care products comprise at least one subtilisin variant that is not a cold water protease.
  • the present invention also provides cleaning compositions comprising at least one subtilisin variant.
  • the cleaning compositions are a granular, powder, solid, bar, liquid, tablet, gel, or paste compositions.
  • the cleaning compositions are detergent compositions.
  • the cleaning compositions are cold water detergent compositions, low pH detergent compositions, and/or compact detergent compositions.
  • the cleaning compositions are laundry detergent compositions, dish detergent compositions, and/or a hard surface cleaning compositions.
  • the dish detergents are hand dishwashing detergent compositions or automatic dishwashing detergent compositions.
  • the cleaning compositions are laundry detergent compositions.
  • the cleaning compositions further comprise at least one bleaching agent.
  • the cleaning compositions are phosphate-free, while in other embodiments the cleaning compositions contain phosphate.
  • the cleaning compositions further comprise at least one additional enzyme.
  • the cleaning compositions the at least one additional enzyme is selected from the group consisting of hemicellulases, cellulases, peroxidases, proteases, metalloproteases, xylanases, lipases, phospholipases, esterases, perhydrolases, cutinases, pectinases, pectate lyases, mannanases, keratinases, reductases, oxidases, phenoloxidases, lipoxygenases, ligninases, pullulanases, tannases, pentosanases, malanases, ⁇ -glucanases, arabinosidases, hyaluronidases, chondroitinases, laccases, and amylases, or any combination thereof.
  • the cleaning compositions comprise at least one subtilisin variant that is not a cold water protease. Such composition may be a fabric and home care product or such
  • the present invention also provides methods of cleaning, comprising contacting a surface or an item with a cleaning composition comprising at least one subtilisin variant provided herein.
  • the methods of cleaning comprise contacting a surface or an item with at least one cleaning composition provided herein.
  • the methods further comprise rinsing the surface or item after contacting the surface or item, respectively, with the cleaning composition.
  • the item is dishware, while in other embodiments, the item is fabric.
  • the methods further comprise the step of rinsing the surface or item after contacting the surface or item with the cleaning composition.
  • the methods further comprise the step of drying the surface or item after rinsing the surface or item.
  • the cleaning compositions comprise at least one subtilisin variant that is not a cold water protease.
  • the present invention provides methods of cleaning a surface or item, comprising: providing the cleaning composition provided herein and a surface or item in need of cleaning; and contacting the cleaning composition with the surface or item in need of cleaning under conditions suitable for the cleansing of the surface of the surface or item, to produce a cleansed surface or item.
  • the methods of the present invention further comprise the step of rinsing the cleansed surface or item to produce a rinsed surface or item.
  • the methods further comprise the step of drying the rinsed surface or item.
  • the cleaning compositions comprise at least one subtilisin variant that is not a cold water protease.
  • FIG. 1 provides an alignment of the mature reference proteases including: BPN′ (SEQ ID NO:1) and GG36 (SEQ ID NO:2).
  • BPN′ SEQ ID NO:1
  • GG36 SEQ ID NO:2
  • Each amino acid position of each protease variant described herein, including each cold water protease variant, is numbered according to the numbering of the corresponding amino acid position in the amino acid sequence of Bacillus amyloliquefaciens subtilisin protease BPN′ (SEQ ID NO:1), as shown in FIG. 1 , as determined by alignment of the protease variant amino acid sequence with the Bacillus amyloliquefaciens subtilisin protease BPN′ amino acid sequence.
  • substitution positions are given in relationship to BPN′.
  • FIG. 2 provides a map of pHPLT-GG36.
  • FIG. 3 provides a map of pRA68.
  • FIG. 4 provides a map of pRA96.
  • the present invention provides serine protease variants. Specifically, the present invention provides serine protease variants having one or more substitutions as compared to a reference serine protease. In addition, the present invention provides compositions comprising these serine protease variants. In some embodiments, the present invention provides cleaning compositions comprising at least one of these serine protease variants.
  • nucleic acids are written left to right in 5′ to 3′ orientation; amino acid sequences are written left to right in amino to carboxy orientation, respectively. It is to be understood that this invention is not limited to the particular methodology, protocols, and reagents described, as these may vary, depending upon the context they are used by those of skill in the art.
  • protease As used herein, the terms “protease” and “proteinase” refer to an enzyme protein that has the ability to break down other proteins.
  • a protease has the ability to conduct “proteolysis,” which begins protein catabolism by hydrolysis of peptide bonds that link amino acids together in a peptide or polypeptide chain forming the protein. This activity of a protease as a protein-digesting enzyme is referred to as “proteolytic activity.”
  • proteolytic activity is referred to as “proteolytic activity.”
  • Many well known procedures exist for measuring proteolytic activity See e.g., Kalisz, “Microbial Proteinases,” In: Fiechter (ed.), Advances in Biochemical Engineering/Biotechnology , (1988)).
  • proteolytic activity may be ascertained by comparative assays which analyze the respective protease's ability to hydrolyze a commercial substrate.
  • Exemplary substrates useful in the analysis of protease or proteolytic activity include, but are not limited to, di-methyl casein (Sigma C-9801), bovine collagen (Sigma C-9879), bovine elastin (Sigma E ⁇ 1625), and bovine keratin (ICN Biomedical 902111). Colorimetric assays utilizing these substrates are well known in the art (See e.g., WO 99/34011 and U.S. Pat. No. 6,376,450, both of which are incorporated herein by reference).
  • the pNA assay (See e.g., Del Mar et al., Anal. Biochem. 99:316-320 [1979]) also finds use in determining the active enzyme concentration for fractions collected during gradient elution. This assay measures the rate at which p-nitroaniline is released as the enzyme hydrolyzes the soluble synthetic substrate, succinyl-alanine-alanine-proline-phenylalanine-p-nitroanilide (suc-AAPF-pNA). The rate of production of yellow color from the hydrolysis reaction is measured at 410 nm on a spectrophotometer and is proportional to the active enzyme concentration. In addition, absorbance measurements at 280 nanometers (nm) can be used to determine the total protein concentration. The active enzyme/total protein ratio gives the enzyme purity.
  • subtilase refers any member of the S8 serine protease family as described in MEROPS—The Peptidase Data base (See, Rawlings et al., MEROPS: the peptidase database, Nucl Acids Res, 34 Database issue, D270-272 [2006]).
  • the peptidase family S8 contains the serine endopeptidase subtilisin and its homologues (Rawlings and Barrett, Biochem J., 290:205-218, [1993]).
  • Family S8 also known as the subtilase family, is the second largest family of serine peptidases.
  • a typical S8 protein structure consists of three layers with a seven-stranded ⁇ sheet sandwiched between two layers of helices.
  • Subtilisin (S08.001) is the type structure for clan SB (SB).
  • SB subtilisin
  • subtilisin and chymotrypsin (S01.001) can be superimposed, which suggests the similarity is the result of convergent rather than divergent evolution.
  • proteases that are similar to a reference protease (which may be a wild-type subtilisin protease), particularly in their function, but have mutations in their amino acid sequence that make them different in sequence from the wild-type protease or any starting reference protease (i.e., “parent” protease) from which the variant protease is derived.
  • a reference protease which may be a wild-type subtilisin protease
  • parent protease
  • the present invention provides “GG36 variants,” (or “GG36 subtilisin variants”) wherein the mutations are present in the mature GG36 sequence set forth in SEQ ID NO:2.
  • the reference protease be limited to any particular amino acid sequence.
  • the term encompass variants of a parent protease wherein the parent protease's sequence is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO:2.
  • the term “cold water protease variant” means a protease variant of a parent protease, wherein the B. lentus subtilisin GG36 protease has the amino acid sequence of SEQ ID NO:2, wherein said protease variant has one or more of the following characteristics: a) a Test Method 2 performance index of at least 1.1, at least 1.2, at least 1.3, at least 1.4, at least 1.5, at least 1.6, at least 1.7, at least 1.8, at least 1.9, at least 2, from 1.1 to about 10, from 1.1 to about 8, or even from 1.1 to about 5; b) a Test Method 3 performance index of at least 1.1, at least 1.2, at least 1.3, at least 1.4, at least 1.5, at least 1.6, at least 1.7, at least 1.8, at least 1.9, at least 2, from 1.1 to about 10, from 1.1 to about 8, or even from 1.1 to about 5; c) a Test Method 4 performance index of at least 1.0,
  • Test Method 2 Test Method 3, Test Method 4, and Test Method 6 are explicitly described infra in the section of Example 1 entitled “Test Methods”.
  • the term encompass variants of a parent protease wherein the parent protease's sequence is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO:2.
  • the parent protease i.e., “reference” or “starting” protease
  • the parent protease is a commercially available protease, including but not limited to the proteases sold under the tradenames SAVINASE®, POLARZYME®, KANNASE®, LIQUINASE®, LIQUINASE ULTRA®, SAVINASE ULTRA®, OVOZYME®, (by Novozymes A/S); MAXACAL®, PROPERASE®, PURAFECT®, FN3®, FN4® and PURAFECT OXP®, PURAFASTTM, PURAFECT®PRIME, PURAMAX® (by Danisco US, Genencor Division); and those available from Henkel/Kemira, namely BLAP (sequence shown in FIG.
  • BLAP S99D+S101 R+S103A+V104I+G159S
  • BLAP X BLAP with S3T+V4I+V205I
  • variable polypeptide refers to a polypeptide comprising an amino acid sequence that differs in at least one amino acid residue from the amino acid sequence of a parent or reference polypeptide (including but not limited to wild-type polypeptides).
  • the genus Bacillus includes all species within the genus “ Bacillus ,” as known to those of skill in the art, including but not limited to B. subtilis, B. licheniformis, B. lentus, B. brevis, B. stearothermophilus, B. alkalophilus, B. amyloliquefaciens, B. clausii, B. halodurans, B. megaterium, B. coagulans, B. circulans, B. lautus , and B. thuringiensis . It is recognized that the genus Bacillus continues to undergo taxonomical reorganization.
  • the genus include species that have been reclassified, including but not limited to such organisms as B. stearothermophilus , which is now named “ Geobacillus stearothermophilus .”
  • Geobacillus stearothermophilus The production of resistant endospores in the presence of oxygen is considered the defining feature of the genus Bacillus , although this characteristic also applies to the recently named Alicyclobacillus, Amphibacillus, Aneurinibacillus, Anoxybacillus, Brevibacillus, Filobacillus, Gracilibacillus, Halobacillus, Paenibacillus, Salibacillus, Thermobacillus, Ureibacillus , and Virgibacillus.
  • polynucleotide and “nucleic acid,” which are used interchangeably herein, refer to a polymer of any length of nucleotide monomers covalently bonded in a chain.
  • DNA deoxyribonucleic acid
  • RNA ribonucleic acid
  • polynucleotides or nucleic acids having distinct biological function are examples of polynucleotides or nucleic acids having distinct biological function.
  • Polynucleotides or nucleic acids include, but are not limited to, a single-, double- or triple-stranded DNA, genomic DNA, cDNA, RNA, DNA-RNA hybrid, or a polymer comprising purine and pyrimidine bases, or other natural, chemically, biochemically modified, non-natural or derivatized nucleotide bases.
  • polynucleotides genes, gene fragments, chromosomal fragments, expressed sequence tag(s) (EST(s)), exons, introns, messenger RNA (mRNA), transfer RNA (tRNA), ribosomal RNA (rRNA), ribozymes, complementary DNA (cDNA), recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers.
  • EST(s) expressed sequence tag(s)
  • mRNA messenger RNA
  • tRNA transfer RNA
  • rRNA ribosomal RNA
  • cDNA complementary DNA
  • polynucleotides comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs, uracyl, other sugars and linking groups such as fluororibose and thioate, and nucleotide branches.
  • a sequence of nucleotides is interrupted by non-nucleotide components.
  • mutation refers to changes made in a starting amino acid or nucleic acid sequence. It is intended that the term encompass substitutions, insertions and deletions.
  • vector refers to a nucleic acid construct or polynucleotide construct used to introduce or transfer nucleic acid(s) or polynucleotide(s) into a target cell or tissue.
  • a vector is typically used to introduce foreign DNA into another cell or tissue.
  • a vector generally comprises a DNA sequence that is a transgene and a larger polynucleotide sequence that serves as the “backbone” of the vector.
  • the vector typically serves to transfers genetic information, such as the inserted transgene, to a target cell or tissue so as to isolate, multiply, or express the insert in the target cell or tissue.
  • Vectors include plasmids, cloning vectors, bacteriophages, viruses (e.g., viral vector), cosmids, expression vectors, shuttle vectors, cassettes, and the like.
  • a vector typically includes an origin of replication, a multicloning site, and a selectable marker. The process of inserting a vector into a target cell is typically referred to as transfection. The transfection of a cell with a viral vector is typically referred to as transduction.
  • the present invention includes, in some embodiments, a vector that comprises a DNA sequence encoding a variant protease (e.g., precursor or mature variant protease) that is operably linked to a suitable prosequence (e.g., secretory, signal peptide sequence, etc.) capable of effecting the expression of the DNA sequence in a suitable host.
  • a variant protease e.g., precursor or mature variant protease
  • a suitable prosequence e.g., secretory, signal peptide sequence, etc.
  • expression cassette refers to a nucleic acid construct or vector generated recombinantly or synthetically for the expression of a nucleic acid of interest (e.g., a foreign nucleic acid or transgene) in a target cell.
  • the nucleic acid of interest typically expresses a protein of interest.
  • An expression vector or expression cassette typically comprises a promoter nucleotide sequence that drives or promotes expression of the foreign nucleic acid.
  • the expression vector or cassette also typically includes any other specified nucleic acid elements that permit transcription of a particular nucleic acid in a target cell.
  • a recombinant expression cassette can be incorporated into a plasmid, chromosome, mitochondrial DNA, plastid DNA, virus, or nucleic acid fragment.
  • Some expression vectors have the ability to incorporate and express heterologous DNA fragments in a host cell.
  • Many prokaryotic and eukaryotic expression vectors are commercially available. Selection of appropriate expression vectors is within the knowledge of those of skill in the art. Selection of appropriate expression vectors for expression of a protein from a nucleic acid sequence incorporated into the expression vector is within the knowledge of those of skill in the art.
  • a DNA construct is an artificially constructed segment of nucleic acid that may be introduced into a target cell or tissue.
  • a DNA construct typically comprises a DNA insert comprising a nucleotide sequence encoding a protein of interest that has been subcloned into a vector.
  • the vector may contain bacterial resistance genes for growth in bacteria and a promoter for expression of the protein of interest in an organism.
  • the DNA may be generated in vitro by PCR or any other suitable technique(s) known to those in the art.
  • the DNA construct comprises a nucleic acid sequence of interest.
  • the sequence is operably linked to additional elements such as control elements (e.g., promoters, etc.).
  • the DNA construct may further comprise a selectable marker and may further comprise an incoming sequence flanked by homology boxes.
  • the construct may comprise other non-homologous sequences, added to the ends (e.g., stuffer sequences or flanks). In some embodiments, the ends of the sequence are closed such that the DNA construct forms a closed circle.
  • the nucleic acid sequence of interest which is incorporated into the DNA construct, using techniques well known in the art, may be a wild-type, mutant, or modified nucleic acid.
  • the DNA construct comprises one or more nucleic acid sequences homologous to the host cell chromosome. In other embodiments, the DNA construct comprises one or more non-homologous nucleotide sequences.
  • DNA construct may be used, for example, to: 1) insert heterologous sequences into a desired target sequence of a host cell; and/or 2) mutagenize a region of the host cell chromosome (i.e., replace an endogenous sequence with a heterologous sequence); 3) delete target genes; and/or 4) introduce a replicating plasmid into the host.
  • DNA construct is used interchangeably herein with “expression cassette.”
  • plasmid refers to an extrachromosomal DNA molecule which is capable of replicating independently from the chromosomal DNA.
  • a plasmid is double stranded (ds) and may be circular and is typically used as a cloning vector.
  • the term “introduced” refers to any method suitable for transferring the nucleic acid sequence into the cell. Such methods for introduction include but are not limited to protoplast fusion, transfection, transformation, electroporation, conjugation, and transduction (See e.g., Ferrari et al., “Genetics,” in Hardwood et al. (eds.), Bacillus , Plenum Publishing Corp., pp. 57-72 [1989]).
  • Transformation refers to the genetic alteration of a cell which results from the uptake, genomic incorporation, and expression of genetic material (e.g., DNA).
  • a nucleic acid is “operably linked” with another nucleic acid sequence when it is placed into a functional relationship with another nucleic acid sequence.
  • a promoter or enhancer is operably linked to a nucleotide coding sequence if the promoter affects the transcription of the coding sequence.
  • a ribosome binding site may be operably linked to a coding sequence if it is positioned so as to facilitate translation of the coding sequence.
  • “operably linked” DNA sequences are contiguous. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, synthetic oligonucleotide adaptors or linkers may be used in accordance with conventional practice.
  • gene refers to a polynucleotide (e.g., a DNA segment), that encodes a polypeptide and includes regions preceding and following the coding regions as well as intervening sequences (introns) between individual coding segments (exons).
  • recombinant when used with reference to a cell typically indicates that the cell has been modified by the introduction of a heterologous nucleic acid sequence or that the cell is derived from a cell so modified.
  • a recombinant cell may comprise a gene not found in identical form within the native (non-recombinant) form of the cell, or a recombinant cell may comprise a native gene (found in the native form of the cell) but which has been modified and re-introduced into the cell.
  • a recombinant cell may comprise a nucleic acid endogenous to the cell that has been modified without removing the nucleic acid from the cell; such modifications include those obtained by gene replacement, site-specific mutation, and related techniques known to those of ordinary skill in the art.
  • Recombinant DNA technology includes techniques for the production of recombinant DNA in vitro and transfer of the recombinant DNA into cells where it may be expressed or propagated, thereby producing a recombinant polypeptide.
  • Recombination,” “recombining,” and “recombined” of polynucleotides or nucleic acids refer generally to the assembly or combining of two or more nucleic acid or polynucleotide strands or fragments to generate a new polynucleotide or nucleic acid.
  • the recombinant polynucleotide or nucleic acid is sometimes referred to as a chimera.
  • a nucleic acid or polypeptide is “recombinant” when it is artificial or engineered, or derived from an artificial or engineered protein or nucleic acid.
  • nucleic acid or gene “amplification” refers to a process by which specific DNA sequences are disproportionately replicated such that the amplified nucleic acid or gene becomes present in a higher copy number than was initially present in the genome.
  • selection of cells by growth in the presence of a drug results in the amplification of either the endogenous gene encoding the gene product required for growth in the presence of the drug or by amplification of exogenous (i.e., input) sequences encoding this nucleic acid or gene product or both.
  • “Amplification” is a special case of nucleic acid replication involving template specificity. It is to be contrasted with non-specific template replication (i.e., replication that is template-dependent but not dependent on a specific template). Template specificity is here distinguished from fidelity of replication (i.e., synthesis of the proper polynucleotide sequence) and nucleotide (ribo- or deoxyribo-) specificity. Template specificity is frequently described in terms of “target” specificity. Target sequences are “targets” in the sense that they are sought to be sorted out from other nucleic acid. Amplification techniques have been designed primarily for this sorting out.
  • primer refers to an oligonucleotide (a polymer of nucleotide residues), whether occurring naturally as in a purified restriction digest or produced synthetically, which is capable of acting as a point of initiation of synthesis when placed under conditions in which synthesis of a primer extension product which is complementary to a nucleic acid strand is induced (i.e., in the presence of nucleotides and an inducing agent such as DNA polymerase and at a suitable temperature and pH).
  • a primer is preferably single stranded for maximum efficiency in amplification, but may alternatively be double stranded. If double stranded, the primer is first treated to separate its strands before being used to prepare extension products.
  • the primer is an oligodeoxyribonucleotide.
  • the primer must be sufficiently long to prime the synthesis of extension products in the presence of the inducing agent. The exact length of a primer depends on a variety of factors, including temperature, source of primer, and the use of the method.
  • probe refers to an oligonucleotide, whether occurring naturally as in a purified restriction digest or produced synthetically, recombinantly or by PCR amplification, which is typically capable of hybridizing to another oligonucleotide of interest.
  • a probe may be single-stranded or double-stranded. Probes are useful in the detection, identification and isolation of particular gene sequences. It is contemplated that any probe used in the present invention will be labeled with any “reporter molecule,” so that it is detectable in any detection system, including, but not limited to enzyme (e.g., ELISA, as well as enzyme-based histochemical assays), fluorescent, radioactive, and luminescent systems. It is not intended that the present invention be limited to any particular detection system or label.
  • target when used in reference to the polymerase chain reaction, refers to the region of nucleic acid bounded by the primers used for polymerase chain reaction. Thus, the “target” is sought to be sorted out from other nucleic acid sequences.
  • a nucleotide “segment” is a region of a nucleic acid within the target nucleic acid sequence.
  • PCR polymerase chain reaction
  • amplification reagents refers to those reagents (e.g., deoxyribonucleotide triphosphates, buffer, etc.) needed for amplification except for primers, nucleic acid template, and the amplification enzyme.
  • amplification reagents along with other reaction components are placed and contained in a reaction vessel (test tube, microwell, etc.).
  • restriction endonuclease or “restriction enzyme” refers to an enzyme (e.g., bacterial enzyme) that is capable of cutting double-stranded or single-stranded DNA at or near a specific sequence of nucleotides known as a restriction site.
  • the nucleotide sequence comprising the restriction site is recognized and cleaved by a given restriction endonuclease or restriction enzyme and is frequently the site for insertion of DNA fragments.
  • a restriction site can be engineered into an expression vector or DNA construct.
  • “Homologous recombination” refers to the exchange of DNA fragments between two DNA molecules or paired chromosomes at the site of identical or nearly identical nucleotide sequences. In some embodiments, chromosomal integration is homologous recombination.
  • a nucleic acid or polynucleotide is said to “encode” a polypeptide if, in its native state or when manipulated by methods known to those of skill in the art, it can be transcribed and/or translated to produce the polypeptide or a fragment thereof.
  • the anti-sense strand of such a nucleic acid is also said to encode the sequence.
  • RNA sequence can be transcribed by an RNA polymerase to produce an RNA sequence, but an RNA sequence can be reverse transcribed by reverse transcriptase to produce a DNA sequence.
  • “Host strain” or “host cell” refers to a suitable host for an expression vector comprising a DNA sequence of interest.
  • the DNA sequence of interest may express a protein of interest in the host strain or host cell.
  • a “protein” or “polypeptide” comprises a polymeric sequence of amino acid residues.
  • the terms “protein” and “polypeptide” are used interchangeably herein.
  • the single and 3-letter code for amino acids as defined in conformity with the IUPAC-IUB Joint Commission on Biochemical Nomenclature (JCBN) is used through out this disclosure.
  • the single letter X refers to any of the twenty amino acids. It is also understood that a polypeptide may be coded for by more than one nucleotide sequence due to the degeneracy of the genetic code. Mutations are named by the one letter code for the parent amino acid, followed by a three or two digit position number and then the one letter code for the variant amino acid.
  • mutating glycine (G) at position 87 to serine (S) is represented as “G087S” or “G87S”.
  • Multiple mutations are indicated by inserting a “-” between the mutations.
  • Mutations at positions 87 and 90 are represented as either “G087S-A090Y” or “G87S-A90Y” or “G87S+A90Y” or “G087S+A090Y”.
  • the one letter code “Z” is used.
  • the one letter code “Z” is on the left side of the position number.
  • the one letter code “Z” is on the right side of the position number.
  • the position number is the position number before the inserted amino acid(s), plus 0.01 for each amino acid.
  • an insertion of three amino acids alanine (A), serine (S) and tyrosine (Y) between position 87 and 88 is shown as “Z087.01A-Z087.02S-Z087.03Y.”
  • Z087.01A-Z087.02S-Z087.03Y is shown as “Z087.01A-Z087.02S-Z087.03Y.”
  • prosequence or “propetide sequence” refers to an amino acid sequence between the signal peptide sequence and mature protease sequence that is necessary for the secretion of the protease. Cleavage of the prosequence or propeptide sequence results in a mature active protease.
  • signal sequence refers to a sequence of amino acid residues that may participate in the secretion or direct transport of the mature or precursor form of a protein.
  • the signal sequence is typically located N-terminal to the precursor or mature protein sequence.
  • the signal sequence may be endogenous or exogenous.
  • One exemplary exogenous signal sequence comprises the first seven amino acid residues of the signal sequence from Bacillus subtilis subtilisin fused to the remainder of the signal sequence of the subtilisin from Bacillus lentus (ATCC 21536).
  • a signal sequence is normally absent from the mature protein.
  • a signal sequence is typically cleaved from the protein by a signal peptidase after the protein is transported.
  • hybrid signal sequence refers to signal sequences in which part of sequence is obtained from the expression host fused to the signal sequence of the gene to be expressed. In some embodiments, synthetic sequences are utilized.
  • mature form of a protein, polypeptide, or peptide refers to the functional form of the protein, polypeptide, or peptide without the signal peptide sequence and propeptide sequence.
  • precursor form of a protein or peptide refers to a mature form of the protein having a prosequence operably linked to the amino or carbonyl terminus of the protein.
  • the precursor may also have a “signal” sequence operably linked to the amino terminus of the prosequence.
  • the precursor may also have additional polynucleotides that are involved in post-translational activity (e.g., polynucleotides cleaved therefrom to leave the mature form of a protein or peptide).
  • wild-type in reference to an amino acid sequence or nucleic acid sequence indicates that the amino acid sequence or nucleic acid sequence is native or naturally occurring sequence.
  • naturally-occurring refers to anything (e.g., proteins, amino acids, or nucleic acid sequences) that are found in nature (i.e., have not been manipulated by means of recombinant methods).
  • non-naturally occurring refers to anything that is not found in nature (e.g., recombinant nucleic acids produced in the laboratory).
  • corresponding to or “corresponds to” or “corresponds” refers to an amino acid residue at the enumerated position in a protein or peptide, or an amino acid residue that is analogous, homologous, or equivalent to an enumerated residue in a protein or peptide.
  • corresponding region generally refers to an analogous position along related proteins or a reference protein.
  • the terms “derived from” and “obtained from” refer to not only a protease produced or producible by a strain of the organism in question, but also a protease encoded by a DNA sequence isolated from such strain and produced in a host organism containing such DNA sequence. Additionally, the term refers to a protease which is encoded by a DNA sequence of synthetic and/or cDNA origin and which has the identifying characteristics of the protease in question.
  • proteases derived from Bacillus refers to those enzymes having proteolytic activity which are naturally produced by Bacillus , as well as to serine proteases like those produced by Bacillus sources but which through the use of genetic engineering techniques are produced by non-Bacillus organisms transformed with a nucleic acid encoding the serine proteases.
  • nucleic acids or polypeptide sequences refers to the residues in the two sequences that are the same when aligned for maximum correspondence, as measured using one of the following sequence comparison or analysis algorithms.
  • homologous genes refers to a pair of genes from different, but usually related species, which correspond to each other and which are identical or very similar to each other.
  • the term encompasses genes that are separated by speciation (i.e., the development of new species) (e.g., orthologous genes), as well as genes that have been separated by genetic duplication (e.g., paralogous genes).
  • homology refers to sequence similarity or identity, with identity being preferred. Homology may be determined using standard techniques known in the art (See e.g., Smith and Waterman, Adv. Appl. Math. 2:482 [1981]; Needleman and Wunsch, J. Mol. Biol. 48:443 [1970 ⁇ ; Pearson and Lipman, Proc. Natl. Acad. Sci. USA 85:2444 [1988]; software programs such as GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package (Genetics Computer Group, Madison, Wis.); and Devereux et al., Nucl. Acid Res. 12:387-395 [1984]).
  • PILEUP creates a multiple sequence alignment from a group of related sequences using progressive, pair-wise alignments. It can also plot a tree showing the clustering relationships used to create the alignment. PILEUP uses a simplification of the progressive alignment method of Feng and Doolittle (See, Feng and Doolittle, J. Mol. Evol. 35:351-360 [1987]). The method is similar to that described by Higgins and Sharp (See, Higgins and Sharp, CABIOS 5:151-153 [1989]).
  • Useful PILEUP parameters including a default gap weight of 3.00, a default gap length weight of 0.10, and weighted end gaps.
  • BLAST BLAST algorithm
  • WU-BLAST-2 WU-BLAST-2 uses several search parameters, most of which are set to the default values.
  • the HSP S and HSP S2 parameters are dynamic values and are established by the program itself depending upon the composition of the particular sequence and composition of the particular database against which the sequence of interest is being searched. However, the values may be adjusted to increase sensitivity.
  • the percent sequence identity between a reference sequence and a test sequence of interest may be readily determined by one skilled in the art.
  • the percent identity shared by polynucleotide or polypeptide sequences is determined by direct comparison of the sequence information between the molecules by aligning the sequences and determining the identity by methods known in the art.
  • An example of an algorithm that is suitable for determining sequence similarity is the BLAST algorithm, (See, Altschul, et al., J. Mol. Biol., 215:403-410 [1990]).
  • Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information.
  • This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence that either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence.
  • HSPs high scoring sequence pairs
  • These initial neighborhood word hits act as starting points to find longer HSPs containing them.
  • the word hits are expanded in both directions along each of the two sequences being compared for as far as the cumulative alignment score can be increased. Extension of the word hits is stopped when: the cumulative alignment score falls off by the quantity X from a maximum achieved value; the cumulative score goes to zero or below; or the end of either sequence is reached.
  • the BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment.
  • the BLAST program uses as defaults a wordlength (W) of 11, the BLOSUM62 scoring matrix (See, Henikoff and Henikoff, Proc. Natl. Acad. Sci. USA 89:10915 [1992]) alignments (B) of 50, expectation (E) of 10, M′S, N′-4, and a comparison of both strands.
  • W wordlength
  • B BLOSUM62 scoring matrix
  • E expectation
  • M′S M′S
  • N′-4 a comparison of both strands.
  • the BLAST algorithm then performs a statistical analysis of the similarity between two sequences (See e.g., Karlin and Altschul, supra).
  • One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance.
  • P(N) the smallest sum probability
  • a nucleic acid is considered similar to a serine protease nucleic acid of this invention if the smallest sum probability in a comparison of the test nucleic acid to a serine protease nucleic acid is less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.
  • test nucleic acid encodes a serine protease polypeptide
  • it is considered similar to a specified serine protease nucleic acid if the comparison results in a smallest sum probability of less than about 0.5, and more preferably less than about 0.2.
  • Percent “identical” or “identity” in the context of two or more nucleic acid or polypeptide sequences refers to two or more sequences that are the same or have a specified percentage of nucleic acid residues or amino acid residues, respectively, that are the same, when compared and aligned for maximum similarity, as determined using a sequence comparison algorithm or by visual inspection.
  • “Percent sequence identity” or “% identity” or “% sequence identity or “% amino acid sequence identity” of a subject amino acid sequence to a reference (i.e., query) amino acid sequence means that the subject amino acid sequence is identical (i.e., on an amino acid-by-amino acid basis) by a specified percentage to the query amino acid sequence over a comparison length when the sequences are optimally aligned.
  • 80% amino acid sequence identity or 80% identity with respect to two amino acid sequences means that 80% of the amino acid residues in two optimally aligned amino acid sequences are identical.
  • Percent sequence identity” or “% identity” or “% sequence identity or “% nucleotide sequence identity” of a subject nucleic acid sequence to a reference (i.e. query) nucleic acid sequence means that the subject nucleic acid sequence is identical (i.e., on a nucleotide-by-nucleotide basis for a polynucleotide sequence) by a specified percentage to the query sequence over a comparison length when the sequences are optimally aligned.
  • 80% nucleotide sequence identity or 80% identity with respect to two nucleic acid sequences means that 80% of the nucleotide residues in two optimally aligned nucleic acid sequences are identical.
  • the “percent sequence identity” or “% sequence identity” or “% identity” of a subject sequence to a query sequence can be calculated by optimally aligning the two sequences and comparing the two optimally aligned sequences over the comparison length. The number of positions in the optimal alignment at which identical residues occur in both sequences is determined, thereby providing the number of matched positions, and the number of matched positions is then divided by the total number of positions of the comparison length (which, unless otherwise specified, is the length of the query sequence). The resulting number is multiplied by 100 to yield the percent sequence identity of the subject sequence to the query sequence.
  • Optimal alignment or “optimally aligned” refers to the alignment of two (or more) sequences giving the highest percent identity score.
  • optimal alignment of two protein sequences can be achieved by manually aligning the sequences such that the maximum number of identical amino acid residues in each sequence are aligned together or by using software programs or procedures described herein or known in the art.
  • Optimal alignment of two nucleic acid sequences can be achieved by manually aligning the sequences such that the maximum number of identical nucleotide residues in each sequence are aligned together or by using software programs or procedures described herein or known in the art.
  • two polypeptide sequences are deemed “optimally aligned” when they are aligned using defined parameters, such as a defined amino acid substitution matrix, gap existence penalty (also termed gap open penalty), and gap extension penalty, so as to achieve the highest similarity score possible for that pair of sequences.
  • a defined amino acid substitution matrix such as BLOSUM62 scoring matrix (See, Henikoff and Henikoff, supra) is often used as a default scoring substitution matrix in polypeptide sequence alignment algorithms (e.g., BLASTP).
  • the gap existence penalty is imposed for the introduction of a single amino acid gap in one of the aligned sequences, and the gap extension penalty is imposed for each residue position in the gap.
  • the alignment score is defined by the amino acid positions of each sequence at which the alignment begins and ends (e.g., the alignment window), and optionally by the insertion of a gap or multiple gaps into one or both sequences, so
  • Optimal alignment between two or more sequences can be determined manually by visual inspection or by using a computer, such as, but not limited to for example, the BLASTP program for amino acid sequences and the BLASTN program for nucleic acid sequences (See e.g., Altschul et al., Nucleic Acids Res. 25(17):3389-3402 (1997); See also, the National Center for Biotechnology Information (NCBI) website).
  • a computer such as, but not limited to for example, the BLASTP program for amino acid sequences and the BLASTN program for nucleic acid sequences (See e.g., Altschul et al., Nucleic Acids Res. 25(17):3389-3402 (1997); See also, the National Center for Biotechnology Information (NCBI) website).
  • a polypeptide of interest may be said to be “substantially identical” to a reference polypeptide if the polypeptide of interest comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.5% sequence identity to the amino acid sequence of the reference polypeptide.
  • the percent identity between two such polypeptides can be determined manually by inspection of the two optimally aligned polypeptide sequences or by using software programs or algorithms (e.g., BLAST, ALIGN, CLUSTAL) using standard parameters.
  • One indication that two polypeptides are substantially identical is that the first polypeptide is immunologically cross-reactive with the second polypeptide.
  • polypeptides that differ by conservative amino acid substitutions are immunologically cross-reactive.
  • a polypeptide is substantially identical to a second polypeptide, for example, where the two peptides differ only by a conservative amino acid substitution or one or more conservative amino acid substitutions.
  • a nucleic acid of interest may be said to be “substantially identical” to a reference nucleic acid if the nucleic acid of interest comprises a nucleotide sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.5% sequence identity to the nucleotide sequence of the reference nucleic acid.
  • the percent identity between two such nucleic acids can be determined manually by inspection of the two optimally aligned nucleic acid sequences or by using software programs or algorithms (e.g., BLAST, ALIGN, CLUSTAL) using standard parameters.
  • One indication that two nucleic acid sequences are substantially identical is that the two nucleic acid molecules hybridize to each other under stringent conditions (e.g., within a range of medium to high stringency).
  • a nucleic acid or polynucleotide is “isolated” when it is partially or completely separated from other components, including but not limited to for example, other proteins, nucleic acids, cells, etc.
  • a polypeptide, protein or peptide is “isolated” when it is partially or completely separated from other components, including but not limited to for example, other proteins, nucleic acids, cells, etc.
  • an isolated species is more abundant than are other species in a composition.
  • an isolated species may comprise at least about 50%, about 70%, about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% (on a molar basis) of all macromolecular species present.
  • the species of interest is purified to essential homogeneity (i.e., contaminant species cannot be detected in the composition by conventional detection methods). Purity and homogeneity can be determined using a number of techniques well known in the art, such as agarose or polyacrylamide gel electrophoresis of a protein or nucleic acid sample, followed by visualization upon staining. If desired, a high-resolution technique, such as high performance liquid chromatography (HPLC) or a similar means can be utilized for purification of the material.
  • HPLC high performance liquid chromatography
  • purified as applied to nucleic acids or polypeptides generally denotes a nucleic acid or polypeptide that is essentially free from other components as determined by analytical techniques well known in the art (e.g., a purified polypeptide or polynucleotide forms a discrete band in an electrophoretic gel, chromatographic eluate, and/or a media subjected to density gradient centrifugation).
  • a nucleic acid or polypeptide that gives rise to essentially one band in an electrophoretic gel is “purified.”
  • a purified nucleic acid or polypeptide is at least about 50% pure, usually at least about 75%, about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 99.5%, about 99.6%, about 99.7%, about 99.8% or more pure (e.g., percent by weight on a molar basis).
  • the invention provides methods of enriching compositions for one or more molecules of the invention, such as one or more polypeptides or polynucleotides of the invention.
  • a composition is enriched for a molecule when there is a substantial increase in the concentration of the molecule after application of a purification or enrichment technique.
  • a substantially pure polypeptide or polynucleotide of the invention e.g., substantially pure variant protease or polynucleotide encoding a variant protease of the invention, respectively
  • the invention provides methods of enriching compositions for one or more molecules of the invention, such as one or more polypeptides of the invention (e.g., one or more variant proteases of the invention) or one or more nucleic acids of the invention (e.g., one or more nucleic acids encoding one or more variant proteases of the invention).
  • a composition is enriched for a molecule when there is a substantial increase in the concentration of the molecule after application of a purification or enrichment technique.
  • a substantially pure polypeptide or polynucleotide will typically comprise at least about 55%, about 60%, about 70%, about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98, about 99%, about 99.5% or more by weight (on a molar basis) of all macromolecular species in a particular composition.
  • combinatorial mutagenesis refers to methods in which libraries of nucleic acid variants of a reference nucleic acid sequence are generated. In these libraries, the variants contain one or several mutations chosen from a predefined set of mutations. The methods also provide means to introduce random mutations which were not members of the predefined set of mutations. Some such methods include those set forth in U.S. Pat. No. 6,582,914, hereby incorporated by reference. Some such combinatorial mutagenesis methods include and/or encompass methods embodied in commercially available kits (e.g., QUIKCHANGE® Multi Site-Directed Mutagenesis Kit (Stratagene), PCR fusion/extension PCR).
  • kits e.g., QUIKCHANGE® Multi Site-Directed Mutagenesis Kit (Stratagene), PCR fusion/extension PCR.
  • “having improved properties” used in connection with a variant protease refers to a variant protease with improved or enhanced wash or cleaning performance, and/or improved or enhanced stability optionally with retained wash or cleaning performance, relative to the corresponding reference protease (e.g., wild-type or naturally-occurring protease).
  • the improved properties of a variant protease may comprise improved wash or cleaning performance and/or improved stability.
  • the invention provides variant proteases of the invention that exhibit one of more of the following properties: improved hand wash performance, improved hand or manual dishwashing performance, improved automatic dishwashing performance, improved laundry performance, and/or improved stability relative to a reference protease (e.g., wild-type protease, such as a wild-type subtilisin).
  • a reference protease e.g., wild-type protease, such as a wild-type subtilisin.
  • the term “functional assay” refers to an assay that provides an indication of a protein's activity.
  • the term refers to assay systems in which a protein is analyzed for its ability to function in its usual capacity.
  • a functional assay involves determining the effectiveness of the enzyme in catalyzing a reaction.
  • target property refers to the property of the starting gene that is to be altered. It is not intended that the present invention be limited to any particular target property. However, in some embodiments, the target property is the stability of a gene product (e.g., resistance to denaturation, proteolysis or other degradative factors), while in other embodiments, the level of production in a production host is altered.
  • a property affecting binding to a polypeptide refers to any characteristic or attribute of a nucleic acid that can be selected or detected. These properties include, but are not limited to, a property affecting binding to a polypeptide, a property conferred on a cell comprising a particular nucleic acid, a property affecting gene transcription (e.g., promoter strength, promoter recognition, promoter regulation, enhancer function), a property affecting RNA processing (e.g., RNA splicing, RNA stability, RNA conformation, and post-transcriptional modification), a property affecting translation (e.g., level, regulation, binding of mRNA to ribosomal proteins, post-translational modification).
  • a binding site for a transcription factor, polymerase, regulatory factor, etc., of a nucleic acid may be altered to produce desired characteristics or to identify undesirable characteristics.
  • polypeptide or grammatical equivalents thereof in the context of a polypeptide (including proteins), as used herein, refer to any characteristic or attribute of a polypeptide that can be selected or detected. These properties include, but are not limited to oxidative stability, substrate specificity, catalytic activity, enzymatic activity, thermal stability, alkaline stability, pH activity profile, resistance to proteolytic degradation, K M , k cat , k cat /k M ratio, protein folding, inducing an immune response, ability to bind to a ligand, ability to bind to a receptor, ability to be secreted, ability to be displayed on the surface of a cell, ability to oligomerize, ability to signal, ability to stimulate cell proliferation, ability to inhibit cell proliferation, ability to induce apoptosis, ability to be modified by phosphorylation or glycosylation, and/or ability to treat disease, etc.
  • screening has its usual meaning in the art.
  • a mutant nucleic acid or variant polypeptide encoded therefrom is provided and a property of the mutant nucleic acid or variant polypeptide, respectively, is assessed or determined.
  • the determined property of the mutant nucleic acid or variant polypeptide may be compared to a property of the corresponding precursor (parent) nucleic acid or to the property of the corresponding parent polypeptide, respectively.
  • the screening procedure for obtaining a nucleic acid or protein with an altered property depends upon the property of the starting material the modification of which the generation of the mutant nucleic acid is intended to facilitate.
  • the skilled artisan will therefore appreciate that the invention is not limited to any specific property to be screened for and that the following description of properties lists illustrative examples only. Methods for screening for any particular property are generally described in the art. For example, one can measure binding, pH, specificity, etc., before and after mutation, wherein a change indicates an alteration.
  • the screens are performed in a high-throughput manner, including multiple samples being screened simultaneously, including, but not limited to assays utilizing chips, phage display, and multiple substrates and/or indicators.
  • a screening process encompasses one or more selection steps in which variants of interest are enriched from a population of variants. Examples of these embodiments include the selection of variants that confer a growth advantage to the host organism, as well as phage display or any other method of display, where variants can be captured from a population of variants based on their binding or catalytic properties.
  • a library of variants is exposed to stress (e.g., heat, denaturation, etc.) and subsequently variants that are still intact are identified in a screen or enriched by selection. It is intended that the term encompass any suitable means for selection. Indeed, it is not intended that the present invention be limited to any particular method of screening.
  • modified nucleic acid sequence and “modified gene” are used interchangeably herein to refer to a nucleic acid sequence that includes a deletion, insertion or interruption of naturally occurring (i.e., wild-type) nucleic acid sequence.
  • the expression product of the modified nucleic acid sequence is a truncated protein (e.g., if the modification is a deletion or interruption of the sequence).
  • the truncated protein retains biological activity.
  • the expression product of the modified nucleic acid sequence is an elongated protein (e.g., modifications comprising an insertion into the nucleic acid sequence).
  • a nucleotide insertion in the nucleic acid sequence leads to a truncated protein (e.g., when the insertion results in the formation of a stop codon).
  • an insertion may result in either a truncated protein or an elongated protein as an expression product.
  • a “mutant” nucleic acid sequence typically refers to a nucleic acid sequence that has an alteration in at least one codon occurring in a host cell's wild-type sequence such that the expression product of the mutant nucleic acid sequence is a protein with an altered amino acid sequence relative to the wild-type protein.
  • the expression product may have an altered functional capacity (e.g., enhanced enzymatic activity).
  • alteration in substrate specificity refers to changes in the substrate specificity of an enzyme.
  • a change in substrate specificity is defined as a change in k cat and/or K m for a particular substrate, resulting from mutations of the enzyme or alteration of reaction conditions.
  • the substrate specificity of an enzyme is determined by comparing the catalytic efficiencies it exhibits with different substrates. These determinations find particular use in assessing the efficiency of mutant enzymes, as it is generally desired to produce variant enzymes that exhibit greater ratios of k cat /K m for substrates of interest. However, it is not intended that the present invention be limited to any particular substrate composition or substrate specificity.
  • surface property is used in reference to electrostatic charge, as well as properties such as the hydrophobicity and hydrophilicity exhibited by the surface of a protein.
  • net charge is defined as the sum of all charges present in a molecule.
  • Net charge changes are made to a parent protein molecule to provide a variant that has a net charge that differs from that of the parent molecule (i.e., the variant has a net charge that is not the same as that of the parent molecule). For example, substitution of a neutral amino acid with a negatively charged amino acid or a positively charged amino acid with a neutral amino acid results in net charge of ⁇ 1 with respect to the parent molecule. Substitution of a positively charged amino acid with a negatively charged amino acid results in a net charge of ⁇ 2 with respect to the parent.
  • Substitution of a neutral amino acid with a positively charged amino acid or a negatively charged amino acid with a neutral amino acid results in net charge of +1 with respect to the parent.
  • Substitution of a negatively charged amino acid with a positively charged amino acid results in a net charge of +2 with respect to the parent.
  • the net charge of a parent protein can also be altered by deletion and/or insertion of charged amino acids
  • thermostyrene and thermostable refer to proteases that retain a specified amount of enzymatic activity after exposure to identified temperatures over a given period of time under conditions prevailing during the proteolytic, hydrolyzing, cleaning or other process of the invention, while being exposed to altered temperatures. “Altered temperatures” encompass increased or decreased temperatures.
  • the proteases retain at least about 50%, about 60%, about 70%, about 75%, about 80%, about 85%, about 90%, about 92%, about 95%, about 96%, about 97%, about 98%, or about 99% proteolytic activity after exposure to altered temperatures over a given time period, for example, at least about 60 minutes, about 120 minutes, about 180 minutes, about 240 minutes, about 300 minutes, etc.
  • enhanced stability in the context of an oxidation, chelator, thermal and/or pH stable protease refers to a higher retained proteolytic activity over time as compared to other proteases (e.g., subtilisin proteases) and/or wild-type enzymes.
  • diminished stability in the context of an oxidation, chelator, thermal and/or pH stable protease refers to a lower retained proteolytic activity over time as compared to other proteases (e.g., subtilisin proteases) and/or wild-type enzymes.
  • cleaning activity refers to a cleaning performance achieved by a variant protease or reference protease under conditions prevailing during the proteolytic, hydrolyzing, cleaning, or other process of the invention.
  • cleaning performance of a variant protease or reference protease may be determined by using various assays for cleaning one or more various enzyme sensitive stains on an item or surface (e.g., a stain resulting from food, grass, blood, ink, milk, oil, and/or egg protein).
  • Cleaning performance of a variant or reference protease can be determined by subjecting the stain on the item or surface to standard wash condition(s) and assessing the degree to which the stain is removed by using various chromatographic, spectrophotometric, or other quantitative methodologies.
  • Exemplary cleaning assays and methods are known in the art and include, but are not limited to those described in WO 99/34011 and U.S. Pat. No. 6,605,458, both of which are herein incorporated by reference, as well as those cleaning assays and methods included in the Examples provided below.
  • cleaning effective amount of a variant protease or reference protease refers to the amount of protease that achieves a desired level of enzymatic activity in a specific cleaning composition. Such effective amounts are readily ascertained by one of ordinary skill in the art and are based on many factors, such as the particular protease used, the cleaning application, the specific composition of the cleaning composition, and whether a liquid or dry (e.g., granular, tablet, bar) composition is required, etc.
  • cleaning adjunct material refers to any liquid, solid, or gaseous material included in cleaning composition other than a variant protease of the invention.
  • the cleaning compositions of the present invention include one of more cleaning adjunct materials.
  • Each cleaning adjunct material is typically selected depending on the particular type and form of cleaning composition (e.g., liquid, granule, powder, bar, paste, spray, tablet, gel, foam, or other composition).
  • each cleaning adjunct material is compatible with the protease enzyme used in the composition.
  • enhanced performance in the context of cleaning activity refers to an increased or greater cleaning activity by an enzyme on certain enzyme sensitive stains such as egg, milk, grass, ink, oil, and/or blood, as determined by usual evaluation after a standard wash cycle and/or multiple wash cycles.
  • the term “diminished performance” in the context of cleaning activity refers to a decreased or lesser cleaning activity by an enzyme on certain enzyme sensitive stains such as egg, milk, grass or blood, as determined by usual evaluation after a standard wash cycle.
  • a comparative or reference protease e.g., commercially available proteases
  • OPTIMASETM protease Genencor
  • PURAFECTTM protease products Genencor
  • SAVINASETM protease Novozymes
  • BPN′-variants See e.g., U.S.
  • Cleaning performance can be determined by comparing the variant proteases of the present invention with reference subtilisin proteases in various cleaning assays concerning enzyme sensitive stains such as grass, blood, ink, oil, and/or milk as determined by usual spectrophotometric or analytical methodologies after standard wash cycle conditions.
  • the term “consumer product” means fabric and home care product.
  • the term “fabric and home care product” or “fabric and household care product” includes products generally intended to be used or consumed in the form in which they are sold and that are for treating fabrics, hard surfaces and any other surfaces, and cleaning systems all for the care and cleaning of inanimate surfaces, as well as fabric conditioner products and other products designed specifically for the care and maintenance of fabrics, and air care products, including: air care including air fresheners and scent delivery systems, car care, pet care, livestock care, personal care, jewelry care, dishwashing, fabric conditioning (including softening and/or freshening), laundry detergency, laundry and rinse additive and/or care, pre-treatment cleaning compositions, hard surface cleaning and/or treatment including floor and toilet bowl cleaners, glass cleaners and/or treatments, tile cleaners and/or treatments, ceramic cleaners and/or treatments, and other cleaning for consumer or institutional use.
  • the fabric and home care products are suitable for use on wounds and/or skin.
  • non-fabric and home care products refers to compositions that are added to other compositions to produce an end product that may be a fabric and home care product.
  • institutions refers to products suitable for use in institutions including but not limited to schools, hospitals, factories, stores, corporations, buildings, restaurants, office complexes and buildings, processing and/or manufacturing plants, veterinary hospitals, factory farms, factory ranches, etc.
  • cleaning and/or treatment composition is a subset of fabric and home care products that includes, unless otherwise indicated, compositions suitable for cleaning and/or treating items.
  • Such products include, but are not limited to, products for treating fabrics, hard surfaces and any other surfaces in the area of fabric and home care, including: air care including air fresheners and scent delivery systems, car care, dishwashing, fabric conditioning (including softening and/or freshening), laundry detergency, laundry and rinse additive and/or care, hard surface cleaning and/or treatment including floor and toilet bowl cleaners, granular or powder-form all-purpose or “heavy-duty” washing agents, especially cleaning detergents; liquid, gel or paste-form all-purpose washing agents, especially the so-called heavy-duty liquid types; liquid fine-fabric detergents; hand dishwashing agents or light duty dishwashing agents, especially those of the high-foaming type; machine dishwashing agents, including the various tablet, granular, liquid and rinse-aid types for household and institutional use: car or carpet shampoos
  • cleaning composition or “cleaning formulation” of the invention refers to any composition of the invention useful for removing or eliminating a compound (e.g., undesired compound) from an object, item or surface to be cleaned, including, but not limited to for example, a fabric, fabric item, dishware item, tableware item, glassware item, contact lens, other solid substrate, hair (shampoo) (including human or animal hair), skin (soap or and cream), teeth (mouthwashes, toothpastes), surface of an item or object (e.g., hard surfaces, such as the hard surface of a table, table top, wall, furniture item, floor, ceiling, non-dishware item, non-tableware item, etc.), filters, membranes (e.g., filtration membranes, including but not limited to ultrafiltration membranes), etc.
  • a compound e.g., undesired compound
  • surface of an item or object e.g., hard surfaces, such as the hard surface of a table, table top, wall, furniture item, floor, ceiling,
  • the term encompasses any material and/or added compound selected for the particular type of cleaning composition desired and the form of the product (e.g., liquid, gel, granule, spray, or other composition), as long as the composition is compatible with the protease and other enzyme(s) used in the composition.
  • the specific selection of cleaning composition materials are readily made by considering the surface, object, item, or fabric to be cleaned, and the desired form of the composition for the cleaning conditions during use.
  • Cleaning compositions and cleaning formulations include any composition that is suited for cleaning, bleaching, disinfecting, and/or sterilizing any object, item, and/or surface.
  • Such compositions and formulations include, but are not limited to for example, liquid and/or solid compositions, including cleaning or detergent compositions (e.g., liquid, tablet, gel, bar, granule, and/or solid laundry cleaning or detergent compositions and fine fabric detergent compositions; hard surface cleaning compositions and formulations, such as for glass, wood, ceramic and metal counter tops and windows; carpet cleaners; oven cleaners; fabric fresheners; fabric softeners; and textile, laundry booster cleaning or detergent compositions, laundry additive cleaning compositions, and laundry pre-spotter cleaning compositions; dishwashing compositions, including hand or manual dishwash compositions (e.g., “hand” or “manual” dishwashing detergents) and automatic dishwashing compositions (e.g., “automatic dishwashing detergents”).
  • cleaning or detergent compositions e.g., liquid, tablet, gel, bar,
  • Cleaning composition or cleaning formulations include, unless otherwise indicated, granular or powder-form all-purpose or heavy-duty washing agents, especially cleaning detergents; liquid, granular, gel, solid, tablet, or paste-form all-purpose washing agents, especially the so-called heavy-duty liquid (HDL) detergent or heavy-duty powder detergent (HDD) types; liquid fine-fabric detergents; hand or manual dishwashing agents, including those of the high-foaming type; hand or manual dishwashing, automatic dishwashing, or dishware or tableware washing agents, including the various tablet, powder, solid, granular, liquid, gel, and rinse-aid types for household and institutional use; liquid cleaning and disinfecting agents, including antibacterial hand-wash types, cleaning bars, mouthwashes, denture cleaners, car shampoos, carpet shampoos, bathroom cleaners; hair shampoos and/or hair-rinses for humans and other animals; shower gels and foam baths and metal cleaners; as well as cleaning auxiliaries, such as bleach additives and “stain-stick”
  • HDL heavy
  • fabric cleaning compositions include hand and machine laundry detergent compositions including laundry additive compositions and compositions suitable for use in the soaking and/or pretreatment of stained fabrics (e.g., clothes, linens, and other textile materials).
  • non-fabric cleaning compositions include non-textile (i.e., non-fabric) surface cleaning compositions, including, but not limited to for example, hand or manual or automatic dishwashing detergent compositions, oral cleaning compositions, denture cleaning compositions, and personal cleansing compositions.
  • the term “fabric and/or hard surface cleaning and/or treatment composition” is a subset of cleaning and treatment compositions that includes, unless otherwise indicated, granular or powder-form all-purpose or “heavy-duty” washing agents, especially cleaning detergents; liquid, gel or paste-form all-purpose washing agents, especially the so-called heavy-duty liquid types; liquid fine-fabric detergents; hand dishwashing agents or light duty dishwashing agents, especially those of the high-foaming type; machine dishwashing agents, including the various tablet, granular, liquid and rinse-aid types for household and institutional use; liquid cleaning and disinfecting agents, car or carpet shampoos, bathroom cleaners including toilet bowl cleaners; fabric conditioning products including softening and/or freshening that may be in liquid, solid and/or dryer sheet form; as well as cleaning auxiliaries such as bleach additives and “stain-stick” or pre-treat types, substrate-laden products such as dryer added sheets. All of such products which are applicable may be in standard, concentrated or even highly concentrated form even to
  • the term “detergent composition” or “detergent formulation” is used in reference to a composition intended for use in a wash medium for the cleaning of soiled or dirty objects, including particular fabric and/or non-fabric objects or items.
  • Such compositions of the present invention are not limited to any particular detergent composition or formulation.
  • the detergents of the invention comprise at least one variant protease of the invention and, in addition, one or more surfactants, transferase(s), hydrolytic enzymes, oxido reductases, builders (e.g., a builder salt), bleaching agents, bleach activators, bluing agents, fluorescent dyes, caking inhibitors, masking agents, enzyme activators, antioxidants, and/or solubilizers.
  • a builder salt is a mixture of a silicate salt and a phosphate salt, preferably with more silicate (e.g., sodium metasilicate) than phosphate (e.g., sodium tripolyphosphate).
  • silicate e.g., sodium metasilicate
  • phosphate e.g., sodium tripolyphosphate
  • Some compositions of the invention such as, but not limited to, cleaning compositions or detergent compositions, do not contain any phosphate (e.g., phosphate salt or phosphate builder).
  • bleaching refers to the treatment of a material (e.g., fabric, laundry, pulp, etc.) or surface for a sufficient length of time and/or under appropriate pH and/or temperature conditions to effect a brightening (i.e., whitening) and/or cleaning of the material.
  • a material e.g., fabric, laundry, pulp, etc.
  • chemicals suitable for bleaching include, but are not limited to, for example, ClO 2 , H 2 O 2 , peracids, NO 2 , etc.
  • wash performance of a protease refers to the contribution of a variant protease to washing that provides additional cleaning performance to the detergent as compared to the detergent without the addition of the variant protease to the composition. Wash performance is compared under relevant washing conditions. In some test systems, other relevant factors, such as detergent composition, sud concentration, water hardness, washing mechanics, time, pH, and/or temperature, can be controlled in such a way that condition(s) typical for household application in a certain market segment (e.g., hand or manual dishwashing, automatic dishwashing, dishware cleaning, tableware cleaning, fabric cleaning, etc.) are imitated.
  • condition(s) typical for household application in a certain market segment e.g., hand or manual dishwashing, automatic dishwashing, dishware cleaning, tableware cleaning, fabric cleaning, etc.
  • relevant washing conditions is used herein to indicate the conditions, particularly washing temperature, time, washing mechanics, sud concentration, type of detergent and water hardness, actually used in households in a hand dishwashing, automatic dishwashing, or laundry detergent market segment.
  • improved wash performance is used to indicate that a better end result is obtained in stain removal under relevant washing conditions, or that less variant protease, on weight basis, is needed to obtain the same end result relative to the corresponding wild-type or starting parent protease.
  • the term “disinfecting” refers to the removal of contaminants from the surfaces, as well as the inhibition or killing of microbes on the surfaces of items. It is not intended that the present invention be limited to any particular surface, item, or contaminant(s) or microbes to be removed.
  • inorganic filler salts are conventional ingredients of detergent compositions in powder form.
  • the filler salts are present in substantial amounts, typically about 17 to about 35% by weight of the total composition.
  • the filler salt is present in amounts not exceeding about 15% of the total composition.
  • the filler salt is present in amounts that do not exceed about 10%, or more preferably, about 5%, by weight of the composition.
  • the inorganic filler salts are selected from the alkali and alkaline-earth-metal salts of sulfates and chlorides.
  • the filler salt is sodium sulfate.
  • the position of an amino acid residue in a given amino acid sequence is typically numbered herein using the numbering of the position of the corresponding amino acid residue of the B. amyloliquefaciens subtilisin BPN′ amino acid sequence shown in SEQ ID NO:1.
  • the B. amyloliquefaciens subtilisin BPN′ amino acid sequence of SEQ ID NO:1 thus serves as a reference sequence.
  • a given amino acid sequence such as a variant protease amino acid sequence described herein, can be aligned with the BPN′ sequence (SEQ ID NO:1) using an alignment algorithm as described herein, and an amino acid residue in the given amino acid sequence that aligns (preferably optimally aligns) with an amino acid residue in the BPN′ sequence can be conveniently numbered by reference to the corresponding amino acid residue in the subtilisin BPN′ sequence.
  • subtilisin variant protease can be described as a variant protease of the GG36 protease shown in SEQ ID NO:2
  • polypeptides of the invention include isolated, recombinant, substantially pure, or non-naturally occurring variant protease polypeptides, including for example, variant subtilisin polypeptides, having enzymatic activity (e.g., proteolytic activity).
  • polypeptides of the invention are useful in cleaning applications and may be incorporated into cleaning compositions that are useful in methods of cleaning an item or a surface (e.g., of surface of an item) in need of cleaning.
  • a variant protease of the invention comprises a “variant subtilisin.” In some embodiments, the invention provides a “ Bacillus sp. variant protease.” In some embodiments, the invention provides a “ Bacillus sp. variant subtilisin.”
  • the invention includes an isolated, recombinant, substantially pure, or non-naturally occurring variant protease having proteolytic activity, which polypeptide comprises a polypeptide sequence having at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, at least about 99.5%, or 100% sequence identity to the amino acid sequences encoding the variant proteases provided herein.
  • the variant protease polypeptides of the invention have enzymatic activities (e.g., proteolytic activities) and thus are useful in cleaning applications, including but not limited to, methods for cleaning dishware items, tableware items, fabrics, and items having hard surfaces (e.g., the hard surface of a table, table top, wall, furniture item, floor, ceiling, etc.).
  • enzymatic activity e.g., protease activity
  • a variant protease polypeptide of the invention can be determined readily using procedures well known to those of ordinary skill in the art.
  • the Examples presented infra describe methods for evaluating the enzymatic activity, cleaning performance, and/or washing performance.
  • the performance of variant proteases of the invention in removing stains e.g., a proteinaceous stain
  • cleaning hard surfaces e.g., a proteinaceous stain
  • cleaning laundry, dishware or tableware item(s) can be readily determined using procedures well known in the art and/or by using procedures set forth in the Examples.
  • a polypeptide of the invention can be subject to various changes, such as one or more amino acid insertions, deletions, and/or substitutions, either conservative or non-conservative, including where such changes do not substantially alter the enzymatic activity of the polypeptide.
  • a nucleic acid of the invention can also be subject to various changes, such as one or more substitutions of one or more nucleic acids in one or more codons such that a particular codon encodes the same or a different amino acid, resulting in either a silent variation (e.g., mutation in a nucleotide sequence results in a silent mutation in the amino acid sequence, for example when the encoded amino acid is not altered by the nucleic acid mutation) or non-silent variation, one or more deletions of one or more nucleic acids (or codons) in the sequence, one or more additions or insertions of one or more nucleic acids (or codons) in the sequence, and/or cleavage of or one or more truncations of one
  • a nucleic acid of the invention can also be modified to include one or more codons that provide for optimum expression in an expression system (e.g., bacterial expression system), while, if desired, said one or more codons still encode the same amino acid(s).
  • an expression system e.g., bacterial expression system
  • the present invention provides a genus of polypeptides comprising variant protease polypeptides having the desired enzymatic activity (e.g., protease activity or cleaning performance activity) which comprise sequences having the amino acid substitutions described herein and also which comprise one or more additional amino acid substitutions, such as conservative and non-conservative substitutions, wherein the polypeptide exhibits, maintains, or approximately maintains the desired enzymatic activity (e.g., protease activity or subtilisin activity, as reflected in the cleaning activity or performance of the variant protease).
  • Amino acid substitutions in accordance with the invention may include, but are not limited to, one or more non-conservative substitutions and/or one or more conservative amino acid substitutions.
  • a conservative amino acid residue substitution typically involves exchanging a member within one functional class of amino acid residues for a residue that belongs to the same functional class (identical amino acid residues are considered functionally homologous or conserved in calculating percent functional homology).
  • a conservative amino acid substitution typically involves the substitution of an amino acid in an amino acid sequence with a functionally similar amino acid. For example, alanine, glycine, serine, and threonine are functionally similar and thus may serve as conservative amino acid substitutions for one another. Aspartic acid and glutamic acid may serve as conservative substitutions for one another. Asparagine and glutamine may serve as conservative substitutions for one another. Arginine, lysine, and histidine may serve as conservative substitutions for one another. Isoleucine, leucine, methionine, and valine may serve as conservative substitutions for one another. Phenylalanine, tyrosine, and tryptophan may serve as conservative substitutions for one another.
  • amino acids can be grouped by similar function or chemical structure or composition (e.g., acidic, basic, aliphatic, aromatic, sulfur-containing).
  • an aliphatic grouping may comprise: Glycine (G), Alanine (A), Valine (V), Leucine (L), Isoleucine (I).
  • the invention provides an isolated or recombinant variant protease polypeptide (e.g., variant subtilisin) having proteolytic activity, said variant protease polypeptide comprising an amino acid sequence having at least about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 99.5% sequence identity to the amino acid sequence of SEQ ID NO:2.
  • variant protease polypeptide e.g., variant subtilisin
  • a conservative substitution of one amino acid for another in a variant protease of the invention is not expected to alter significantly the enzymatic activity or cleaning performance activity of the variant protease.
  • Enzymatic activity or cleaning performance activity of the resultant protease can be readily determined using the standard assays and the assays described herein.
  • Conservatively substituted variations of a polypeptide sequence of the invention include substitutions of a small percentage, sometimes less than about 25%, about 20%, about 15%, about 14%, about 13%, about 12%, about 11%, about 10%, about 9%, about 8%, about 7%, or about 6% of the amino acids of the polypeptide sequence, or less than about 5%, about 4%, about 3%, about 2%, or about 1%, of the amino acids of the polypeptide sequence, with a conservatively selected amino acid of the same conservative substitution group.
  • polypeptides of the invention may have cleaning abilities that may be compared to known proteases, including known subtilisins.
  • exemplary known subtilisin proteases include, but are not limited to, for example, B. lentus subtilisin GG36, B. amyloliquefaciens subtilisin BPN′, B. amyloliquefaciens subtilisin BPN′-Y217L, and B. clausii PB92.
  • the amino acid sequence of the mature B. lentus subtilisin GG36 protein is:
  • the amino acid sequence of mature B. amyloliquefaciens subtilisin BPN′ protein is:
  • the present invention provides polypeptides comprising subtilisin variants of Bacillus subtilisin, wherein the subtilisin variant is a mature form having proteolytic activity and comprises an amino acid sequence comprising a combination of amino acid substitutions selected from: X1R, X2W, X2M, X2R, X2A, X2S, X3R, X4R, X4C, X4S, X8A, X9F, X9W, X9A, X10S, X10M, X10H, X10A, X12R, X12F, X14K, X14F, X14Q, X15R, X15F, X16S, X17R, X17M, X17F, X18R, X18K, X20F, X20R, X20K, X22Y, X22A, X22R, X22V, X22Q,
  • the present invention further provides polypeptides comprising subtilisin variants of a Bacillus subtilisin, wherein the subtilisin variant is a mature form having proteolytic activity and comprises an amino acid sequence comprising a combination of amino acid substitutions selected from: X165, X18R, X20R, X22A, X24R, X43R/D, X45T, X76D, X101A, X103G, X104L, X111V, X128N, X148I, X230E, X242R, and X249R, wherein the amino acid positions of the subtilisin variant are numbered by correspondence with the amino acid sequence of B. amyloliquefaciens subtilisin BPN′ set forth as SEQ ID NO:1.
  • the present invention also provides polypeptides comprising subtilisin variants of a Bacillus subtilisin, wherein the subtilisin variant is a mature form having proteolytic activity and comprises an amino acid sequence comprising a combination of amino acid substitutions selected from: X1R, X230E, X271L, X115R, X20R, X249R, X235F, X27V/F/L, X75E, X82R, X18R, X269R, X43D, X43R, X76D, X45T, X212F, X242R, X24R, X78R, X9A, X22R, X121E, X244R, X28E, X30E, X4R, and X241R, wherein the amino acid positions of the subtilisin variant are numbered by correspondence with the amino acid sequence of B. amyloliquefaciens subtilisin BPN′ set
  • the present invention further provides polypeptides comprising subtilisin variants of a Bacillus subtilisin, wherein the subtilisin variant is a mature form having proteolytic activity and comprises an amino acid sequence comprising a combination of amino acid substitutions selected from: X062E-X158E, X103G-X158E, X128N-X158E, X016S-X158E, X104L-X158E, X089P-X158E, X111V-X158E, X022A-X158E, X101A-X158E, X148I-X158E, X129E-X158E, X022A-X089P, X016S-X089P, X062E-X089P, X062E-X271F, X158E-X271F, X186H-X271F, X129E-X271F, X111V-X271F, X209
  • the present invention also provides polypeptides comprising subtilisin variants of a Bacillus subtilisin, wherein the subtilisin variant is a mature form having proteolytic activity and comprises an amino acid sequence comprising a combination of amino acid substitutions selected from: X018R-X241R, X020R-X241R, X024R-X241R, X009A-X241R, X020R-X241R, X004R-X241R, X043R-X241R, X078R-X241R, X022R-X241R, X115R-X241R, X001R-X241R, X212F-X241R, X082R-X241R, X018R-X244R, X024R-X244R, X078R-X244R, X020R-X244R, X212F-X244
  • subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X020R-X-43R, X020K-X062E, X024F-X116L, X020K-X024F, X024R-X174T, X024R-X118R, X024R-X235F, X024R-X086R, X024R-X086W, X078R-X118R, X033S-X118R, X033S-X235F, X209A-X241R, X020R-X076D, X018R-X245R, X024R-X045T, X232V-X245R, X118R-X172V, X118R-X194T, X008T-X024R
  • subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X020R-X076D, X024R-X045T, X230E-X249R, X018R-X045T, X018R-X245R, X101G-X232V, X024R-X232V, X232V-X245R, X024R-X101G, X018R-X104I, X018R-X103A, X101G-X249R, X232V-X249R, X103A-X232V, X076D-X245R, X101G-X104I, X104I-X232V, X076D-X249R, X024R-X076D, X024F-X116L, X020K
  • subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X004R-X009A-X020R-X242R, X020R-X043R-X241R, X020R-X242R-X269R, X004R-X009A-X020R-X043R, X004R-X020R-X249R, X018R-X024R-X244R, X009A-X022R-X212F-X241R, X020R-X043R-X269R, X018R-X024R-X242R, X004R-X009A-X043R-X241R, X020R-X043R-X244R, X020R-X022R-X24
  • subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X018R-X020R-X043D-X045T-X230E, X018R-X043R-X045T-X242R-X249R, X024R-X043D-X249R, X018R-X020R-X045T, X020R-X024R-X076D-X249R, X024R-X043R-X230E-X242R, X018R-X024R-X043D-X230E, X020R-X076D, X018R-X024R-X043D-X076D-X249R, X024R-X043R-X076D-X249R, X024R-X043R-X076D-X249R
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X101G-X103A-X104I-X232V-X236H-X245R-X252K, X101G-X103A-X104I-X232V-X245R-X248R, X101G-X103A-X104I-X159R-X232V-X245R-X248D, X101G-X103A-X104I-X159D-X232V-X245R-X248R, X101G-X103A-X104I-X232V-X245R, X101G-X103A-X104I-X232V-X245R, X101G-X103A-X104I-X159D-X232V-X245R, and X101G-X103A-X104I-X232
  • subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X101G-X103A-X104I-X129E-X188D-X232V-X238R-X245R-X248D, X024R-X101G-X103A-X104I-X129E-X158E-X188D-X232V-X245R-X248D-X249R, X022A-X101G-X103A-X104I-X129E-X158E-X188D-X232V-X245R-X248D-X249R, X022A-X024R-X101G-X103A-X104I-X129E-X158E-X188D-X232V-X245R-X248D-X249R, X024R-X101G-X103A-X104I-X129E-X158E-X188D-
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X022A-X024R-X101G-X103A-X104I-X158E-X232V-X245R-X248D-X249R, X022A-X024R-X101G-X103A-X104I-X129E-X232V-X245R-X248D-X249R, X024R-X101G-X103A-X104I-X158E-X159E-X232V-X238R-X245R-X248D, X024R-X101G-X103A-X104I-X232V-X245R-X248D-X249R, X101G-X103A-X104I-X158E-X232V-X245R-X248D-X2
  • subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X104L-X128N-X158E-X186H-X249R, X128N-X158E-X188D-X249R, X062E-X128N-X158E-X159E-X271F, X062E-X158E-X188D-X249R-X271F, X062E-X158E-X186H-X249R-X271F, X128N-X158E-X188D-X209E-X271F, X062E-X159E-X188D-X249R, X016S-X062E-X158E-X186H-X249R, X062E-X158E-X159E-X249R, X101A-X128
  • subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X001R-X101G-X103A-X104I-X232V-X245R, X004R-X101G-X103A-X104I-X232V-X245R, X043R-X101G-X103A-X104I-X232V-X245R-X271L, X078R-X101G-X103A-X104I-X232V-X245R, X004R-X043R-X101G-X103A-X104I-X232V-X245R, X018R-X043R-X101G-X103A-X104I-X232V-X245R, X020R-X101G-X103A-X104I-X232V-X245R, X101G-
  • subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X020R-X022W-X078R-X101A-X103A-X104I-X116S-X213A-X215F-X232V-X245R, X018R-X078R-X101G-X103A-X104I-X232V-X245R, X024R-X045T-X101G-X103A-X104I-X232V-X245R-X269R, X020R-X022W-X078R-X101G-X103A-X104I-X116A-X232V-X245R, X020R-X22W-X101G-X103A-X104I-X232V-X245R, X018R-X043R-X101G-X
  • subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X018R-X024R-X043R-X076D-X249R-X269R, X018R-X022R-X024R-X043R-X076D-X249R, X018R-X043D-X101G-X103A-X104I-X232V-X245R, X020R-X043D-X101G-X103A-X104I-X232V-X245R, X043D-X101G-X103A-X104I-X232V-X245R, X043D-X101G-X103A-X104I-X232V-X245R-X269R, X043D-X078R-X101G-X103A-X104I-X232V-X245R, X043R
  • subtilisin variants wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X020R-X101A-X103A-X104I-X118R-X232V-X245R, X020R-X024R-X116A-X213A, X043R-X101A-X116A-X215F-X269R, X024R-X043R-X101A-X116A, X024R-X043R-X101A-X116A-X215F-X269R, X020R-X101G-X103A-X104I-X215F-X232V-X245R, X043R-X101A-X269R, X024R-X043R-X116A-X213A-X269R, X020R-X024R-X0024R-X0
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X043R-X076D-X101A-X103A-X104I-X158E-X188D-X232V-X245R-X248D-X249R-X271F, X024R-X043R-X076D-X101A-X103A-X104I-X158E-X188D-X217E-X232V-X245R-X248D-X249R, X101A-X103A-X104I-X158E-X188D-X232V-X245R-X248D-X249R, X101A-X103A-X104I-X158E-X188D-X232V-X245R-X248D-X249R-X271F-X271F, X
  • subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X022A-X101G-X103A-X104I-X159D-X217E-X232V-X245R-X248D-X271F, X022A-X043R-X101G-X103A-X104I-X159D-X188D-X217E-X232V-X245R-X248D-X271F, X022A-X101G-X103A-X104I-X159D-X188D-X232V-X245R-X248D-X271F, X043R-X101A-X103A-X104I-X158E-X188D-X217E-X232V-X245R-X248D-X249R, X043R-X076D-X
  • subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X017R-X022A-X076D-X101G-X103A-X104I-X159D-X188D-X232V-X245R-X248D-X271F, X022A-X043R-X101G-X103A-X104I-X159D-X232V-X245R-X248D-X271F, X022A-X101G-X103A-X104I-X159D-X188D-X232V-X245R-X248D-X249R-X271F, X017R-X022A-X076D-X101G-X103A-X104I-X159D-X232V-X245R-X248D-X271F, X022A-X076D-X101G-X103A-X
  • subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X101S-X103A-X104I-X158E-X188D-X232V-X245R-X248D-X249R, X101S-X103G-X104V-X158E-X188D-X232V-X245R-X248D-X249R, X101G-X103S-X104I-X158E-X188D-X232V-X245R-X248D-X249R, X101A-X103A-X104I-X158E-X188D-X232V-X245R-X248D-X249R, X101A-X103A-X104I-X158E-X188D-X232V-X245R-X248D-X249R, X101A-X103A-X104L-X158E-X188D-X
  • subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X026F-X051W-X104L-X106E, X026F-X031F-X078N-X102A-X160D, X020K-X100S-X116L-X158E-X166D-X243F, X033S-X043W-X218D-X239G-X243F, X022L-X038F-X048R-X062E-X100S-X186K, X101D-X103N-X116L-X144R-X215D, X104L-X105T-X213A-X217E-X256N, X043W-X101D-X212M-X243F, X026F-X048R-X105T-X213A-X213A-X213A-X2213A-
  • subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X022A-X024R-X101D-X103A-X104I-X118R-X159D-X188D-X232V-X248D-X271F, X022A-X024R-X103A-X104I-X129E-X159D-X188D-X232V-X248D-X271F, X022A-X024R-X103A-X104I-X118R-X159D-X188D-X217D-X232V-X248D, X022A-X024R-X101D-X103A-X104I-X118R-X129E-X159D-X188D-X232V-X245R-X248D, X022A-X024R-X101D-X-X103A-X104I-X118R-X
  • subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X020K-X024F-X062E-X188D-X239G, X024F-X062E-X116L-X239G, X020K-X023A-X062E-X188D, X020K-X023A-X024F-X062E-X118R-X188D-X213A, X020K-X043W-X062E-X116L-X188D-X213A-X239G, X023A-X062E-X116L-X118R, X023A-X024F-X062E-X116L-X118R, X024F-X116L, X024F-X062E-X188D-X213A, X020K-X043W-X062E-
  • subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X020K-X023A-X043W-X118R-X128I-X129E-X159D-X188D, X024F-X118R-X128I-X129E-X159D, X020K-X024F-X062E-X116L-X118R-X188D, X020K-X062E-X116L-X118R-X188D, X062E-X116L-X118R-X213A, X020K-X023A-X062E-X116L-X188D, X062E-X116L-X118R-X188D, X020K-X062E-X116L-X213A, X020K-X023A-X062E-X116L-X188D, X062E-
  • subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X087R-X101G-X103A-X104I-X109R-X212P-X232V-X245R-X271V, X101G-X103A-X104I-X109R-X232V-X245R, X101G-X103A-X104I-X109R-X212P-X232V-X245R-X271V, X101G-X103A-X104I-X109R-X212P-X232V-X245R, X076D-587R-X103A-X104I-X212P-X271V, X076D-X103A-X104I-X109R, X076D-X103A-X104I-X109R, X076D-X103A-X104I-X212P-X271V, X076D-
  • subtilisin variants wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X024R-X086W-X118R, X024R-X078R-X086W-X243F, X024R-X033S-X086S-X087N-X209A, X033S-X118R, X024R-X078R-X086W-X118R-X270T, X024R-X033S-X086W-X118R, X078R-X086W-X243F, X033S-X078R-X086W-X118R-X209A, X033S-X078R-X209A, X086W-X118R-X243F, X024R-X086W, X078R-X086W-X243F, X0
  • subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X020R-X087D-X101G-X103A-X104I-X232V-X245R, X020R-X101G-X103A-X104I-X150L-X232V-X245R, X018R-X020R-X024R-X076D-X087D-X249R, X018R-X020R-X024R-X076D-X150L-X249R, X018R-X024R-X043R-X076D-X087D-X249R, X018R-X024R-X043R-X076D-X087D-X249R, X018R-X024R-X043R-X076D-X150L-X249R, X018R-
  • subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X024R-X101G-X103A-X104I-X129Q-X158E-X188D-X217E-X232V-X245R-X248D-X249R, X024R-X101G-X103A-X104I-X130A-X158E-X183D-X188D-X232V-X245R-X248D-X249R, X024R-X101G-X103A-X104I-X129Q-X158E-X183D-X188D-X232V-X245R-X248D-X249R, X101G-X103A-X104I-X130A-X158E-X188D-X232V-X245R-X248D-X249R, X101G-X103A-X104I-X130A-X
  • subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X101G-X103A-X104I-X232V-X222Q-X245R, X101G-X103A-X104I-X158E-X188D-X222S-X232V-X245R-X248D-X249R, X101G-X103A-X104I-X158E-X188D-X222Q-X232V-X245R-X248D-X249R, X076D-X101G-X103A-X104I-X232V-X222Q-X245R, X101G-X103A-X104I-X232V-X222S-X245R, X076D-X101G-X103A-X104I-X232V-X222S-X245R, X076D-X101G-X103A-X104I-X232
  • subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: X024R-X101G-X103A-X104I-X128L-X129Q-X158E-X188D-X232V-X245R-X248D-X249R, X101G-X103A-X104I-X130A-X158E-X188D-X232V-X245R-X248D-X249R, X024R-X101G-X103A-X104I-X158E-X188D-X232V-X245R-X248D-X249R, X101G-X103A-X104I-X128L-X129Q-X158E-X188D-X232V-X245R-X248D-X249R, X101G-X103A-X104I-X129Q, X158E-X188D-X232V-
  • the present invention further provides polypeptides comprising subtilisin variants of a Bacillus subtilisin, wherein the subtilisin variant is a mature form having proteolytic activity and comprises an amino acid sequence comprising a combination of amino acid substitutions selected from: X101G-X103A-X104I, X22A-X101A-X209E, S103G-L111V-G159E, X22A-X103G-X159E, X22A-X111V-X159E, X22A-X128N-X271F-X209E, X22A-X103G-X111V, X62E-X111V-X128N, X22A-X111V-X128N, X22A-X62E-X111V, X101A-X103G-X104L-X188D, X101G-X103A-X104I-X159D, X101A-X103G-X104L-X128N,
  • the present invention further provides polypeptides comprising subtilisin variants of a Bacillus subtilisin, wherein the subtilisin variant is a mature form having proteolytic activity and comprises an amino acid sequence comprising a combination of amino acid substitutions selected from: X103A-X104I-X159D-X232V-X236H-X245R-X248D-X252K, X101G-X104I-X159D-X232V-X236H-X245R-X248D-X252K, X101G-X103A-X159D-X232V-X236H-X245R-X248D-X252K, X101G-X103A-X104L-X232V-X236H-X245R-X248D-X252K, X101G-X103A-X104L-X232V-X236H-X245R-X248D-X252K, X101G-X103
  • the present invention further provides polypeptides comprising subtilisin variants of a Bacillus subtilisin, wherein the subtilisin variant is a mature form having proteolytic activity and comprises an amino acid sequence comprising a combination of amino acid substitutions selected from: X101G-X103A-X104I-X159D-X232V-X245R-X248D, X101G-X103A-X104I-X159D-X232V-X245R-X248D-X271F, X101G-X103A-X104I-X159D-X232V-X245R-X248D-X238R, X101G-X103A-X104I-X159D-X232V-X245R-X248D-X248R, X101G-X103A-X104I-X159D-X232V-X245R-X248D-X248R, X101G-X103A-X104I-X159D-
  • the present invention further provides polypeptides comprising subtilisin variants of a Bacillus subtilisin, wherein the subtilisin variant is a mature form having proteolytic activity and comprises an amino acid sequence comprising a combination of amino acid substitutions selected from: X20R-X43R-X249R, X20R-X22R-X43R, X20R-X43R-X242R, X20R-X43R-X271L, X20R-X43R-X244R, X20R-X24R-X43R-X242R, X9A-X22R-X78R-X212F-X241R, X9A-X20R-X43R-X212F, X9A-X43R-X212F, X20R-X43R-X212F, X20R-X22R-X43R-X212F, X24R-X78R-X212F, X9A-X43R-X
  • the present invention further provides polypeptides comprising subtilisin variants of a Bacillus subtilisin, wherein the subtilisin variant is a mature form having proteolytic activity and comprises an amino acid sequence comprising a combination of amino acid substitutions selected from: X101G-X103A-X104I-X232V-X245R-X248D, X101G-X103A-X104I-X159D-X232V-X245R, X101G-X103A-X104I-X159R-X232V-X245R-X248D, X101G-X103A-X104I-X159D-X232V-X245R-X248R, X101G-X103A-X104I-X232V-X245R, X101G-X103A-X104I-X232V-X245R, X101G-X103A-X104I-X232V-X245R, X101G-X103A-X104
  • the present invention further provides polypeptides comprising subtilisin variants of a Bacillus subtilisin, wherein the subtilisin variant is a mature form having proteolytic activity and comprises an amino acid sequence comprising a combination of amino acid substitutions selected from: X16S, X22A, X24R, X62E, X76D, X89P, X101A/G, X103G/A, X104L/I, X111V, X128N, X129E, X232V, X148I, X158E, X159D/E, X166D, X186H, X188D, X209E, X236H, X238R, X245R, X248D/R, X249R, X252K/R, X253R, and X271F, wherein the amino acid positions of the subtilisin variant are numbered by correspondence with the amino acid sequence of B. amylo
  • the present invention further provides polypeptides comprising subtilisin variants of a Bacillus subtilisin, wherein the subtilisin variant is a mature form having proteolytic activity and comprises an amino acid sequence comprising a combination of amino acid substitutions selected from: N062E-A158E, S103G-A158E, S128N-A158E, A016S-A158E, V104L-A158E, E089P-A158E, L111V-A158E, T022A-A158E, S101A-A158E, L148I-A158E, P129E-A158E, T022A-E089P, A016S-E089P, N062E-E089P, N062E-E271F, A158E-E271F, R186H-E271F, P129E-E271F, L111V-E271F, Y209E-E271F, A016S-E271F, S188
  • the present invention further provides polypeptides comprising subtilisin variants having proteolytic activity comprising an amino acid sequence comprising a combination of amino acid substitutions selected from: N018R-W241R, G020R-W241R, S024R-W241R, S009A-W241R, G020R-W241R, V004R-W241R, N043R-W241R, S078R-W241R, T022R-W241R, G115R-W241R, A001R-W241R, S212F-W241R, L082R-W241R, N018R-V244R, S024R-V244R, S078R-V244R, G020R-V244R, S212F-V244R, S009A-V244R, L082R-V244R, A001R-V244R, N043R-V244R
  • subtilisin variants wherein said subtilisin variant is a mature form having proteolytic activity and comprises an amino acid sequence comprising a combination of amino acid substitutions selected from: G020R-N043R, N062E-A158E, S103G-A158E, S128N-A158E, A016S-A158E, V104L-A158E, E089P-A158E, L111V-A158E, T022A-A158E, S101A-A158E, L148I-A158E, P129E-A158E, T022A-E089P, A016S-E089P, N062E-E089P, N062E-E271F, A158E-E271F, R186H-E271F, P129E-E271F, L111V-E271F, Y209E-E271F, A016S-E271F, S188D-E271
  • the present invention further provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: G020R-N043R, G020K-N062E, S024F-N116L, G020K-S024F, S024R-A174T, S024R-G118R, S024R-K235F, S024R-P086R, S024R-P086W, S078R-G118R, T033S-G118R, T033S-K235F, Y209A-W241R, G020R-N076D, N018R-Q245R, S024R-R045T, A232V-Q245R, G118R-A172V, G118R-A194T, 1008T-S024R, K235F-N243F, N018R-S103A, N
  • the present invention further provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: G020R-N076D, S024R-R045T, A230E-H249R, N018R-R045T, N018R-Q245R, S101G-A232V, S024R-A232V, A232V-Q245R, S024R-S101G, N018R-V104I, N018R-S103A, S101G-H249R, A232V-H249R, S103A-A232V, N076D-Q245R, S101G-V104I, V104I-A232V, N076D-H249R, S024R-N076D, S024F-N116L, G020K-S024F, G020K-N062E, T033S
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: V004R-S009A-G020R-S242R, G020R-N043R-W241R, G020R-S242R-N269R, V004R-S009A-G020R-N043R, V004R-G020R-H249R, N018R-S024R-V244R, S009A-T022R-S212F-W241R, G020R-N043R-N269R, N018R-S024R-S242R, V004R-S009A-N043R-W241R, G020R-N043R-V244R, G020R-T022R-S242R, V004R-G020
  • subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: N018R-G020R-N043D-R045T-A230E, N018R-N043R-R045T-S242R-H249R, S024R-N043D-H249R, N018R-G020R-R045T, G020R-S024R-N076D-H249R, S024R-N043R-A230E-S242R, N018R-S024R-N043D-A230E, G020R-N076D, N018R-S024R-N043D-N076D-H249R, S024R-N043R-N076D-H249R, N018R-S024R-R045T-S
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: S101G-S103A-V104I-A232V-Q236H-Q245R-N252K, S101G-S103A-V104I-A232V-Q245R-N248R, S101G-S103A-V104I-G159R-A232V-Q245R-N248D, S101G-S103A-V104I-G159D-A232V-Q245R-N248R, S101G-S103A-V104I-A232V-Q245R, S101G-S103A-V104I-G159D-A232V-Q245R, and S101G-S103A-V104I-A232V-Q245R-N248D, wherein the amino acid positions of the subtilisin variant are numbered by correspondence
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: S101G-S103A-V104I-P129E-S188D-A232V-N238R-Q245R-N248D, S024R-S101G-S103A-V104I-P129E-A158E-S188D-A232V-Q245R-N248D-H249R, T022A-S101G-S103A-V104I-P129E-A158E-S188D-A232V-Q245R-N248D-H249R, T022A-S024R-S101G-S103A-V104I-P129E-A158E-S188D-A232V-Q245R-N248D-H249R, S024R-S101G-S103A-V104I-P129
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: T022A-S024R-S101G-S103A-V104I-A158E-A232V-Q245R-N248D-H249R, T022A-S024R-S101G-S103A-V104I-P129E-A232V-Q245R-N248D-H249R, S024R-S101G-S103A-V104I-A158E-G159E-A232V-N238R-Q245R-N248D, S024R-S101G-S103A-V104I-A232V-Q245R-N248D-H249R, S101G-S103A-V104I-A158E-A232V-Q245R-N248D-H249R, S101
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: V104L-S128N-A158E-R186H-H249R, S128N-A158E-S188D-H249R, N062E-S128N-A158E-G159E-E271F, N062E-A158E-S188D-H249R-E271F, N062E-A158E-R186H-H249R-E271F, S128N-A158E-S188D-Y209E-E271F, N062E-G159E-S188D-H249R, A016S-N062E-A158E-R186H-H249R, N062E-A158E-G159E-H249R, S101A-S128N-A158E-Y209
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: A001R-S101G-S103A-V104I-A232V-Q245R, V004R-S101G-S103A-V104I-A232V-Q245R, N043R-S101G-S103A-V104I-A232V-Q245R-E271L, S078R-S101G-S103A-V104I-A232V-Q245R, V004R-N043R-S101G-S103A-V104I-A232V-Q245R, N018R-N043R-S101G-S103A-V104I-A232V-Q245R, G020R-S101G-S103A-V104I-A232V-Q245R, S101G-S103A-V104I
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: G020R-T022W-S078R-S101A-S103A-V104I-N116S-T213A-A215F-A232V-Q245R, N018R-S078R-S101G-S103A-V104I-A232V-Q245R, S024R-R045T-S101G-S103A-V104I-A232V-Q245R-N269R, G020R-T022W-S078R-S101G-S103A-V104I-N116A-A232V-Q245R, G020R-T22W-S101G-S103A-V104I-A232V-Q245R, N018R-N043R-S101G-S103A-V104
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: N018R-S024R-N043R-N076D-H249R-N269R, N018R-T022R-S024R-N043R-N076D-H249R, N018R-N043D-S101G-S103A-V104I-A232V-Q245R, G020R-N043D-S101G-S103A-V104I-A232V-Q245R, N043D-S101G-S103A-V104I-A232V-Q245R, N043D-S101G-S103A-V104I-A232V-Q245R-N269R, N043D-S078R-S101G-S103A-V104I-A232V-Q2
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: G020R-S101A-S103A-V104I-G118R-A232V-Q245R, G020R-S024R-N116A-T213A, N043R-S101A-N116A-A215F-N269R, S024R-N043R-S101A-N116A, S024R-N043R-S101A-N116A-A215F-N269R, G020R-S101G-S103A-V104I-A215F-A232V-Q245R, N043R-S101A-N269R, S024R-N043R-N116A-T213A-N269R, G020R-S024R-N043R-R045T-
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: N043R-N076D-S101A-S103A-V104I-A158E-S188D-A232V-Q245R-N248D-H249R-E271F, S024R-N043R-N076D-S101A-S103A-V104I-A158E-S188D-L217E-A232V-Q245R-N248D-H249R, S101A-S103A-V104I-A158E-S188D-A232V-Q245R-N248D-H249R-E271F-E271F, S101A-S103A-V104I-A158E-S188D-L217E-A232V-Q245R-N248D-H249R-E
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: T022A-S101G-S103A-V104I-G159D-L217E-A232V-Q245R-N248D-E271F, T022A-N043R-S101G-S103A-V104I-G159D-S188D-L217E-A232V-Q245R-N248D-E271F, T022A-S101G-S103A-V104I-G159D-S188D-A232V-Q245R-N248D-E271F, N043R-S101A-S103A-V104I-A158E-S188D-L217E-A232V-Q245R-N248D-H249R, N043R-N076D-S101A-S
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: H017R-T022A-N076D-S101G-S103A-V104I-G159D-S188D-A232V-Q245R-N248D-E271F, T022A-N043R-S101G-S103A-V104I-G159D-A232V-Q245R-N248D-E271F, T022A-S101G-S103A-V104I-G159D-S188D-A232V-Q245R-N248D-H249R-E271F, H017R-T022A-N076D-S101G-S103A-V104I-G159D-A232V-Q245R-N248D-E271F, T022A-N076D
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: S101S-S103A-V104I-A158E-S188D-A232V-Q245R-N248D-H249R, S101S-S103G-V104V-A158E-S188D-A232V-Q245R-N248D-H249R, S101G-S103S-V104I-A158E-S188D-A232V-Q245R-N248D-H249R, S101A-S103A-V104I-A158E-S188D-A232V-Q245R-N248D-H249R, S101A-S103A-V104I-A158E-S188D-A232V-Q245R-N248D-H249R, S101A-S103A-V104L-
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: V026F-V051W-V104L-S106E, V026F-L031F-S078N-G102A-S160D, G020K-G100S-N116L-A158E-S166D-N243F, T033S-N043W-N218D-P239G-N243F, T022L-T038F-A048R-N062E-G100S-R186K, S101D-S103N-N116L-S144R-A215D, V104L-S105T-T213A-L217E-S256N, N043W-S101D-S212M-N243F, V026F-A048R-S105T-T213A-N218D-T224A, S
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: T022A-S024R-S101D-S103A-V104I-G118R-G159D-S188D-A232V-N248D-E271F, T022A-S024R-S103A-V104I-P129E-G159D-S188D-A232V-N248D-E271F, T022A-S024R-S103A-V104I-G118R-G159D-S188D-L217D-A232V-N248D, T022A-S024R-S101D-S103A-V104I-G118R-P129E-G159D-S188D-A232V-Q245R-N248D, T022A-S024R-S101D-S103A-V
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: G020K-S024F-N062E-S188D-P239G, S024F-N062E-N116L-P239G, G020K-G023A-N062E-S188D, G020K-G023A-S024F-N062E-G118R-S188D-T213A, G020K-N043W-N062E-N116L-S188D-T213A-P239G, G023A-N062E-N116L-G118R, G023A-S024F-N062E-N116L-G118R, S024F-N116L, S024F-N062E-S188D-T213A, G023A-N062E-
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: G020K-G023A-N043W-G118R-S128I-P129E-G159D-S188D, S024F-G118R-S128I-P129E-G159D, G020K-S024F-N062E-N116L-G118R-S188D, G020K-N062E-N116L-S188D, N062E-N116L-G118R-T213A, G020K-G023A-N062E-N116L-S188D, N062E-N116L-G118R-S188D, G020K-N062E-N116L-T213A, G020K-G023A-N062E-N116L-S188D, N062E
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: S087R-S101G-S103A-V104I-Q109R-S212P-A232V-Q245R-E271V, S101G-S103A-V104I-Q109R-A232V-Q245R, S101G-S103A-V104I-Q109R-S212P-A232V-Q245R-E271V, S101G-S103A-V104I-Q109R-S212P-A232V-Q245R, N076D-587R-S103A-V104I-S212P-E271V, N076D-S103A-V104I-Q109R, N076D-S103A-V104I-S212P-E271V, N076D-S103A-V104I-Q109R
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: S024R-P086W-G118R, S024R-S078R-P086W-N243F, S024R-T033S-P086S-S087N-Y209A, T033S-G118R, S024R-S078R-P086W-G118R-A270T, S024R-T033S-P086W-G118R, S078R-P086W-N243F, T033S-S078R-P086W-G118R-Y209A, T033S-S078R-Y209A, P086W-G118R-N243F, S024R-P086W, S078R-P086W-K235F, S024R-G118R
  • the present invention also provides isolated protease variants wherein said protease variant comprises one or more, preferably two or more or preferably three or more of the following mutations X1R, X2S, X4R, X4S, X9A, X10S, X14K, X16S, X17R, X18R, X20R, X22A, X22R, X24R, X24W, X25R, X25V, X26F, X42I, X43R, X43A, X46R, X52F, X52E, X52N, X57R, X59A, X62E, X62Q, X68A, X68C, X71G, X72C, X74C.
  • the present invention also provides isolated protease variants, wherein said protease variant comprises one or more of the following set of mutations:
  • the present invention also provides isolated protease variants, wherein said protease variant has at least one, or even two or more charged mutations selected from the group consisting of N062E, S101D, P129E, A158E, G159D/E, S166D, and/or S188D, preferably having a charge of 0, ⁇ 1, ⁇ 2, ⁇ 3, ⁇ 4 or ⁇ 5, preferably 0, ⁇ 1, ⁇ 2 or ⁇ 3, most preferably ⁇ 1 or ⁇ 2 relative to the enzyme of SEQ ID NO:1.
  • Said protease variants can also include any of the variants listed in the application.
  • the present invention also provides isolated protease variants, wherein said protease variant has one or two or more charged mutations selected from the group consisting of N018R, G020K/R, T022R, S024R, N043R, Q245R, H249R and/or N269R, preferably having a charge of 0, +1, +2, +3, +4 or +5, preferably +1, +2 or +3, most preferably +2 relative to the enzyme of SEQ ID NO:1.
  • Said protease variants can also include any of the variants listed in the application.
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: G020R-S087D-S101G-S103A-V104I-A232V-Q245R, G020R-S101G-S103A-V104I-V150L-A232V-Q245R, N018R-G020R-S024R-N076D-S087D-H249R, N018R-G020R-S024R-N076D-V150L-H249R, N018R-S024R-N043R-N076D-S087D-H249R, N018R-S024R-N043R-N076D-S087D-H249R, N018R-S024R-N043R-N076D-V150L-H249
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: S024R-S101G-S103A-V104I-P129Q-A158E-S188D-L217E-A232V-Q245R-N248D-H249R, S024R-S101G-S103A-V104I-S130A-A158E-N183D-S188D-A232V-Q245R-N248D-H249R, S024R-S101G-S103A-V104I-P129Q-A158E-N183D-S188D-A232V-Q245R-N248D-H249R, S101G-S103A-V104I-S130A-A158E-S188D-A232V-Q245R-N248D-H249R, S101G-S103A
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: S101G-S103A-V104I-A232V-M222Q-Q245R, S101G-S103A-V104I-A158E-S188D-M222S-A232V-Q245R-N248D-H249R, S101G-S103A-V104I-A158E-S188D-M222Q-A232V-Q245R-N248D-H249R, N076D-S101G-S103A-V104I-A232V-M222Q-Q245R, S101G-S103A-V104I-A232V-M222S-Q245R, N076D-S101G-S103A-V104I-A232V-M222S-Q245R, N076D-S101G-S103
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: S024R-S101G-S103A-V104I-S128L-P129Q-A158E-S188D-A232V-Q245R-N248D-H249R, S101G-S103A-V104I-S130A-A158E-S188D-A232V-Q245R-N248D-H249R, S024R-S101G-S103A-V104I-A158E-S188D-A232V-Q245R-N248D-H249R, S101G-S103A-V104I-S128L-P129Q-A158E-S188D-A232V-Q245R-N248D-H249R, S101G-S103A-V104I-S128L-P129
  • the present invention further provides polypeptides comprising subtilisin variants having proteolytic activity comprising an amino acid sequence comprising a combination of amino acid substitutions selected from: S101G-S103A-V104I, T22A-S101A-Y209E, S103G-L111V-G159E, T22A-S103G-G159E, T22A-L111V-G159E, T22A-S128N-E271F-Y209E, T22A-S103G-L111V, N62E-L111V-S128N, T22A-L111V-S128N, T22A-N62E-L111V, S101A-S103G-V104L-S188D, S101G-S103A-V104I-G159D, S101A-S103G-V104L-S128N, T22A-S101A-G159E, S101A-S103G-V104L, S101A-S103G-V104L
  • the present invention further provides polypeptides comprising subtilisin variants having proteolytic activity comprising an amino acid sequence comprising a combination of amino acid substitutions selected from: S103A-V104I-G159D-A232V-Q236H-Q245R-N248D-N252K, S101G-V104I-G159D-A232V-Q236H-Q245R-N248D-N252K, S101G-S103A-G159D-A232V-Q236H-Q245R-N248D-N252K, S101G-S103A-V104L-A232V-Q236H-Q245R-N248D-N252K, S101G-S103A-V104L-G159D-Q236H-Q245R-N248D-N252K, S101G-S103A-V104L-G159D-Q236H-Q245R-N248D-N252
  • the present invention further provides polypeptides comprising subtilisin variants having proteolytic activity comprising an amino acid sequence comprising a combination of amino acid substitutions selected from: S101G-S103A-V104I-G159D-A232V-Q245R-N248D, S101G-S103A-V104I-G159D-A232V-Q245R-N248D-E271F, S101G-S103A-V104I-G159D-A232V-Q245R-N248D-N238R, S101G-S103A-V104I-G159D-A232V-Q245R-N248D-N248R, S101G-S103A-V104I-G159D-A232V-Q245R-N248D-T253R, S101G-S103A-V104I-G159D-A232V-Q245R-N248D-524R, S101G-S103A-V104I
  • the present invention further provides polypeptides comprising subtilisin variants having proteolytic activity comprising an amino acid sequence comprising a combination of amino acid substitutions selected from: A1R, A230E, E271L, G115R, G20R, H249R, K235F, K27V/F/L, L75E, L82R, N18R, N269R, N43D, N43R, N76D, R45T, S212F, S242R, S24R, S78R, S9A, T22R, V121E, V244R, V28E, V30E, V4R, W241R, G20R-N43R-H249R, G20R-T22R-N43R, G20R-N43R-S242R, G20R-N43R-E271L, G20R-N43R-V244R, G20R-S24R-N43R-S242R, S9A-T22R-S78R
  • the present invention further provides polypeptides comprising subtilisin variants having proteolytic activity and comprising an amino acid sequence comprising a combination of amino acid substitutions selected from: S101G-S103A-V104I-A232V-Q245R-N248D, S101G-S103A-V104I-G159D-A232V-Q245R, S101G-S103A-V104I-G159R-A232V-Q245R-N248D, S101G-S103A-V104I-G159D-A232V-Q245R-N248R, S101G-S103A-V104I-A232V-Q245R, S101G-S103A-V104I-A232V-Q245R-N248R, S101G-S103A-V104I-A232V-Q245R-N248R, S101G-S103A-V104I-G159R-A232V-Q245R-N248R
  • the present invention further provides polypeptides comprising subtilisin variants having proteolytic activity and comprising an amino acid sequence comprising a combination of amino acid substitutions selected from: A16S, T22A, S24R, N62E, N76D, E89P, S101A/G, S103G/A, V104L/I, L111V, S128N, P129E, A232V, L148I, A158E, G159D/E, R186H, S188D, Y209E, Q236H, Q245R, N248D/R, H249R, N252K/R, T253R, and E271F wherein amino acid positions of the subtilisin variant are numbered by correspondence with the amino acid sequence of B. amyloliquefaciens subtilisin BPN′ set forth as SEQ ID NO:1.
  • the present invention also provides protease variants of Bacillus lentus subtilisin GG36 protease, wherein the Bacillus lentus subtilisin GG36 protease comprises the amino acid sequence shown in SEQ ID NO:2, wherein the protease variant comprises an amino acid sequence which differs from the amino acid sequence of SEQ ID NO:2 in no more than two, three, four, five, six, seven, eight, nine, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 mutations selected from the group of G20K, G20R, G23A, S24F, S24R, N43R, N43W, R45T, N62E, N76D, S101A, N116A, N116L, G118R, S128I, P129E, S188D, T213A, A215F, L217E, P239G, and N269R, wherein amino acid positions of the protease variant are numbered according to the numbering of corresponding amino acid positions
  • the present invention further provides polypeptides comprising subtilisin variants having proteolytic activity and comprising an amino acid sequence comprising a combination of amino acid substitutions selected from: A1R, Q2S, Q2M, Q2A, Q2R, Q2W, S3R, V4R, V4S, V4C, I8A, S9A, S9F, S9W, R10S, R10A, R10H, R10M, Q12F, Q12R, P14K, P14F, P14Q, A15R, A15F, A16S, H17R, H17M, H17F, N18R, N18K, G20F, G20K, G20R, T22A, T22R, T22Y, T22V, T22Q, T22L, T22W, G23A, G23S, G23F, S24R, S24F, S24W, S24Q, S24H, S24L, G25V, G25F, G25R, V
  • the present invention further provides polypeptides comprising protease variant of Bacillus lentus subtilisin GG36 protease, wherein the Bacillus lentus subtilisin GG36 protease comprises the amino acid sequence shown in SEQ ID NO:2, and wherein the protease variant comprises an amino acid sequence which differs from the amino acid sequence of SEQ ID NO:2 in no more than two, three, four, five, six, seven, eight, nine, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, or 50 mutations at amino acid positions selected from amino acid 1, 2, 3, 4, 8, 9, 10, 12, 14, 15, 16, 17, 18, 20, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 33, 34, 35, 36, 38, 40, 42, 43, 45, 46, 48, 50, 51, 52, 55, 57, 59, 60, 62, 63, 64, 68, 69, 71, 72, 74, 75, 76, 78, 79, 81, 82, 85,
  • the present invention further provides polypeptides comprising protease variants of Bacillus lentus subtilisin GG36 protease, wherein the Bacillus lentus subtilisin GG36 protease comprises the amino acid sequence shown in SEQ ID NO:2, and wherein the protease variant comprises an amino acid sequence which differs from the amino acid sequence of SEQ ID NO:2 in no more than two, three, four, five, six, seven, eight, nine, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, or 50 mutations selected from the group of A1R, Q2S, Q2M, Q2A, Q2R, Q2W, S3R, V4R, V4S, V4C, I8A, S9A, S9F, S9W, R10S, R10A, R10H, R10M, Q12F, Q12R, P14K, P14F, P14Q, A15R, A15F, A16S, H17
  • the present invention further provides polypeptides comprising protease variants of Bacillus lentus subtilisin GG36 protease, wherein the Bacillus lentus subtilisin GG36 protease comprises the amino acid sequence shown in SEQ ID NO:2, and wherein the protease variant comprises an amino acid sequence which differs from the amino acid sequence of SEQ ID NO:2 in no more than two, three, four, five, six, seven, eight, nine, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, or 50 mutations selected from the group of A1R, Q2S, V4R, V4S, S9A, R105, P14K, A16S, H17R, N18R, G20R, T22A, T22R, S24R, S24W, G25R, G25V, V26F, L42I, N43R, N43A, G46R, P52F, P52E, P52N, T57R, Q59A
  • the present invention further provides polypeptides comprising protease variants of Bacillus lentus subtilisin GG36 protease, wherein the Bacillus lentus subtilisin GG36 protease comprises the amino acid sequence shown in SEQ ID NO:2, and wherein the protease variant comprises an amino acid sequence which differs from the amino acid sequence of SEQ ID NO:2 in no more than two, three, four, five, six, seven, eight, nine, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, or 50 mutations selected from the group of A1R, Q2S, V4R, V4S, S9A, R105, P14K, A16S, H17R, N18R, G20R, T22A, T22R, S24R, S24W, G25R, G25V, V26F, L421, N43R, N43A, G46R, P52F, P52E, P52N, T57R, Q59A,
  • the present invention further provides polypeptides comprising protease variants of Bacillus lentus subtilisin GG36 protease, wherein the Bacillus lentus subtilisin GG36 protease comprises the amino acid sequence shown in SEQ ID NO:2, wherein the protease variant comprises an amino acid sequence which differs from the amino acid sequence of SEQ ID NO:2 in no more than two, three, four, five, six, seven, eight, nine, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, or 50 mutations selected from the group of A16S, T22A, S24R, N62E, N76D, E89P, S101A/G, S103G/A, V104L/I, L111V, S128N, P129E, A232V, L148I, A158E, G159D/E, R186H, S188D, Y209E, Q236H, Q245R, N248D/R, H249
  • the present invention also provides protease variants of Bacillus lentus subtilisin GG36 protease, wherein the Bacillus lentus subtilisin GG36 protease comprises the amino acid sequence shown in SEQ ID NO:2, wherein the protease variant comprises an amino acid sequence which differs from the amino acid sequence of SEQ ID NO:2 in no more than two, three, four, five, six, seven, eight, nine, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 mutations selected from the group of G20K, G20R, G23A, S24F, S24R, N43R, N43W, R45T, N62E, N76D, S101A, N116A, N116L, G118R, S128I, P129E, S188D, T213A, A215F, L217E, P239G, and N269R, wherein amino acid positions of the protease variant are numbered according to the numbering of corresponding amino acid positions
  • the present invention further provides polypeptides comprising protease variants of Bacillus lentus subtilisin GG36 protease, wherein the Bacillus lentus subtilisin GG36 protease comprises the amino acid sequence shown in SEQ ID NO:2, and wherein the protease variant comprises an amino acid sequence which differs from the amino acid sequence of SEQ ID NO:2 in no more than two, three, four, five, six, seven, eight, nine, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45 or 50 mutations selected from the group of A16S, T22A, S24R, N62E, N76D, E89P, S101A/G, S103G/A, V104L/I, L111V, S128N, P129E, A232V, L148I, A158E, G159D/E, R186H, S188D, Y209E, Q236H, Q245R, N248D/R, H249
  • the present invention further provides polypeptides comprising protease variants comprising an amino acid sequence which differs from the amino acid sequence of SEQ ID NO:2, and wherein the total net charge of the protease variant is 0, +1, +2, +3, +4, +5, ⁇ 1, ⁇ 2, ⁇ 3, ⁇ 4, or ⁇ 5 relative to the total net charge of the Bacillus lentus subtilisin GG36 protease, and wherein amino acid positions of the protease variant are numbered according to the numbering of corresponding amino acid positions in the amino acid sequence of Bacillus amyloliquefaciens subtilisin BPN′ shown in SEQ ID NO:1 as determined by alignment of the protease variant amino acid sequence with the Bacillus amyloliquefaciens subtilisin BPN′ amino acid sequence.
  • the present invention also provides protease variants comprising amino acid sequence which differs from the amino acid sequence of SEQ ID NO:2, and wherein the total net charge of the protease variant is 0 relative to the total net charge of the Bacillus lentus subtilisin GG36 protease, and wherein amino acid positions of the protease variant are numbered according to the numbering of corresponding amino acid positions in the amino acid sequence of Bacillus amyloliquefaciens subtilisin BPN′ shown in SEQ ID NO:1 as determined by alignment of the protease variant amino acid sequence with the Bacillus amyloliquefaciens subtilisin BPN′ amino acid sequence.
  • the present invention also provides protease variants comprising amino acid sequence which differs from the amino acid sequence of SEQ ID NO:2 wherein the protease variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: G020R-N043R, G020K-N062E, S024F-N116L, G020K-S024F, S024R-A174T, S024R-G118R, S024R-K235F, S024R-P086R, S024R-P086W, S078R-G118R, T033S-G118R, T033S-K235F, Y209A-W241R, G020R-N076D, N018R-Q245R, S024R-R045T, A232V-Q245R, G118R-A172V, G118R-A194T, 1008T-S024
  • the present invention also provides protease variants comprising amino acid sequence which differs from the amino acid sequence of SEQ ID NO:2 wherein the protease variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: G020R-N076D, S024R-R045T, A230E-H249R, N018R-R045T, N018R-Q245R, S101G-A232V, S024R-A232V, A232V-Q245R, S024R-S101G, N018R-V104I, N018R-S103A, S101G-H249R, A232V-H249R, S103A-A232V, N076D-Q245R, S101G-V104I, V104I-A232V, N076D-H249R, S024R-N076D, S024F-N116L, G020K
  • the present invention also provides protease variants comprising amino acid sequence which differs from the amino acid sequence of SEQ ID NO:2 wherein the protease variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: G020K-G023A-N043W-G118R-S128I-P129E-G159D-S188D, G020K-G023A-N062E-N116L, G020K-G023A-N062E-N116L-S188D, G020K-G023A-N062E-N116L-S188D-T213A, G020K-G1005-N116L-A158E-S166D-N243F, G020K-N043W-N062E-N116L-S188D, G020K-N062E, G020K-N062E-N116L, G020K-N062E
  • the present invention also provides protease variants comprising amino acid sequence which differs from the amino acid sequence of SEQ ID NO:2 wherein the protease variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: A016S-N062E-A158E-H249R-E271F, A016S-N062E-S128N-R186H-E271F, A016S-N062E-V104L-R186H-S188D-E271F, A016S-S101A-S128N-R186H, A016S-S128N-A158E-R186H, A016S-V104L-A158E-R186H-E271F, A016S-V104L-S188D-H249R, A158E-R186H-H249R, A158E-R186H-S188D-H249R-E271F, G
  • the present invention also provides protease variants comprising amino acid sequence which differs from the amino acid sequence of SEQ ID NO:2 wherein the protease variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: A016S-S128N-R186H-E271F, N076D-S101G-S103A-V104I-A158E-S188D-M222S-A232V-Q245R-N248D-H249R, S024R-S101G-S103A-V104I-S128L-P129Q-A158E-N183D-S188D-A232V-Q245R-N248D-H249R, S024R-S101G-S103A-V104I-S128L-P129Q-A158E-S188D-A232V-Q245R-N248D-H249R, S024R-S101G-S
  • the present invention also provides protease variants comprising amino acid sequence which differs from the amino acid sequence of SEQ ID NO:2 wherein the protease variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: G118R-Y209A, G118R-Y209A-N243F, L021M-S024R-T033S, P005S-S078R-G118R-W241R, P086W-G118R-A 133V, P086W-G118R-N243F, P086W-G118R-Y209A, P086W-Y209A-N243F, S024R-A174T, S024R-G118R, S024R-G118R-Y209A, S024R-G118R-Y209A-K235F, S024R-G118R-Y209A-N243F, S024R-K235F
  • the present invention also provides protease variants comprising amino acid sequence which differs from the amino acid sequence of SEQ ID NO:2 wherein the protease variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: S101G-S103A-V104I-A232V-Q236H-Q245R-N252K, S101G-S103A-V104I-A232V-Q245R-N248R, S101G-S103A-V104I-G159R-A232V-Q245R-N248D, A232V-Q245R, E089I-N117F-N185I-A215F-L233C, G020R-E089I-L217E, G020R-G023A-V104L-Y192W-L233C, G020R-N043D-R045T-N076D-S242R-H249R, G0
  • the present invention also provides protease variants comprising amino acid sequence which differs from the amino acid sequence of SEQ ID NO:2 wherein the protease variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: A015T-T033S, A016T-N043R-R045T-N076D-S101G-S103A-V104I-A232V-Q245R-N269R, A230E-H249R, A232V-H249R, E089I-S105T-N116A-A215F-S216F, E089I-Y091F-N185I-G211Q-A270C, G020R-A0905-S101G-S103A-V104I-N116A-N183D-T213A-A215F-A232V-Q245R, G020R-N043D-S078R-S101G-S103
  • preferred proteases comprise at least one, or even two or more charged mutations selected from the group consisting of N062E, S101D, P129E, A158E, G159D/E, S166D, and/or S188D.
  • Such proteases are particularly preferred for incorporation into detergent compositions suitable for addition to water to make a wash liquor preferably having low ionic strength or low detergent concentration.
  • these proteases will form part of a detergent composition that is added to water, either for a handwashing or machine washing process, typically within a washing machine, to form a wash liquor, whose conductivity is from about 0.1 mS/cm to about 3 mS/cm, from about 0.3 mS/cm to about 2.5 mS/cm, or even from about 0.5 mS/cm to about 2 mS/cm.
  • such proteases that comprise at least one, or even two or more charged mutations selected from the group consisting of N062E, S101D, P129E, A158E, G159D/E, S166D, and/or S188D have a charge of 0, ⁇ 1, ⁇ 2, ⁇ 3, ⁇ 4 or ⁇ 5, preferably 0, ⁇ 1, ⁇ 2 or ⁇ 3, most preferably ⁇ 1 or ⁇ 2 relative to the enzyme of SEQ ID NO:1.
  • proteases for use in the invention:
  • (a) comprise one or more charged mutations selected from the group consisting of N062E, S101D, P129E, A158E, G159D/E, S166D, and/or S188D; (b) have a charge of 0, ⁇ 1, ⁇ 2, ⁇ 3, ⁇ 4 or ⁇ 5, preferably 0, ⁇ 1, ⁇ 2 or ⁇ 3, most preferably ⁇ 1 or ⁇ 2 relative to the enzyme of SEQ ID NO:1; and (c) comprise one, two, three or more mutations to arrive at a desired net charge selected from the group comprising G20K, S024R, G118R, Q245R, H249R and/or E271F/L.
  • mutants to arrive at a desired net charge it is intended to mean that when the enzyme variant is compared to the Bacillus lentus subtilisin GG36 protease, the total net charge of the variant relative to Bacillus lentus subtilisin GG36 can be adjusted to be within the preferred range by selecting one or more further mutations preferably selected from the mutations identified, for example listed in (c) above.
  • these preferred proteases form part of a detergent composition that is added to water, either in a hand or machine washing process, typically within a washing machine, to form a wash liquor, whose conductivity is from about 0.1 mS/cm to about 3 mS/cm, from about 0.3 mS/cm to about 2.5 mS/cm, or even from about 0.5 mS/cm to about 2 mS/cm.
  • preferred proteases comprise at least one or two or more charged mutations selected from the group consisting of N018R, G020K/R, T022R, S024R, N043R, Q245R, H249R and/or N269R.
  • Such proteases are particularly preferred for incorporation into detergent compositions which will be added to water to make a wash liquor preferably having high ionic strength or high detergent concentration.
  • these preferred proteases may form part of a detergent composition that is added to water, either for hand washing or machine washing, typically within a washing machine, to form a wash liquor, whose conductivity is from above about 3 mS/cm to about 30 mS/cm, from about 3.5 mS/cm to about 20 mS/cm, or even from about 4 mS/cm to about 10 mS/cm.
  • such proteases comprise at least one, or two or even more charged mutations selected from the group consisting of N018R, G020K/R, T022R, S024R, N043R, Q245R, H249R and/or N269R have a charge of 0, +1, +2, +3, +4 or +5, preferably +1, +2 or +3, most preferably +2 relative to the enzyme of SEQ ID NO:1.
  • (a) comprise one or two or more charged mutations selected from the group consisting of N018R, G020K/R, T022R, S024R, N043R, Q245R, H249R and/or N269R; (b) have a charge of 0, +1, +2, +3, +4 or +5, preferably +1, +2 or +3, most preferably +2 relative to the enzyme of SEQ ID NO:1; and (c) comprise mutations to arrive at a desired net charge selected from the group consisting of N043D, R045T, N076D and/or A230E.
  • these proteases form part of a detergent composition that is added to water either in a hand or machine washing process, typically within a washing machine, to form a wash liquor, whose conductivity is from above about 3 mS/cm to about 30 mS/cm, from about 3.5 mS/cm to about 20 mS/cm, or even from about 4 mS/cm to about 10 mS/cm.
  • the present invention further provides polypeptides comprising protease variants having one or more of the following characteristics: a) a Test Method 2 performance index of at least 1.1, at least 1.2, at least 1.3, at least 1.4, at least 1.5, at least 1.6, at least 1.7, at least 1.8, at least 1.9, at least 2, from 1.1 to about 10, from 1.1 to about 8, or even from 1.1 to about 5; b) a Test Method 3 performance index of at least 1.1, at least 1.2, at least 1.3, at least 1.4, at least 1.5, at least 1.6, at least 1.7, at least 1.8, at least 1.9, at least 2, from 1.1 to about 10, from 1.1 to about 8, or even from 1.1 to about 5; c) a Test Method 4 performance index of at least 1.0, at least 1.1, at least 1.2, at least 1.3, at least 1.4, at least 1.5, at least 1.6, at least 1.7, at least 1.8, at least 1.9, at least 2, from 1.0 to about 10, from
  • the invention provides isolated, non-naturally occurring, or recombinant nucleic acids (also referred to herein as “polynucleotides”), which may be collectively referred to as “nucleic acids of the invention” or “polynucleotides of the invention”, which encode polypeptides of the invention.
  • Nucleic acids of the invention including all described below, are useful in recombinant production (e.g., expression) of polypeptides of the invention, typically through expression of a plasmid expression vector comprising a sequence encoding the polypeptide of interest or fragment thereof.
  • polypeptides include variant protease polypeptides, including variant subtilisin polypeptides having enzymatic activity (e.g., proteolytic activity) which are useful in cleaning applications and cleaning compositions for cleaning an item or a surface (e.g., surface of an item) in need of cleaning.
  • variant protease polypeptides including variant subtilisin polypeptides having enzymatic activity (e.g., proteolytic activity) which are useful in cleaning applications and cleaning compositions for cleaning an item or a surface (e.g., surface of an item) in need of cleaning.
  • the invention provides an isolated, recombinant, substantially pure, or non-naturally occurring nucleic acid comprising a nucleotide sequence encoding any polypeptide (including any fusion protein, etc.) of the invention described above in the section entitled “Polypeptides of the Invention” and elsewhere herein.
  • the invention also provides an isolated, recombinant, substantially pure, or non-naturally-occurring nucleic acid comprising a nucleotide sequence encoding a combination of two or more of any polypeptides of the invention described above and elsewhere herein.
  • variant protease comprising an amino acid sequence which differs from the amino acid sequence of SEQ ID NO:2 by no more than 50, no more than 40, no more than 30, no more than 35, no more than 25, no more than 20, no more than 19, no more than 18, no more than 17, no more than 16, no more than 15, no more than 14, no more than 13, no more than 12, no more than 11, no more than 10, no more than 9, no more than 8, no more than 7, no more than 6, no more than 5, no more than 4, no more than 3, no more than 2, or no more than 1 amino acid residue(s), wherein amino acid positions of the variant subtilisin are numbered according to the numbering of corresponding amino acid positions in the amino acid sequence of Bacillus amyloliquefaciens subtilisin BPN′ shown in SEQ
  • the present invention provides nucleic acids encoding a subtilisin variant of Bacillus subtilisin, wherein the subtilisin variant is a mature form having proteolytic activity and comprises an amino acid sequence comprising a combination of amino acid substitutions selected from: X1R, X2W, X2M, X2R, X2A, X2S, X3R, X4R, X4C, X4S, X8A, X9F, X9W, X9A, X10S, X10M, X10H, X10A, X12R, X12F, X14K, X14F, X14Q, X15R, X15F, X16S, X17R, X17M, X17F, X18R, X18K, X20F, X20R, X20K, X22Y, X22A, X22R, X22V, X22
  • the present invention provides nucleic acids encoding a Bacillus subtilisin, wherein the subtilisin variant is a mature form having proteolytic activity and comprises an amino acid sequence comprising a combination of amino acid substitutions selected from: X16S, X18R, X20R, X22A, X24R, X43R/D, X45T, X76D, X101A, X103G, X104L, X111V, X128N, X148I, X230E, X242R, and X249R, wherein the amino acid positions of the subtilisin variant are numbered by correspondence with the amino acid sequence of B. amyloliquefaciens subtilisin BPN′ set forth as SEQ ID NO:1.
  • the present invention provides nucleic acids encoding a Bacillus subtilisin, wherein the subtilisin variant is a mature form having proteolytic activity and comprises an amino acid sequence comprising a combination of amino acid substitutions selected from: X1R, X230E, X271L, X115R, X20R, X249R, X235F, X27V/F/L, X75E, X82R, X18R, X269R, X43D, X43R, X76D, X45T, X212F, X242R, X24R, X78R, X9A, X22R, X121E, X244R, X28E, X30E, X4R, and X241R, wherein the amino acid positions of the subtilisin variant are numbered by correspondence with the amino acid sequence of B. amyloliquefaciens subtilisin BPN′ set forth as SEQ ID NO
  • the present invention provides nucleic acids encoding a Bacillus subtilisin wherein the subtilisin variant is a mature form having proteolytic activity and comprises an amino acid sequence comprising a combination of amino acid substitutions selected from: X062E-X158E, X103G-X158E, X128N-X158E, X016S-X158E, X104L-X158E, X089P-X158E, X111V-X158E, X022A-X158E, X101A-X158E, X148I-X158E, X129E-X158E, X022A-X089P, X016S-X089P, X062E-X089P, X062E-X271F, X158E-X271F, X186H-X271F, X129E-X271F, X111V-X271F, X209E-X271F,
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant wherein the subtilisin variant is a mature form having proteolytic activity and comprises an amino acid sequence comprising a combination of amino acid substitutions selected from: X018R-X241R, X020R-X241R, X024R-X241R, X009A-X241R, X020R-X241R, X004R-X241R, X043R-X241R, X078R-X241R, X022R-X241R, X115R-X241R, X001R-X241R, X212F-X241R, X082R-X241R, X018R-X244R, X024R-X244R, X078R-X244R, X020R-X244R, X212F-X244R, X009
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant, wherein the subtilisin variant is a mature form having proteolytic activity and comprises an amino acid sequence comprising a combination of amino acid substitutions selected from: X020R-X-43R, X020K-X062E, X024F-X116L, X020K-X024F, X024R-X174T, X024R-X118R, X024R-X235F, X024R-X086R, X024R-X086W, X078R-X118R, X033S-X118R, X033S-X235F, X209A-X241R, X020R-X076D, X018R-X245R, X024R-X045T, X232V-X245R, X118R-X172V, X118R-X194T
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant, wherein the subtilisin variant is a mature form having proteolytic activity and comprises an amino acid sequence comprising a combination of amino acid substitutions selected from: X020R-X076D, X024R-X045T, X230E-X249R, X018R-X045T, X018R-X245R, X101G-X232V, X024R-X232V, X232V-X245R, X024R-X101G, X018R-X104I, X018R-X103A, X101G-X249R, X232V-X249R, X103A-X232V, X076D-X245R, X101G-X104I, X104I-X232V, X076D-X249R, X024R-X076D, X024
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant, wherein the subtilisin variant is a mature form having proteolytic activity and comprises an amino acid sequence comprising a combination of amino acid substitutions selected from: X004R-X009A-X020R-X242R, X020R-X043R-X241R, X020R-X242R-X269R, X004R-X009A-X020R-X043R, X004R-X020R-X249R, X018R-X024R-X244R, X009A-X022R-X212F-X241R, X020R-X043R-X269R, X018R-X024R-X242R, X004R-X009A-X043R-X241R, X020R-X043R-X244R, X
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant, wherein the subtilisin variant is a mature form having proteolytic activity and comprises an amino acid sequence comprising a combination of amino acid substitutions selected from: X018R-X020R-X043D-X045T-X230E, X018R-X043R-X045T-X242R-X249R, X024R-X043D-X249R, X018R-X020R-X045T, X020R-X024R-X076D-X249R, X024R-X043R-X230E-X242R, X018R-X024R-X043D-X230E, X020R-X076D, X018R-X024R-X043D-X076D-X249R, X024R-X043R-X076D-
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant, wherein the subtilisin variant is a mature form having proteolytic activity and comprises an amino acid sequence comprising a combination of amino acid substitutions selected from: X101G-X103A-X104I-X232V-X236H-X245R-X252K, X101G-X103A-X104I-X232V-X245R-X248R, X101G-X103A-X104I-X159R-X232V-X245R-X248D, X101G-X103A-X104I-X159D-X232V-X245R-X248R, X101G-X103A-X104I-X232V-X245R, X101G-X103A-X104I-X232V-X245R, X101G-X103A-X104I-X159D-X232V-X245R, and X101G-
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant, wherein the subtilisin variant is a mature form having proteolytic activity and comprises an amino acid sequence comprising a combination of amino acid substitutions selected from: X101G-X103A-X104I-X129E-X188D-X232V-X238R-X245R-X248D, X024R-X101G-X103A-X104I-X129E-X158E-X188D-X232V-X245R-X248D-X249R, X022A-X101G-X103A-X104I-X129E-X158E-X188D-X232V-X245R-X248D-X249R, X022A-X024R-X101G-X103A-X104I-X129E-X158E-X188D-X232V-X245R-X248D-X249R, X022A
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant, wherein the subtilisin variant is a mature form having proteolytic activity and comprises an amino acid sequence comprising a combination of amino acid substitutions selected from: X022A-X024R-X101G-X103A-X104I-X158E-X232V-X245R-X248D-X249R, X022A-X024R-X101G-X103A-X104I-X129E-X232V-X245R-X248D-X249R, X024R-X101G-X103A-X104I-X158E-X159E-X232V-X238R-X245R-X248D, X024R-X101G-X103A-X104I-X232V-X245R-X248D-X249R, X101G-X103A-X104I-X158E-X232V-X2
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant, wherein the subtilisin variant is a mature form having proteolytic activity and comprises an amino acid sequence comprising a combination of amino acid substitutions selected from: X104L-X128N-X158E-X186H-X249R, X128N-X158E-X188D-X249R, X062E-X128N-X158E-X159E-X271F, X062E-X158E-X188D-X249R-X271F, X062E-X158E-X186H-X249R-X271F, X128N-X158E-X188D-X209E-X271F, X062E-X159E-X188D-X249R, X016S-X062E-X158E-X186H-X249R, X062E-X158E-X159E-X2
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant, wherein the subtilisin variant is a mature form having proteolytic activity and comprises an amino acid sequence comprising a combination of amino acid substitutions selected from: X001R-X101G-X103A-X104I-X232V-X245R, X004R-X101G-X103A-X104I-X232V-X245R, X043R-X101G-X103A-X104I-X232V-X245R-X271L, X078R-X101G-X103A-X104I-X232V-X245R, X004R-X043R-X101G-X103A-X104I-X232V-X245R, X018R-X043R-X101G-X103A-X104I-X232V-X245R, X020R-X101G-X103A-X104I-X232V
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant, wherein the subtilisin variant is a mature form having proteolytic activity and comprises an amino acid sequence comprising a combination of amino acid substitutions selected from: X020R-X022W-X078R-X101A-X103A-X104I-X116S-X213A-X215F-X232V-X245R, X018R-X078R-X101G-X103A-X104I-X232V-X245R, X024R-X045T-X101G-X103A-X104I-X232V-X245R-X269R, X020R-X022W-X078R-X101G-X103A-X104I-X116A-X232V-X245R, X020R-X22W-X101G-X103A-X104I-X232V-X245R, X018R
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant, wherein the subtilisin variant is a mature form having proteolytic activity and comprises an amino acid sequence comprising a combination of amino acid substitutions selected from: X018R-X024R-X043R-X076D-X249R-X269R, X018R-X022R-X024R-X043R-X076D-X249R, X018R-X043D-X101G-X103A-X104I-X232V-X245R, X020R-X043D-X101G-X103A-X104I-X232V-X245R, X043D-X101G-X103A-X104I-X232V-X245R, X043D-X101G-X103A-X104I-X232V-X245R-X269R, X043D-X078R-X
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant, wherein the subtilisin variant is a mature form having proteolytic activity and comprises an amino acid sequence comprising a combination of amino acid substitutions selected from: X020R-X101A-X103A-X104I-X118R-X232V-X245R, X020R-X024R-X116A-X213A, X043R-X101A-X116A-X215F-X269R, X024R-X043R-X101A-X116A, X024R-X043R-X101A-X116A-X215F-X269R, X020R-X101G-X103A-X104I-X215F-X232V-X245R, X043R-X101A-X269R, X024R-X043R-X116A-X213A-X269R, X
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant, wherein the subtilisin variant is a mature form having proteolytic activity and comprises an amino acid sequence comprising a combination of amino acid substitutions selected from: X043R-X076D-X101A-X103A-X104I-X158E-X188D-X232V-X245R-X248D-X249R-X271F, X024R-X043R-X076D-X101A-X103A-X104I-X158E-X188D-X217E-X232V-X245R-X248D-X249R, X101A-X103A-X104I-X158E-X188D-X232V-X245R-X248D-X249R, X101A-X103A-X104I-X158E-X188D-X232V-X245R-X248D-X249R-X27
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant, wherein the subtilisin variant is a mature form having proteolytic activity and comprises an amino acid sequence comprising a combination of amino acid substitutions selected from: X022A-X101G-X103A-X104I-X159D-X217E-X232V-X245R-X248D-X271F, X022A-X043R-X101G-X103A-X104I-X159D-X188D-X217E-X232V-X245R-X248D-X271F, X022A-X101G-X103A-X104I-X159D-X188D-X232V-X245R-X248D-X271F, X043R-X101A-X103A-X104I-X158E-X188D-X217E-X232V-X245R-X248D-X249R,
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant, wherein the subtilisin variant is a mature form having proteolytic activity and comprises an amino acid sequence comprising a combination of amino acid substitutions selected from: X017R-X022A-X076D-X101G-X103A-X104I-X159D-X188D-X232V-X245R-X248D-X271F, X022A-X043R-X101G-X103A-X104I-X159D-X232V-X245R-X248D-X271F, X022A-X101G-X103A-X104I-X159D-X188D-X232V-X245R-X248D-X249R-X271F, X017R-X022A-X076D-X101G-X103A-X104I-X159D-X232V-X245R-X248D-
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant, wherein the subtilisin variant is a mature form having proteolytic activity and comprises an amino acid sequence comprising a combination of amino acid substitutions selected from: X101S-X103A-X104I-X158E-X188D-X232V-X245R-X248D-X249R, X101S-X103G-X104V-X158E-X188D-X232V-X245R-X248D-X249R, X101G-X103S-X104I-X158E-X188D-X232V-X245R-X248D-X249R, X101A-X103A-X104I-X158E-X188D-X232V-X245R-X248D-X249R, X101A-X103A-X104I-X158E-X188D-X232V-X245R-X248D-X2
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant, wherein the subtilisin variant is a mature form having proteolytic activity and comprises an amino acid sequence comprising a combination of amino acid substitutions selected from: X026F-X051W-X104L-X106E, X026F-X031F-X078N-X102A-X160D, X020K-X100S-X116L-X158E-X166D-X243F, X033S-X043W-X218D-X239G-X243F, X022L-X038F-X048R-X062E-X100S-X186K, X101D-X103N-X116L-X144R-X215D, X104L-X105T-X213A-X217E-X256N, X043W-X101D-X212M-X243F, X026F-X048R-
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant, wherein the subtilisin variant is a mature form having proteolytic activity and comprises an amino acid sequence comprising a combination of amino acid substitutions selected from: X022A-X024R-X101D-X103A-X104I-X118R-X159D-X188D-X232V-X248D-X271F, X022A-X024R-X103A-X104I-X129E-X159D-X188D-X232V-X248D-X271F, X022A-X024R-X103A-X104I-X118R-X159D-X188D-X217D-X232V-X248D, X022A-X024R-X101D-X103A-X104I-X118R-X129E-X159D-X188D-X232V-X245R-X248D, X022A
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant, wherein the subtilisin variant is a mature form having proteolytic activity and comprises an amino acid sequence comprising a combination of amino acid substitutions selected from: X020K-X024F-X062E-X188D-X239G, X024F-X062E-X116L-X239G, X020K-X023A-X062E-X188D, X020K-X023A-X024F-X062E-X118R-X188D-X213A, X020K-X043W-X062E-X116L-X188D-X213A-X239G, X023A-X062E-X116L-X118R, X023A-X024F-X062E-X116L-X118R, X024F-X116L, X024F-X062E-
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant, wherein the subtilisin variant is a mature form having proteolytic activity and comprises an amino acid sequence comprising a combination of amino acid substitutions selected from: X020K-X023A-X043W-X118R-X128I-X129E-X159D-X188D, X024F-X118R-X128I-X129E-X159D, X020K-X024F-X062E-X116L-X118R-X188D, X020K-X062E-X116L-X188D, X062E-X116L-X118R-X213A, X020K-X023A-X062E-X116L-X188D, X062E-X116L-X118R-X188D, X020K-X062E-X116L-X118R-X188D, X020K-
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant, wherein the subtilisin variant is a mature form having proteolytic activity and comprises an amino acid sequence comprising a combination of amino acid substitutions selected from: X087R-X101G-X103A-X104I-X109R-X212P-X232V-X245R-X271V, X101G-X103A-X104I-X109R-X232V-X245R, X101G-X103A-X104I-X109R-X212P-X232V-X245R-X271V, X101G-X103A-X104I-X109R-X212P-X232V-X245R, X076D-S87R-X103A-X104I-X212P-X271V, X076D-X103A-X104I-X109R, X076D-X103A-X104I-X109R, X0
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant, wherein the subtilisin variant is a mature form having proteolytic activity and comprises an amino acid sequence comprising a combination of amino acid substitutions selected from: X024R-X086W-X118R, X024R-X078R-X086W-X243F, X024R-X033S-X086S-X087N-X209A, X033S-X118R, X024R-X078R-X086W-X118R-X270T, X024R-X033S-X086W-X118R, X078R-X086W-X243F, X033S-X078R-X086W-X118R-X209A, X033S-X078R-X209A, X086W-X118R-X243F, X024R-X086W,
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant, wherein the subtilisin variant is a mature form having proteolytic activity and comprises an amino acid sequence comprising a combination of amino acid substitutions selected from: X020R-X087D-X101G-X103A-X104I-X232V-X245R, X020R-X101G-X103A-X104I-X150L-X232V-X245R, X018R-X020R-X024R-X076D-X087D-X249R, X018R-X020R-X024R-X076D-X150L-X249R, X018R-X024R-X043R-X076D-X087D-X249R, X018R-X024R-X043R-X076D-X087D-X249R, X018R-X024R-
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant, wherein the subtilisin variant is a mature form having proteolytic activity and comprises an amino acid sequence comprising a combination of amino acid substitutions selected from: X024R-X101G-X103A-X104I-X129Q-X158E-X188D-X217E-X232V-X245R-X248D-X249R, X024R-X101G-X103A-X104I-X130A-X158E-X183D-X188D-X232V-X245R-X248D-X249R, X024R-X101G-X103A-X104I-X129Q-X158E-X183D-X188D-X232V-X245R-X248D-X249R, X101G-X103A-X104I-X130A-X158E-X188D-X232V-X245R-X248
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant, wherein the subtilisin variant is a mature form having proteolytic activity and comprises an amino acid sequence comprising a combination of amino acid substitutions selected from: X101G-X103A-X104I-X232V-X222Q-X245R, X101G-X103A-X104I-X158E-X188D-X222S-X232V-X245R-X248D-X249R, X101G-X103A-X104I-X158E-X188D-X222Q-X232V-X245R-X248D-X249R, X076D-X101G-X103A-X104I-X232V-X222Q-X245R, X101G-X103A-X104I-X232V-X222S-X245R, X076D-X101G-X103A-X104I-X232V-X222S-
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant, wherein the subtilisin variant is a mature form having proteolytic activity and comprises an amino acid sequence comprising a combination of amino acid substitutions selected from: X024R-X101G-X103A-X104I-X128L-X129Q-X158E-X188D-X232V-X245R-X248D-X249R, X101G-X103A-X104I-X130A-X158E-X188D-X232V-X245R-X248D-X249R, X024R-X101G-X103A-X104I-X158E-X188D-X232V-X245R-X248D-X249R, X101G-X103A-X104I-X128L-X129Q-X158E-X188D-X232V-X245R-X248D-X249R, X101G-
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant, wherein the subtilisin variant is a mature form having proteolytic activity and comprises an amino acid sequence comprising a combination of amino acid substitutions selected from: X101G-X103A-X104I, X22A-X101A-X209E, S103G-L111V-G159E, X22A-X103G-X159E, X22A-X111V-X159E, X22A-X128N-X271F-X209E, X22A-X103G-X111V, X62E-X111V-X128N, X22A-X111V-X128N, X22A-X62E-X111V, X101A-X103G-X104L-X188D, X101G-X103A-X104I-X159D, X101A-X103G-X104L-X128N, X22A-X
  • the present invention provides nucleic acids encoding Bacillus subtilisin variants of a Bacillus subtilisin, wherein the subtilisin variant is a mature form having proteolytic activity and comprises an amino acid sequence comprising a combination of amino acid substitutions selected from: X103A-X104I-X159D-X232V-X236H-X245R-X248D-X252K, X101G-X104I-X159D-X232V-X236H-X245R-X248D-X252K, X101G-X103A-X159D-X232V-X236H-X245R-X248D-X252K, X101G-X103A-X104L-X232V-X236H-X245R-X248D-X252K, X101G-X103A-X104L-X232V-X236H-X245R-X248D-X252K, X101G
  • the present invention provides nucleic acids encoding Bacillus subtilisin variant, wherein the subtilisin variant is a mature form having proteolytic activity and comprises an amino acid sequence comprising a combination of amino acid substitutions selected from: X101G-X103A-X104I-X159D-X232V-X245R-X248D, X101G-X103A-X104I-X159D-X232V-X245R-X248D-X271F, X101G-X103A-X104I-X159D-X232V-X245R-X248D-X238R, X101G-X103A-X104I-X159D-X232V-X245R-X248D-X248R, X101G-X103A-X104I-X159D-X232V-X245R-X248D-X248R, X101G-X103A-X104I-X159D-X232V-X245
  • the present invention provides nucleic acids encoding a Bacillus subtilisin, wherein the subtilisin variant is a mature form having proteolytic activity and comprises an amino acid sequence comprising a combination of amino acid substitutions selected from: X20R-X43R-X249R, X20R-X22R-X43R, X20R-X43R-X242R, X20R-X43R-X271L, X20R-X43R-X244R, X20R-X24R-X43R-X242R, X9A-X22R-X78R-X212F-X241R, X9A-X20R-X43R-X212F, X9A-X43R-X212F, X20R-X43R-X212F, X20R-X22R-X43R-X212F, X24R-X78R-X212F, X9A-X43R-X78R, X9
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant of a Bacillus subtilisin, wherein the subtilisin variant is a mature form having proteolytic activity and comprises an amino acid sequence comprising a combination of amino acid substitutions selected from: X101G-X103A-X104I-X232V-X245R-X248D, X101G-X103A-X104I-X159D-X232V-X245R, X101G-X103A-X104I-X159R-X232V-X245R-X248D, X101G-X103A-X104I-X159D-X232V-X245R-X248R, X101G-X103A-X104I-X232V-X245R, X101G-X103A-X104I-X232V-X245R, X101G-X103A-X104I-X232V-X245R, X101G-X103
  • the present invention provides nucleic acids encoding a Bacillus subtilisin, wherein the subtilisin variant is a mature form having proteolytic activity and comprises an amino acid sequence comprising a combination of amino acid substitutions selected from: X16S, X22A, X24R, X62E, X76D, X89P, X101A/G, X103G/A, X104L/I, X111V, X128N, X129E, X232V, X148I, X158E, X159D/E, X166D, X186H, X188D, X209E, X236H, X238R, X245R, X248D/R, X249R, X252K/R, X253R, and X271F, wherein the amino acid positions of the subtilisin variant are numbered by correspondence with the amino acid sequence of B. amyloliquefaciens subtil
  • the present invention provides nucleic acids encoding Bacillus subtilisin, wherein the subtilisin variant is a mature form having proteolytic activity and comprises an amino acid sequence comprising a combination of amino acid substitutions selected from: N062E-A158E, S103G-A158E, S128N-A158E, A016S-A158E, V104L-A158E, E089P-A158E, L111V-A158E, T022A-A158E, S101A-A158E, L148I-A158E, P129E-A158E, T022A-E089P, A016S-E089P, N062E-E089P, N062E-E271F, A158E-E271F, R186H-E271F, P129E-E271F, L111V-E271F, Y209E-E271F, A016S-E271F, S188D-E271F, T
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant having proteolytic activity comprising an amino acid sequence comprising a combination of amino acid substitutions selected from: N018R-W241R, G020R-W241R, S024R-W241R, S009A-W241R, G020R-W241R, V004R-W241R, N043R-W241R, S078R-W241R, T022R-W241R, G115R-W241R, A001R-W241R, S212F-W241R, L082R-W241R, N018R-V244R, S024R-V244R, S078R-V244R, G020R-V244R, S212F-V244R, S009A-V244R, L082R-V244R, A001R-V244R, N043R-
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant having proteolytic activity comprising an amino acid sequence comprising a combination of amino acid substitutions selected from: G020R-N043R, G020K-N062E, S024F-N116L, G020K-S024F, S024R-A174T, S024R-G118R, S024R-K235F, S024R-P086R, S024R-P086W, S078R-G118R, T033S-G118R, T033S-K235F, Y209A-W241R, G020R-N076D, N018R-Q245R, S024R-R045T, A232V-Q245R, G118R-A172V, G118R-A194T, 1008T-S024R, K235F-N243F, N018R-S103A, N018R
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant having proteolytic activity comprising an amino acid sequence comprising a combination of amino acid substitutions selected from: G020R-N076D, S024R-R045T, A230E-H249R, N018R-R045T, N018R-Q245R, S101G-A232V, S024R-A232V, A232V-Q245R, S024R-S101G, N018R-V104I, N018R-S103A, S101G-H249R, A232V-H249R, S103A-A232V, N076D-Q245R, S101G-V104I, V104I-A232V, N076D-H249R, S024R-N076D, S024F-N116L, G020K-S024F, G020K-N062E, T033S-G118
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant having proteolytic activity comprising an amino acid sequence comprising a combination of amino acid substitutions selected from: V004R-S009A-G020R-S242R, G020R-N043R-W241R, G020R-S242R-N269R, V004R-S009A-G020R-N043R, V004R-G020R-H249R, N018R-S024R-V244R, S009A-T022R-S212F-W241R, G020R-N043R-N269R, N018R-S024R-S242R, V004R-S009A-N043R-W241R, G020R-N043R-V244R, G020R-T022R-S242R, V004R-G020R-N
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant having proteolytic activity comprising an amino acid sequence comprising a combination of amino acid substitutions selected from: N018R-G020R-N043D-R045T-A230E, N018R-N043R-R045T-S242R-H249R, S024R-N043D-H249R, N018R-G020R-R045T, G020R-S024R-N076D-H249R, S024R-N043R-A230E-S242R, N018R-S024R-N043D-A230E, G020R-N076D, N018R-S024R-N043D-N076D-H249R, S024R-N043R-N076D-H249R, N018R-S024R-R045T-S242
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant having proteolytic activity comprising an amino acid sequence comprising a combination of amino acid substitutions selected from: S101G-S103A-V104I-A232V-Q236H-Q245R-N252K, S101G-S103A-V104I-A232V-Q245R-N248R, S101G-S103A-V104I-G159R-A232V-Q245R-N248D, S101G-S103A-V104I-G159D-A232V-Q245R-N248R, S101G-S103A-V104I-A232V-Q245R, S101G-S103A-V104I-G159D-A232V-Q245R, and S101G-S103A-V104I-A232V-Q245R-N248D, wherein the amino acid positions of the subtilisin variant are numbered by correspondence with the amino
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant having proteolytic activity comprising an amino acid sequence comprising a combination of amino acid substitutions selected from: S101G-S103A-V104I-P129E-S188D-A232V-N238R-Q245R-N248D, S024R-S101G-S103A-V104I-P129E-A158E-S188D-A232V-Q245R-N248D-H249R, T022A-S101G-S103A-V104I-P129E-A158E-S188D-A232V-Q245R-N248D-H249R, T022A-S024R-S101G-S103A-V104I-P129E-A158E-S188D-A232V-Q245R-N248D-H249R, S024R-S101G-S103A-V104I-P129E-A
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant having proteolytic activity comprising an amino acid sequence comprising a combination of amino acid substitutions selected from: T022A-S024R-S101G-S103A-V104I-A158E-A232V-Q245R-N248D-H249R, T022A-S024R-S101G-S103A-V104I-P129E-A232V-Q245R-N248D-H249R, S024R-S101G-S103A-V104I-A158E-G159E-A232V-N238R-Q245R-N248D, S024R-S101G-S103A-V104I-A232V-Q245R-N248D-H249R, S101G-S103A-V104I-A158E-A232V-Q245R-N248D-H249R, S101G-S
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant having proteolytic activity comprising an amino acid sequence comprising a combination of amino acid substitutions selected from: V104L-S128N-A158E-R186H-H249R, S128N-A158E-S188D-H249R, N062E-S128N-A158E-G159E-E271F, N062E-A158E-S188D-H249R-E271F, N062E-A158E-R186H-H249R-E271F, S128N-A158E-S188D-Y209E-E271F, N062E-G159E-S188D-H249R, A016S-N062E-A158E-R186H-H249R, N062E-A158E-G159E-H249R, S101A-S128N-A158E-Y209E-H
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant having proteolytic activity comprising an amino acid sequence comprising a combination of amino acid substitutions selected from: A001R-S101G-S103A-V104I-A232V-Q245R, V004R-S101G-S103A-V104I-A232V-Q245R, N043R-S101G-S103A-V104I-A232V-Q245R-E271L, S078R-S101G-S103A-V104I-A232V-Q245R, V004R-N043R-S101G-S103A-V104I-A232V-Q245R, N018R-N043R-S101G-S103A-V104I-A232V-Q245R, G020R-S101G-S103A-V104I-A232V-Q245R, S101G-S103A-V104I-A232
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant having proteolytic activity comprising an amino acid sequence comprising a combination of amino acid substitutions selected from: G020R-T022W-S078R-S101A-S103A-V104I-N116S-T213A-A215F-A232V-Q245R, N018R-S078R-S101G-S103A-V104I-A232V-Q245R, S024R-R045T-S101G-S103A-V104I-A232V-Q245R-N269R, G020R-T022W-S078R-S101G-S103A-V104I-N116A-A232V-Q245R, G020R-T22W-S101G-S103A-V104I-A232V-Q245R, N018R-N043R-S101G-S103A-V104I-A
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant having proteolytic activity comprising an amino acid sequence comprising a combination of amino acid substitutions selected from: N018R-S024R-N043R-N076D-H249R-N269R, N018R-T022R-S024R-N043R-N076D-H249R, N018R-N043D-S101G-S103A-V104I-A232V-Q245R, G020R-N043D-S101G-S103A-V104I-A232V-Q245R, N043D-S101G-S103A-V104I-A232V-Q245R, N043D-S101G-S103A-V104I-A232V-Q245R-N269R, N043D-S078R-S101G-S103A-V104I-A232V-Q245R,
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant having proteolytic activity comprising an amino acid sequence comprising a combination of amino acid substitutions selected from: G020R-S101A-S103A-V104I-G118R-A232V-Q245R, G020R-S024R-N116A-T213A, N043R-S101A-N116A-A215F-N269R, S024R-N043R-S101A-N116A, S024R-N043R-S101A-N116A-A215F-N269R, G020R-S101G-S103A-V104I-A215F-A232V-Q245R, N043R-S101A-N269R, S024R-N043R-N116A-T213A-N269R, G020R-S024R-N043R-R045T-S101A
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant having proteolytic activity comprising an amino acid sequence comprising a combination of amino acid substitutions selected from: N043R-N076D-S101A-S103A-V104I-A158E-S188D-A232V-Q245R-N248D-H249R-E271F, S024R-N043R-N076D-S101A-S103A-V104I-A158E-S188D-L217E-A232V-Q245R-N248D-H249R, S101A-S103A-V104I-A158E-S188D-A232V-Q245R-N248D-H249R-E271F-E271F, S101A-S103A-V104I-A158E-S188D-L217E-A232V-Q245R-N248D-H249R-E271F
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant having proteolytic activity comprising an amino acid sequence comprising a combination of amino acid substitutions selected from: T022A-S101G-S103A-V104I-G159D-L217E-A232V-Q245R-N248D-E271F, T022A-N043R-S101G-S103A-V104I-G159D-S188D-L217E-A232V-Q245R-N248D-E271F, T022A-S101G-S103A-V104I-G159D-S188D-A232V-Q245R-N248D-E271F, N043R-S101A-S103A-V104I-A158E-S188D-L217E-A232V-Q245R-N248D-H249R, N043R-N076D-S101A-S103A-
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant having proteolytic activity comprising an amino acid sequence comprising a combination of amino acid substitutions selected from: H017R-T022A-N076D-S101G-S103A-V104I-G159D-S188D-A232V-Q245R-N248D-E271F, T022A-N043R-S101G-S103A-V104I-G159D-A232V-Q245R-N248D-E271F, T022A-S101G-S103A-V104I-G159D-S188D-A232V-Q245R-N248D-H249R-E271F, H017R-T022A-N076D-S101G-S103A-V104I-G159D-A232V-Q245R-N248D-E271F, T022A-N076D-S101
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant having proteolytic activity comprising an amino acid sequence comprising a combination of amino acid substitutions selected from: S101S-S103A-V104I-A158E-S188D-A232V-Q245R-N248D-H249R, S101S-S103G-V104V-A158E-S188D-A232V-Q245R-N248D-H249R, S101G-S103S-V104I-A158E-S188D-A232V-Q245R-N248D-H249R, S101A-S103A-V104I-A158E-S188D-A232V-Q245R-N248D-H249R, S101A-S103A-V104I-A158E-S188D-A232V-Q245R-N248D-H249R, S101A-S103A-V104L-A158E
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant having proteolytic activity comprising an amino acid sequence comprising a combination of amino acid substitutions selected from: V026F-V051W-V104L-S106E, V026F-L031F-S078N-G102A-S160D, G020K-G100S-N116L-A158E-S166D-N243F, T033S-N043W-N218D-P239G-N243F, T022L-T038F-A048R-N062E-G100S-R186K, S101D-S103N-N116L-S144R-A215D, V104L-S105T-T213A-L217E-S256N, N043W-S101D-S212M-N243F, V026F-A048R-S105T-T213A-N218D-T224A, S024F
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant having proteolytic activity comprising an amino acid sequence comprising a combination of amino acid substitutions selected from: T022A-S024R-S101D-S103A-V104I-G118R-G159D-S188D-A232V-N248D-E271F, T022A-S024R-S103A-V104I-P129E-G159D-S188D-A232V-N248D-E271F, T022A-S024R-S103A-V104I-G118R-G159D-S188D-L217D-A232V-N248D, T022A-S024R-S101D-S103A-V104I-G118R-P129E-G159D-S188D-A232V-Q245R-N248D, T022A-S024R-S101D-S103A-V104I-
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant having proteolytic activity comprising an amino acid sequence comprising a combination of amino acid substitutions selected from: G020K-S024F-N062E-S188D-P239G, S024F-N062E-N116L-P239G, G020K-G023A-N062E-S188D, G020K-G023A-S024F-N062E-G118R-S188D-T213A, G020K-N043W-N062E-N116L-S188D-T213A-P239G, G023A-N062E-N116L-G118R, G023A-S024F-N062E-N116L-G118R, S024F-N116L, S024F-N062E-S188D-T213A, G023A-N062E-N116L
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant having proteolytic activity comprising an amino acid sequence comprising a combination of amino acid substitutions selected from: G020K-G023A-N043W-G118R-S128I-P129E-G159D-S188D, S024F-G118R-S128I-P129E-G159D, G020K-S024F-N062E-N116L-G118R-S188D, G020K-N062E-N116L-S188D, N062E-N116L-G118R-T213A, G020K-G023A-N062E-N116L-S188D, N062E-N116L-G118R-S188D, G020K-N062E-N116L-T213A, G020K-G023A-N062E-N116L-S188D, N062E-N116
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant having proteolytic activity comprising an amino acid sequence comprising a combination of amino acid substitutions selected from: S087R-S101G-S103A-V104I-Q109R-S212P-A232V-Q245R-E271V, S101G-S103A-V104I-Q109R-A232V-Q245R, S101G-S103A-V104I-Q109R-S212P-A232V-Q245R-E271V, S101G-S103A-V104I-Q109R-S212P-A232V-Q245R, N076D ⁇ 587R-S103A-V104I-S212P-E271V, N076D-S103A-V104I-Q109R, N076D-S103A-V104I-S212P-E271V, N076D-S103A-V104I-Q109R, N
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant having proteolytic activity comprising an amino acid sequence comprising a combination of amino acid substitutions selected from: S024R-P086W-G118R, S024R-S078R-P086W-N243F, S024R-T033S-P086S-S087N-Y209A, T033S-G118R, S024R-S078R-P086W-G118R-A270T, S024R-T033S-P086W-G118R, S078R-P086W-N243F, T033S-S078R-P086W-G118R-Y209A, T033S-S078R-Y209A, P086W-G118R-N243F, S024R-P086W, S078R-P086W-K235F, S024R-G118R, S0
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant having proteolytic activity comprising an amino acid sequence comprising a combination of amino acid substitutions selected from: G020R-S087D-S101G-S103A-V104I-A232V-Q245R, G020R-S101G-S103A-V104I-V150L-A232V-Q245R, N018R-G020R-S024R-N076D-S087D-H249R, N018R-G020R-S024R-N076D-V150L-H249R, N018R-S024R-N043R-N076D-S087D-H249R, N018R-S024R-N043R-N076D-S087D-H249R, N018R-S024R-N043R-N076D-V150L-H249R, N
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant having proteolytic activity comprising an amino acid sequence comprising a combination of amino acid substitutions selected from: S024R-S101G-S103A-V104I-P129Q-A158E-S188D-L217E-A232V-Q245R-N248D-H249R, S024R-S101G-S103A-V104I-S130A-A158E-N183D-S188D-A232V-Q245R-N248D-H249R, S024R-S101G-S103A-V104I-P129Q-A158E-N183D-S188D-A232V-Q245R-N248D-H249R, S101G-S103A-V104I-S130A-A158E-S188D-A232V-Q245R-N248D-H249R, S101G-S103A-V104
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant having proteolytic activity comprising an amino acid sequence comprising a combination of amino acid substitutions selected from: S101G-S103A-V104I-A232V-M222Q-Q245R, S101G-S103A-V104I-A158E-S188D-M222S-A232V-Q245R-N248D-H249R, S101G-S103A-V104I-A158E-S188D-M222Q-A232V-Q245R-N248D-H249R, N076D-S101G-S103A-V104I-A232V-M222Q-Q245R, S101G-S103A-V104I-A232V-M222S-Q245R, N076D-S101G-S103A-V104I-A232V-M222S-Q245R, N076D-S101G-S103A-V
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant having proteolytic activity comprising an amino acid sequence comprising a combination of amino acid substitutions selected from: S024R-S101G-S103A-V104I-S128L-P129Q-A158E-S188D-A232V-Q245R-N248D-H249R, S101G-S103A-V104I-S130A-A158E-S188D-A232V-Q245R-N248D-H249R, S024R-S101G-S103A-V104I-A158E-S188D-A232V-Q245R-N248D-H249R, S101G-S103A-V104I-S128L-P129Q-A158E-S188D-A232V-Q245R-N248D-H249R, S101G-S103A-V104I-S128L-P129Q-A
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant having proteolytic activity comprising an amino acid sequence comprising a combination of amino acid substitutions selected from: S101G-S103A-V104I, T22A-S101A-Y209E, S103G-L111V-G159E, T22A-S103G-G159E, T22A-L111V-G159E, T22A-S128N-E271F-Y209E, T22A-S103G-L111V, N62E-L111V-S128N, T22A-L111V-S128N, T22A-N62E-L111V, S101A-S103G-V104L-S188D, S101G-S103A-V104I-G159D, S101A-S103G-V104L-S128N, T22A-S101A-G159E, S101A-S103G-V104L, S101A-S103G
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant having proteolytic activity comprising an amino acid sequence comprising a combination of amino acid substitutions selected from: S103A-V104I-G159D-A232V-Q236H-Q245R-N248D-N252K, S101G-V104I-G159D-A232V-Q236H-Q245R-N248D-N252K, S101G-S103A-G159D-A232V-Q236H-Q245R-N248D-N252K, S101G-S103A-V104L-A232V-Q236H-Q245R-N248D-N252K, S101G-S103A-V104L-G159D-Q236H-Q245R-N248D-N252K, S101G-S103A-V104L-G159D-Q236H-Q245R-N248D
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant having proteolytic activity comprising an amino acid sequence comprising a combination of amino acid substitutions selected from: S101G-S103A-V104I-G159D-A232V-Q245R-N248D, S101G-S103A-V104I-G159D-A232V-Q245R-N248D-E271F, S101G-S103A-V104I-G159D-A232V-Q245R-N248D-N238R, S101G-S103A-V104I-G159D-A232V-Q245R-N248D-N248R, S101G-S103A-V104I-G159D-A232V-Q245R-N248D-T253R, S101G-S103A-V104I-G159D-A232V-Q245R-N248D ⁇ 524R, S101G-S103
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant having proteolytic activity comprising an amino acid sequence comprising a combination of amino acid substitutions selected from: A1R, A230E, E271L, G115R, G20R, H249R, K235F, K27V/F/L, L75E, L82R, N18R, N269R, N43D, N43R, N76D, R45T, S212F, S242R, S24R, S78R, S9A, T22R, V121E, V244R, V28E, V30E, V4R, W241R, G20R-N43R-H249R, G20R-T22R-N43R, G20R-N43R-S242R, G20R-N43R-E271L, G20R-N43R-V244R, G20R-S24R-N43R-S242R, S9A-T22R
  • the present invention provides nucleic acids encoding Bacillus subtilisin variant having proteolytic activity and comprising an amino acid sequence comprising a combination of amino acid substitutions selected from: S101G-S103A-V104I-A232V-Q245R-N248D, S101G-S103A-V104I-G159D-A232V-Q245R, S101G-S103A-V104I-G159R-A232V-Q245R-N248D, S101G-S103A-V104I-G159D-A232V-Q245R-N248R, S101G-S103A-V104I-A232V-Q245R, S101G-S103A-V104I-A232V-Q245R, S101G-S103A-V104I-A232V-Q245R-N248R, S101G-S103A-V104I-G159R-A232V-Q245R-N248R, S101
  • the present invention provides nucleic acids encoding Bacillus subtilisin variant having proteolytic activity and comprising an amino acid sequence comprising a combination of amino acid substitutions selected from: A16S, T22A, S24R, N62E, N76D, E89P, S101A/G, S103G/A, V104L/I, L111V, S128N, P129E, A232V, L148I, A158E, G159D/E, R186H, S188D, Y209E, Q236H, Q245R, N248D/R, H249R, N252K/R, T253R, and E271F wherein amino acid positions of the subtilisin variant are numbered by correspondence with the amino acid sequence of B. amyloliquefaciens subtilisin BPN′ set forth as SEQ ID NO:1.
  • the present invention also provides protease variants of Bacillus lentus subtilisin GG36 protease, wherein the Bacillus lentus subtilisin GG36 protease comprises the amino acid sequence shown in SEQ ID NO:2, wherein the protease variant comprises an amino acid sequence which differs from the amino acid sequence of SEQ ID NO:2 in no more than two, three, four, five, six, seven, eight, nine, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 mutations selected from the group of G20K, G20R, G23A, S24F, S24R, N43R, N43W, R45T, N62E, N76D, S101A, N116A, N116L, G118R, S128I, P129E, S188D, T213A, A215F, L217E, P239G, and N269R, wherein amino acid positions of the protease variant are numbered according to the numbering of corresponding amino acid positions
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant having proteolytic activity and comprising an amino acid sequence comprising a combination of amino acid substitutions selected from: A1R, Q2S, Q2M, Q2A, Q2R, Q2W, S3R, V4R, V4S, V4C, I8A, S9A, S9F, S9W, R10S, R10A, R10H, R10M, Q12F, Q12R, P14K, P14F, P14Q, A15R, A15F, A16S, H17R, H17M, H17F, N18R, N18K, G20F, G20K, G20R, T22A, T22R, T22Y, T22V, T22Q, T22L, T22W, G23A, G23S, G23F, S24R, S24F, S24W, S24Q, S24H, S24L, G25V, G25F, G
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant of Bacillus lentus subtilisin GG36 protease, wherein the Bacillus lentus subtilisin GG36 protease comprises the amino acid sequence shown in SEQ ID NO:2, and wherein the protease variant comprises an amino acid sequence which differs from the amino acid sequence of SEQ ID NO:2 in no more than two, three, four, five, six, seven, eight, nine, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 mutations at amino acid positions selected from amino acid 1, 2, 3, 4, 8, 9, 10, 12, 14, 15, 16, 17, 18, 20, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 33, 34, 35, 36, 38, 40, 42, 43, 45, 46, 48, 50, 51, 52, 55, 57, 59, 60, 62, 63, 64, 68, 69, 71, 72, 74, 75, 76, 78, 79, 81, 82, 85, 86, 89
  • amyloliquefaciens subtilisin BPN′ set forth as SEQ ID NO:1, wherein amino acid positions of the protease variant are numbered according to the numbering of corresponding amino acid positions in the amino acid sequence of Bacillus amyloliquefaciens subtilisin BPN′ shown in SEQ ID NO:1 as determined by alignment of the variant protease amino acid sequence with the Bacillus amyloliquefaciens subtilisin BPN′ amino acid sequence.
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant of Bacillus lentus subtilisin GG36 protease, wherein the Bacillus lentus subtilisin GG36 protease comprises the amino acid sequence shown in SEQ ID NO:2, and wherein the protease variant comprises an amino acid sequence which differs from the amino acid sequence of SEQ ID NO:2 in no more than two, three, four, five, six, seven, eight, nine, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, or 50 mutations selected from the group of A1R, Q2S, Q2M, Q2A, Q2R, Q2W, S3R, V4R, V4S, V4C, I8A, S9A, S9F, S9W, R10S, R10A, R10H, R10M, Q12F, Q12R, P14K, P14F, P14Q, A15R, A15F, A16S
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant of Bacillus lentus subtilisin GG36 protease, wherein the Bacillus lentus subtilisin GG36 protease comprises the amino acid sequence shown in SEQ ID NO:2, and wherein the protease variant comprises an amino acid sequence which differs from the amino acid sequence of SEQ ID NO:2 in no more than two, three, four, five, six, seven, eight, nine, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, or 50 mutations selected from the group of A1R, Q2S, V4R, V4S, S9A, R105, P14K, A16S, H17R, N18R, G20R, T22A, T22R, S24R, S24W, G25R, G25V, V26F, L42I, N43R, N43A, G46R, P52F, P52E, P52N, T57R,
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant of Bacillus lentus subtilisin GG36 protease, wherein the Bacillus lentus subtilisin GG36 protease comprises the amino acid sequence shown in SEQ ID NO:2, and wherein the protease variant comprises an amino acid sequence which differs from the amino acid sequence of SEQ ID NO:2 in no more than two, three, four, five, six, seven, eight, nine, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, or 50 mutations selected from the group of A1R, Q2S, V4R, V4S, S9A, R105, P14K, A16S, H17R, N18R, G20R, T22A, T22R, S24R, S24W, G25R, G25V, V26F, L42I, N43R, N43A, G46R, P52F, P52E, P52N, T57R,
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant of Bacillus lentus subtilisin GG36 protease, wherein the Bacillus lentus subtilisin GG36 protease comprises the amino acid sequence shown in SEQ ID NO:2, and wherein the protease variant comprises an amino acid sequence which differs from the amino acid sequence of SEQ ID NO:2 in no more than two, three, four, five, six, seven, eight, nine, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, or 50 mutations selected from the group of A16S, T22A, S24R, N62E, N76D, E89P, S101A/G, S103G/A, V104L/I, L111V, S128N, P129E, A232V, L148I, A158E, G159D/E, R186H, S188D, Y209E, Q236H, Q245R, N248D/R
  • the present invention also provides protease variants of Bacillus lentus subtilisin GG36 protease, wherein the Bacillus lentus subtilisin GG36 protease comprises the amino acid sequence shown in SEQ ID NO:2, wherein the protease variant comprises an amino acid sequence which differs from the amino acid sequence of SEQ ID NO:2 in no more than two, three, four, five, six, seven, eight, nine, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 mutations selected from the group of A165, T22A, S24R, N62E, N76D, E89P, S101A/G, S103G/A, V104L/I, L111V, S128N, P129E, A232V, L148I, A158E, G159D/E, R186H, S188D, Y209E, Q236H, Q245R, N248D/R, H249R, N252K/R, T253R, and
  • the present invention provides nucleic acids encoding Bacillus subtilisin variant of Bacillus lentus subtilisin GG36 protease, wherein the Bacillus lentus subtilisin GG36 protease comprises the amino acid sequence shown in SEQ ID NO:2, and wherein the protease variant comprises an amino acid sequence which differs from the amino acid sequence of SEQ ID NO:2 in no more than two, three, four, five, six, seven, eight, nine, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, or 50 mutations selected from the group of A16S, T22A, S24R, N62E, N76D, E89P, S101A/G, S103G/A, V104L/I, L111V, S128N, P129E, A232V, L148I, A158E, G159D/E, R186H, S188D, Y209E, Q236H, Q245R, N248D/R, H
  • the present invention also provides protease variants of Bacillus lentus subtilisin GG36 protease, wherein the Bacillus lentus subtilisin GG36 protease comprises the amino acid sequence shown in SEQ ID NO:2, wherein the protease variant comprises an amino acid sequence which differs from the amino acid sequence of SEQ ID NO:2 in no more than two, three, four, five, six, seven, eight, nine, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 mutations selected from the group of G20K, G20R, G23A, S24F, S24R, N43R, N43W, R45T, N62E, N76D, S101A, N116A, N116L, G118R, S128I, P129E, S188D, T213A, A215F, L217E, P239G, and N269R, wherein amino acid positions of the protease variant are numbered according to the numbering of corresponding amino acid positions
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant comprising an amino acid sequence which differs from the amino acid sequence of SEQ ID NO:2, and wherein the total net charge of the protease variant is +1, +2, +3, +4, +5, 0, ⁇ 1, ⁇ 2, ⁇ 3, ⁇ 4, or ⁇ 5 relative to the total net charge of the Bacillus lentus subtilisin GG36 protease, and wherein amino acid positions of the protease variant are numbered according to the numbering of corresponding amino acid positions in the amino acid sequence of Bacillus amyloliquefaciens subtilisin BPN′ shown in SEQ ID NO:1 as determined by alignment of the protease variant amino acid sequence with the Bacillus amyloliquefaciens subtilisin BPN′ amino acid sequence.
  • the present invention also provides protease variants comprising amino acid sequence which differs from the amino acid sequence of SEQ ID NO:2, and wherein the total net charge of the protease variant is 0 relative to the total net charge of the Bacillus lentus subtilisin GG36 protease, and wherein amino acid positions of the protease variant are numbered according to the numbering of corresponding amino acid positions in the amino acid sequence of Bacillus amyloliquefaciens subtilisin BPN′ shown in SEQ ID NO:1 as determined by alignment of the protease variant amino acid sequence with the Bacillus amyloliquefaciens subtilisin BPN′ amino acid sequence.
  • the present invention provides nucleic acids encoding a Bacillus subtilisin variant having one or more of the following characteristics: a) a Test Method 2 performance index of at least 1.1, at least 1.2, at least 1.3, at least 1.4, at least 1.5, at least 1.6, at least 1.7, at least 1.8, at least 1.9, at least 2, from 1.1 to about 10, from 1.1 to about 8, or even from 1.1 to about 5; b) a Test Method 3 performance index of at least 1.1, at least 1.2, at least 1.3, at least 1.4, at least 1.5, at least 1.6, at least 1.7, at least 1.8, at least 1.9, at least 2, from 1.1 to about 10, from 1.1 to about 8, or even from 1.1 to about 5; c) a Test Method 4 performance index of at least 1.0, at least 1.1, at least 1.2, at least 1.3, at least 1.4, at least 1.5, at least 1.6, at least 1.7, at least 1.8, at least 1.9, at least 2, from 1.0 to
  • suitable cold water protease variants are variants of a parent protease, said parent protease's sequence being at least 97%, at least 99% or 100% identical to the amino acid sequence of SEQ ID NO:1, said protease variant having one or more of the following characteristics:
  • Test Method 2 Test Method 3, Test Method 4, and Test Method 6 are explicitly described infra in the section of Example 1 entitled “Test Methods”. All mutations referenced herein utilize the BPN′ numbering scheme as shown in FIG. 1 .
  • the variants referenced herein refer to variants having amino acid sequences compared to the amino acid sequence of SEQ ID NO:2, using the BPN′ numbering scheme.
  • the variants provided herein refer to variants of a parent protease, wherein the parent protease's sequence being at least 97%, at least 99% or 100% identical to the amino acid sequence of SEQ ID NO:1.
  • Suitable cold water proteases can be derived from subtilisins, particularly those derived from subtilisin Bacillus lentus GG36 of SEQ ID NO:2 and in some embodiments, comprise one or more of the following mutations: A1R, Q2S, V4R, V4S, S9A, R105, P14K, A16S, H17R, N18R, G20R, T22A, T22R, S24R, S24W, G25R, G25V, V26F, L42I, N43R, N43A, G46R, P52F, P52E, P52N, T57R, Q59A, N62E, N62Q, V68A, V68C, T71G, 172C, A74C.
  • suitable cold water protease variants include subtilisins, particularly those derived from Bacillus lentus GG36 of SEQ ID NO:2, comprising one or more of the following sets of mutations: T022R-S024R, S009A-E271L, N018R-W241R, N018R-G115R, N043R-H249R, G020R-H249R, V004R-H249R, G020R-S024R, N018R-H249R, S009A-G020R, G020R-W241R, S009A-S078R, G020R-G115R, N018R-S024R, S024R-S242R, T022R-G115R, N018R-N043R, G020R-N043R, N018R-S242R, S242R-N269R, N018R
  • the present invention further provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: G020R-N043R, G020K-N062E, S024F-N116L, G020K-S024F, S024R-A174T, S024R-G118R, S024R-K235F, S024R-P086R, S024R-P086W, S078R-G118R, T033S-G118R, T033S-K235F, Y209A-W241R, G020R-N076D, N018R-Q245R, S024R-R045T, A232V-Q245R, G118R-A172V, G118R-A194T, 1008T-S024R, K235F-N243F, N018R-S103A, N
  • the present invention further provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: G020R-N076D, S024R-R045T, A230E-H249R, N018R-R045T, N018R-Q245R, S101G-A232V, S024R-A232V, A232V-Q245R, S024R-S101G, N018R-V104I, N018R-S103A, S101G-H249R, A232V-H249R, S103A-A232V, N076D-Q245R, S101G-V104I, V104I-A232V, N076D-H249R, S024R-N076D, S024F-N116L, G020K-S024F, G020K-N062E, T033S
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: V004R-S009A-G020R-S242R, G020R-N043R-W241R, G020R-S242R-N269R, V004R-S009A-G020R-N043R, V004R-G020R-H249R, N018R-S024R-V244R, S009A-T022R-S212F-W241R, G020R-N043R-N269R, N018R-S024R-S242R, V004R-S009A-N043R-W241R, G020R-N043R-V244R, G020R-T022R-S242R, V004R-G020
  • subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: N018R-G020R-N043D-R045T-A230E, N018R-N043R-R045T-S242R-H249R, S024R-N043D-H249R, N018R-G020R-R045T, G020R-S024R-N076D-H249R, S024R-N043R-A230E-S242R, N018R-S024R-N043D-A230E, G020R-N076D, N018R-S024R-N043D-N076D-H249R, S024R-N043R-N076D-H249R, N018R-S024R-R045T-S
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: S101G-S103A-V104I-A232V-Q236H-Q245R-N252K, S101G-S103A-V104I-A232V-Q245R-N248R, S101G-S103A-V104I-G159R-A232V-Q245R-N248D, S101G-S103A-V104I-G159D-A232V-Q245R-N248R, S101G-S103A-V104I-A232V-Q245R, S101G-S103A-V104I-G159D-A232V-Q245R, and S101G-S103A-V104I-A232V-Q245R-N248D, wherein the amino acid positions of the subtilisin variant are numbered by correspondence
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: S101G-S103A-V104I-P129E-S188D-A232V-N238R-Q245R-N248D, S024R-S101G-S103A-V104I-P129E-A158E-S188D-A232V-Q245R-N248D-H249R, T022A-S101G-S103A-V104I-P129E-A158E-S188D-A232V-Q245R-N248D-H249R, T022A-S024R-S101G-S103A-V104I-P129E-A158E-S188D-A232V-Q245R-N248D-H249R, S024R-S101G-S103A-V104I-P129
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: T022A-S024R-S101G-S103A-V104I-A158E-A232V-Q245R-N248D-H249R, T022A-S024R-S101G-S103A-V104I-P129E-A232V-Q245R-N248D-H249R, S024R-S101G-S103A-V104I-A158E-G159E-A232V-N238R-Q245R-N248D, S024R-S101G-S103A-V104I-A232V-Q245R-N248D-H249R, S101G-S103A-V104I-A158E-A232V-Q245R-N248D-H249R, S101
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: V104L-S128N-A158E-R186H-H249R, S128N-A158E-S188D-H249R, N062E-S128N-A158E-G159E-E271F, N062E-A158E-S188D-H249R-E271F, N062E-A158E-R186H-H249R-E271F, S128N-A158E-S188D-Y209E-E271F, N062E-G159E-S188D-H249R, A016S-N062E-A158E-R186H-H249R, N062E-A158E-G159E-H249R, S101A-S128N-A158E-Y209
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: A001R-S101G-S103A-V104I-A232V-Q245R, V004R-S101G-S103A-V104I-A232V-Q245R, N043R-S101G-S103A-V104I-A232V-Q245R-E271L, S078R-S101G-S103A-V104I-A232V-Q245R, V004R-N043R-S101G-S103A-V104I-A232V-Q245R, N018R-N043R-S101G-S103A-V104I-A232V-Q245R, G020R-S101G-S103A-V104I-A232V-Q245R, S101G-S103A-V104I
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: G020R-T022W-S078R-S101A-S103A-V104I-N116S-T213A-A215F-A232V-Q245R, N018R-S078R-S101G-S103A-V104I-A232V-Q245R, S024R-R045T-S101G-S103A-V104I-A232V-Q245R-N269R, G020R-T022W-S078R-S101G-S103A-V104I-N116A-A232V-Q245R, G020R-T22W-S101G-S103A-V104I-A232V-Q245R, N018R-N043R-S101G-S103A-V104
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: N018R-S024R-N043R-N076D-H249R-N269R, N018R-T022R-S024R-N043R-N076D-H249R, N018R-N043D-S101G-S103A-V104I-A232V-Q245R, G020R-N043D-S101G-S103A-V104I-A232V-Q245R, N043D-S101G-S103A-V104I-A232V-Q245R, N043D-S101G-S103A-V104I-A232V-Q245R-N269R, N043D-S078R-S101G-S103A-V104I-A232V-Q2
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: G020R-S101A-S103A-V104I-G118R-A232V-Q245R, G020R-S024R-N116A-T213A, N043R-S101A-N116A-A215F-N269R, S024R-N043R-S101A-N116A, S024R-N043R-S101A-N116A-A215F-N269R, G020R-S101G-S103A-V104I-A215F-A232V-Q245R, N043R-S101A-N269R, S024R-N043R-N116A-T213A-N269R, G020R-S024R-N043R-R045T-
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: N043R-N076D-S101A-S103A-V104I-A158E-S188D-A232V-Q245R-N248D-H249R-E271F, S024R-N043R-N076D-S101A-S103A-V104I-A158E-S188D-L217E-A232V-Q245R-N248D-H249R, S101A-S103A-V104I-A158E-S188D-A232V-Q245R-N248D-H249R-E271F-E271F, S101A-S103A-V104I-A158E-S188D-L217E-A232V-Q245R-N248D-H249R-E
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: T022A-S101G-S103A-V104I-G159D-L217E-A232V-Q245R-N248D-E271F, T022A-N043R-S101G-S103A-V104I-G159D-S188D-L217E-A232V-Q245R-N248D-E271F, T022A-S101G-S103A-V104I-G159D-S188D-A232V-Q245R-N248D-E271F, N043R-S101A-S103A-V104I-A158E-S188D-L217E-A232V-Q245R-N248D-H249R, N043R-N076D-S101A-S
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: H017R-T022A-N076D-S101G-S103A-V104I-G159D-S188D-A232V-Q245R-N248D-E271F, T022A-N043R-S101G-S103A-V104I-G159D-A232V-Q245R-N248D-E271F, T022A-S101G-S103A-V104I-G159D-S188D-A232V-Q245R-N248D-H249R-E271F, H017R-T022A-N076D-S101G-S103A-V104I-G159D-A232V-Q245R-N248D-E271F, T022A-N076D
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: S101S-S103A-V104I-A158E-S188D-A232V-Q245R-N248D-H249R, S101S-S103G-V104V-A158E-S188D-A232V-Q245R-N248D-H249R, S101G-S103S-V104I-A158E-S188D-A232V-Q245R-N248D-H249R, S101A-S103A-V104I-A158E-S188D-A232V-Q245R-N248D-H249R, S101A-S103A-V104I-A158E-S188D-A232V-Q245R-N248D-H249R, S101A-S103A-V104L-
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: V026F-V051W-V104L-S106E, V026F-L031F-S078N-G102A-S160D, G020K-G100S-N116L-A158E-S166D-N243F, T033S-N043W-N218D-P239G-N243F, T022L-T038F-A048R-N062E-G100S-R186K, S101D-S103N-N116L-S144R-A215D, V104L-S105T-T213A-L217E-S256N, N043W-S101D-S212M-N243F, V026F-A048R-S105T-T213A-N218D-T224A, S
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: T022A-S024R-S101D-S103A-V104I-G118R-G159D-S188D-A232V-N248D-E271F, T022A-S024R-S103A-V104I-P129E-G159D-S188D-A232V-N248D-E271F, T022A-S024R-S103A-V104I-G118R-G159D-S188D-L217D-A232V-N248D, T022A-S024R-S101D-S103A-V104I-G118R-P129E-G159D-S188D-A232V-Q245R-N248D, T022A-S024R-S101D-S103A-V
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: G020K-S024F-N062E-S188D-P239G, S024F-N062E-N116L-P239G, G020K-G023A-N062E-S188D, G020K-G023A-S024F-N062E-G118R-S188D-T213A, G020K-N043W-N062E-N116L-S188D-T213A-P239G, G023A-N062E-N116L-G118R, G023A-S024F-N062E-N116L-G118R, S024F-N116L, S024F-N062E-S188D-T213A, G023A-N062E-
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: G020K-G023A-N043W-G118R-S128I-P129E-G159D-S188D, S024F-G118R-S128I-P129E-G159D, G020K-S024F-N062E-N116L-G118R-S188D, G020K-N062E-N116L-S188D, N062E-N116L-G118R-T213A, G020K-G023A-N062E-N116L-S188D, N062E-N116L-G118R-S188D, G020K-N062E-N116L-T213A, G020K-G023A-N062E-N116L-S188D, N062E
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: S087R-S101G-S103A-V104I-Q109R-S212P-A232V-Q245R-E271V, S101G-S103A-V104I-Q109R-A232V-Q245R, S101G-S103A-V104I-Q109R-S212P-A232V-Q245R-E271V, S101G-S103A-V104I-Q109R-S212P-A232V-Q245R, N076D ⁇ 587R-S103A-V104I-S212P-E271V, N076D-S103A-V104I-Q109R, N076D-S103A-V104I-S212P-E271V, N076D-S103A-V104I-Q109
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: S024R-P086W-G118R, S024R-S078R-P086W-N243F, S024R-T033S-P086S-S087N-Y209A, T033S-G118R, S024R-S078R-P086W-G118R-A270T, S024R-T033S-P086W-G118R, S078R-P086W-N243F, T033S-S078R-P086W-G118R-Y209A, T033S-S078R-Y209A, P086W-G118R-N243F, S024R-P086W, S078R-P086W-K235F, S024R-G118R
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: G020R-S087D-S101G-S103A-V104I-A232V-Q245R, G020R-S101G-S103A-V104I-V150L-A232V-Q245R, N018R-G020R-S024R-N076D-S087D-H249R, N018R-G020R-S024R-N076D-V150L-H249R, N018R-S024R-N043R-N076D-S087D-H249R, N018R-S024R-N043R-N076D-S087D-H249R, N018R-S024R-N043R-N076D-V150L-H249
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: S024R-S101G-S103A-V104I-P129Q-A158E-S188D-L217E-A232V-Q245R-N248D-H249R, S024R-S101G-S103A-V104I-S130A-A158E-N183D-S188D-A232V-Q245R-N248D-H249R, S024R-S101G-S103A-V104I-P129Q-A158E-N183D-S188D-A232V-Q245R-N248D-H249R, S101G-S103A-V104I-S130A-A158E-S188D-A232V-Q245R-N248D-H249R, S101G-S103A
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: S101G-S103A-V104I-A232V-M222Q-Q245R, S101G-S103A-V104I-A158E-S188D-M222S-A232V-Q245R-N248D-H249R, S101G-S103A-V104I-A158E-S188D-M222Q-A232V-Q245R-N248D-H249R, N076D-S101G-S103A-V104I-A232V-M222Q-Q245R, S101G-S103A-V104I-A232V-M222S-Q245R, N076D-S101G-S103A-V104I-A232V-M222S-Q245R, N076D-S101G-S103
  • the present invention also provides isolated subtilisin variants, wherein the subtilisin variants are mature forms having proteolytic activity and comprise amino acid sequences comprising a combination of amino acid substitutions selected from: S024R-S101G-S103A-V104I-S128L-P129Q-A158E-S188D-A232V-Q245R-N248D-H249R, S101G-S103A-V104I-S130A-A158E-S188D-A232V-Q245R-N248D-H249R, S024R-S101G-S103A-V104I-A158E-S188D-A232V-Q245R-N248D-H249R, S101G-S103A-V104I-S128L-P129Q-A158E-S188D-A232V-Q245R-N248D-H249R, S101G-S103A-V104I-S128L-P129
  • suitable cold water protease variants include variants of subtilisins, particularly those derived from Bacillus lentus GG36 of SEQ ID NO:2, wherein the variants comprise three, four, five, six, seven, eight, nine, 10, 11, 12, 13, 14 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or even 25 mutations within the group of positions comprising positions 1, 2, 4, 9, 10, 14, 16, 17, 18, 20, 22, 24, 25, 26, 42, 43, 46, 52, 57, 59, 62, 68, 71, 72, 74, 75, 76, 78, 82, 86, 89, 91, 94, 100, 101, 103, 104, 106, 108, 111, 112, 115, 117, 118, 121, 128, 129, 144, 148, 158, 159, 160, 166, 185, 186, 188, 197, 203, 209, 210, 212, 214, 215, 217, 224, 230, 231, 236, 23
  • suitable cold water protease variants include variants of subtilisins, particularly those derived from Bacillus lentus GG36 of SEQ ID NO:2, wherein the variants comprise a total of three, four, five, six, seven, eight, nine, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or even 25 mutations selected from: A1R, Q2S, V4R, V4S, S9A, R105, P14K, A16S, H17R, N18R, G20R, T22A, T22R, S24R, S24W, G25R, G25V, V26F, L42I, N43R, N43A, G46R, P52F, P52E, P52N, T57R, Q59A, N62E, N62Q, V68A, V68C, T71G, 172C, A74C.
  • the cold water protease variant comprises one or more mutations, and having a total net charge of ⁇ 5, ⁇ 4, ⁇ 3, ⁇ 2, ⁇ 1 or 0 relative to B. lentus subtilisin GG36 wild-type (SEQ ID NO:2)
  • the cold water protease variants are low ionic strength cold water protease variants.
  • Such low ionic strength cold water protease variants comprising one or more mutations, and having a total net charge of ⁇ 5, ⁇ 4, ⁇ 3, ⁇ 2, ⁇ 1 or 0 relative to B. lentus subtilisin GG36 protease wild-type (SEQ ID NO:2).
  • these mutations are selected from: two or more of the following mutations: A1R, Q2S, V4R, V4S, S9A, R105, P14K, A16S, T22A, T22R, S24R, G25V, V26F, L421, P52F, P52E, P52N, N62E, N62Q, V68A, V68C, T71G, 172C, A74C.
  • the above low ionic strength cold water protease variants form part of a detergent composition that is diluted in water, typically within a laundry washing machine, to form a laundry detergent wash liquor, whose conductivity is from about 0.1 mS/cm to about 3 mS/cm, from about 0.3 mS/cm to about 2.5 mS/cm, or even from about 0.5 mS/cm to about 2 mS/cm
  • the cold water protease variants are high ionic strength cold water protease variants.
  • Such high ionic strength cold water protease variants comprise two or more mutations, and have a total net charge of +5, +4, +3, +2, +1 or 0 relative to B. lentus subtilisin GG36 protease wild-type (SEQ ID NO:2).
  • these mutations are selected from: two or more of the following mutations V4R, H17R, N18R, G20R, T22R, S24R, S24W, G25R, N43R, N43A, G46R, P52F, P52N, T57R, Q59A, N62Q, T71G, L75R, N76D, S78R, L82R, P86W, E89P, E89W, E89T, E89I, E89H, E89V, V104L, S106V, S106G, G115R, G1181, V121F, S144R, N185I, D197F, Y209N, Y2095, L217E, A231I, P239R, P239S, W241R, S242R, S242L, N243R, V244R, N248I, H249R, N252R, T253R, E271T, E271V, E271
  • the above high ionic strength cold water protease variants form part of a detergent composition that is diluted in water, typically within a laundry washing machine, to form a laundry detergent wash liquor, whose conductivity is from about 3 mS/cm to about 30 mS/cm, from about 3.5 mS/cm to about 20 mS/cm, or even from about 4 mS/cm to about 10 mS/cm.
  • the charge of the cold water protease variants is expressed relative to B. lentus subtilisin GG36 protease wild-type having the amino acid sequence of SEQ ID NO:2.
  • the amino acids that impart a single negative charge are D and E and those that impart a single positive charge are R, H and K.
  • Any amino acid change versus SEQ ID NO:2 that changes a charge is used to calculate the charge of the cold water protease variant. For example, introducing a negative charge mutation from a wild-type neutral position will add a net charge of ⁇ 1 to the cold water protease variant, whereas introducing a negative charge mutation (D or E) from a wild-type positive amino acid residue (R, H or K) will add a net charge of ⁇ 2.
  • the preferred charge range for cold water proteases to be used in low conductivity laundry detergent solutions is ⁇ 5, ⁇ 4, ⁇ 3, ⁇ 2, ⁇ 1, 0, particularly ⁇ 2, ⁇ 1
  • the preferred charge range for cold water proteases to be used in high conductivity laundry detergent solutions is +5, +4, +3, +2, +1, 0, particularly +2, +1.
  • “Low conductivity laundry detergent solutions” are defined as having a conductivity of from about 0.1 mS/cm to about 3 mS/cm, from about 0.3 mS/cm to about 2.5 mS/cm, or even from about 0.5 mS/cm to about 2 mS/cm. “High conductivity laundry detergent solutions” are defined as having a conductivity of from about 3 mS/cm to about 30 mS/cm, from about 3.5 mS/cm to about 20 mS/cm, or even from about 4 mS/cm to about 10 mS/cm. It is intended that the above examples be non-limiting. Once mutations are combined to optimize cold water performance, the enzyme charge can also be balanced by mutations in further positions.
  • the invention provides an isolated, recombinant, substantially pure, or non-naturally occurring variant protease (e.g., variant subtilisin) having proteolytic activity, said variant protease comprising an amino acid sequence which differs from the amino acid sequence shown in SEQ ID NO:2 by no more than 50, no more than 45, no more than 40, no more than 35, no more than 30, no more than 25, no more than 20, no more than 19, no more than 18, no more than 17, no more than 16, no more than 15, no more than 14, no more than 13, no more than 12, no more than 11, no more than 10, no more than 9, or no more than 8 amino acid residues, wherein amino acid positions are numbered according to the numbering of corresponding amino acid positions in the amino acid sequence of Bacillus amyloliquefaciens subtilisin BPN′ shown in SEQ ID NO:1, as determined by alignment of the variant protease amino acid sequence with the Bacillus amyloliquefaciens subtilisin BPN′ amino acid sequence, wherein the variant proteas
  • the invention provides an isolated, recombinant, substantially pure, or non-naturally occurring variant protease (e.g., variant subtilisin) having proteolytic activity, said variant protease comprising an amino acid sequence which differs from the amino acid sequence shown in SEQ ID NO:2 by no more than 50, no more than 45, no more than 40, no more than 35, no more than 30, no more than 25, no more than 20, no more than 19, no more than 18, no more than 17, no more than 16, no more than 15, no more than 14, no more than 13, no more than 12, no more than 11, no more than 10, no more than 9, no more than 6, no more than 5, no more than 4, no more than 3, no more than 2 amino acid residues, wherein amino acid positions are numbered according to the numbering of corresponding amino acid positions in the amino acid sequence of Bacillus amyloliquefaciens subtilisin BPN′ shown in SEQ ID NO:1, as determined by alignment of the variant protease amino acid sequence with the Bacillus amyloliquefaci
  • Nucleic acids of the invention can be generated by using any suitable synthesis, manipulation, and/or isolation techniques, or combinations thereof.
  • a polynucleotide of the invention may be produced using standard nucleic acid synthesis techniques, such as solid-phase synthesis techniques that are well-known to those skilled in the art. In such techniques, fragments of up to 50 or more nucleotide bases are typically synthesized, then joined (e.g., by enzymatic or chemical ligation methods, or polymerase mediated recombination methods) to form essentially any desired continuous nucleic acid sequence.
  • nucleic acids of the invention can be also facilitated (or alternatively accomplished) by any suitable method known in the art, including but not limited to chemical synthesis using the classical phosphoramidite method (See e.g., Beaucage et al. Tetrahedron Letters 22:1859-69 [1981]); or the method described by Matthes et al. (See, Matthes et al., EMBO J. 3:801-805 [1984], as is typically practiced in automated synthetic methods. Nucleic acids of the invention also can be produced by using an automatic DNA synthesizer.
  • Customized nucleic acids can be ordered from a variety of commercial sources (e.g., The Midland Certified Reagent Company, the Great American Gene Company, Operon Technologies Inc., and DNA2.0). Other techniques for synthesizing nucleic acids and related principles are known in the art (See e.g., Itakura et al., Ann. Rev. Biochem. 53:323 [1984]; and Itakura et al., Science 198:1056 [1984]).
  • nucleotides of the invention may also be obtained by screening cDNA libraries (e.g., cDNA libraries generated using mutagenesis techniques commonly used in the art, including those described herein) using one or more oligonucleotide probes that can hybridize to or PCR-amplify polynucleotides which encode a variant protease polypeptide(s) of the invention.
  • cDNA libraries e.g., cDNA libraries generated using mutagenesis techniques commonly used in the art, including those described herein
  • oligonucleotide probes that can hybridize to or PCR-amplify polynucleotides which encode a variant protease polypeptide(s) of the invention.
  • nucleic acids of the invention can be obtained by altering a naturally occurring polynucleotide backbone (e.g., that encodes an enzyme or parent protease) by, for example, a known mutagenesis procedure (e.g., site-directed mutagenesis, site saturation mutagenesis, and in vitro recombination).
  • a naturally occurring polynucleotide backbone e.g., that encodes an enzyme or parent protease
  • mutagenesis procedure e.g., site-directed mutagenesis, site saturation mutagenesis, and in vitro recombination.
  • a variety of methods are known in the art that are suitable for generating modified polynucleotides of the invention that encode variant proteases of the invention, including, but not limited to, for example, site-saturation mutagenesis, scanning mutagenesis, insertional mutagenesis, deletion mutagenesis, random mutagenesis, site-directed mutagenesis, and directed-evolution, as well as various other recombinatorial approaches.
  • Methods for making modified polynucleotides and proteins include DNA shuffling methodologies, methods based on non-homologous recombination of genes, such as ITCHY (See, Ostermeier et al., 7:2139-44 [1999]), SCRACHY (See, Lutz et al.
  • the present invention provides isolated or recombinant vectors comprising at least one polynucleotide of the invention described herein (e.g., a polynucleotide encoding a variant protease of the invention described herein), isolated or recombinant expression vectors or expression cassettes comprising at least one nucleic acid or polynucleotide of the invention, isolated, substantially pure, or recombinant DNA constructs comprising at least one nucleic acid or polynucleotide of the invention, isolated or recombinant cells comprising at least one polynucleotide of the invention, cell cultures comprising cells comprising at least one polynucleotide of the invention, cell cultures comprising at least one nucleic acid or polynucleotide of the invention, and compositions comprising one or more such vectors, nucleic acids, expression vectors, expression cassettes, DNA constructs, cells, cell cultures, or any combination or mixtures thereof.
  • the invention provides recombinant cells comprising at least one vector (e.g., expression vector or DNA construct) of the invention which comprises at least one nucleic acid or polynucleotide of the invention. Some such recombinant cells are transformed or transfected with such at least one vector. Such cells are typically referred to as host cells. Some such cells comprise bacterial cells, including, but are not limited to Bacillus sp. cells, such as B. subtilis cells. The invention also provides recombinant cells (e.g., recombinant host cells) comprising at least one variant protease of the invention.
  • vector e.g., expression vector or DNA construct
  • Some such recombinant cells are transformed or transfected with such at least one vector.
  • Such cells are typically referred to as host cells. Some such cells comprise bacterial cells, including, but are not limited to Bacillus sp. cells, such as B. subtilis cells.
  • the invention also provides recombinant cells (e.g.,
  • the invention provides a vector comprising a nucleic acid or polynucleotide of the invention.
  • the vector is an expression vector or expression cassette in which a polynucleotide sequence of the invention which encodes a variant protease of the invention is operably linked to one or additional nucleic acid segments required for efficient gene expression (e.g., a promoter operably linked to the polynucleotide of the invention which encodes a variant protease of the invention).
  • a vector may include a transcription terminator and/or a selection gene, such as an antibiotic resistance gene that enables continuous cultural maintenance of plasmid-infected host cells by growth in antimicrobial-containing media.
  • An expression vector may be derived from plasmid or viral DNA, or in alternative embodiments, contains elements of both.
  • Exemplary vectors include, but are not limited to pXX, pC194, pJH101, pE194, pHP13 (See, Harwood and Cutting [eds.], Chapter 3 , Molecular Biological Methods for Bacillus , John Wiley & Sons [1990]; suitable replicating plasmids for B. subtilis include those listed on p.
  • a protein of interest e.g., variant protease
  • at least one expression vector comprising at least one copy of a polynucleotide encoding the modified protease, and preferably comprising multiple copies, is transformed into the cell under conditions suitable for expression of the protease.
  • a polynucleotide sequence encoding the variant protease (as well as other sequences included in the vector) is integrated into the genome of the host cell, while in other embodiments, a plasmid vector comprising a polynucleotide sequence encoding the variant protease remains as autonomous extra-chromosomal element within the cell.
  • the invention provides both extrachromosomal nucleic acid elements as well as incoming nucleotide sequences that are integrated into the host cell genome.
  • the vectors described herein are useful for production of the variant proteases of the invention.
  • a polynucleotide construct encoding the variant protease is present on an integrating vector that enables the integration and optionally the amplification of the polynucleotide encoding the variant protease into the bacterial chromosome. Examples of sites for integration are well known to those skilled in the art.
  • transcription of a polynucleotide encoding a variant protease of the invention is effectuated by a promoter that is the wild-type promoter for the selected precursor protease.
  • the promoter is heterologous to the precursor protease, but is functional in the host cell.
  • suitable promoters for use in bacterial host cells include, but are not limited to, for example, the amyE, amyQ, amyL, pstS, sacB, pSPAC, pAprE, pVeg, pHpaII promoters, the promoter of the B. stearothermophilus maltogenic amylase gene, the B.
  • amyloliquefaciens (BAN) amylase gene, the B. subtilis alkaline protease gene, the B. clausii alkaline protease gene the B. pumilis xylosidase gene, the B. thuringiensis cryIIIA, and the B. licheniformis alpha-amylase gene.
  • Additional promoters include, but are not limited to the A4 promoter, as well as phage Lambda P R or P L promoters, and the E. coli lac, trp or tac promoters.
  • Variant proteases of the present invention can be produced in host cells of any suitable Gram-positive microorganism, including bacteria and fungi.
  • the variant protease is produced in host cells of fungal and/or bacterial origin.
  • the host cells are Bacillus sp., Streptomyces sp., Escherichia sp. or Aspergillus sp.
  • the variant proteases are produced by Bacillus sp. host cells. Examples of Bacillus sp. host cells that find use in the production of the variant proteases of the invention include, but are not limited to B. licheniformis, B. lentus, B. subtilis, B.
  • B. subtilis host cells are used for production of variant proteases.
  • U.S. Pat. Nos. 5,264,366 and 4,760,025 describe various Bacillus host strains that can be used for producing variant proteases of the invention, although other suitable strains can be used.
  • the host strain is a recombinant strain, wherein a polynucleotide encoding a polypeptide of interest has been introduced into the host.
  • the host strain is a B. subtilis host strain and particularly a recombinant Bacillus subtilis host strain. Numerous B.
  • subtilis strains are known, including, but not limited to for example, 1A6 (ATCC 39085), 168 (1A01), SB19, W23, Ts85, B637, PB1753 through PB1758, PB3360, JH642, 1A243 (ATCC 39,087), ATCC 21332, ATCC 6051, MI113, DE100 (ATCC 39,094), GX4931, PBT 110, and PEP 211 strain (See e.g., Hoch et al., Genetics 73:215-228 [1973]; See also, U.S. Pat. Nos. 4,450,235 and 4,302,544, and EP 0134048, each of which is incorporated by reference in its entirety). The use of B.
  • subtilis as an expression host cells is well known in the art (See e.g., Palva et al., Gene 19:81-87 [1982]; Fahnestock and Fischer, J. Bacteriol., 165:796-804 [1986]; and Wang et al., Gene 69:39-47 [1988]).
  • the Bacillus host cell is a Bacillus sp. that includes a mutation or deletion in at least one of the following genes, degU, degS, degR and degQ.
  • the mutation is in a degU gene, and more preferably the mutation is degU(Hy)32 (See e.g., Msadek et al., J. Bacteriol. 172:824-834 [1990]; and Olmos et al., Mol. Gen. Genet. 253:562-567 [1997]).
  • One suitable host strain is a Bacillus subtilis carrying a degU32(Hy) mutation.
  • the Bacillus host comprises a mutation or deletion in scoC4 (See e.g., Caldwell et al., J. Bacteriol. 183:7329-7340 [2001]); spoIIE (See e.g., Arigoni et al., Mol. Microbiol. 31:1407-1415 [1999]); and/or oppA or other genes of the opp operon (See e.g., Perego et al., Mol. Microbiol. 5:173-185 [1991]).
  • scoC4 See e.g., Caldwell et al., J. Bacteriol. 183:7329-7340 [2001]
  • spoIIE See e.g., Arigoni et al., Mol. Microbiol. 31:1407-1415 [1999]
  • oppA or other genes of the opp operon See e.g., Perego et al., Mol. Microbiol. 5:17
  • an altered Bacillus host cell strain that can be used to produce a variant protease of the invention is a Bacillus host strain that already includes a mutation in one or more of the above-mentioned genes.
  • Bacillus sp. host cells that comprise mutation(s) and/or deletions of endogenous protease genes find use.
  • the Bacillus host cell comprises a deletion of the aprE and the nprE genes. In other embodiments, the Bacillus sp. host cell comprises a deletion of 5 protease genes, while in other embodiments, the Bacillus sp. host cell comprises a deletion of 9 protease genes (See e.g., U.S. Pat. Appln. Pub. No. 2005/0202535, incorporated herein by reference).
  • Host cells are transformed with at least one nucleic acid encoding at least one variant protease of the invention using any suitable method known in the art.
  • the nucleic acid is typically introduced into a microorganism, in some embodiments, preferably an E. coli cell or a competent Bacillus cell.
  • Methods for introducing a nucleic acid (e.g., DNA) into Bacillus cells or E. coli cells utilizing plasmid DNA constructs or vectors and transforming such plasmid DNA constructs or vectors into such cells are well known.
  • the plasmids are subsequently isolated from E. coli cells and transformed into Bacillus cells.
  • it is not essential to use intervening microorganisms such as E. coli and in some embodiments, a DNA construct or vector is directly introduced into a Bacillus host.
  • nucleic acid or polynucleotide sequences of the invention into Bacillus cells (See e.g., Ferrari et al., “Genetics,” in Harwood et al. [eds.], Bacillus , Plenum Publishing Corp. [1989], pp. 57-72; Saunders et al., J. Bacteriol. 157:718-726 [1984]; Hoch et al., J. Bacteriol. 93:1925-1937 [1967]; Mann et al., Current Microbiol. 13:131-135 [1986]; Holubova, Folia Microbiol.
  • Methods of transformation are used to introduce a DNA construct or vector comprising a nucleic acid encoding a variant protease of the present invention into a host cell.
  • Methods known in the art to transform Bacillus cells include such methods as plasmid marker rescue transformation, which involves the uptake of a donor plasmid by competent cells carrying a partially homologous resident plasmid (See, Contente et al., Plasmid 2:555-571 [1979]; Haima et al., Mol. Gen. Genet. 223:185-191 [1990]; Weinrauch et al., J. Bacteriol. 154:1077-1087 [1983]; and Weinrauch et al., J. Bacteriol. 169:1205-1211 [1987]).
  • the incoming donor plasmid recombines with the homologous region of the resident “helper” plasmid in a process that mimics chromosomal transformation.
  • host cells are directly transformed with a DNA construct or vector comprising a nucleic acid encoding a variant protease of the invention (i.e., an intermediate cell is not used to amplify, or otherwise process, the DNA construct or vector prior to introduction into the host cell).
  • Introduction of the DNA construct or vector of the invention into the host cell includes those physical and chemical methods known in the art to introduce a nucleic acid sequence (e.g., DNA sequence) into a host cell without insertion into a plasmid or vector. Such methods include, but are not limited to calcium chloride precipitation, electroporation, naked DNA, liposomes and the like.
  • DNA constructs or vector are co-transformed with a plasmid, without being inserted into the plasmid.
  • a selective marker is deleted from the altered Bacillus strain by methods known in the art (See, Stahl et al., J. Bacteriol. 158:411-418 [1984]; and Palmeros et al., Gene 247:255-264 [2000]).
  • the transformed cells of the present invention are cultured in conventional nutrient media.
  • suitable specific culture conditions such as temperature, pH and the like are known to those skilled in the art and are well described in the scientific literature.
  • the invention provides a culture (e.g., cell culture) comprising at least one variant protease or at least one nucleic acid of the invention.
  • compositions comprising at least one nucleic acid, vector, or DNA construct of the invention.
  • host cells transformed with at least one polynucleotide sequence encoding at least one variant protease of the invention are cultured in a suitable nutrient medium under conditions permitting the expression of the present protease, after which the resulting protease is recovered from the culture.
  • the medium used to culture the cells comprises any conventional medium suitable for growing the host cells, such as minimal or complex media containing appropriate supplements. Suitable media are available from commercial suppliers or may be prepared according to published recipes (See e.g., the catalogues of the American Type Culture Collection).
  • the protease produced by the cells is recovered from the culture medium by conventional procedures, including, but not limited to for example, separating the host cells from the medium by centrifugation or filtration, precipitating the proteinaceous components of the supernatant or filtrate by means of a salt (e.g., ammonium sulfate), chromatographic purification (e.g., ion exchange, gel filtration, affinity, etc.). Any method suitable for recovering or purifying a variant protease finds use in the present invention.
  • a salt e.g., ammonium sulfate
  • chromatographic purification e.g., ion exchange, gel filtration, affinity, etc.
  • a variant protease produced by a recombinant host cell is secreted into the culture medium.
  • a nucleic acid sequence that encodes a purification facilitating domain may be used to facilitate purification of soluble proteins.
  • a vector or DNA construct comprising a polynucleotide sequence encoding a variant protease may further comprise a nucleic acid sequence encoding a purification facilitating domain to facilitate purification of the variant protease (See e.g., Kroll et al., DNA Cell Biol. 12:441-53 [1993]).
  • Such purification facilitating domains include, but are not limited to, for example, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals (See, Porath, Protein Expr. Purif. 3:263-281 [1992]), protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (e.g., protein A domains available from Immunex Corp., Seattle, Wash.).
  • metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals (See, Porath, Protein Expr. Purif. 3:263-281 [1992]
  • protein A domains that allow purification on immobilized immunoglobulin
  • the domain utilized in the FLAGS extension/affinity purification system e.g., protein A domains available from Immunex Corp., Seattle, Wash.
  • cleavable linker sequence such as Factor XA or enterokinase (e.g., sequences available from Invitrogen, San Diego, Calif.) between the purification domain and the heterologous protein also find use to facilitate purification.
  • enterokinase e.g., sequences available from Invitrogen, San Diego, Calif.
  • Assays for detecting and measuring the enzymatic activity of an enzyme are well known.
  • Various assays for detecting and measuring activity of proteases are also known to those of ordinary skill in the art.
  • assays are available for measuring protease activity that are based on the release of acid-soluble peptides from casein or hemoglobin, measured as absorbance at 280 nm or colorimetrically using the Folin method, well known to those skilled in the art.
  • exemplary assays involve the solubilization of chromogenic substrates (See e.g., Ward, “Proteinases,” in Fogarty (ed.)., Microbial Enzymes and Biotechnology , Applied Science, London, [1983], pp. 251-317).
  • Other exemplary assays include, but are not limited to succinyl-Ala-Ala-Pro-Phe-para nitroanilide assay (suc-AAPF-pNA) and the 2,4,6-trinitrobenzene sulfonate sodium salt assay (TNBS assay).
  • suc-AAPF-pNA succinyl-Ala-Ala-Pro-Phe-para nitroanilide assay
  • TNBS assay 2,4,6-trinitrobenzene sulfonate sodium salt assay
  • Numerous additional references known to those in the art provide suitable methods (See e.g., Wells et al., Nucleic Acids Res. 11:7911
  • a variety of methods can be used to determine the level of production of a mature protease (e.g., mature variant proteases of the present invention) in a host cell. Such methods include, but are not limited to, for example, methods that utilize either polyclonal or monoclonal antibodies specific for the protease. Exemplary methods include, but are not limited to enzyme-linked immunosorbent assays (ELISA), radioimmunoassays (RIA), fluorescent immunoassays (FIA), and fluorescent activated cell sorting (FACS). These and other assays are well known in the art (See e.g., Maddox et al., J. Exp. Med. 158:1211 [1983]).
  • ELISA enzyme-linked immunosorbent assays
  • RIA radioimmunoassays
  • FACS fluorescent activated cell sorting
  • the invention provides methods for making or producing a mature variant protease of the invention.
  • a mature variant protease does not include a signal peptide or a propeptide sequence.
  • Some methods comprise making or producing a variant protease of the invention in a recombinant bacterial host cell, such as for example, a Bacillus sp. cell (e.g., a B. subtilis cell).
  • the invention provides a method of producing a variant protease of the invention, the method comprising cultivating a recombinant host cell comprising a recombinant expression vector comprising a nucleic acid encoding a variant protease of the invention under conditions conducive to the production of the variant protease. Some such methods further comprise recovering the variant protease from the culture.
  • the invention provides methods of producing a variant protease of the invention, the methods comprising: (a) introducing a recombinant expression vector comprising a nucleic acid encoding a variant protease of the invention into a population of cells (e.g., bacterial cells, such as B. subtilis cells); and (b) culturing the cells in a culture medium under conditions conducive to produce the variant protease encoded by the expression vector. Some such methods further comprise: (c) isolating the variant protease from the cells or from the culture medium.
  • a recombinant expression vector comprising a nucleic acid encoding a variant protease of the invention into a population of cells (e.g., bacterial cells, such as B. subtilis cells); and (b) culturing the cells in a culture medium under conditions conducive to produce the variant protease encoded by the expression vector.
  • Some such methods further comprise: (c) isolating the variant protease
  • the protease variants of the present invention can be used in compositions comprising an adjunct material and a protease variant, wherein the composition is a fabric and home care product.
  • the fabric and home care product compositions comprise at least one protease variant comprising one or more, preferably two or more of the following mutations X1R, X2S, X4R, X4S, X9A, X105, X14K, X165, X17R, X18R, X20R, X22A, X22R, X24R, X24W, X25R, X25V, X26F, X42I, X43R, X43A, X46R, X52F, X52E, X52N, X57R, X59A, X62E, X62Q, X68A, X68C, X71G, X72C, X74C.
  • the fabric and home care product compositions comprise at least one protease variant comprising one or more of the following of sets of mutations X022R-X024R, X009A-X271L, X018R-X241R, X018R-X115R, X043R-X249R, X020R-X249R, X004R-X249R, X020R-X024R, X018R-X249R, X009A-X020R, X020R-X241R, X009A-X078R, X020R-X115R, X018R-X024R, X024R-X242R, X022R-X115R, X018R-X043R, X020R-X043R, X018R-X242R, X242R-X269R, X0
  • the fabric and home care product compositions comprise at least one protease variant comprising one or more of the following of sets of mutations X022R-X024R, X009A-X271L, X018R-X241R, X018R-X115R, X043R-X249R, X020R-X249R, X004R-X249R, X020R-X024R, X018R-X249R, X009A-X020R, X020R-X241R, X009A-X078R, X020R-X115R, X018R-X024R, X024R-X242R, X022R-X115R, X018R-X043R, X020R-X043R, X018R-X242R, X242R-X269R, X0
  • the fabric and home care product compositions comprise at least one protease variant comprising a total of three, four, five, six, seven, eight, nine, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or even 25 mutations selected from: X1R, X2S, V4R, V4S, X9A, X10S, X14K, X16S, H17R, X18R, X20R, X22A, X22R, X24R, X24W, X25R, X25V, X26F, X42I, X43R, X43A, G46R, X52F, X52E, X52N, T57R, Q59A, X62E, X62Q, X68A, X68C, X71G, X72C, X74C, X75A, X75F, X75R, X76D, X78R, L
  • the fabric and home care product compositions comprise at least one protease variant comprising: two or more of the following mutations: X1R, X2S, V4R, V4S, X9A, X10S, X14K, X16S, X22A, X22R, X24R, X25V, X26F, X42I, X52F, X52E, X52N, X62E, X62Q, X68A, X68C, X71G, X72C, X74C, X75A, X75F, X78R, X89P, X89T, X89G, X89H, X89W, X91N, X94N, X100S, X101A, X101N, X101G, X101D, X103G, X103N, X104L, X104I, X108I, X111
  • the fabric and home care product compositions comprise at least one protease variant comprising: two or more of the following mutations X4R, X17R, X18R, X20R, X22R, X24R, X24W, X25R, X43R, X43A, X46R, X52F, X52N, X57R, X59A, X62Q, X71G, X75R, X76D, X78R, X82R, X86W, X89P, X89W, X89T, X89I, X89H, X89V, X104L, X106V, X106G, X115R, X1181, X121F, X144R, X185I, X197F, X209N, X2095, X217E, X231I, X239R, X239S, X24
  • the protease variant(s) of the fabric and home care product compositions are derived from a parent protease that is commercially available (e.g., SAVINASE®, POLARZYME®, KANNASE®, LIQUINASE®, LIQUINASE ULTRA®, SAVINASE ULTRA®, or OVOZYME® by Novozymes A/S); MAXACAL®, PROPERASE®, PURAFECT®, FN3®, FN4® and PURAFECT OXP®, PURAFASTTM, PURAFECT® PRIME, or PURAMAX® by Genencor International) and those available from Henkel/Kemira, namely BLAP (sequence shown in FIG.
  • a parent protease that is commercially available (e.g., SAVINASE®, POLARZYME®, KANNASE®, LIQUINASE®, LIQUINASE ULTRA®, SAVINASE ULTRA®, or OVOZY
  • BLAP BLAP with S3T+V4I+V2051.
  • the fabric and home care product compositions comprise at least one protease variant whose parent has proteolytic activity, wherein the variant protease comprises an amino acid sequence which differs from the amino acid sequence shown in SEQ ID NO:2 by no more than 50, no more than 40, no more than 35, no more than 30, no more than 25, no more than 20, no more than 19, no more than 18, no more than 17, no more than 16, no more than 15, no more than 14, no more than 13, no more than 12, no more than 11, no more than 10, no more than 9, or no more than 8 amino acid residues, wherein amino acid positions are numbered according to the numbering of corresponding amino acid positions in the amino acid sequence of Bacillus amyloliquefaciens subtilisin BPN′ shown in SEQ ID NO:1, as determined by alignment of the variant protease amino acid sequence with the Bacillus amyloliquefaciens subtilisin BPN′ amino acid sequence, wherein the variant subtilisin includes one of the following sets of substitutions: X101G-X103
  • the fabric and home care product compositions comprise at least one protease variant comprises one or more, or even two or more of the following mutations A1R, Q2S, V4R, V4S, S9A, R105, P14K, A16S, H17R, N18R, G20R, T22A, T22R, S24R, S24W, G25R, G25V, V26F, L42I, N43R, N43A, G46R, P52F, P52E, P52N, T57R, Q59A, N62E, N62Q, V68A, V68C, T71G, 172C, A74C.
  • the fabric and home care product compositions comprise at least one protease variant comprising one or more of the following of sets of mutations T022R-S024R, S009A-E271L, N018R-W241R, N018R-G115R, N043R-H249R, G020R-H249R, V004R-H249R, G020R-S024R, N018R-H249R, S009A-G020R, G020R-W241R, S009A-S078R, G020R-G115R, N018R-S024R, S024R-S242R, T022R-G115R, N018R-N043R, G020R-N043R, N018R-S242R, S242R-N269R, N018R-V244R, S024R-N269R, G020
  • the fabric and home care product compositions comprise at least one protease variant comprising one or more of the following of sets of mutations T022R-S024R, S009A-E271L, N018R-W241R, N018R-G115R, N043R-H249R, G020R-H249R, V004R-H249R, G020R-S024R, N018R-H249R, S009A-G020R, G020R-W241R, S009A-S078R, G020R-G115R, N018R-S024R, S024R-S242R, T022R-G115R, N018R-N043R, G020R-N043R, N018R-S242R, S242R-N269R, N018R-V244R, S024R-N269R, G020
  • the fabric and home care product compositions comprise at least one protease variant comprising three, four, five, six, seven, eight, nine, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or even 25 mutations within the group of positions comprising positions 1, 2, 4, 9, 10, 14, 16, 17, 18, 20, 22, 24, 25, 26, 42, 43, 46, 52, 57, 59, 62, 68, 71, 72, 74, 75, 76, 78, 82, 86, 89, 91, 94, 100, 101, 103, 104, 106, 108, 111, 112, 115, 117, 118, 121, 128, 129, 144, 148, 158, 159, 160, 166, 185, 186, 188, 197, 203, 209, 210, 212, 214, 215, 217, 224, 230, 231, 236, 238, 239, 241, 242, 243, 244, 248, 249, 250, 252, 253, 262,
  • the fabric and home care product compositions comprise at least one protease variant comprising a total of three, four, five, six, seven, eight, nine, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or even 25 mutations selected from: A1R, Q2S, V4R, V4S, S9A, R10S, P14K, A16S, H17R, N18R, G20R, T22A, T22R, S24R, S24W, G25R, G25V, V26F, L42I, N43R, N43A, G46R, P52F, P52E, P52N, T57R, Q59A, N62E, N62Q, V68A, V68C, T71G, 172C, A74C, L75A, L75F, L75R, N76D, S78R, L82R, P86W, E89P, E89T, E89G, E89H, E89I, E89V, E89
  • the fabric and home care product compositions comprise at least one protease variant comprising: two or more of the following mutations: A1R, Q2S, V4R, V4S, S9A, R10S, P14K, A16S, T22A, T22R, S24R, G25V, V26F, L42I, P52F, P52E, P52N, N62E, N62Q, V68A, V68C, T71G, 172C, A74C.
  • the fabric and home care product compositions comprise at least one protease variant, wherein at least one protease variant is a mature form having proteolytic activity and which comprises amino acid sequences comprising a combination of amino acid substitutions selected from: X1R, X230E, X271L, X115R, X20R, X249R, X235F, X27V/F/L, X75E, X82R, X18R, X269R, X43D, X43R, X76D, X45T, X212F, X242R, X24R, X78R, X9A, X22R, X121E, X244R, X28E, X30E, X4R, and X241R, wherein the amino acid positions of the subtilisin variant are numbered by correspondence with the amino acid sequence of B. amyloliquefaciens subtilisin BPN′ set
  • the fabric and home care product compositions comprise at least one protease variant, wherein at least one protease variant comprises an amino acid sequence which differs from the amino acid sequence of SEQ ID NO:2 in no more than two, three, four, five, six, seven, eight, nine, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 mutations selected from the group of A1R, A230E, E271L, G115R, G20R, H249R, K235F, K27V/F/L, L75E, L82R, N18R, N269R, N43D, N43R, N76D, R45T, S212F, S242R, S24R, S78R, S9A, T22R, V121E, V244R, V28E, V30E, V4R, and W241R, wherein amino acid positions of the protease variant are numbered according to the numbering of corresponding amino acid positions in the amino acid sequence of Bacillus
  • the fabric and home care product compositions comprise at least one protease variant, wherein at least one protease variant comprises an amino acid sequence which differs from the amino acid sequence of SEQ ID NO:2 in no more than two, three, four, five, six, seven, eight, nine, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 mutations selected from the group of A1R, A230E, E271L, G115R, G20R, H249R, K235F, K27V/F/L, L75E, L82R, N18R, N269R, N43D, N43R, N76D, R45T, S212F, S242R, S24R, S78R, S9A, T22R, V121E, V244R, V28E, V30E, V4R, and W241R, and optionally comprises at least one mutation selected from the group of S103A, G159D, Q236H, Q245R, N248D
  • the fabric and home care product compositions comprise at least one protease variant, wherein at least one protease variant is a mature form having proteolytic activity and which comprises amino acid sequences comprising a combination of amino acid substitutions selected from: X16S, X18R, X20R, X22A, X24R, X43R/D, X45T, X76D, X101A, X103G, X104L, X111V, X128N, X148I, X230E, X242R, and X249R, wherein the amino acid positions of the subtilisin variant are numbered by correspondence with the amino acid sequence of B. amyloliquefaciens subtilisin BPN′ set forth as SEQ ID NO:1.
  • the fabric and home care product compositions comprise at least one protease variant, wherein at least one protease variant is a mature form having proteolytic activity and which comprises amino acid sequences comprising a combination of amino acid substitutions selected from: A16S, N18R, G20R, T22A, S24R, N43R, N43D, R45T, N76D, S101A, S103G, V104L, L111V, S128N, L148I, A230E, S242R, and H249R, wherein the amino acid positions of the subtilisin variant are numbered by correspondence with the amino acid sequence of B. amyloliquefaciens subtilisin BPN′ set forth as SEQ ID NO:1.
  • the fabric and home care product compositions comprise at least one protease variant, wherein at least one protease variant is a mature form having proteolytic activity and comprises an amino acid sequence comprising a combination of amino acid substitutions selected from: X20R-X43R-X249R, X20R-X22R-X43R, X20R-X43R-X242R, X20R-X43R-X271L, X20R-X43R-X244R, X20R-X24R-X43R-X242R, X9A-X22R-X78R-X212F-X241R, X9A-X20R-X43R-X212F, X9A-X43R-X212F, X20R-X43R-X212F, X20R-X22R-X43R-X212F, X24R-X78R-X212F, X9A-X43R-X78
  • the fabric and home care product compositions comprise at least one protease variant, wherein at least one protease variant is a mature form having proteolytic activity and comprises an amino acid sequence comprising a combination of amino acid substitutions selected from: A1R, A230E, E271L, G115R, G20R, H249R, K235F, K27V/F/L, L75E, L82R, N18R, N269R, N43D, N43R, N76D, R45T, S212F, S242R, S24R, S78R, S9A, T22R, V121E, V244R, V28E, V30E, V4R, W241R, G20R-N43R-H249R, G20R-T22R-N43R, G20R-N43R-S242R, G20R-N43R-E271L, G20R-N43R-V244R, G20R-S24R,
  • the fabric and home care product compositions comprise at least one protease variant, wherein at least one protease variant is a mature form having proteolytic activity and comprises an amino acid sequence comprising a combination of amino acid substitutions selected from: X101G-X103A-X104I-X232V-X245R-X248D, X101G-X103A-X104I-X159D-X232V-X245R, X101G-X103A-X104I-X159R-X232V-X245R-X248D, X101G-X103A-X104I-X159D-X232V-X245R-X248R, X101G-X103A-X104I-X232V-X245R, X101G-X103A-X104I-X232V-X245R, X101G-X103A-X104I-X232V-X245R, X101G-X103A-X104I-X232V
  • the fabric and home care product compositions comprise at least one protease variant, wherein at least one protease variant is a mature form having proteolytic activity and which comprises amino acid sequences comprising a combination of amino acid substitutions selected from: S101G-S103A-V104I-A232V-Q245R-N248D, S101G-S103A-V104I-G159D-A232V-Q245R, S101G-S103A-V104I-G159R-A232V-Q245R-N248D, S101G-S103A-V104I-G159D-A232V-Q245R-N248R, S101G-S103A-V104I-A232V-Q245R, S101G-S103A-V104I-A232V-Q245R, S101G-S103A-V104I-A232V-Q245R-N248R, S101G-S103A-V104I-A232V-Q
  • said composition comprises a cold water protease variant, wherein said cold water protease variant is a mature form having proteolytic activity and comprises amino acid sequences comprising a combination of amino acid substitutions selected from: X16S, X22A, X24R, X62E, X76D, X89P, X101A/G, X103G/A, X104L/I, X111V, X128N, X129E, X232V, X148I, X158E, X159D/E, X166D, X186H, X188D, X209E, X236H, X238R, X245R, X248D/R, X249R, X252K/R, X253R, and X271F, wherein the amino acid positions of the subtilisin variant are numbered by correspondence with the amino acid sequence of B. amyloliquefaci
  • the fabric and home care product compositions comprise at least one protease variant, wherein at least one protease variant is a mature form having proteolytic activity and comprises an amino acid sequence comprising a combination of amino acid substitutions selected from: A16S, T22A, S24R, N62E, N76D, E89P, S101A/G, S103G/A, V104L/I, L111V, S128N, P129E, A232V, L148I, A158E, G159D/E, R186H, S188D, Y209E, Q236H, Q245R, N248D/R, H249R, N252K/R, T253R, and E271F wherein amino acid positions of the subtilisin variant are numbered by correspondence with the amino acid sequence of B. amyloliquefaciens subtilisin BPN′ set forth as SEQ ID NO:1.
  • the present invention also provides protease variants of Bacillus lentus subtilisin GG36 protease, wherein the Bacillus lentus subtilisin GG36 protease comprises the amino acid sequence shown in SEQ ID NO:2, wherein the protease variant comprises an amino acid sequence which differs from the amino acid sequence of SEQ ID NO:2 in no more than two, three, four, five, six, seven, eight, nine, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 mutations selected from the group of A16S, T22A, S24R, N62E, N76D, E89P, S101A/G, S103G/A, V104L/I, L111V, S128N, P129E, A232V, L148I, A158E, G159D/E, R186H, S188D, Y209E, Q236H, Q245R, N248D/R, H249R, N252K/R, T253R,
  • the fabric and home care product compositions comprise at least one protease variant that comprises an amino acid sequence which differs from the amino acid sequence of SEQ ID NO:2 in no more than two, three, four, five, six, seven, eight, nine, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 mutations selected from the group of A16S, T22A, S24R, N62E, N76D, E89P, S101A/G, S103G/A, V104L/I, L111V, S128N, P129E, A232V, L148I, A158E, G159D/E, R186H, S188D, Y209E, Q236H, Q245R, N248D/R, H249R, N252K/R, T253R, and E271F, wherein amino acid positions of the protease variant are numbered according to the numbering of corresponding amino acid positions in the amino acid sequence of Bacillus amyloliquef
  • the present invention also provides protease variants of Bacillus lentus subtilisin GG36 protease, wherein the Bacillus lentus subtilisin GG36 protease comprises the amino acid sequence shown in SEQ ID NO:2, wherein the protease variant comprises an amino acid sequence which differs from the amino acid sequence of SEQ ID NO:2 in no more than two, three, four, five, six, seven, eight, nine, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 mutations selected from the group of A16S, T22A, S24R, N62E, N76D, E89P, S101A/G, S103G/A, V104L/I, L111V, S128N, P129E, A232V, L148I, A158E, G159D/E, R186H, S188D, Y209E, Q236H, Q245R, N248D/R, H249R, N252K/R, T253R,
  • the fabric and home care product compositions comprise at least one protease variant comprising an amino acid sequence which differs from the amino acid sequence of SEQ ID NO:2 and wherein the total net charge of the protease variant is 0, +1, +2, +3, +4, +5, ⁇ 1, ⁇ 2, ⁇ 3, ⁇ 4, or ⁇ 5 relative to the total net charge of the Bacillus lentus subtilisin GG36 protease, and wherein amino acid positions of the protease variant are numbered according to the numbering of corresponding amino acid positions in the amino acid sequence of Bacillus amyloliquefaciens subtilisin BPN′ shown in SEQ ID NO:1, as determined by alignment of the protease variant amino acid sequence with the Bacillus amyloliquefaciens subtilisin BPN′ amino acid sequence.
  • the fabric and home care product compositions comprise at least one protease variant comprising an amino acid sequence which differs from the amino acid sequence of SEQ ID NO:2 in no more than two, three, four, five, six, seven, eight, nine, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 mutations selected from the group of A1R, Q2S, V4R, V4S, S9A, R105, P14K, A16S, H17R, N18R, G20R, T22A, T22R, S24R, S24W, G25R, G25V, V26F, L42I, N43R, N43A, G46R, P52F, P52E, P52N, T57R, Q59A, N62E, N62Q, V68A, V68C, T71G, 172C, A74C.
  • the fabric and home care product compositions comprise at least one protease variant comprising an amino acid sequence which differs from the amino acid sequence of SEQ ID NO:2 in no more than two, three, four, five, six, seven, eight, nine, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 mutations selected from the group of A16S, T22A, S24R, N62E, N76D, E89P, S101A/G, S103G/A, V104L/I, L111V, S128N, P129E, A232V, L148I, A158E, G159D/E, R186H, S188D, Y209E, Q236H, Q245R, N248D/R, H249R, N252K/R, T253R, and E271F, wherein amino acid positions of the protease variant are numbered according to the numbering of corresponding amino acid positions in the amino acid sequence of Bacillus amyloliquef
  • the fabric and home care product compositions comprise at least one protease variant comprising an amino acid sequence which differs from the amino acid sequence of SEQ ID NO:2 in no more than two, three, four, five, six, seven, eight, nine, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 mutations selected from the group of A1R, A230E, E271L, G115R, G20R, H249R, K235F, K27V/F/L, L75E, L82R, N18R, N269R, N43D, N43R, N76D, R45T, S212F, S242R, S24R, S78R, S9A, T22R, V121E, V244R, V28E, V30E, V4R, and W241R, wherein amino acid positions of the protease variant are numbered according to the numbering of corresponding amino acid positions in the amino acid sequence of Bacillus amyloliquefaciens subtilis subtilis subtil
  • the fabric and home care product compositions comprise at least one protease variant comprising an amino acid sequence which differs from the amino acid sequence of SEQ ID NO:2, wherein said protease variant comprises an amino acid sequence which differs from the amino acid sequence of SEQ ID NO:2 in no more than two, three, four, five, six, seven, eight, nine, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 mutations selected from the group of A1R, A230E, E271L, G115R, G20R, H249R, K235F, K27V/F/L, L75E, L82R, N18R, N269R, N43D, N43R, N76D, R45T, S212F, S242R, S24R, S78R, S9A, T22R, V121E, V244R, V28E, V30E, V4R, and W241R, and optionally comprises at least one mutation selected from the group of S103A,
  • the fabric and home care product compositions comprise at least one protease variant comprising two or more of the following mutations V4R, H17R, N18R, G20R, T22R, S24R, S24W, G25R, N43R, N43A, G46R, P52F, P52N, T57R, Q59A, N62Q, T71G, L75R, N76D, S78R, L82R, P86W, E89P, E89W, E89T, E89I, E89H, E89V, V104L, S106V, S106G, G115R, G118I, V121F, S144R, N185I, D197F, Y209N, Y2095, L217E, A231I, P239R, P239S, W241R, S242R, S242L, N243R, V244R, N248I, H249R, N252R, T253R,
  • the fabric and home care product compositions comprising at least one protease variant comprise at least one adjunct material selected from an encapsulate comprising a perfume, a hueing agent, surfactants, builders, chelating agents, dye transfer inhibiting agents, dispersants, additional enzymes, enzyme stabilizers, catalytic materials, bleach activators, hydrogen peroxide, sources of hydrogen peroxide, preformed peracids, polymeric dispersing agents, clay soil removal/anti-redeposition agents, brighteners, suds suppressors, dyes, perfumes, structure elasticizing agents, fabric softeners, carriers, hydrotropes, processing aids, solvents, pigments and mixtures thereof.
  • an encapsulate comprising a perfume, a hueing agent, surfactants, builders, chelating agents, dye transfer inhibiting agents, dispersants, additional enzymes, enzyme stabilizers, catalytic materials, bleach activators, hydrogen peroxide, sources of hydrogen peroxide, preformed peracids, polymeric dispersing agents, clay soil removal/
  • the fabric and home care product compositions comprise at least one adjunct material selected from perfume encapsulates, fabric hueing agents, cold-water soluble brighteners, a bleach catalyst that may comprise a material selected from iminium cations, iminium polyions; iminium zwitterions; modified amines; modified amine oxides; N-sulphonyl imines; N-phosphonyl imines; N-acyl imines; thiadiazole dioxides; perfluoroimines; cyclic sugar ketones and mixtures thereof; first wash lipases; bacterial cleaning cellulases; Guerbet nonionic surfactants; and mixtures thereof.
  • a bleach catalyst that may comprise a material selected from iminium cations, iminium polyions; iminium zwitterions; modified amines; modified amine oxides; N-sulphonyl imines; N-phosphonyl imines; N-acyl imines; thiadiazole dioxides; perfluoroimines; cyclic
  • the fabric and home care product compositions comprising at least one protease variant further comprise at least one additional non-immunoequivalent protease selected from subtilisins (EC 3.4.21.62); trypsin-like or chymotrypsin-like proteases; metalloproteases; and mixtures thereof.
  • the fabric and home care product compositions comprising at least one protease variant further comprise at least one additional non-immunoequivalent protease selected from: subtilisins (EC 3.4.21.62) derived from B. subtilis, B. amyloliquefaciens, B. pumilus and B. gibsonii ; trypsin proteases and/or chymotrypsin proteases derived from Cellulomonas; metalloproteases derived from Bacillus amyloliquefaciens ; and mixtures thereof.
  • subtilisins EC 3.4.21.62
  • B. subtilis B. amyloliquefaciens
  • B. pumilus and B. gibsonii B. subtilisins
  • trypsin proteases and/or chymotrypsin proteases derived from Cellulomonas
  • metalloproteases derived from Bacillus amyloliquefaciens ; and mixtures thereof.
  • the fabric and home care product compositions comprising at least one protease variant further comprise at least one additional enzyme selected from hemicellulases, peroxidases, proteases, cellulases, cellobiose dehydrogenases, xyloglucanases, xylanases, lipases, phospholipases, esterases, cutinases, pectinases, mannanases, pectate lyases, keratinases, reductases, oxidases, phenoloxidases, lipoxygenases, ligninases, pullulanases, tannases, pentosanases, lichenases glucanases, arabinosidases, hyaluronidases, chondroitinases, laccases, amylases, and mixtures thereof.
  • additional enzyme selected from hemicellulases, peroxidases, proteases, cellulases, cellobiose dehydr
  • the fabric and home care product compositions comprising at least one protease variant further comprise at least one additional enzyme selected from first-wash lipases; alpha-amylases; bacterial cleaning cellulases; and mixtures thereof.
  • the fabric and home care product compositions comprising at least one protease variant further comprise at least one of the following: an encapsulate comprising a perfume comprises a perfume micro capsule; a hueing agent comprising a material selected from basic, acid, hydrophobic, direct and polymeric dyes, and dye-conjugates having a peak absorption wavelength of from 550 nm to 650 nm and mixtures thereof; a detersive surfactant comprising a material selected from anionic detersive surfactants, non-ionic detersive surfactant, cationic detersive surfactants, zwitterionic detersive surfactants and amphoteric detersive surfactants and mixtures thereof; a builder comprising a material selected from zeolites, phosphates and mixtures thereof; a silicate salt comprising a material selected from sodium silicate, potassium silicate and mixtures thereof; a brightener comprising a material selected from cold-water soluble brighteners and mixtures thereof;
  • the fabric and home care product compositions comprising at least one protease variant comprise a fabric hueing agent selected from the group consisting of dyes; dye-clay conjugates comprising at least one cationic-basic dye and a smectite clay; and mixtures thereof.
  • the fabric and home care product compositions comprising at least one protease variant comprise at least one fabric hueing agent selected from small molecule dyes; polymeric dyes and mixtures thereof; dye-clay conjugates comprising at least one cationic-basic dye and a smectite clay; and mixtures thereof.
  • the fabric and home care product compositions comprising at least one protease variant are provided in single or multiple-compartment unit doses.
  • the composition is a multi-compartment unit dose, wherein the protease variant is in a different compartment than any source of hydrogen peroxide and/or chelant and/or additional enzyme.
  • the fabric and home care product compositions comprising at least one protease variant comprises a wash liquor, wherein at least one protease variant comprises: two or more of the following mutations: A1R, Q2S, V4R, V4S, S9A, R10S, P14K, A16S, T22A, T22R, S24R, G25V, V26F, L42I, P52F, P52E, P52N, N62E, N62Q, V68A, V68C, T71G, 172C, A74C.
  • lentus subtilisin GG36 protease having the amino acid sequence of SEQ ID NO:1 and; wherein the wash liquor has a conductivity of from about 0.1 mS/cm to about 3 mS/cm, from about 0.3 mS/cm to about 2.5 mS/cm, or even from about 0.5 mS/cm to about 2 mS/cm.
  • the fabric and home care product compositions comprising at least one protease variant comprises a wash liquor comprising an adjunct material, wherein at least one protease variant comprises: two or more of the following mutations V4R, H17R, N18R, G20R, T22R, S24R, S24W, G25R, N43R, N43A, G46R, P52F, P52N, T57R, Q59A, N62Q, T71G, L75R, N76D, S78R, L82R, P86W, E89P, E89W, E89T, E89I, E89H, E89V, V104L, S106V, S106G, G115R, G118I, V121F, S144R, N185I, D197F, Y209N, Y2095, L217E, A231I, P239R, P239S, W241R, S242R, S242L, N243R, V244
  • lentus subtilisin GG36 protease having the amino acid sequence of SEQ ID NO:2; and said laundry detergent wash liquor having conductivity of from about 3 mS/cm to about 30 mS/cm, from about 3.5 mS/cm to about 20 mS/cm, or even from about 4 mS/cm to about 10 mS/cm.
  • the fabric and home care product compositions comprising at least one protease variant comprise one or more of the following ingredients (based on total composition weight): from about 0.0005 wt % to about 0.1 wt %, from about 0.001 wt % to about 0.05 wt %, or even from about 0.002 wt % to about 0.03 wt % of said cold water protease variant; and one or more of the following: from about 0.00003 wt % to about 0.1 wt % fabric hueing agent; from about 0.001 wt % to about 5 wt %, perfume capsules; from about 0.001 wt % to about 1 wt %, cold-water soluble brighteners; from about 0.00003 wt % to about 0.1 wt % bleach catalysts; from about 0.00003 wt % to about 0.1 wt % first wash lipases; from about 0.00003 wt % to about 0.1
  • the fabric and home care product composition is a granular or powder laundry detergent that does not comprise a cold water protease.
  • the fabric and home care product composition is a liquid laundry detergent, a dish washing detergent.
  • the fabric and home care product is provided in any suitable form, including a fluid or solid.
  • the fabric and home care product may be in the form of a unit dose pouch, especially when in the form of a liquid, and typically the fabric and home care product is at least partially, or even completely, enclosed by a water-soluble pouch.
  • the fabric and home care product may have any combination of parameters and/or characteristics detailed above.
  • all component or composition levels provided herein are made in reference to the active level of that component or composition, and are exclusive of impurities, for example, residual solvents or by-products, which may be present in commercially available sources.
  • Enzyme components weights are based on total active protein. All percentages and ratios are calculated by weight unless otherwise indicated. All percentages and ratios are calculated based on the total composition unless otherwise indicated.
  • the enzymes levels are expressed by pure enzyme by weight of the total composition and unless otherwise specified, the detergent ingredients are expressed by weight of the total compositions.
  • the cleaning compositions of the present invention further comprise adjunct materials including, but not limited to, surfactants, builders, bleaches, bleach activators, bleach catalysts, other enzymes, enzyme stabilizing systems, chelants, optical brighteners, soil release polymers, dye transfer agents, dispersants, suds suppressors, dyes, perfumes, colorants, filler salts, hydrotropes, photoactivators, fluorescers, fabric conditioners, hydrolyzable surfactants, preservatives, anti-oxidants, anti-shrinkage agents, anti-wrinkle agents, germicides, fungicides, color speckles, silvercare, anti-tarnish and/or anti-corrosion agents, alkalinity sources, solubilizing agents, carriers, processing aids, pigments, and pH control agents (See e.g., U.S.
  • adjunct materials including, but not limited to, surfactants, builders, bleaches, bleach activators, bleach catalysts, other enzymes, enzyme stabilizing systems, chelants, optical brighteners,
  • the cleaning compositions of the present invention are advantageously employed for example, in laundry applications, hard surface cleaning, dishwashing applications, as well as cosmetic applications such as dentures, teeth, hair and skin.
  • the enzymes of the present invention are ideally suited for laundry applications.
  • the enzymes of the present invention find use in granular and liquid compositions.
  • the variant proteases of the present invention also find use in cleaning additive products.
  • low temperature solution cleaning applications find use.
  • the present invention provides cleaning additive products including at least one enzyme of the present invention is ideally suited for inclusion in a wash process when additional bleaching effectiveness is desired. Such instances include, but are not limited to low temperature solution cleaning applications.
  • the additive product is in its simplest form, one or more proteases.
  • the additive is packaged in dosage form for addition to a cleaning process.
  • the additive is packaged in dosage form for addition to a cleaning process where a source of peroxygen is employed and increased bleaching effectiveness is desired.
  • any suitable single dosage unit form finds use with the present invention, including but not limited to pills, tablets, gelcaps, or other single dosage units such as pre-measured powders or liquids.
  • filler(s) or carrier material(s) are included to increase the volume of such compositions.
  • suitable filler or carrier materials include, but are not limited to, various salts of sulfate, carbonate and silicate as well as talc, clay and the like.
  • Suitable filler or carrier materials for liquid compositions include, but are not limited to water or low molecular weight primary and secondary alcohols including polyols and diols. Examples of such alcohols include, but are not limited to, methanol, ethanol, propanol and isopropanol.
  • the compositions contain from about 5% to about 90% of such materials. Acidic fillers find use to reduce pH.
  • the cleaning additive includes adjunct ingredients, as more fully described below.
  • the present cleaning compositions and cleaning additives require an effective amount of at least one of the protease variants provided herein, alone or in combination with other proteases and/or additional enzymes.
  • the required level of enzyme is achieved by the addition of one or more protease variants of the present invention.
  • the present cleaning compositions comprise at least about 0.0001 weight percent, from about 0.0001 to about 10, from about 0.001 to about 1, or even from about 0.01 to about 0.1 weight percent of at least one of the variant proteases of the present invention.
  • the cleaning compositions herein are typically formulated such that, during use in aqueous cleaning operations, the wash water will have a pH of from about 5.0 to about 11.5 or even from about 7.5 to about 10.5.
  • Liquid product formulations are typically formulated to have a neat pH from about 3.0 to about 9.0 or even from about 3 to about 5.
  • Granular laundry products are typically formulated to have a pH from about 9 to about 11. Techniques for controlling pH at recommended usage levels include the use of buffers, alkalis, acids, etc., and are well known to those skilled in the art.
  • Suitable “low pH cleaning compositions” typically have a neat pH of from about 3 to about 5, and are typically free of surfactants that hydrolyze in such a pH environment.
  • surfactants include sodium alkyl sulfate surfactants that comprise at least one ethylene oxide moiety or even from about 1 to about 16 moles of ethylene oxide.
  • Such cleaning compositions typically comprise a sufficient amount of a pH modifier, such as sodium hydroxide, monoethanolamine or hydrochloric acid, to provide such cleaning composition with a neat pH of from about 3 to about 5.
  • Such compositions typically comprise at least one acid stable enzyme.
  • the compositions are liquids, while in other embodiments, they are solids.
  • the pH of such liquid compositions is typically measured as a neat pH.
  • the pH of such solid compositions is measured as a 10% solids solution of said composition wherein the solvent is distilled water. In these embodiments, all pH measurements are taken at 20° C., unless otherwise indicated.
  • the variant protease(s) when the variant protease(s) is/are employed in a granular composition or liquid, it is desirable for the variant protease to be in the form of an encapsulated particle to protect the variant protease from other components of the granular composition during storage.
  • encapsulation is also a means of controlling the availability of the variant protease during the cleaning process.
  • encapsulation enhances the performance of the variant protease(s) and/or additional enzymes.
  • the variant proteases of the present invention are encapsulated with any suitable encapsulating material known in the art.
  • the encapsulating material typically encapsulates at least part of the catalyst for the variant protease(s) of the present invention.
  • the encapsulating material is water-soluble and/or water-dispersible.
  • the encapsulating material has a glass transition temperature (Tg) of 0° C. or higher. Glass transition temperature is described in more detail in WO 97/11151.
  • the encapsulating material is typically selected from consisting of carbohydrates, natural or synthetic gums, chitin, chitosan, cellulose and cellulose derivatives, silicates, phosphates, borates, polyvinyl alcohol, polyethylene glycol, paraffin waxes, and combinations thereof.
  • the encapsulating material When the encapsulating material is a carbohydrate, it is typically selected from monosaccharides, oligosaccharides, polysaccharides, and combinations thereof. In some typical embodiments, the encapsulating material is a starch (See e.g., EP 0 922 499; U.S. Pat. No. 4,977,252; U.S. Pat. No. 5,354,559, and U.S. Pat. No. 5,935,826).
  • the encapsulating material is a microsphere made from plastic such as thermoplastics, acrylonitrile, methacrylonitrile, polyacrylonitrile, polymethacrylonitrile and mixtures thereof; commercially available microspheres that find use include, but are not limited to those supplied by EXPANCEL® (Stockviksverken, Sweden), and PM 6545, PM 6550, PM 7220, PM 7228, EXTENDOSPHERES®, LUXSIL®, Q-CEL®, and SPHERICEL® (PQ Corp., Valley Forge, Pa.).
  • plastic such as thermoplastics, acrylonitrile, methacrylonitrile, polyacrylonitrile, polymethacrylonitrile and mixtures thereof
  • commercially available microspheres that find use include, but are not limited to those supplied by EXPANCEL® (Stockviksverken, Sweden), and PM 6545, PM 6550, PM 7220, PM 7228, EXTENDOSPHERES®, LUXSIL®, Q
  • variant proteases of the present invention find particular use in the cleaning industry, including, but not limited to laundry and dish detergents. These applications place enzymes under various environmental stresses.
  • the variant proteases of the present invention provide advantages over many currently used enzymes, due to their stability under various conditions.
  • wash conditions including varying detergent formulations, wash water volumes, wash water temperatures, and lengths of wash time, to which proteases involved in washing are exposed.
  • detergent formulations used in different geographical areas have different concentrations of their relevant components present in the wash water.
  • European detergents typically have about 4500-5000 ppm of detergent components in the wash water
  • Japanese detergents typically have approximately 667 ppm of detergent components in the wash water.
  • detergents typically have about 975 ppm of detergent components present in the wash water.
  • a low detergent concentration system includes detergents where less than about 800 ppm of the detergent components are present in the wash water.
  • Japanese detergents are typically considered low detergent concentration system as they have approximately 667 ppm of detergent components present in the wash water.
  • a medium detergent concentration includes detergents where between about 800 ppm and about 2000 ppm of the detergent components are present in the wash water.
  • North American detergents are generally considered to be medium detergent concentration systems as they have approximately 975 ppm of detergent components present in the wash water. Brazil typically has approximately 1500 ppm of detergent components present in the wash water.
  • a high detergent concentration system includes detergents where greater than about 2000 ppm of the detergent components are present in the wash water.
  • European detergents are generally considered to be high detergent concentration systems as they have approximately 4500-5000 ppm of detergent components in the wash water.
  • Latin American detergents are generally high suds phosphate builder detergents and the range of detergents used in Latin America can fall in both the medium and high detergent concentrations as they range from 1500 ppm to 6000 ppm of detergent components in the wash water. As mentioned above, Brazil typically has approximately 1500 ppm of detergent components present in the wash water.
  • high suds phosphate builder detergent geographies may have high detergent concentration systems up to about 6000 ppm of detergent components present in the wash water.
  • concentrations of detergent compositions in typical wash solutions throughout the world varies from less than about 800 ppm of detergent composition (“low detergent concentration geographies”), for example about 667 ppm in Japan, to between about 800 ppm to about 2000 ppm (“medium detergent concentration geographies”), for example about 975 ppm in U.S. and about 1500 ppm in Brazil, to greater than about 2000 ppm (“high detergent concentration geographies”), for example about 4500 ppm to about 5000 ppm in Europe and about 6000 ppm in high suds phosphate builder geographies.
  • low detergent concentration geographies for example about 667 ppm in Japan
  • intermediate detergent concentration geographies for example about 975 ppm in U.S. and about 1500 ppm in Brazil
  • high detergent concentration geographies for example about 4500 ppm to about 5000 ppm in Europe and about 6000 ppm in high suds phosphate builder geographies.
  • concentrations of the typical wash solutions are determined empirically. For example, in the U.S., a typical washing machine holds a volume of about 64.4 L of wash solution. Accordingly, in order to obtain a concentration of about 975 ppm of detergent within the wash solution about 62.79 g of detergent composition must be added to the 64.4 L of wash solution. This amount is the typical amount measured into the wash water by the consumer using the measuring cup provided with the detergent.
  • the temperature of the wash water in Japan is typically less than that used in Europe.
  • the temperature of the wash water in North America and Japan is typically between about 10 and about 30° C. (e.g., about 20° C.)
  • the temperature of wash water in Europe is typically between about 30 and about 60° C. (e.g., about 40° C.).
  • cold water is typically used for laundry, as well as dish washing applications.
  • the “cold water washing” of the present invention utilizes “cold water detergent” suitable for washing at temperatures from about 10° C. to about 40° C., or from about 20° C. to about 30° C., or from about 15° C. to about 25° C., as well as all other combinations within the range of about 15° C. to about 35° C., and all ranges within 10° C. to 40° C.
  • Water hardness is usually described in terms of the grains per gallon mixed Ca 2+ /Mg 2+ .
  • Hardness is a measure of the amount of calcium (Ca 2+ ) and magnesium (Mg 2+ ) in the water. Most water in the United States is hard, but the degree of hardness varies. Moderately hard (60-120 ppm) to hard (121-181 ppm) water has 60 to 181 parts per million (parts per million converted to grains per U.S. gallon is ppm # divided by 17.1 equals grains per gallon) of hardness minerals.
  • European water hardness is typically greater than about 10.5 (for example about 10.5 to about 20.0) grains per gallon mixed Ca 2+ /Mg 2+ (e.g., about 15 grains per gallon mixed Ca 2+ /Mg 2+ ).
  • North American water hardness is typically greater than Japanese water hardness, but less than European water hardness.
  • North American water hardness can be between about 3 to about 10 grains, about 3 to about 8 grains or about 6 grains.
  • Japanese water hardness is typically lower than North American water hardness, usually less than about 4, for example about 3 grains per gallon mixed Ca 2+ /Mg 2+ .
  • the present invention provides variant proteases that show surprising wash performance in at least one set of wash conditions (e.g., water temperature, water hardness, and/or detergent concentration).
  • the variant proteases of the present invention are comparable in wash performance to other subtilisin proteases.
  • the variant proteases of the present invention exhibit enhanced wash performance as compared to subtilisin proteases currently commercially available.
  • the variant proteases provided herein exhibit enhanced oxidative stability, enhanced thermal stability, enhanced cleaning capabilities under various conditions, and/or enhanced chelator stability.
  • the variant proteases of the present invention find use in cleaning compositions that do not include detergents, again either alone or in combination with builders and stabilizers.
  • the cleaning compositions comprise at least one variant protease of the present invention at a level from about 0.00001% to about 10% by weight of the composition and the balance (e.g., about 99.999% to about 90.0%) comprising cleaning adjunct materials by weight of composition.
  • the cleaning compositions of the present invention comprises at least one variant protease at a level of about 0.0001% to about 10%, about 0.001% to about 5%, about 0.001% to about 2%, about 0.005% to about 0.5% by weight of the composition and the balance of the cleaning composition (e.g., about 99.9999% to about 90.0%, about 99.999% to about 98%, about 99.995% to about 99.5% by weight) comprising cleaning adjunct materials.
  • the cleaning compositions of the present invention comprise one or more additional detergent enzymes, which provide cleaning performance and/or fabric care and/or dishwashing benefits.
  • suitable enzymes include, but are not limited to, hemicellulases, cellulases, peroxidases, proteases, xylanases, lipases, phospholipases, esterases, cutinases, pectinases, pectate lyases, mannanases, keratinases, reductases, oxidases, phenoloxidases, lipoxygenases, ligninases, pullulanases, tannases, pentosanases, malanases, ⁇ -glucanases, arabinosidases, hyaluronidases, chondroitinases, laccases, and amylases, or any combinations or mixtures thereof.
  • a combination of enzymes comprising conventional applicable enzymes like protease, lipase, cutinase and/or cellulase in conjunction with amylase is used.
  • any other suitable protease finds use in the compositions of the present invention.
  • Suitable proteases include those of animal, vegetable or microbial origin. In some embodiments, microbial proteases are used. In some embodiments, chemically or genetically modified mutants are included.
  • the protease is a serine protease, preferably an alkaline microbial protease or a trypsin-like protease.
  • alkaline proteases examples include subtilisins, especially those derived from Bacillus (e.g., subtilisin, lentus, amyloliquefaciens, subtilisin Carlsberg, subtilisin 309, subtilisin 147 and subtilisin 168). Additional examples include those mutant proteases described in U.S. Pat. Nos. RE 34,606, 5,955,340, 5,700,676, 6,312,936, and 6,482,628, all of which are incorporated herein by reference. Additional protease examples include, but are not limited to trypsin (e.g., of porcine or bovine origin), and the Fusarium protease described in WO 89/06270.
  • subtilisins especially those derived from Bacillus (e.g., subtilisin, lentus, amyloliquefaciens, subtilisin Carlsberg, subtilisin 309, subtilisin 147 and subtilisin 168). Additional examples include those mutant proteases described in U.S.
  • commercially available protease enzymes that find use in the present invention include, but are not limited to MAXATASE®, MAXACALTM, MAXAPEMTM, OPTICLEAN®, OPTIMASE®, PROPERASE®, PURAFECT®, PURAFECT® OXP, PURAMAXTM, EXCELLASETM, and PURAFASTTM (Genencor); ALCALASE®, SAVINASE®, PRIMASE®, DURAZYMTM, POLARZYME®, OVOZYME®, KANNASE®, LIQUANASE®, NEUTRASE®, RELASE® and ESPERASE® (Novozymes); BLAPTM and BLAPTM variants (Henkel Garandit GmbH auf Aktien, Duesseldorf, Germany), and KAP ( B.
  • metalloproteases find use in the present invention, including but not limited to the neutral metalloprotease described in WO 07/044,993.
  • any suitable lipase finds use in the present invention.
  • Suitable lipases include, but are not limited to those of bacterial or fungal origin. Chemically or genetically modified mutants are encompassed by the present invention.
  • useful lipases include Humicola lanuginosa lipase (See e.g., EP 258 068, and EP 305 216), Rhizomucor miehei lipase (See e.g., EP 238 023), Candida lipase, such as C. antarctica lipase (e.g., the C. antarctica lipase A or B; See e.g., EP 214 761), Pseudomonas lipases such as P.
  • alcaligenes lipase and P. pseudoalcaligenes lipase See e.g., EP 218 272), P. cepacia lipase (See e.g., EP 331 376), P. stutzeri lipase (See e.g., GB 1,372,034), P. fluorescens lipase, Bacillus lipase (e.g., B. subtilis lipase [Dartois et al., Biochem. Biophys. Acta 1131:253-260 [1993]); B. stearothermophilus lipase [See e.g., JP 64/744992]; and B. pumilus lipase [See e.g., WO 91/16422]).
  • B. subtilis lipase e.g., B. subtilis lipase [Dartois et al., Biochem. Biophys. Acta 1131:
  • cloned lipases find use in some embodiments of the present invention, including but not limited to Penicillium camembertii lipase (See, Yamaguchi et al., Gene 103:61-67 [1991]), Geotricum candidum lipase (See, Schimada et al., J. Biochem., 106:383-388 [1989]), and various Rhizopus lipases such as R. delemar lipase (See, Hass et al., Gene 109:117-113 [1991]), a R. niveus lipase (Kugimiya et al., Biosci. Biotech. Biochem. 56:716-719 [1992]) and R. oryzae lipase.
  • Penicillium camembertii lipase See, Yamaguchi et al., Gene 103:61-67 [1991]
  • Geotricum candidum lipase See, Schimada
  • cutinases Other types of lipolytic enzymes such as cutinases also find use in some embodiments of the present invention, including but not limited to the cutinase derived from Pseudomonas mendocina (See, WO 88/09367), and the cutinase derived from Fusarium solani pisi (See, WO 90/09446).
  • lipases include commercially available lipases such as M1 LIPASETM, LUMA FASTTM, and LIPOMAXTM (Genencor); LIPEX®, LIPOLASE® and LIPOLASE® ULTRA (Novozymes); and LIPASE PTM “Amano” (Amano Pharmaceutical Co. Ltd., Japan).
  • the cleaning compositions of the present invention further comprise lipases at a level from about 0.00001% to about 10% of additional lipase by weight of the composition and the balance of cleaning adjunct materials by weight of composition. In some other embodiments of the present invention, the cleaning compositions of the present invention also comprise lipases at a level of about 0.0001% to about 10%, about 0.001% to about 5%, about 0.001% to about 2%, about 0.005% to about 0.5% lipase by weight of the composition.
  • any suitable amylase finds use in the present invention.
  • any amylase e.g., alpha and/or beta
  • suitable amylases include, but are not limited to those of bacterial or fungal origin. Chemically or genetically modified mutants are included in some embodiments.
  • Amylases that find use in the present invention include, but are not limited to ⁇ -amylases obtained from B. licheniformis (See e.g., GB 1,296,839).
  • amylases that find use in the present invention include, but are not limited to DURAMYL®, TERMAMYL®, FUNGAMYL®, STAINZYME®, STAINZYME PLUS®, STAINZYME ULTRA®, and BANTM (Novozymes), as well as POWERASETM, RAPIDASE® and MAXAMYL® P (Genencor).
  • the cleaning compositions of the present invention further comprise amylases at a level from about 0.00001% to about 10% of additional amylase by weight of the composition and the balance of cleaning adjunct materials by weight of composition.
  • the cleaning compositions of the present invention also comprise amylases at a level of about 0.0001% to about 10%, about 0.001% to about 5%, about 0.001% to about 2%, about 0.005% to about 0.5% amylase by weight of the composition.
  • any suitable cellulase finds used in the cleaning compositions of the present invention.
  • Suitable cellulases include, but are not limited to those of bacterial or fungal origin. Chemically or genetically modified mutants are included in some embodiments.
  • Suitable cellulases include, but are not limited to Humicola insolens cellulases (See e.g., U.S. Pat. No. 4,435,307).
  • Especially suitable cellulases are the cellulases having color care benefits (See e.g., EP 0 495 257).
  • cellulases that find use in the present include, but are not limited to CELLUZYME®, CAREZYME® (Novozymes), and KAC-500(B)TM (Kao Corporation).
  • cellulases are incorporated as portions or fragments of mature wild-type or variant cellulases, wherein a portion of the N-terminus is deleted (See e.g., U.S. Pat. No. 5,874,276).
  • the cleaning compositions of the present invention further comprise cellulases at a level from about 0.00001% to about 10% of additional cellulase by weight of the composition and the balance of cleaning adjunct materials by weight of composition.
  • the cleaning compositions of the present invention also comprise cellulases at a level of about 0.0001% to about 10%, about 0.001% to about 5%, about 0.001% to about 2%, about 0.005% to about 0.5% cellulase by weight of the composition.
  • mannanase suitable for use in detergent compositions also finds use in the present invention.
  • Suitable mannanases include, but are not limited to those of bacterial or fungal origin. Chemically or genetically modified mutants are included in some embodiments.
  • Various mannanases are known which find use in the present invention (See e.g., U.S. Pat. No. 6,566,114, U.S. Pat. No. 6,602,842, and U.S. Pat. No. 6,440,991, all of which are incorporated herein by reference).
  • the cleaning compositions of the present invention further comprise mannanases at a level from about 0.00001% to about 10% of additional mannanase by weight of the composition and the balance of cleaning adjunct materials by weight of composition.
  • the cleaning compositions of the present invention also comprise mannanases at a level of about 0.0001% to about 10%, about 0.001% to about 5%, about 0.001% to about 2%, about 0.005% to about 0.5% mannanase by weight of the composition.
  • peroxidases are used in combination with hydrogen peroxide or a source thereof (e.g., a percarbonate, perborate or persulfate) in the compositions of the present invention.
  • oxidases are used in combination with oxygen. Both types of enzymes are used for “solution bleaching” (i.e., to prevent transfer of a textile dye from a dyed fabric to another fabric when the fabrics are washed together in a wash liquor), preferably together with an enhancing agent (See e.g., WO 94/12621 and WO 95/01426).
  • Suitable peroxidases/oxidases include, but are not limited to those of plant, bacterial or fungal origin.
  • the cleaning compositions of the present invention further comprise peroxidase and/or oxidase enzymes at a level from about 0.00001% to about 10% of additional peroxidase and/or oxidase by weight of the composition and the balance of cleaning adjunct materials by weight of composition.
  • the cleaning compositions of the present invention also comprise, peroxidase and/or oxidase enzymes at a level of about 0.0001% to about 10%, about 0.001% to about 5%, about 0.001% to about 2%, about 0.005% to about 0.5% peroxidase and/or oxidase enzymes by weight of the composition.
  • additional enzymes find use, including but not limited to perhydrolases (See e.g., WO 05/056782).
  • mixtures of the above mentioned enzymes are encompassed herein, in particular one or more additional protease, amylase, lipase, mannanase, and/or at least one cellulase. Indeed, it is contemplated that various mixtures of these enzymes will find use in the present invention.
  • the varying levels of the variant protease(s) and one or more additional enzymes may both independently range to about 10%, the balance of the cleaning composition being cleaning adjunct materials. The specific selection of cleaning adjunct materials are readily made by considering the surface, item, or fabric to be cleaned, and the desired form of the composition for the cleaning conditions during use (e.g., through the wash detergent use).
  • cleaning adjunct materials include, but are not limited to, surfactants, builders, bleaches, bleach activators, bleach catalysts, other enzymes, enzyme stabilizing systems, chelants, optical brighteners, soil release polymers, dye transfer agents, dye transfer inhibiting agents, catalytic materials, hydrogen peroxide, sources of hydrogen peroxide, preformed peracids, polymeric dispersing agents, clay soil removal agents, structure elasticizing agents, dispersants, suds suppressors, dyes, perfumes, colorants, filler salts, hydrotropes, photoactivators, fluorescers, fabric conditioners, fabric softeners, carriers, hydrotropes, processing aids, solvents, pigments, hydrolyzable surfactants, preservatives, anti-oxidants, anti-shrinkage agents, anti-wrinkle agents, germicides, fungicides, color speckles, silvercare, anti-tarnish and/or anti-corrosion agents, alkalinity sources, solubilizing agents, carriers, processing aids, pigments, pigments
  • an effective amount of one or more variant protease(s) provided herein is included in compositions useful for cleaning a variety of surfaces in need of proteinaceous stain removal.
  • cleaning compositions include cleaning compositions for such applications as cleaning hard surfaces, fabrics, and dishes.
  • the present invention provides fabric cleaning compositions, while in other embodiments, the present invention provides non-fabric cleaning compositions.
  • the present invention also provides cleaning compositions suitable for personal care, including oral care (including dentrifices, toothpastes, mouthwashes, etc., as well as denture cleaning compositions), skin, and hair cleaning compositions. It is intended that the present invention encompass detergent compositions in any form (i.e., liquid, granular, bar, semi-solid, gels, emulsions, tablets, capsules, etc.).
  • compositions of the present invention preferably contain at least one surfactant and at least one builder compound, as well as one or more cleaning adjunct materials preferably selected from organic polymeric compounds, bleaching agents, additional enzymes, suds suppressors, dispersants, lime-soap dispersants, soil suspension and anti-redeposition agents and corrosion inhibitors.
  • cleaning adjunct materials preferably selected from organic polymeric compounds, bleaching agents, additional enzymes, suds suppressors, dispersants, lime-soap dispersants, soil suspension and anti-redeposition agents and corrosion inhibitors.
  • laundry compositions also contain softening agents (i.e., as additional cleaning adjunct materials).
  • the compositions of the present invention also find use detergent additive products in solid or liquid form.
  • the density of the laundry detergent compositions herein ranges from about 400 to about 1200 g/liter, while in other embodiments, it ranges from about 500 to about 950 g/liter of composition measured at 20° C.
  • compositions of the invention preferably contain at least one surfactant and preferably at least one additional cleaning adjunct material selected from organic polymeric compounds, suds enhancing agents, group II metal ions, solvents, hydrotropes and additional enzymes.
  • various cleaning compositions such as those provided in U.S. Pat. No. 6,605,458, find use with the variant proteases of the present invention.
  • the compositions comprising at least one variant protease of the present invention is a compact granular fabric cleaning composition, while in other embodiments, the composition is a granular fabric cleaning composition useful in the laundering of colored fabrics, in further embodiments, the composition is a granular fabric cleaning composition which provides softening through the wash capacity, in additional embodiments, the composition is a heavy duty liquid fabric cleaning composition.
  • the compositions comprising at least one variant protease of the present invention are fabric cleaning compositions such as those described in U.S. Pat. Nos. 6,610,642 and 6,376,450.
  • the variant proteases of the present invention find use in granular laundry detergent compositions of particular utility under European or Japanese washing conditions (See e.g., U.S. Pat. No. 6,610,642).
  • the present invention provides hard surface cleaning compositions comprising at least one variant protease provided herein.
  • the compositions comprising at least one variant protease of the present invention is a hard surface cleaning composition such as those described in U.S. Pat. Nos. 6,610,642, 6,376,450, and 6,376,450.
  • the present invention provides dishwashing compositions comprising at least one variant protease provided herein.
  • the compositions comprising at least one variant protease of the present invention is a hard surface cleaning composition such as those in U.S. Pat. Nos. 6,610,642 and 6,376,450.
  • the present invention provides dishwashing compositions comprising at least one variant protease provided herein.
  • the compositions comprising at least one variant protease of the present invention comprise oral care compositions such as those in U.S. Pat. Nos. 6,376,450, and 6,376,450.
  • the formulations and descriptions of the compounds and cleaning adjunct materials contained in the aforementioned U.S. Pat. Nos. 6,376,450, 6,605,458, 6,605,458, and 6,610,642, find use with the variant proteases provided herein.
  • the cleaning compositions of the present invention are formulated into any suitable form and prepared by any process chosen by the formulator, non-limiting examples of which are described in U.S. Pat. Nos. 5,879,584, 5,691,297, 5,574,005, 5,569,645, 5,565,422, 5,516,448, 5,489,392, and 5,486,303, all of which are incorporated herein by reference.
  • the pH of such composition is adjusted via the addition of a material such as monoethanolamine or an acidic material such as HCl.
  • adjuncts illustrated hereinafter are suitable for use in the instant cleaning compositions.
  • these adjuncts are incorporated for example, to assist or enhance cleaning performance, for treatment of the substrate to be cleaned, or to modify the aesthetics of the cleaning composition as is the case with perfumes, colorants, dyes or the like. It is understood that such adjuncts are in addition to the variant proteases of the present invention. The precise nature of these additional components, and levels of incorporation thereof, will depend on the physical form of the composition and the nature of the cleaning operation for which it is to be used.
  • Suitable adjunct materials include, but are not limited to, surfactants, builders, chelating agents, dye transfer inhibiting agents, deposition aids, dispersants, additional enzymes, and enzyme stabilizers, catalytic materials, bleach activators, bleach boosters, hydrogen peroxide, sources of hydrogen peroxide, preformed peracids, polymeric dispersing agents, clay soil removal/anti-redeposition agents, brighteners, suds suppressors, dyes, perfumes, structure elasticizing agents, fabric softeners, carriers, hydrotropes, processing aids and/or pigments.
  • suitable examples of such other adjuncts and levels of use are found in U.S. Pat. Nos. 5,576,282, 6,306,812, and 6,326,348, incorporated by reference.
  • the aforementioned adjunct ingredients may constitute the balance of the cleaning compositions of the present invention.
  • the cleaning compositions according to the present invention comprise at least one surfactant and/or a surfactant system wherein the surfactant is selected from nonionic surfactants, anionic surfactants, cationic surfactants, ampholytic surfactants, zwitterionic surfactants, semi-polar nonionic surfactants and mixtures thereof.
  • the surfactant is selected from nonionic surfactants, anionic surfactants, cationic surfactants, ampholytic surfactants, zwitterionic surfactants, semi-polar nonionic surfactants and mixtures thereof.
  • the composition typically does not contain alkyl ethoxylated sulfate, as it is believed that such surfactant may be hydrolyzed by such compositions the acidic contents.
  • the surfactant is present at a level of from about 0.1% to about 60%, while in alternative embodiments the level is from about 1% to about 50%, while in still further embodiments the level is from about 5% to about 40%, by weight of the cleaning composition.
  • the cleaning compositions of the present invention comprise one or more detergent builders or builder systems. In some embodiments incorporating at least one builder, the cleaning compositions comprise at least about 1%, from about 3% to about 60% or even from about 5% to about 40% builder by weight of the cleaning composition.
  • Builders include, but are not limited to, the alkali metal, ammonium and alkanolammonium salts of polyphosphates, alkali metal silicates, alkaline earth and alkali metal carbonates, aluminosilicates, polycarboxylate compounds, ether hydroxypolycarboxylates, copolymers of maleic anhydride with ethylene or vinyl methyl ether, 1,3,5-trihydroxy benzene-2,4,6-trisulphonic acid, and carboxymethyloxysuccinic acid, the various alkali metal, ammonium and substituted ammonium salts of polyacetic acids such as ethylenediamine tetraacetic acid and nitrilotriacetic acid, as well as polycarboxylates such as mellitic acid, succinic acid, citric acid, oxydisuccinic acid, polymaleic acid, benzene 1,3,5-tricarboxylic acid, carboxymethyloxysuccinic acid, and soluble salts
  • the builders form water-soluble hardness ion complexes (e.g., sequestering builders), such as citrates and polyphosphates (e.g., sodium tripolyphosphate and sodium tripolyphospate hexahydrate, potassium tripolyphosphate, and mixed sodium and potassium tripolyphosphate, etc.). It is contemplated that any suitable builder will find use in the present invention, including those known in the art (See e.g., EP 2 100 949).
  • water-soluble hardness ion complexes e.g., sequestering builders
  • citrates and polyphosphates e.g., sodium tripolyphosphate and sodium tripolyphospate hexahydrate, potassium tripolyphosphate, and mixed sodium and potassium tripolyphosphate, etc.
  • polyphosphates e.g., sodium tripolyphosphate and sodium tripolyphospate hexahydrate, potassium tripolyphosphate, and mixed sodium and potassium tripolyphosphate,
  • the cleaning compositions of the present invention contain at least one chelating agent.
  • Suitable chelating agents include, but are not limited to copper, iron and/or manganese chelating agents and mixtures thereof.
  • the cleaning compositions of the present invention comprise from about 0.1% to about 15% or even from about 3.0% to about 10% chelating agent by weight of the subject cleaning composition.
  • the cleaning compositions provided herein contain at least one deposition aid.
  • Suitable deposition aids include, but are not limited to, polyethylene glycol, polypropylene glycol, polycarboxylate, soil release polymers such as polytelephthalic acid, clays such as kaolinite, montmorillonite, atapulgite, illite, bentonite, halloysite, and mixtures thereof.
  • anti-redeposition agents find use in some embodiments of the present invention.
  • non-ionic surfactants find use.
  • non-ionic surfactants find use for surface modification purposes, in particular for sheeting, to avoid filming and spotting and to improve shine.
  • these non-ionic surfactants also find use in preventing the re-deposition of soils.
  • the anti-redeposition agent is a non-ionic surfactant as known in the art (See e.g., EP 2 100 949).
  • the cleaning compositions of the present invention include one or more dye transfer inhibiting agents.
  • Suitable polymeric dye transfer inhibiting agents include, but are not limited to, polyvinylpyrrolidone polymers, polyamine N-oxide polymers, copolymers of N-vinylpyrrolidone and N-vinylimidazole, polyvinyloxazolidones and polyvinylimidazoles or mixtures thereof.
  • the cleaning compositions of the present invention comprise from about 0.0001% to about 10%, from about 0.01% to about 5%, or even from about 0.1% to about 3% by weight of the cleaning composition.
  • silicates are included within the compositions of the present invention.
  • sodium silicates e.g., sodium disilicate, sodium metasilicate, and crystalline phyllosilicates
  • silicates find use.
  • silicates are present at a level of from about 1% to about 20%.
  • silicates are present at a level of from about 5% to about 15% by weight of the composition.
  • the cleaning compositions of the present invention also contain dispersants.
  • Suitable water-soluble organic materials include, but are not limited to the homo- or co-polymeric acids or their salts, in which the polycarboxylic acid comprises at least two carboxyl radicals separated from each other by not more than two carbon atoms.
  • the enzymes used in the cleaning compositions are stabilized by any suitable technique.
  • the enzymes employed herein are stabilized by the presence of water-soluble sources of calcium and/or magnesium ions in the finished compositions that provide such ions to the enzymes.
  • the enzyme stabilizers include oligosaccharides, polysaccharides, and inorganic divalent metal salts, including alkaline earth metals, such as calcium salts. It is contemplated that various techniques for enzyme stabilization will find use in the present invention.
  • the enzymes employed herein are stabilized by the presence of water-soluble sources of zinc (II), calcium (II) and/or magnesium (II) ions in the finished compositions that provide such ions to the enzymes, as well as other metal ions (e.g., barium (II), scandium (II), iron (II), manganese (II), aluminum (III), Tin (II), cobalt (II), copper (II), nickel (II), and oxovanadium (IV). Chlorides and sulfates also find use in some embodiments of the present invention.
  • water-soluble sources of zinc (II), calcium (II) and/or magnesium (II) ions in the finished compositions that provide such ions to the enzymes, as well as other metal ions (e.g., barium (II), scandium (II), iron (II), manganese (II), aluminum (III), Tin (II), cobalt (II), copper (II), nickel (II), and
  • oligosaccharides and polysaccharides are known in the art (See e.g., WO 07/145,964).
  • reversible protease inhibitors also find use, such as boron-containing compounds (e.g., borate, 4-formyl phenyl boronic acid) and/or a tripeptide aldehyde find use to further improve stability, as desired.
  • bleaches, bleach activators and/or bleach catalysts are present in the compositions of the present invention.
  • the cleaning compositions of the present invention comprise inorganic and/or organic bleaching compound(s).
  • Inorganic bleaches include, but are not limited to perhydrate salts (e.g., perborate, percarbonate, perphosphate, persulfate, and persilicate salts).
  • inorganic perhydrate salts are alkali metal salts.
  • inorganic perhydrate salts are included as the crystalline solid, without additional protection, although in some other embodiments, the salt is coated. Any suitable salt known in the art finds use in the present invention (See e.g., EP 2 100 949).
  • bleach activators are used in the compositions of the present invention.
  • Bleach activators are typically organic peracid precursors that enhance the bleaching action in the course of cleaning at temperatures of 60° C. and below.
  • Bleach activators suitable for use herein include compounds which, under perhydrolysis conditions, give aliphatic peroxoycarboxylic acids having preferably from about 1 to about 10 carbon atoms, in particular from about 2 to about 4 carbon atoms, and/or optionally substituted perbenzoic acid. Additional bleach activators are known in the art and find use in the present invention (See e.g., EP 2 100 949).
  • the cleaning compositions of the present invention further comprise at least one bleach catalyst.
  • the manganese triazacyclononane and related complexes find use, as well as cobalt, copper, manganese, and iron complexes. Additional bleach catalysts find use in the present invention (See e.g., U.S. Pat. No. 4,246,612, U.S. Pat. No. 5,227,084, U.S. Pat. No. 4,810,410, WO 99/06521, and EP 2 100 949).
  • the cleaning compositions of the present invention contain one or more catalytic metal complexes.
  • a metal-containing bleach catalyst finds use.
  • the metal bleach catalyst comprises a catalyst system comprising a transition metal cation of defined bleach catalytic activity, (e.g., copper, iron, titanium, ruthenium, tungsten, molybdenum, or manganese cations), an auxiliary metal cation having little or no bleach catalytic activity (e.g., zinc or aluminum cations), and a sequestrate having defined stability constants for the catalytic and auxiliary metal cations, particularly ethylenediaminetetraacetic acid, ethylenediaminetetra (methylenephosphonic acid) and water-soluble salts thereof are used (See e.g., U.S.
  • the cleaning compositions of the present invention are catalyzed by means of a manganese compound.
  • a manganese compound Such compounds and levels of use are well known in the art (See e.g., U.S. Pat. No. 5,576,282).
  • cobalt bleach catalysts find use in the cleaning compositions of the present invention.
  • Various cobalt bleach catalysts are known in the art (See e.g., U.S. Pat. Nos. 5,597,936 and 5,595,967) and are readily prepared by known procedures.
  • the cleaning compositions of the present invention include a transition metal complex of a macropolycyclic rigid ligand (MRL).
  • MRL macropolycyclic rigid ligand
  • the compositions and cleaning processes provided by the present invention are adjusted to provide on the order of at least one part per hundred million of the active MRL species in the aqueous washing medium, and in some embodiments, provide from about 0.005 ppm to about 25 ppm, more preferably from about 0.05 ppm to about 10 ppm, and most preferably from about 0.1 ppm to about 5 ppm, of the MRL in the wash liquor.
  • transition-metals in the instant transition-metal bleach catalyst include, but are not limited to manganese, iron and chromium.
  • MRLs also include, but are not limited to special ultra-rigid ligands that are cross-bridged (e.g., 5,12-diethyl-1,5,8,12-tetraazabicyclo[6.6.2]hexadecane). Suitable transition metal MRLs are readily prepared by known procedures (See e.g., WO 2000/32601, and U.S. Pat. No. 6,225,464).
  • the cleaning compositions of the present invention comprise metal care agents.
  • Metal care agents find use in preventing and/or reducing the tarnishing, corrosion, and/or oxidation of metals, including aluminum, stainless steel, and non-ferrous metals (e.g., silver and copper). Suitable metal care agents include those described in EP 2 100 949, WO 9426860 and WO 94/26859).
  • the metal care agent is a zinc salt.
  • the cleaning compositions of the present invention comprise from about 0.1% to about 5% by weight of one or more metal care agent.
  • the cleaning compositions of the present invention are formulated into any suitable form and prepared by any process chosen by the formulator, non-limiting examples of which are described in U.S. Pat. Nos. 5,879,584, 5,691,297, 5,574,005, 5,569,645, 5,516,448, 5,489,392, and 5,486,303, all of which are incorporated herein by reference.
  • the pH of such composition is adjusted via the addition of an acidic material such as HCl.
  • the cleaning compositions disclosed herein of find use in cleaning a situs (e.g., a surface, item, dishware, or fabric).
  • a situs e.g., a surface, item, dishware, or fabric.
  • the situs is optionally washed and/or rinsed.
  • “washing” includes but is not limited to, scrubbing, and mechanical agitation.
  • the cleaning compositions are typically employed at concentrations of from about 500 ppm to about 15,000 ppm in solution.
  • the wash solvent is water
  • the water temperature typically ranges from about 5° C. to about 90° C. and, when the situs comprises a fabric, the water to fabric mass ratio is typically from about 1:1 to about 30:1.
  • the cleaning compositions of the present invention are formulated into any suitable form and prepared by any suitable process chosen by the formulator, (See e.g., U.S. Pat. Nos. 5,879,584, 5,691,297, 5,574,005, 5,569,645, 5,565,422, 5,516,448, 5,489,392, 5,486,303, 4,515,705, 4,537,706, 4,515,707, 4,550,862, 4,561,998, 4,597,898, 4,968,451, 5,565,145, 5,929,022, 6,294,514 and 6,376,445).
  • the cleaning compositions of the present invention are provided in unit dose form, including tablets, capsules, sachets, pouches, and multi-compartment pouches.
  • the unit dose format is designed to provide controlled release of the ingredients within a multi-compartment pouch (or other unit dose format). Suitable unit dose and controlled release formats are known in the art (See e.g., EP 2 100 949, WO 02/102955, U.S. Pat. Nos. 4,765,916 and 4,972,017, and WO 04/111178 for materials suitable for use in unit dose and controlled release formats).
  • the unit dose form is provided by tablets wrapped with a water-soluble film or water-soluble pouches.
  • Various formats for unit doses are provided in EP 2 100 947, and are known in the art.
  • the cleaning compositions of the present invention find use in cleaning surfaces (e.g., dishware), laundry, hard surfaces, contact lenses, etc.
  • at least a portion of the surface is contacted with at least one embodiment of the cleaning compositions of the present invention, in neat form or diluted in a wash liquor, and then the surface is optionally washed and/or rinsed.
  • “washing” includes, but is not limited to, scrubbing, and mechanical washing.
  • the cleaning compositions of the present invention are used at concentrations of from about 500 ppm to about 15,000 ppm in solution.
  • the wash solvent is water
  • the water temperature typically ranges from about 5° C. to about 90° C.
  • the present invention provides methods for cleaning or washing an item or surface (e.g., hard surface) in need of cleaning, including, but not limited to methods for cleaning or washing a dishware item, a tableware item, a fabric item, a laundry item, personal care item, etc., or the like, and methods for cleaning or washing a hard or soft surface (e.g., a hard surface of an item).
  • an item or surface e.g., hard surface
  • a hard or soft surface e.g., a hard surface of an item.
  • the present invention provides a method for cleaning an item, object, or surface in need of cleaning, the method comprising contacting the item or surface (or a portion of the item or surface desired to be cleaned) with at least one variant subtilisin protease of the present invention or a composition of the present invention for a sufficient time and/or under conditions suitable and/or effective to clean the item, object, or surface to a desired degree.
  • Some such methods further comprise rinsing the item, object, or surface with water.
  • the cleaning composition is a dishwashing detergent composition and the item or object to be cleaned is a dishware item or tableware item.
  • a “dishware item” is an item generally used in serving or eating food.
  • a dishware item can be, but is not limited to for example, a dish, plate, cup, bowl, etc., and the like.
  • tableware is a broader term that includes, but is not limited to for example, dishes, cutlery, knives, forks, spoons, chopsticks, glassware, pitchers, sauce boats, drinking vessels, serving items, etc. It is intended that “tableware item” includes any of these or similar items for serving or eating food.
  • the cleaning composition is an automatic dishwashing detergent composition or a hand dishwashing detergent composition and the item or object to be cleaned is a dishware or tableware item.
  • the cleaning composition is a laundry detergent composition (e.g., a power laundry detergent composition or a liquid laundry detergent composition), and the item to be cleaned is a fabric item.
  • the cleaning composition is a laundry pre-treatment composition.
  • the present invention provides methods for cleaning or washing a fabric item optionally in need of cleaning or washing, respectively.
  • the methods comprise providing a composition comprising the variant protease, including but not limited to fabric or laundry cleaning composition, and a fabric item or laundry item in need of cleaning, and contacting the fabric item or laundry item (or a portion of the item desired to be cleaned) with the composition under conditions sufficient or effective to clean or wash the fabric or laundry item to a desired degree.
  • the present invention provides a method for cleaning or washing an item or surface (e.g., hard surface) optionally in need of cleaning, the method comprising providing an item or surface to be cleaned or washed and contacting the item or surface (or a portion of the item or surface desired to be cleaned or washed) with at least one subtilisin variant of the invention or a composition of the invention comprising at least one such subtilisin variant for a sufficient time and/or under conditions sufficient or effective to clean or wash the item or surface to a desired degree.
  • an item or surface e.g., hard surface
  • the method comprising providing an item or surface to be cleaned or washed and contacting the item or surface (or a portion of the item or surface desired to be cleaned or washed) with at least one subtilisin variant of the invention or a composition of the invention comprising at least one such subtilisin variant for a sufficient time and/or under conditions sufficient or effective to clean or wash the item or surface to a desired degree.
  • compositions include, but are not limited to for example, a cleaning composition or detergent composition of the invention (e.g., a hand dishwashing detergent composition, hand dishwashing cleaning composition, laundry detergent or fabric detergent or laundry or fabric cleaning composition, liquid laundry detergent, liquid laundry cleaning composition, powder laundry detergent composition, powder laundry cleaning composition, automatic dishwashing detergent composition, laundry booster cleaning or detergent composition, laundry cleaning additive, and laundry pre-spotter composition, etc.).
  • a cleaning composition or detergent composition of the invention e.g., a hand dishwashing detergent composition, hand dishwashing cleaning composition, laundry detergent or fabric detergent or laundry or fabric cleaning composition, liquid laundry detergent, liquid laundry cleaning composition, powder laundry detergent composition, powder laundry cleaning composition, automatic dishwashing detergent composition, laundry booster cleaning or detergent composition, laundry cleaning additive, and laundry pre-spotter composition, etc.
  • the method is repeated one or more times, particularly if additional cleaning or washing is desired.
  • the method optionally further comprises allowing the item or surface to remain in contact with the at least one variant protease or composition for a period
  • the methods further comprise rinsing the item or surface with water and/or another liquid. In some embodiments, the methods further comprise contacting the item or surface with at least one variant protease of the invention or a composition of the invention again and allowing the item or surface to remain in contact with the at least one variant protease or composition for a period of time sufficient to clean or wash the item or surface to the desired degree.
  • the cleaning composition is a dishwashing detergent composition and the item to be cleaned is a dishware or tableware item. In some embodiments of the present methods, the cleaning composition is an automatic dishwashing detergent composition or a hand dishwashing detergent composition and the item to be cleaned is a dishware or tableware item. In some embodiments of the methods, the cleaning composition is a laundry detergent composition and the item to be cleaned is a fabric item.
  • the present invention also provides methods of cleaning a tableware or dishware item in an automatic dishwashing machine, the method comprising providing an automatic dishwashing machine, placing an amount of an automatic dishwashing composition comprising at least one subtilisin variant of the present invention or a composition of the invention sufficient to clean the tableware or dishware item in the machine (e.g., by placing the composition in an appropriate or provided detergent compartment or dispenser in the machine), putting a dishware or tableware item in the machine, and operating the machine so as to clean the tableware or dishware item (e.g., as per the manufacturer's instructions).
  • the methods include any automatic dishwashing composition described herein, which comprises, but is not limited to at least one subtilisin variant provided herein.
  • the amount of automatic dishwashing composition to be used can be readily determined according to the manufacturer's instructions or suggestions and any form of automatic dishwashing composition comprising at least one variant protease of the invention (e.g., liquid, powder, solid, gel, tablet, etc.), including any described herein, may be employed.
  • any form of automatic dishwashing composition comprising at least one variant protease of the invention (e.g., liquid, powder, solid, gel, tablet, etc.), including any described herein, may be employed.
  • the present invention also provides methods for cleaning a surface, item or object optionally in need of cleaning, the method comprises contacting the item or surface (or a portion of the item or surface desired to be cleaned) with at least one variant subtilisin of the present invention or a cleaning composition of the invention in neat form or diluted in a wash liquor for a sufficient time and/or under conditions sufficient or effective to clean or wash the item or surface to a desired degree.
  • the surface, item, or object may then be (optionally) washed and/or rinsed if desired.
  • “washing” includes, but is not limited to for example, scrubbing and mechanical agitation.
  • the cleaning compositions are employed at concentrations of from about 500 ppm to about 15,000 ppm in solution (e.g., aqueous solution).
  • aqueous solution e.g., water
  • the water temperature typically ranges from about 5° C. to about 90° C. and when the surface, item or object comprises a fabric, the water to fabric mass ratio is typically from about 1:1 to about 30:1.
  • the present invention also provides methods of cleaning a laundry or fabric item in an washing machine, the method comprising providing an washing machine, placing an amount of a laundry detergent composition comprising at least one variant subtilisin of the invention sufficient to clean the laundry or fabric item in the machine (e.g., by placing the composition in an appropriate or provided detergent compartment or dispenser in the machine), placing the laundry or fabric item in the machine, and operating the machine so as to clean the laundry or fabric item (e.g., as per the manufacturer's instructions).
  • the methods of the present invention include any laundry washing detergent composition described herein, comprising but not limited to at least one of any variant subtilisin provided herein.
  • laundry detergent composition to be used can be readily determined according to manufacturer's instructions or suggestions and any form of laundry detergent composition comprising at least one variant protease of the invention (e.g., solid, powder, liquid, tablet, gel, etc.), including any described herein, may be employed.
  • any form of laundry detergent composition comprising at least one variant protease of the invention (e.g., solid, powder, liquid, tablet, gel, etc.), including any described herein, may be employed.
  • RNA ribonucleic acid
  • MgCl 2 magnesium chloride
  • NaCl sodium chloride
  • w/v weight to volume
  • v/v volume to volume
  • w/w weight to weight
  • g gravity
  • OD optical density
  • ppm parts per million
  • leading “0” is indicated, in order to provide a three number designation for each site (e.g., “001” is the same as “1,” so “A001C” is the same as “A1C”). In some lists, the leading “0” is not included.
  • X refers to any amino acid.
  • the enzymes levels are expressed by pure enzyme by weight of the total composition and unless otherwise specified, the detergent ingredients are expressed by weight of the total compositions.
  • the abbreviated component identifications therein have the following meanings:
  • Plurafac LF404 being an alcohol with an average degree of ethoxylation of 3.8 and an average degree of propoxylation of 4.5.
  • QAS R 2 •N + (CH 3 ) 2 (C 2 H 4 OH) with R 2 C 12 -C 14 .
  • Silicate Amorphous Sodium Silicate (SiO 2 :Na 2 O ratio 1.6-3.2:1).
  • Metasilicate Sodium metasilicate (SiO 2 :Na 2 O ratio 1.0).
  • STPP Sodium Tripolyphosphate.
  • MA/AA Random copolymer of 4:1 acrylate/maleate, average molecular weight about 70,000-80,000.
  • AA Sodium polyacrylate polymer of average molecular weight 4,500.
  • Polycarboxylate Copolymer comprising mixture of carboxylated monomers such as acrylate, maleate and methyacrylate with a MW ranging between 2,000-80,000 such as Sokolan commercially available from BASF, being a copolymer of acrylic acid, MW4,500.
  • BB1 3-(3,4-Dihydroisoquinolinium)propane sulfonate
  • BB2 1-(3,4-dihydroisoquinolinium)-decane-2-sulfate
  • PB1 Sodium perborate monohydrate.
  • PB4 Sodium perborate tetrahydrate of nominal formula NaBO 3 •4H 2 O.
  • Percarbonate Sodium percarbonate of nominal formula 2Na 2 CO 3 •3H 2 O 2 .
  • TAED Tetraacetyl ethylene diamine. NOBS Nonanoyloxybenzene sulfonate in the form of the sodium salt.
  • DTPA Diethylene triamine pentaacetic acid.
  • HEDP 1,1-hydroxyethane diphosphonic acid.
  • DETPMP Diethyltriamine penta (methylene) phosphonate marketed by Monsanto under the Trade name Dequest 2060.
  • EDDS Ethylenediamine-N,N′-disuccinic acid, (S,S) isomer in the form of its sodium salt Diamine Dimethyl aminopropyl amine; 1,6-hezane diamine; 1,3-propane diamine; 2-methyl-1,5-pentane diamine; 1,3-pentanediamine; 1- methyl-diaminopropane.
  • Aldose oxidase Oxidase enzyme sold under the tradename Aldose Oxidase by Novozymes A/S Galactose oxidase Galactose oxidase from Sigma nprE The recombinant form of neutral metalloprotease expressed in Bacillus subtilis (See e.g., WO 07/044993) PMN Purified neutral metalloprotease from Bacillus amyloliquefacients .
  • Amylase A suitable amylolytic enzyme, such as those sold under the tradenames PURAFECT ® Ox described in WO 94/18314, WO96/05295 sold by Genencor; NATALASE ®, TERMAMYL ®, FUNGAMY1 ® and DURAMYL TM, all available from Novozymes A/S.
  • Lipase A suitable lipolytic enzyme such as those sold under the tradenames LIPEX ®, LIPOLASE ®, LIPOLASE ® Ultra by Novozymes A/S and Lipomax TM by Gist-Brocades.
  • Cellulase A suitable cellulytic enzyme such as those sold under the tradenames CAREZYME ®, CELLUZYME ®, and/or ENDOLASE ® by Novozymes A/S.
  • Pectin Lyase A suitable pectin lyase, such as those sold under the tradenames PECTAWAY ® and PECTAWASH ® available from Novozymes A/S.
  • PVP Polyvinylpyrrolidone with an average molecular weight of 60,000 PVNO Polyvinylpyridine-N-Oxide, with an average molecular weight of 50,000.
  • PVPVI Copolymer of vinylimidazole and vinylpyrrolidone with an average molecular weight of 20,000.
  • Brightener 1 Disodium 4,4′-bis(2-sulphostyryl)biphenyl. Silicone antifoam Polydimethylsiloxane foam controller with siloxane-oxyalkylene copolymer as dispersing agent with a ratio of said foam controller to said dispersing agent of 10:1 to 100:1. Suds Suppressor 12% Silicone/silica, 18% stearyl alcohol, 70% starch in granular form. SRP 1 Anionically end capped poly esters. PEG X Polyethylene glycol, of a molecular weight of x.
  • NA and WE North American (NA) and Western European (WE) heavy duty liquid laundry (HDL) detergents
  • heat inactivation of the enzymes present in commercially-available detergents is performed by placing pre-weighed liquid detergent (in a glass bottle) in a water bath at 95° C. for 2 hours.
  • the incubation time for heat inactivation of NA and WE auto dish washing (ADW) detergents is 8 hours. Both un-heated and heated detergents are assayed within 5 minutes of dissolving the detergent to accurately determine percentage deactivated. Enzyme activity is tested by the AAPF assay.
  • Table C provides granular laundry detergent compositions produced in accordance with the invention suitable for laundering fabrics.
  • Detergent Compositions Component 1 2 3 4 5 6 Linear alkylbenzenesulfonate 15 12 20 10 12 13 with aliphatic carbon chain length C 11 -C 12 Other surfactants 1.6 1.2 1.9 3.2 0.5 1.2 Phosphate builder(s) 2 3 4 Zeolite 1 1 4 1 Silicate 4 5 2 3 3 5 Sodium Carbonate 2 5 5 4 0 3 Polyacrylate (MW 4500) 1 0.6 1 1 1.5 1 Carboxymethyl cellulose 1 — 0.3 — 1.1 — (Finnfix BDA ex CPKelco) Celluclean ® (15.6 mg/g) 0.23 0.17 0.5 0.2 0.2 0.6 Cold Water Protease* 0.23 0.17 0.05 0.2 0.03 0.1 Stainzyme Plus ® (14 mg/g) 0.23 0.17 0.5 0.2 0.2 0.6 Mannaway 4.0 T (4 mg/g) 0.1 0.1 0.1 Lipex 100 T (18
  • the molecular weight of the polyethylene oxide backbone is about 6000 and the weight ratio of the polyethylene oxide to polyvinyl acetate is about 40 to 60 and no more than 1 grafting point per 50 ethylene oxide units.
  • 2 Polyethylenimine (MW 600) with 20 ethoxylate groups per —NH.
  • Reversible protease inhibitor of structure: 5 Ethoxylated thiophene Hueing Dye is as described in U.S. Pat. No. 7,208,459 B2.
  • Table D provides granular laundry detergent compositions suitable for top-loading automatic washing machines (detergent compositions 7-9) and front loading washing machines (detergent compositions 10-11).
  • the GG36 protease variant tested and/or cold water protease of the present invention is added separately to these formulations.
  • surfactant ingredients can be obtained from any suitable supplier, including but not limited to BASF (e.g., LUTENSOL®), Shell Chemicals, Stepan, Huntsman, and Clariant (e.g., PRAEPAGEN®).
  • Zeolite can be obtained from sources such as Industrial Zeolite.
  • Citric acid and sodium citrate can be obtained from sources such as Jungbunzlauer.
  • Sodium percarbonate, sodium carbonate, sodium bicarbonate and sodium sesquicarbonate can be obtained from sources such as Solvay.
  • Acrylate/maleate copolymers can be obtained from sources such as BASF.
  • Carboxymethylcellulose and hydrophobically modified carboxymethyl cellulose can be obtained from sources such as CPKelco. C.I.
  • Fluorescent Brightener 260 can be obtained from 3V Sigma (e.g., OPTIBLANC®, OPTIBLANC® 2M/G, OPTIBLANC® 2MG/LT Extra, or OPTIBLANC® Ecobright.
  • Tetrasodium S,S-ethylenediamine disuccinate can be obtained from sources such as Innospec.
  • Terephthalate co-polymer can be obtained from Clariant (e.g., REPELOTEX SF 2).
  • Clariant e.g., REPELOTEX SF 2
  • 1-Hydroxyethane-1,1-diphosphonic acid can be obtained from Thermphos.
  • the enzymes NATALASE®, TERMAMYL®, STAINZYME PLUS®, CELLUCLEAN® and MANNAWAY® can be obtained from Novozymes.
  • Zinc phthalocyanine tetrasulfonate can be obtained from Ciba Specialty Chemicals (e.g., TINOLUX® BMC).
  • Suds suppressor granule can be obtained from Dow Corning.
  • random graft copolymer is a polyvinyl acetate grafted polyethylene oxide copolymer having a polyethylene oxide backbone and multiple polyvinyl acetate side chains. The molecular weight of the polyethylene oxide backbone is about 6000 and the weight ratio of the polyethylene oxide to polyvinyl acetate is about 40 to 60 and no more than 1 grafting point per 50 ethylene oxide units.
  • Tables E-G provide additional granular detergent compositions suitable for washing machines (detergents 36a-n).
  • the GG36 protease variant tested or cold water protease of the present invention is added separately to these formulations.
  • Detergent Composition Component 36a 36b 36c 36d 36e Surfactants C 10 Nonionic 0.1843 C 16-17 Branched alkyl sulfate 3.53 3.53 3.53 C 12-14 alkyl sulphate Sodium linear alkylbenzenesulfonate 8.98 8.98 8.98 13.58 14.75 with aliphatic chain length C 11 -C 12 Sodium C 14/15 alcohol ethoxy-3- 1.28 1.28 1.28 sulfate Sodium C 14/15 alkyl sulphate 2.36 2.36 2.36 C 14/15 alcohol ethoxylate with average 7 moles of ethoxylation mono-C 8-10 alkyl mono-hydroxyethyl di- methyl quaternary ammonium chloride Di methyl hydroxyl ethyl lauryl 0.1803 ammonium chloride Zeolite A 15.31 15.31 15.31 4.47 Bentonite 8.35 Sodium Silicate 1.6.ratio 0.16
  • Detergent Composition Component 36k 36l 36m 36n Surfactants C 10 Nonionic 0.1979 0.1979 0.1979 0.1979 C 16-17 Branched alkyl sulfate C 12-14 alkyl sulphate Sodium linear alkylbenzenesulfonate 8.92 8.92 11.5 11.5 with aliphatic chain length C 11 -C 12 Sodium C 14/15 alcohol ethoxy-3- 1.62 1.62 1.125 1.125 sulfate Sodium C 14/15 alkyl sulphate C 14/15 alcohol ethoxylate with average 7 1.0 1.0 1.5 1.5 moles of ethoxylation mono-C 8-10 alkyl mono-hydroxyethyl di- methyl quaternary ammonium chloride Di methyl hydroxyl ethyl lauryl ammonium chloride Zeolite A 1.63 1.63 2.0 2.0 Sodium Silicate 1.6.
  • Fluorescent Brightener 351 (Tinopal ® CBS) Suds suppressor granule 0.042 0.042 0.042 0.042 Hydrophobically modified carboxy methyl cellulose (Finnifix ® SH-1) Bentonite Miscellaneous (Dyes, perfumes, process Balance Balance Balance Balance Balance aids, moisture and sodium sulphate) Notes for detergent compositions 36 a-n in Tables E, F, G: Surfactant ingredients can be obtained from BASF, Ludwigshafen, Germany (Lutensol ®); Shell Chemicals, London, UK; Stepan, Northfield, Illinois, USA; Huntsman, Huntsman, Salt Lake City, Utah, USA; Clariant, Sulzbach, Germany (Praepagen ®).
  • Zeolite can be obtained from Industrial Zeolite (UK) Ltd, Grays, Essex, UK. Citric acid and sodium citrate can be obtained from Jungbunzlauer, Basel, Switzerland. Sodium percarbonate, sodium carbonate, sodium bicarbonate and sodium sesquicarbonate can be obtained from Solvay, Brussels, Belgium. Acrylate/maleate copolymers can be obtained from BASF, Ludwigshafen, Germany. Carboxymethylcellulose and hydrophobically modified carboxymethyl cellulose can be obtained from CPKelco, Arnhem, The Netherlands. C.I.
  • Fluorescent Brightener 260 can be obtained from 3V Sigma, Bergamo, Italy as Optiblanc ® Optiblanc ® 2M/G, Optiblanc ® 2MG/LT Extra, or Optiblanc ® Ecobright.
  • Tetrasodium S,S-ethylenediamine disuccinate can be obtained from Innospec, Ellesmere Port, UK.
  • Terephthalate co-polymer can be obtained from Clariant under the tradename Repelotex SF 2.
  • 1-Hydroxyethane-1,1-diphosphonic acid can be obtained from Thermphos, Vlissingen-Oost, The Netherlands.
  • Enzymes Natalase ®, Termamyl ®, Stainzyme Plus ®, Celluclean ® and Mannaway ® can be obtained from Novozymes, Bagsvaerd, Denmark.
  • Zinc phthalocyanine tetrasulfonate can be obtained from Ciba Specialty Chemicals, Basel, Switzerland, as Tinolux ® BMC. Suds suppressor granule can be obtained from Dow Corning, Barry, UK.
  • Random graft copolymer is a polyvinyl acetate grafted polyethylene oxide copolymer having a polyethylene oxide backbone and multiple polyvinyl acetate side chains.
  • the molecular weight of the polyethylene oxide backbone is about 6000 and the weight ratio of the polyethylene oxide to polyvinyl acetate is about 40 to 60 and no more than 1 grafting point per 50 ethylene oxide units.
  • the assays were performed using a Biomek FX Robot (Beckman Coulter) or a multichannel pipettor (e.g., Rainin PipetLite, Mettler-Toledo) and a SpectraMAX MTP Reader (type 340; Molecular Devices).
  • a Biomek FX Robot Beckman Coulter
  • a multichannel pipettor e.g., Rainin PipetLite, Mettler-Toledo
  • SpectraMAX MTP Reader type 340; Molecular Devices.
  • a protocol to define whether a dye or pigment material is a fabric hueing agent for the purpose of the invention is provided below:
  • the BMI microswatch assay is run using the granular detergent composition 10 (See Table D, above).
  • the laundry detergent is dissolved in water that has a hardness of 12 gpg and adjusted to a temperature of 16° C., and the protease variant enzyme of interest is added.
  • Performance of the protease variant enzymes is then determined as per the BMI microswatch assay described.
  • the performance index is determined by comparing the performance of the protease variant enzyme with that of the B. lentus GG36 subtilisin enzyme having the amino acid sequence of SEQ ID NO:2, with in all cases the enzyme dosage range being 0.1-5 ppm.
  • Protease variant enzymes having a performance index of 1.1 or greater are viewed to be cold water proteases.
  • the BMI microswatch assay provided below is run using the granular laundry detergent composition 7 (See Table D, above).
  • the laundry detergent is dissolved in water that has a hardness of 6 gpg and adjusted to a temperature of 16° C., the GG36 protease variant enzyme of interest is added.
  • Performance of the GG36 protease variant enzymes is then determined as per the BMI microswatch assay described.
  • the performance index is determined by comparing the performance of the GG36 protease variant enzyme with that of the B. lentus GG36 subtilisin enzyme having the amino acid sequence of SEQ ID NO:2, with in all cases the enzyme dosage range being 0.1-5 ppm.
  • GG36 protease variant enzymes having a performance index of 1.1 or greater are viewed to be cold water proteases.
  • the BMI microswatch assay is run using the granular laundry detergent composition 7 (See Table D, above).
  • the laundry detergent is dissolved in water that has a hardness of 6 gpg and adjusted to a temperature of 16° C., and the GG36 protease variant enzyme of interest is added.
  • Performance of the GG36 protease variant enzymes is then determined as per the BMI microswatch assay described.
  • the performance index is determined by comparing the performance of the GG36 protease variant enzyme with that of a reference enzyme GG36-A158E, said GG36-A158E reference enzyme consisting of the B.
  • GG36 protease variant enzymes having a performance index of 1.0 or greater are viewed to be cold water proteases.
  • the BMI microswatch assay is run using one of the detergents 36a 36n in Table 1-2.
  • the detergent is dissolved in water that has a hardness as specified in Table 1-2 and adjusted to a temperature of 16° C.
  • Performance of the variant enzymes is then determined as per the BMI microswatch assay described.
  • the performance index is determined by comparing the performance of the variant with that of the enzyme of SEQ ID NO:2, with the enzyme dosage range being 0.1-5 ppm in all cases. Enzymes having a performance index of 1.1 or greater are viewed to be cold water proteases.
  • B. subtilis cultures were grown 2-3 days at 37° C., shaking at 250-300 rpm with humidified aeration.
  • the cells were removed from the enzyme-containing culture supernatant, by centrifugation and/or filtration.
  • the protease/protein/enzyme concentration was determined using a TCA precipitation assay.
  • An aliquot (20-25 ul) of culture supernatant was transferred to a 96-well flat bottom microtiter plate (MTP; Costar 9017 medium binding clear polystyrene plate) containing 100 ⁇ L/well of 0.25 N HCl.
  • the “baseline” read was determined by light scattering/absorbance reading at 405 nm following 5 seconds of mixing.
  • a standard curve can be created by calibrating the TCA readings with AAPF protease assays (see below) of clones with known specific activity.
  • the TCA results are linear with respect to protein concentration from 50 to 500 parts per million (ppm) of protein (where 1 ppm corresponds to 1 mg/L) and can thus be plotted directly against enzyme performance for the purpose of choosing variants with desired performance.
  • the reagent solutions used were: 100 mM Tris/HCl, pH 8.6, containing 0.005% TWEEN®-80 (Tris dilution buffer); 100 mM Tris buffer, pH 8.6, containing 1 mM CaCl 2 and 0.005% TWEEN®-80 (Tris/Ca buffer); and 160 mM suc-AAPF-pNA in DMSO (suc-AAPF-pNA stock solution) (Sigma: S-7388).
  • suc-AAPF-pNA working solution 1 ml suc-AAPF-pNA stock solution was added to 100 ml Tris/Ca buffer and mixed well for at least 10 seconds.
  • the assay was performed by adding 10 ⁇ l of diluted protease solution to each well of a 96-well MTP, immediately followed by the addition of 190 ⁇ l of 1 mg/ml suc-AAPF-pNA working solution. The solutions were mixed for 5 sec, and the absorbance change in kinetic mode (25 readings in 5 minutes) was read at 405 nm in an MTP reader, at 25° C.
  • Eglin c serine protease concentration and specific activity was determined by titration with an inhibitor called eglin c.
  • Eglin c from the leech Hirudo medicinalis is a tight-binding protein inhibitor of subtilisins and ASP protease (Heinz et al., Biochemistry, 31: 8755-66 [1992]), and can therefore be used to measure protease enzyme concentration, which in turn permits specific activity to be calculated.
  • the gene for eglin c was synthesized and expressed in E. coli by standard methods. Its properties and inhibitory potency were the same as eglin c purchased from Sigma.
  • a sample of Bacillus lentus subtilisin of known specific activity was diluted in 100 mM Tris buffer, pH 8.6, containing 1 mM CaCl 2 and 0.005% TWEEN®-80 (Tris/Ca buffer), to a concentration appropriate for AAPF protease assay described above.
  • Tris/Ca buffer Tris/Ca buffer
  • Several dilutions of the eglin c stock solution were also made in the Tris/Ca buffer.
  • An aliquot of each diluted eglin c solution was mixed with an equal volume of the diluted Bacillus lentus subtilisin solution.
  • the concentration of eglin c in each sample was then calculated based on the decrease of the observed protease activity as compared to the uninhibited subtilisin sample that was mixed with Tris/Ca buffer only (without eglin c).
  • concentration of eglin c in the stock solution was determined
  • subtilisin variants were diluted in 100 mM Tris buffer, pH 8.6, containing 1 mM CaCl 2 and 0.005% TWEEN®-80 (Tris/Ca buffer). Several dilutions of the eglin c stock solution of known concentration were also made in the Tris/Ca buffer. An aliquot of each diluted eglin c solution was mixed with an equal volume of a subtilisin variant solution. The mixed solutions were incubated at room temperature for 15-30 minutes and the protease activity of each sample was then measured by AAPF assay.
  • the concentration of the eglin c necessary for the complete inhibition of each subtilisin enzyme variant was calculated. This concentration is equivalent to the enzyme concentration in the sample.
  • An aliquot of the Tris/Ca buffer only, without eglin c, was also mixed with each subtilisin variant sample and the protease activity in the absence of eglin c was measured by AAPF assay. The specific activity of the subtilisin variants was then calculated using the enzyme concentrations as determined above.
  • BMI blood, milk and ink stained microswatches
  • MTP 96 well microtiter plates
  • Detergents 7-11 and 36a-n were prepared by mixing for at least 30 minutes in 2 mM sodium carbonate, buffered to pH 10.3 with the appropriate level of water hardness (3:1 Ca:Mg.—CaCl 2 : MgCl 2 .6H 2 O) in Milli-Q water as described in Table 1-1 and Table 1-2.
  • the detergents were aliquoted into 50 ml conical tubes (Falcon), centrifuged to remove precipitate, and chilled on ice for 30 minutes prior to use.
  • Enzyme concentrations were equalized to a desired fixed concentration ranging from 20-50 ppm relative to a standard of purified GG36.
  • the specific activity of GG36 using AAPF as a substrate was used to convert baseline subtracted TCA values into enzyme concentration in ppm.
  • enzyme concentration was determined in ppm, a simple formula was used to calculate the volume of each variant required to add to a fixed volume of buffer (300-600 ⁇ L) in order to achieve the desired stock enzyme concentration:
  • a Perkin-Elmer Janus robot with a Versispan 8 channel arm was used to dispense variable volumes of enzyme from the source plate (Axygen half deep well plate with pooled harvested variants used in the TCA enzyme concentration assay) into the buffer-filled destination plate using conductive tips. Samples were mixed three times by pipetting up and down. The accuracy of the enzyme dilutions was validated by measuring the AAPF activity of the equalized plate and comparing it to that of the source plate, to verify that the correct dilutions had been made.
  • the MTP was sealed with foil (Bio-Rad) and incubated in iEMS incubator/shaker (Thermo/Labsystems) pre-set to 16° C. in a cold room set to 4° C. or at 32° C. on the benchtop for 30 minutes at 1400 rpm. Following incubation, 120 ⁇ L of supernatant was transferred to a fresh MTP (Corning 9017) and read at 600 nm using the SpectraMax reader. True absorbance readings were obtained by subtracting a blank control (no enzyme) from each value.
  • a performance index (PI) was calculated for each variant.
  • the performance index is the ratio of the absorbance of the supernatant produced by variant enzyme cleaning to the absorbance produced by GG36 cleaning at a fixed enzyme concentration.
  • PI values were calculated by dividing the absorbance of a variant by that of the control on a given plate.
  • a standard curve e.g. Langmuir or four parameter logistic nonlinear regression model fit
  • the performance of the variants can be directly compared to the control at any enzyme concentration.
  • the PI is determined by dividing the absorbance of the variants by the calculated absorbance for the control at the same enzyme concentration.
  • the reagents used were dodecyllbenzene sulfonate, sodium salt (DOBS; Sigma No. D-2525), TWEEN®-80 (Sigma No. P-8074), di-sodium EDTA (Siegfried Handel No. 164599-02), HEPES (Sigma No.
  • V- or U-bottom MTP as dilution plates (Greiner 651101 and 650161 respectively), F-bottom MTP (Corning 9017) for unstress and LAS/EDTA buffer as well as for suc-AAPF-pNA plates, Biomek FX (Beckman Coulter), Spectramax Plus 384 MTP Reader (Molecular Devices), and iEMS Incubator/Shaker (Thermo/Labsystems).
  • the iEMS incubator/shaker (Thermo/Labsystems) is set at 29° C. Culture supernatants were diluted into plates containing unstress buffer to a concentration of 25 ppm (master dilution plate). For the assay, 20 ⁇ l of sample from the master dilution plate is added to plates containing 180 ⁇ l unstress buffer to give a final incubation concentration of 2.5 ppm. The contents were mixed and kept at room temperature and the AAPF assay is performed on this plate.
  • the final detergent, water hardness and buffer concentrations are determined based on the assay system to be used (e.g., North American, Japanese, Western European, or Central European conditions).
  • the stain removal performance of the protease variants is determined in commercially available detergents. Heat inactivation of commercial detergent formulas serves to destroy the enzymatic activity of any protein components while retaining the properties of non-enzymatic components. Thus, this method is suitable for preparing commercially purchased detergents for use in testing the enzyme variants of the present invention.
  • 96-well baked egg yolk substrate plates are prepared from chicken egg yolks.
  • Chicken egg yolks are separated from the whites, released from the membrane sac, and diluted 20% (vol/weight) with Milli-Q water.
  • the diluted yolk is stirred for 15 min at room temperature using a magnetic stirrer.
  • Five ⁇ L are carefully pipetted into the center of each well of a 96-well V-bottom plate (Costar #3894) using an 8-channel pipette.
  • the plates are baked at 90° C. for 1 hour and cooled at room temperature.
  • the baked egg yolk substrate plates are stored at room temperature and used within one week of preparation.
  • Automatic dish detergents are prepared as described herein and pre-heated to 50° C. A 190 ⁇ L aliquot of detergent is added to each well of the 96-well plate using an 8-channel pipette.
  • Automatic dish detergents are prepared as described herein.
  • the equipment used included a New Brunswick Innova 4230 shaker/incubator and a SpectraMAX (type 340) MTP reader.
  • the MTPs are obtained from Costar (type 9017).
  • Aged egg yolk with pigment swatches (CS-38) are obtained from Center for Test Materials (Vlaardingen, Netherlands).
  • the fabric is washed with water.
  • One microswatch is placed in each well of a 96-well microtiter plate.
  • the test detergent is equilibrated at 50° C. 190 ⁇ l of detergent solution is added to each well of the MTP, containing microswatches.
  • pre-washed microswatches find use. This type of microswatch is pre-washed in deionised water for 20 minutes at ambient temperature. After the pre-washing step, the swatches are put on top of paper towels to dry. The air-dried swatches are then punched using a 1 ⁇ 4 circular die on an expulsion press. Finally two microswatches are put into each well of a 96-well MTP vertically to expose the whole surface area (i.e. not flat on the bottom of the well).
  • Samples of protease variants to be tested are obtained from filtered culture broth of cultures grown in MTP plates.
  • the equipment used is a Biomek FX Robot (Beckman Coulter), a SpectraMAX MTP Reader (type 340; Molecular Devices), an iEMS incubator/shaker (Thermo/Labsystems); F-bottom MTPs (Costar type 9017 used for reading reaction plates after incubation); and V-bottom MTPs (Greiner 651101 used for pre-dilution of supernatant).
  • the proteases hydrolyze the substrate and liberate pigment and insoluble particles from the substrate.
  • the rate of turbidity is a measure of enzyme activity.
  • the stain removal performance of reference serine proteases and variants therefrom on microswatches is determined on a MTP scale in commercially available detergent (Calgonit 5 MD. CS-38 microswatches (egg-yolk with pigment, aged by heating), obtained from CFT Vlaardingen are used as substrate. Two swatches are used per well. ADW tablets from Calgonit 5 in 1 are used to prepare the detergent solution. To inactivate the protease activity present in the tablets, a 21 g tablet is dissolved in Milli-Q water heated in a water bath to a temperature of 60° C. The solution is cooled to room temperature and the volume of water adjusted to 700 mL.
  • the solution is further diluted with water to achieve a final concentration of 3 g/l.
  • the enzyme samples are prediluted in 10 mM NaCl, 0.1 mM CaCl 2 , 0.005% TWEEN®-80 solution and tested at appropriate concentrations.
  • the incubator is set at the desired temperature of 50° C.
  • 72 ⁇ l of dilution buffer is added to the empty V-bottom plate (i.e., a “dilution plate”) followed by 8 ⁇ l supernatant.
  • 9 ⁇ l from the dilution plate is added to plates containing the microswatches incubated in 171 ⁇ l detergent solution.
  • 9 ⁇ l from the dilution plate is added to plates containing the microswatches to give a total dilution of supernatant of 200 ⁇ .
  • the microswatch plate (with detergent and enzyme) is covered with tape and placed in the incubator/shaker for 30 minutes at 1400 rpm.
  • the absorbance value obtained is corrected for the blank value (substrate without enzyme), providing a measure of hydrolytic activity.
  • the performance index is calculated.
  • the performance index compares the performance of the variant (actual value) and the standard enzyme (theoretical value) at the same protein concentration.
  • the theoretical values can be calculated, using the parameters of the Langmuir equation of the standard enzyme.
  • the stainless steel sheets (10 ⁇ 15 cm; brushed on one side) used in these experiments are thoroughly washed at 95° C. in a laboratory dishwasher with a high-alkalinity commercial detergent (e.g., ECOLAB® detergent; Henkel) to provide sheets that are clean and grease-free. These sheets are deburred prior to their first use.
  • the sheets are dried for 30 minutes at 80° C. in a thermal cabinet before being soiled with egg yolk.
  • the surfaces to be brushed are not touched prior to soiling. Also, no water stains or fluff on the surfaces are permitted.
  • the cooled sheets are weighed before soiling.
  • the egg yolks are prepared by separating the yolks of approximately 10-11 eggs (200 g of egg yolk) from the whites.
  • the yolks are stirred with a fork in a glass beaker to homogenize the yolk suspension.
  • the yolks are then strained (approx 05 mm mesh) to remove coarse particles and any egg shell fragments.
  • a flat brush (2.5′′) is used to apply 1.0 ⁇ 0.1 g egg yolk suspension as uniformly as possible over an area of 140 cm 2 on the brushed sides of each of the stainless steel sheets, leaving an approx. 1 cm wide unsoiled rim (adhesive tape is used if needed).
  • the soiled sheets are dried horizontally (to prevent formation of droplets on the edges of the sheets), at room temperature for 4 hours (max. 24 h).
  • the sheets are immersed for 30 seconds in boiling, demineralized water (using a holding device if necessary). Then, the sheets are dried again for 30 min at 80° C. After drying and cooling, the sheets are weighed. After weighing, the sheets are left for at least 24 hours (20° C., 40-60% relatively humidity) before submitting them to the wash test. In order to meet the testing requirements, only sheets with 500 ⁇ 100 mg/140 cm 2 (egg yolk after denaturation), are used in the testing. After the wash tests are conducted, the sheets are dried for 30 min at 80° C., in the thermal cabinet, and weighed again after cooling. The percent cleaning performance is determined by dividing the (mg of egg yolk released by washing ⁇ 100) by the (mg of denatured egg yolk applied).
  • dessert plates (Arzberg, white, glazed porcelain) conforming to EN 50242, form 1495, No. 0219, diameter 19 cm are used.
  • a total of 225 g lean pork and beef (half and half) is finely chopped and cooled, after removing visible fat.
  • the mixture is twice run through a mincer. Temperatures above 35° C. are avoided.
  • 225 g of the minced meat is mixed with 75 g of egg (white and yolk mixed together). The preparation is then frozen up to three months at ⁇ 18° C., prior to use. If pork is not available, beef is used.
  • the minced meat and egg mixture (300 g) is brought up to room temperature and mixed with 80 ml synthetic water. The mixture is then homogenized using a kitchen hand blender for 2 min. Then, a fork is used to spread 3 g of the minced meat/egg/water mixture on each white porcelain plate, leaving an approx. 2 cm wide unsoiled margin around the rim. The amount applied is 11.8 ⁇ 0.5 mg/cm 2 .
  • the plates are dried for 2 hours at 120° C. in a preheated thermal cabinet. As soon as the plates are cooled, they are ready for use. The plates are stacked with paper towels between each of the plates.
  • the plates are sprayed with ninhydrin solution (1% ethanol) for better identification of the minced meat residues.
  • ninhydrin solution 1% ethanol
  • the plates are heated for 10 min at 80° C. in the thermal cabinet. Evaluation of the washing performance is done by visually inspecting the color reactions of the minced meat residues with reference to the IKW photographic catalogue (IKW).
  • the stainless steel sheets (10 ⁇ 15 cm; brushed on one side) used in these experiments are thoroughly washed at 95° C. in a laboratory dishwasher with a high-alkalinity commercial detergent to remove grease and clean the sheets.
  • the sheets are polished dry with a cellulose cloth.
  • the surfaces to be brushed are not touched prior to soiling. Also, no water stains or fluff on the surfaces are permitted.
  • the sheets are placed in a thermal cabinet at 80° C., for 30 min. The cooled sheets are weighed before soiling.
  • the egg yolks and whites of whole raw eggs (3-4 eggs; 160 g/egg) are placed in a bowl and beaten with an egg whisk. Then, 50 ml semi-skimmed UHT (1.5% fat, ultra-high temperature, homogenized) milk are added to the mixture. The milk and egg are mixed without generating froth.
  • a flat brush is used to uniformly distribute 1.0 ⁇ 0.1 g of the egg/milk mixture on the brushed side of the stainless steel sheets, using a balance to check the distribution. A margin of approximately 1.0 cm is left around the short sides of the sheets.
  • the soiled sheets are dried horizontally (to prevent formation of droplets on the edges of the sheets), at room temperature for 4 hours (max. 24 h).
  • the sheets are then immersed for 30 seconds in boiling, demineralized water (using a holding device if necessary). Then, the sheets are dried again for 30 min at 80° C. After drying and cooling, the sheets are weighed. After weighing, the sheets are left for at least 24 hours (20° C., 40-60% relatively humidity), before submitting them to the wash test. In order to meet the testing requirements, only sheets with 190 ⁇ 10 mg egg yolk are used.
  • the sheets are dried for 30 min at 80° C., in the thermal cabinet, and weighed again after cooling.
  • the percentage cleaning performance is determined by dividing the (mg of egg/milk released by washing ⁇ 100) by the (mg of egg/milk applied).
  • Pasta sauce (390 g) is mixed with 150 g of boiled spaghetti pasta, 25 g of minced meat (improved IKW composition-a combination of 225 gram fat free minced meat and 75 gram egg yolk) and 50 g of Grozette Formaggio cheese.
  • a spoon is used to spread 3 g of this mixture on each white porcelain plate (Arzberg, 19 cm diameter, white, glazed porcelain, conforming to EN 50242, form 1495, No. 0219) leaving an approximately 2 cm wide unsoiled margin around the rim.
  • the plates are dried by baking them for 2 hours at 120° C. in an oven. As soon as the plates are cooled, they are ready for use.
  • the plates are stacked with paper towels between each of the plates for storage.
  • the plates are sprayed with iodine solution (0.05N) for better identification of the carbohydrate residues. Evaluation of the washing performance is done by visually inspecting the color reactions of the carbohydrate residues with reference to the IKW photographic catalogue (IKW) and rated on a scale of 0-10 (10 being clean).
  • IKW IKW photographic catalogue
  • the performance index compares the performance of the variant (measured value) and the standard enzyme (theoretical value) at the same protein concentration.
  • the theoretical values can be calculated, using the parameters of a performance dose response curve of the standard protease
  • GG36 SELs The construction of GG36 SELs described in this example was performed by GENEART using their proprietary methods and technology platform for gene optimization, gene synthesis, library generation and analysis (WO 2004/059556A3, European Patent Nos. 0 200 362 and 0 201 184; and U.S. Pat. Nos. 4,683,195, 4,683,202 and 6,472,184).
  • the GG36 SELs were produced at positions pre-selected by the inventors using the pHPLT-GG36 B. subtilis expression plasmid (See, FIG. 2 ). This B. subtilis expression plasmid contains the GG36 expression cassette shown below, the B.
  • licheniformis LAT promoter Plat
  • additional elements from pUB110 McKenzie et al., Plasmid, 15:93-103, 1986
  • reppUB replicase gene
  • neo neomycin/kanamycin resistance gene
  • bleo bleomycin resistance marker
  • FIG. 2 The pHPLT-GG36 plasmid map is provided at FIG. 2 .
  • the GG36 expression cassette sequence is provided below.
  • GG36 The DNA sequence of GG36 (the signal sequence is shown in lower case letters, propeptide in lower case, underlined text, and GG36 mature sequence in uppercase letters) is provided below:
  • GG36 The protein sequence of GG36 (the signal sequence is shown in lower case letters, propeptide in lower case, underlined text, and GG36 mature protease sequence in uppercase letters) is provided below:
  • the method of mutagenesis was based on the codon-specific mutation approach in which all possible amino acid substitutions are simultaneously created at a specific codon of interest using forward and reverse mutagenesis primers that contain a degenerate codon, NNS ((A,C,T or G), (A,C,T or G), (C or G)) at the site of interest.
  • each of the GG36 SELs three PCR reactions were performed: two mutagenesis reactions (primary PCR1 and PCR2) to introduce the mutated codon of interest in the mature GG36 DNA sequence using the NNS forward and reverse mutagenesis primers (25-45 nucleotides long), and a third reaction to fuse the two mutagenesis PCR products together to construct the pHPLT-GG36 expression vector having the desired mutated codons in the mature GG36 sequence.
  • the Phusion High-Fidelity DNA Polymerase (Finnzymes catalog no. F-530L) was used for all PCRs, and the reactions were executed according to manufacturer's protocols that were supplied with the polymerase.
  • F-530L The Phusion High-Fidelity DNA Polymerase
  • 1 ⁇ L (10 ⁇ M) of each of the pHPLT-BglII-Fw primer and a NNS reverse mutagenesis primer were used
  • 1 (10 ⁇ M) of the pHPLT-BglII-Rv primer and a NNS forward mutagenesis primer were used.
  • Each reaction also included 1 ⁇ L of the pHPLT-GG36 plasmid template DNA (0.1-1 ng/ ⁇ L).
  • the amplified linear 859 bp fragment encoding the GG36 variant gene was purified (using QIAGEN® Qiaquick PCR purification kit) and digested with the SacI and HindIII restriction enzymes to create cohesive ends on both sides of the fusion fragment. About 50 ng of plasmid pHPLT-GG36 was also purified after digestion with SacI and HindIII, resulting in a 3.9 kb vector backbone fragment. The digested vector fragment was ligated with 50 ng of the digested 859 bp fragment encoding the variant enzyme using the T4 DNA ligase (Invitrogen) following the manufacturer's protocol for cloning of cohesive ends. Subsequently, the ligation mixture was used to transform B.
  • T4 DNA ligase Invitrogen
  • subtilis cells ( ⁇ aprE, ⁇ nprE, oppA, ⁇ spoIIE, degUHy32, ⁇ amyE::[xylR,pxylA-comK]) as described (WO 2002/014490).
  • the B. subtilis strains carrying the GG36 variant plasmids were inoculated into microtiter plates containing 150 ⁇ l Luria broth medium supplemented with 10 ⁇ g/ml neomycin. Plates were grown overnight at 37° C. with 300 rpm shaking and 80% humidity using Enzyscreen lids for microtiter plates (Enzyscreen). Ten microliters from the overnight culture plate were used to inoculate a new microtiter plate containing 190 ⁇ l of MBD medium (a MOPS based defined medium) with 10 ug/ml neomycin. MBD medium was prepared essentially as known in the art (See, Neidhardt et al., J.
  • the micronutrients were made up as a 100 ⁇ stock solution containing in one liter, 400 mg FeSO 4 7H 2 O, 100 mg MnSO 4 .H 2 O, 100 mg ZnSO 4 7H 2 O, 50 mg CuCl 2 2H 2 O, 100 mg CoCl 2 6H 2 O, 100 mg NaMoO 4 2H 2 O, 100 mg Na 2 B 4 O 7 10H 2 O, 10 ml of 1M CaCl 2 , and 10 ml of 0.5 M sodium citrate.
  • the MBD medium containing microtiter plates were grown for 68 hours at 37° C., 300 rpm, and 80% humidity using Enzyscreen lids (Enzyscreen) for determining protein expression.
  • the NHJ1 and WCE1 set of GG36 variants described herein were constructed at DNA 2.0, Inc., using the pHPLT-GG36 B. subtilis expression plasmid described above ( FIG. 2 ).
  • the variants were expressed in B. subtilis cells (genotype: ⁇ aprE, ⁇ nprE, amyE::xylRPxylAcomK-phleo) as described in Example 2, and were further characterized using the TCA assay for protein content determination, LAS/EDTA stability assay, and BMI microswatch cleaning assay as described in Example 1.
  • Tables 3-1 and 3-2 In the following Tables, the detergent compositions (“Det.”) correspond to those shown in Table D, above. Also, as indicated, the amino acid position is listed according to BPN′ numbering.
  • GG36 Variant (BPN′ Numbering) N062E-A158E S103G-A158E S128N-A158E A016S-A158E V104L-A158E E089P-A158E L111V-A158E T022A-A158E S101A-A158E L148I-A158E P129E-A158E T022A-E089P A016S-E089P N062E-E089P N062E-E271F A158E-E271F R186H-E271F P129E-E271F L111V-E271F Y209E-E271F A016S-E271F S188D-E271F T022A
  • GG36 Variant BPN′ Numbering
  • the NHJ4 set of GG36 variants described in Table 4-4 below were constructed using the pHPLT-GG36 B. subtilis expression plasmid ( FIG. 2 ) using PCR fusion or the QUIKCHANGE® Multi Site-directed mutagenesis kit (“QCMS kit”; Stratagene) as described below.
  • QCMS kit QUIKCHANGE® Multi Site-directed mutagenesis kit
  • Variants created using the QUIKCHANGE® Multi Site-Directed Mutagenesis are shown in Table 4-4.
  • the parent plasmid pHPLT-GG36 (template DNA) was methylated using two micrograms of DNA and Dam methylase (NEB), according to the manufacturer's instructions.
  • Site-directed mutants were made by a QuikChange® Multi Site-Directed Mutagenesis Kit (“QCMS kit”; Stratagene) following the manufacturer's protocol (See, Table 4-1 for primer sequences).
  • QCMS kit QuikChange® Multi Site-Directed Mutagenesis Kit
  • DNA from the QCMS reaction mixtures was amplified by rolling circle amplification (RCA) using the Illustra Templiphi kit (GE Healthcare) and the reaction was performed according to the manufacturer's protocol.
  • One microliter of ten-fold diluted amplified DNA was used to transform 50 ⁇ L, of competent B. subtilis cells (genotype: ⁇ aprE, ⁇ nprE, amyE::xylRPxylAcomKphleo).
  • the transformation mixture was shaken at 37° C. for 1 hour.
  • Ten microliter aliquots of the transformation mixture were plated on skim milk (1.6%) Luria agar plates supplemented with 10 ng/ml of neomycin (Teknova).
  • the colonies producing a clearing area (halo) on skim milk plates were inoculated in 120 ⁇ l of LB media containing 10 ⁇ g/mL neomycin for plasmid DNA extraction (QIAprep Spin Miniprep kit, Qiagen).
  • the extracted plasmids were sequenced to confirm the presence of the desired mutations.
  • GG36 Ten combinatorial mutants of GG36 were created by extension PCR.
  • the list of mutations introduced in the pHPLT-GG36 plasmid and primers used for this purpose are shown in Table 4-2.
  • To create each mutant several fragments (Table 4-3) were amplified by primers shown in Table 4-2.
  • Each PCR amplification reaction contained 30 ⁇ mol of each primer and 100 ng of the DNA template, pHPLT-GG36 plasmid. Amplifications were carried out using Vent DNA polymerase (NEB).
  • the PCR reaction (20 ⁇ L) was initially heated at 95° C. for 2 5 min followed by 30 cycles of denaturation at 94° C. for 15 sec., annealing at 55° C. for 15 sec. and extension at 72° C. for 1 min.
  • PCR fragments (Table 4-3) for each variant were gel-purified, using a QIAGEN® gel-band purification kit and mixed (50 ng of each fragment). These mixtures served as DNA templates for the extension PCR by primers P5954 and P5955 to generate the full-length gene fragment.
  • the PCR conditions were same as described above, except the extension phase, which was carried out at 72° C. for 2 min.
  • the full-length DNA fragment was gel-purified using a QIAGEN® gel-band purification kit, digested with the BamHI and HindIII restriction enzymes and ligated with the pHPLT-GG36, which was digested with the same restriction enzymes.
  • One microliter of the ligation mixtures was amplified using rolling circle amplification by Illustra Templiphi kit according to the manufacturer's instructions (GE Healthcare) to generate multimeric DNA for transformation into Bacillus subtilis .
  • Products of the rolling circle amplification were diluted 100-times and used to transform B. subtilis cells (genotype: ⁇ aprE, ⁇ nprE, amyE::xylRPxylAcomK-phleo).
  • An aliquot of the transformation mix was plated on LB plates containing 1.6% skim milk and 10 ⁇ g/mL neomycin and incubated overnight at 37° C.
  • the B. subtilis strains carrying the variant plasmids were inoculated into microtiter plates containing 1500 Luria broth medium supplemented with 10 ⁇ g/ml neomycin.
  • the cultures were grown up for protein expression as described in Example 2, and they were filtered through a micro-filter plate (0.22 ⁇ m; Millipore) also as described in Example 2.
  • the resulting filtrate was used for biochemical analysis.
  • the eglin c inhibition assay for protein content determination and BMI microswatch assays tested in various detergents were carried out as described in Example 1. Performance indices are also calculated as described under the BMI assay description in Example 1.
  • Table 4-4 provides information regarding these multiple mutation variants and the results obtained for them.
  • the PI values are relative to GG36.
  • the detergent compositions (“Det.”) correspond to those shown in Table D, above.
  • the amino acid position is listed according to BPN′ numbering.
  • the NHJ3 set of variants described herein are based on a variant of GG36 (referred to as GG36-9) containing the following mutations: S101G, S103A, V104I, G159D, A232V, Q236H, Q245R, N248D, and N252K (BPN′ numbering). These variants were created using the QUIKCHANGE® Lightning Site-Directed Mutagenesis Kit (QCLDS kit; Stratagene), with the pRA68 plasmid (See, FIG. 3 ) as the DNA template. Plasmid pRA68 was derived from the pBN3 vector (See, Babé et al., Biotech. Appl. Biochem. 27:117-124 [1998]).
  • GG36-9 variant The DNA sequence of GG36-9 variant (the signal sequence is shown in lower case letters, propeptide in lower case, underlined text, and GG36-9 mature sequence in uppercase letters) is provided below:
  • the protein sequence of the GG36-9 variant (the signal sequence is shown in lower case letters, propeptide in lower case, underlined text, and GG36-9 mature protease sequence in uppercase letters) is provided below:
  • mutagenic primers were designed as shown in Table 5-1 for each of the variants.
  • the mutagenesis reaction for each variant consisted of 0.5 ul of 10 ⁇ Buffer, 0.5 uL of pRA68 plasmid DNA (168 ng/ ⁇ L), 0.50 forward “f” mutagenic primer (25 uM), 0.5 ul reverse “r” mutagenesis primer (25 uM), 1 ul dNTPs (supplied in the QCLSD kit), 1.5 ul Quik solution (supplied in the QCLMS kit), 1 ⁇ l Enzyme blend (supplied in the QCLSD kit), and 40 ul of distilled, deionized water to make up a 50 ⁇ L reaction volume as per the manufacturer's instructions.
  • the cycling program was 1 cycle at 95° C. for 2 minutes, 18 cycles of 95° C. for 20 seconds, 60° C. for 10 seconds and 68° C. for 3 minutes, 22 seconds, and a final cycle of 68° C. for 5 minutes.
  • 1 ⁇ L of DpnI restriction enzyme supplied in the kit was used to digest the plasmid DNA in the reaction, and then 2 ⁇ L, of the reaction was used to transform TOP 10 E. coli competent cells (Invitrogen).
  • the E. coli transformants were selected on Luria broth medium plates containing 50 ug/mL(ppm) carbenicillin after overnight growth at 37° C. Plasmid DNA was extracted from 4-8 E.
  • the plasmids were sequenced to confirm the presence of the desired mutations.
  • the variant plasmids were then transformed into B. subtilis cells as described in Example 2.
  • the B. subtilis variant strains were grown up as described in Example 2 for further biochemical analysis, such as protein content determination using the eglin c inhibition assay (Example 1) and the BMI microswatch cleaning assay (Example 1).
  • the results are provided below in Tables 5-2 and 5-3.
  • the PIs are relative to GG36.
  • the detergent compositions (“Det.”) correspond to those shown in Table D, above.
  • the amino acid position is listed according to BPN′ numbering.
  • the NHJ5 set of variants described herein are based on a variant of GG36 (referred to as GG36-7) containing the following mutations: S101G, S103A, V104I, G159D, A232V, Q245R, N248D, and (BPN′ numbering). These variants were created using the QUIKCHANGE® Lightning Multi Site-Directed Mutagenesis Kit (“QCLMS kit”) with the pRA96 plasmid as the DNA template (See, FIG. 4 ). The mutations incorporated and the sequences of the primers used for introducing the mutations in GG36-7 are shown in Table 6-1. The variants were generated using the methods described in Example 4.The B.
  • subtilis variant strains were grown up as described in Example 2 for further biochemical analysis, such as protein content determination using the eglin c inhibition assay (Example 1) and the BMI microswatch cleaning assay (Example 1). The results are provided below in Table 6-2.
  • the PI values are relative to GG36.
  • the detergent compositions (“Det.”) correspond to those shown in Table D, above. Also, as indicated, the amino acid position is listed according to BPN′ numbering.
  • GG36-7 variant The DNA sequence of GG36-7 variant (the signal sequence is shown in lower case letters, propeptide in lower case, underlined text, and GG36-7 mature protease sequence in uppercase letters) is provided below:
  • GG36-7 variant signal sequence is shown in lower case letters, propeptide in lower case, underlined text, and GG36-7 mature protease sequence in uppercase letters.
  • This Example describes the construction of a GG36 combinatorial library involving one or more of the following mutations: A16S, T22A, S101A, S103G, V104L, L111V, S128N, and L1481
  • the pHPLT-GG36 B. subtilis expression plasmid was provided to DNA 2.0 Inc., for the generation of NHJ2 combinatorial library.
  • a ligation reaction of the constructed NHJ2 library was provided by DNA 2.0, Inc. for transformation in the B. subtilis strain (genotype: ⁇ aprE, ⁇ nprE, amyE::xylRPxylAcomK-phleo).
  • the variants generated containing one or several of the mutations described herein can be tested for cold water cleaning applications using methods and detergent compositions described herein.
  • Additional libraries and variants are constructed using the following set of mutations: A1R, A230E, E271L, G115R, G20R, H249R, K235F, K27V/F/L, L75E, L82R, N18R, N269R, N43D, N43R, N76D, R45T, S212F, S242R, S24R, S78R, S9A, T22R, V121E, V244R, V28E, V30E, V4R, W241R (BPN′ numbering).
  • the pHPLT-GG36 B. subtilis expression plasmid was used to construct the libraries and variants at DNA2.0, Inc. A ligation reaction of the library or variant was transformed in the B.
  • subtilis strain (genotype: ⁇ aprE, ⁇ nprE, amyE::xylRPxylAcomK-phleo).
  • the variants generated containing one or more of these mutations were tested for cold water cleaning in the BMI microswatch cleaning assay (Example 1) using methods and detergent compositions described herein. The results are provided below in Table 8-1.
  • the detergent compositions (“Det.”) correspond to those shown in Table 1-2, above. Also, as indicated, the amino acid position is listed according to BPN′ numbering.
  • Additional sets of GG36 variants are constructed and tested for cold water cleaning applications using methods and detergent compositions described herein include: G20R-N43R-H249R, G20R-T22R-N43R, G20R-N43R-S242R, G20R-N43R-E271L, G20R-N43R-V244R, G20R-S24R-N43R-S242R, S9A-T22R-S78R-S212F-W241R, S9A-G20R-N43R-S212F, S9A-N43R-S212F, G20R-N43R-S212F, G20R-T22R-N43R-S212F, S24R-S78R-S212F, S9A-N43R-S78R, S9A-N43R-S78R, S9A-N43R-S78R-S242R, S9A-G20R-N43R-S78R
  • the WCE2 combinatorial library was generated by DNA 2.0, Inc., using the pHPLT-GG36 B. subtilis expression plasmid.
  • a ligation reaction of the constructed WCE2 library transformed in the B. subtilis strain (genotype: ⁇ aprE, ⁇ nprE, amyE::xylRPxylAcomK-phleo).
  • the set of mutations used to generate the WCE2 library are A230E, G20R, H249R, N18R, N43R/D, N76D, R45T, S242R, and S24R (BPN′ numbering).
  • the variants generated containing one or more of these mutations are tested for cold water cleaning in the BMI microswatch cleaning assay (Example 1) using methods and detergent compositions described herein. The results are provided below in Table 9-1.
  • the detergent compositions (“Det.”) correspond to those shown in Table 1-2 above. Also, as indicated, the amino acid position is listed according to BPN′ numbering.
  • This Example describes the WCE3 set of mutants based on the GG36 variants, GG36-7 (Example 5) and GG36-9 (Example 4). These variants are: S101G-S103A-V104I-A232V-Q245R-N248D, S101G-S103A-V104I-G159D-A232V-Q245R, S101G-S103A-V104I-G159R-A232V-Q245R-N248D, S101G-S103A-V104I-G159D-A232V-Q245R-N248R, S101G-S103A-V104I-A232V-Q245R, S101G-S103A-V104I-A232V-Q245R, S101G-S103A-V104I-A232V-Q245R-N248R, S101G-S103A-V104I-G159R-A232V-Q245R-N248
  • This Example describes the construction of GG36 variants and libraries using one or more of the following mutations: A16S, T22A, S24R, N62E, N76D, E89P, S101A/G, S103G/A, V104L/I, L111V, S128N, P129E, A232V, L148I, A158E, G159D/E, S166D, R186H, S188D, Y209E, Q236H, N238R, Q245R, N248D/R, H249R, N252K/R, T253R, E271F (BPN′ numbering) using a B. subtilis expression plasmid (e.g., pHPLT-GG36; FIG.
  • BPN′ numbering B. subtilis expression plasmid
  • the combinatorial variants were constructed by DNA2.0, Inc., using a B. subtilis expression plasmid (e.g., pHPLT-GG36; FIG. 2 ) and the B. subtilis strain (genotype: ⁇ aprE, ⁇ nprE, amyE::xylRPxylAcomK-phleo).
  • a ligation reaction of each of the constructed libraries using a B. subtilis expression plasmid was transformed in the B.
  • subtilis strain (genotype: ⁇ aprE, ⁇ nprE, amyE::xylRPxylAcomK-phleo).
  • the variants generated containing one or more of the mutations listed above were tested for cold water cleaning in the BMI microswatch assay (Example 1) using detergent compositions described in Table 1-2.
  • This Example describes the construction of GG36 variants and libraries in B. subtilis using one or more of the following mutations (BPN′ numbering): A1R, Q2S, Q2M, Q2A, Q2R, Q2W, S3R, V4R, V4S, V4C, I8A, S9A, S9F, S9W, R10S, R10A, R10H, R10M, Q12F, Q12R, P14K, P14F, P14Q, A15R, A15F, A16S, H17R, H17M, H17F, N18R, N18K, G20F, G20K, G20R, T22A, T22R, T22Y, T22V, T22Q, T22L, T22W, G23A, G23S, G23F, S24R, S24F, S24W, S24Q, S24H, S24L, G25V, G25F, G25R, V26F, K27L
  • This Example describes the cold water cleaning of additional GG36 variants and libraries constructed in B. subtilis Most DNA libraries were synthesized at DNA2.0, Inc., using the pHPLT-GG36 B. subtilis expression plasmid. Ligation reactions of the constructed libraries were transformed in the B. subtilis strain (genotype: ⁇ aprE, ⁇ nprE, amyE::xylRPxylAcomK-phleo after amplification of the DNA using rolling circle amplification as described in Example 4. The WCE9 and NHJ10 library and variants were created by extension PCR or QuickChange mutagenesis (see Example 4 for description of methods). WCE9 and NHJ10 library and variants were also created using the pHPLT-GG36 B.
  • subtilis expression plasmid The variants were expressed in B. subtilis cells (genotype: ⁇ aprE, ⁇ nprE, amyE::xylRPxylAcomK-phleo) as described in Example 1, and were further characterized using the BMI microswatch cleaning assay as described in Example 1.
  • the detergent compositions (“Det.”) correspond to those shown in Table 1-2 above. Also, as indicated, the amino acid position is listed according to BPN′ numbering.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Detergent Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
US13/696,512 2010-05-06 2011-05-05 Compositions and methods comprising serine protease variants (as amended) Abandoned US20130260438A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/696,512 US20130260438A1 (en) 2010-05-06 2011-05-05 Compositions and methods comprising serine protease variants (as amended)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US33215110P 2010-05-06 2010-05-06
US33200610P 2010-05-06 2010-05-06
US39236410P 2010-10-12 2010-10-12
US39218810P 2010-10-12 2010-10-12
US13/696,512 US20130260438A1 (en) 2010-05-06 2011-05-05 Compositions and methods comprising serine protease variants (as amended)
PCT/US2011/035389 WO2011140364A1 (en) 2010-05-06 2011-05-05 Compositions and methods comprising subtilisin variants

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/035389 A-371-Of-International WO2011140364A1 (en) 2010-05-06 2011-05-05 Compositions and methods comprising subtilisin variants

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/831,913 Continuation US20180216092A1 (en) 2010-05-06 2017-12-05 Compositions and methods comprising serine protease variants

Publications (1)

Publication Number Publication Date
US20130260438A1 true US20130260438A1 (en) 2013-10-03

Family

ID=44140761

Family Applications (3)

Application Number Title Priority Date Filing Date
US13/696,512 Abandoned US20130260438A1 (en) 2010-05-06 2011-05-05 Compositions and methods comprising serine protease variants (as amended)
US15/831,913 Abandoned US20180216092A1 (en) 2010-05-06 2017-12-05 Compositions and methods comprising serine protease variants
US16/030,994 Active US11447762B2 (en) 2010-05-06 2018-07-10 Bacillus lentus subtilisin protease variants and compositions comprising the same

Family Applications After (2)

Application Number Title Priority Date Filing Date
US15/831,913 Abandoned US20180216092A1 (en) 2010-05-06 2017-12-05 Compositions and methods comprising serine protease variants
US16/030,994 Active US11447762B2 (en) 2010-05-06 2018-07-10 Bacillus lentus subtilisin protease variants and compositions comprising the same

Country Status (14)

Country Link
US (3) US20130260438A1 (de)
EP (6) EP3868881A3 (de)
JP (6) JP6448904B2 (de)
CN (5) CN103068977A (de)
BR (2) BR112012028467B1 (de)
CA (1) CA2798451C (de)
DK (3) DK2566960T3 (de)
ES (3) ES2625751T3 (de)
HU (3) HUE045202T2 (de)
MX (2) MX336737B (de)
PL (2) PL3095861T3 (de)
RU (2) RU2711984C2 (de)
WO (2) WO2011140364A1 (de)
ZA (1) ZA201208019B (de)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130123162A1 (en) * 2011-11-10 2013-05-16 The Procter & Gamble Company Consumer products
US20140154782A1 (en) * 2011-05-05 2014-06-05 Danisco Us Inc. Compositions and Methods Comprising Serine Protease Variants
WO2016001450A3 (en) * 2014-07-04 2016-04-14 Novozymes A/S Subtilase variants and polynucleotides encoding same
US20170128605A1 (en) * 2015-11-10 2017-05-11 American Sterilizer Company Cleaning and disinfecting composition
US9758286B2 (en) 2015-10-06 2017-09-12 The Procter & Gamble Company Flexible box bag comprising soluble unit dose detergent pouch
US9951301B2 (en) 2015-03-30 2018-04-24 The Procter & Gamble Company Solid free-flowing particulate laundry detergent composition
US9951296B2 (en) 2015-03-30 2018-04-24 The Procter & Gamble Company Solid free-flowing particulate laundry detergent composition
US9957470B2 (en) 2015-03-30 2018-05-01 The Procter & Gamble Company Solid free-flowing particulate laundry detergent composition
US9957466B2 (en) 2015-03-30 2018-05-01 The Procter & Gamble Company Solid free-flowing particulate laundry detergent composition
US10053654B2 (en) 2015-04-02 2018-08-21 The Procter & Gamble Company Solid free-flowing particulate laundry detergent composition
US10550443B2 (en) 2016-12-02 2020-02-04 The Procter & Gamble Company Cleaning compositions including enzymes
US11453871B2 (en) * 2017-03-15 2022-09-27 Danisco Us Inc. Trypsin-like serine proteases and uses thereof
US11492571B2 (en) 2019-10-24 2022-11-08 The Procter & Gamble Company Automatic dishwashing detergent composition comprising a protease
US11708542B2 (en) 2018-06-20 2023-07-25 The Procter & Gamble Company Product comprising polysaccharide derivatives

Families Citing this family (178)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201802775T4 (tr) 2010-03-01 2018-03-21 Procter & Gamble Sübstitüe edilmiş selülozik polimer ve amilaz içeren bileşim.
JP6448904B2 (ja) * 2010-05-06 2019-01-09 ダニスコ・ユーエス・インク サブチリシン変異体を含む組成物及び方法
CN106065381B (zh) * 2011-05-05 2019-07-26 宝洁公司 包含丝氨酸蛋白酶变体的组合物和方法
EP2540824A1 (de) 2011-06-30 2013-01-02 The Procter & Gamble Company Reinigungszusammensetzungen mit Amylasevariantenreferenz zu einem Sequenzprotokoll
EP2551335A1 (de) 2011-07-25 2013-01-30 The Procter & Gamble Company Flüssige Waschmittelzusammensetzung mit stabilisiertem Enzym
DK3354728T3 (da) 2012-12-21 2020-07-27 Danisco Us Inc Alpha-amylase-varianter
WO2014099525A1 (en) 2012-12-21 2014-06-26 Danisco Us Inc. Paenibacillus curdlanolyticus amylase, and methods of use, thereof
WO2014164834A1 (en) 2013-03-11 2014-10-09 Danisco Us Inc. Alpha-amylase combinatorial variants
US20160122738A1 (en) 2013-05-29 2016-05-05 Danisco Us Inc. Novel metalloproteases
US20160108388A1 (en) 2013-05-29 2016-04-21 Danisco Us Inc. Novel metalloproteases
EP3004342B1 (de) 2013-05-29 2023-01-11 Danisco US Inc. Neuartige metalloproteasen
US20160160202A1 (en) 2013-05-29 2016-06-09 Danisco Us Inc. Novel metalloproteases
WO2014200657A1 (en) 2013-06-13 2014-12-18 Danisco Us Inc. Alpha-amylase from streptomyces xiamenensis
WO2014200656A1 (en) 2013-06-13 2014-12-18 Danisco Us Inc. Alpha-amylase from streptomyces umbrinus
WO2014200658A1 (en) 2013-06-13 2014-12-18 Danisco Us Inc. Alpha-amylase from promicromonospora vindobonensis
WO2014204596A1 (en) 2013-06-17 2014-12-24 Danisco Us Inc. Alpha-amylase from bacillaceae family member
US20160186102A1 (en) 2013-10-03 2016-06-30 Danisco Us Inc. Alpha-amylases from exiguobacterium, and methods of use, thereof
WO2015050723A1 (en) 2013-10-03 2015-04-09 Danisco Us Inc. Alpha-amylases from exiguobacterium, and methods of use, thereof
EP3058055A1 (de) 2013-10-15 2016-08-24 Danisco US Inc. Tongranulat
WO2015073772A1 (en) 2013-11-14 2015-05-21 Danisco Us Inc. Stable enzymes by glycation reduction
MX2016006489A (es) 2013-11-20 2016-08-03 Danisco Us Inc Alfa-amilasas variantes que tienen susceptibilidad reducida a la escision por proteasas y metodos de uso.
WO2015089441A1 (en) 2013-12-13 2015-06-18 Danisco Us Inc. Serine proteases of bacillus species
EP3080263B1 (de) 2013-12-13 2019-07-03 Danisco US Inc. Serinproteasen des bazillus gibsonii-clade
JP6598778B2 (ja) 2013-12-16 2019-10-30 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー ポリα−１，３−グルカンエーテル化合物を含む洗濯洗剤又は衣類柔軟剤
KR102410391B1 (ko) 2013-12-18 2022-06-16 뉴트리션 앤드 바이오사이언시스 유에스에이 4, 인크. 양이온성 폴리 알파-1,3-글루칸 에테르
EP3097172A1 (de) 2014-01-22 2016-11-30 The Procter & Gamble Company Verfahren zur behandlung von textilstoffen
EP3097174A1 (de) 2014-01-22 2016-11-30 The Procter & Gamble Company Verfahren zur behandlung von textilstoffen
EP3097175B1 (de) 2014-01-22 2018-10-17 The Procter and Gamble Company Gewebebehandlungszusammensetzung
EP3097173B1 (de) 2014-01-22 2020-12-23 The Procter and Gamble Company Gewebebehandlungszusammensetzung
WO2015123323A1 (en) 2014-02-14 2015-08-20 E. I. Du Pont De Nemours And Company Poly-alpha-1,3-1,6-glucans for viscosity modification
EP3116914B8 (de) 2014-03-11 2021-04-21 E. I. du Pont de Nemours and Company Oxidierter poly-alpha-1,3-glucan als waschmittelbuilder
EP3587569B1 (de) 2014-03-21 2022-08-03 Danisco US Inc. Serinproteasen aus einer bacillus-spezies
US9714403B2 (en) 2014-06-19 2017-07-25 E I Du Pont De Nemours And Company Compositions containing one or more poly alpha-1,3-glucan ether compounds
US9771548B2 (en) 2014-06-19 2017-09-26 E I Du Pont De Nemours And Company Compositions containing one or more poly alpha-1,3-glucan ether compounds
EP3878960A1 (de) * 2014-07-04 2021-09-15 Novozymes A/S Subtilasevarianten und polynukleotide zur codierung davon
US20170233710A1 (en) 2014-10-17 2017-08-17 Danisco Us Inc. Serine proteases of bacillus species
EP3172329A1 (de) 2014-10-24 2017-05-31 Danisco US Inc. Verfahren zur herstellung von alkoholen durch verwendung einer tripeptidylpeptidase
WO2016069552A1 (en) 2014-10-27 2016-05-06 Danisco Us Inc. Serine proteases
EP3212783A1 (de) 2014-10-27 2017-09-06 Danisco US Inc. Serinproteasen
WO2016069548A2 (en) 2014-10-27 2016-05-06 Danisco Us Inc. Serine proteases
WO2016069557A1 (en) 2014-10-27 2016-05-06 Danisco Us Inc. Serine proteases of bacillus species
EP3957729A1 (de) 2014-10-27 2022-02-23 Danisco US Inc. Serinproteasen
US20160137956A1 (en) 2014-11-17 2016-05-19 The Procter & Gamble Company Benefit agent delivery compositions
US10760036B2 (en) 2014-12-15 2020-09-01 Henkel Ag & Co. Kgaa Detergent composition comprising subtilase variants
JP6770519B2 (ja) 2014-12-23 2020-10-14 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニーＥ．Ｉ．Ｄｕ Ｐｏｎｔ Ｄｅ Ｎｅｍｏｕｒｓ Ａｎｄ Ｃｏｍｐａｎｙ 酵素により製造されるセルロース
EP3075826B1 (de) 2015-03-30 2018-01-31 The Procter and Gamble Company Feste freifliessende partikelförmige waschmittelzusammensetzung
EP3075823A1 (de) 2015-03-30 2016-10-05 The Procter and Gamble Company Sprühgetrockneter waschmittelzusammensetzungs-basispartikel
US20160289609A1 (en) 2015-03-30 2016-10-06 The Procter & Gamble Company Solid free-flowing particulate laundry detergent composition
US20160289616A1 (en) 2015-03-30 2016-10-06 The Procter & Gamble Company Solid free-flowing particulate laundry detergent composition
WO2016160868A1 (en) 2015-03-30 2016-10-06 The Procter & Gamble Company Solid free-flowing particulate laundry detergent composition
US20160289610A1 (en) 2015-04-02 2016-10-06 The Procter & Gamble Company Solid free-flowing particulate laundry detergent composition
WO2016161219A1 (en) 2015-04-02 2016-10-06 The Procter & Gamble Company Solid free-flowing particulate laundry detergent composition
CN107532116B (zh) 2015-04-29 2021-05-07 宝洁公司 处理织物的方法
WO2016176241A1 (en) 2015-04-29 2016-11-03 The Procter & Gamble Company Detergent composition
EP3088505B1 (de) 2015-04-29 2020-06-03 The Procter and Gamble Company Verfahren zur behandlung eines stoffes
CN107548415A (zh) 2015-04-29 2018-01-05 宝洁公司 洗涤织物的方法
EP3088502B1 (de) 2015-04-29 2018-05-23 The Procter and Gamble Company Verfahren zur behandlung eines stoffes
WO2016183509A1 (en) 2015-05-13 2016-11-17 Danisco Us Inc. AprL-CLADE PROTEASE VARIANTS AND USES THEREOF
WO2016201069A1 (en) 2015-06-09 2016-12-15 Danisco Us Inc Low-density enzyme-containing particles
WO2016201044A1 (en) 2015-06-09 2016-12-15 Danisco Us Inc Osmotic burst encapsulates
WO2016201040A1 (en) 2015-06-09 2016-12-15 Danisco Us Inc. Water-triggered enzyme suspension
JP7015695B2 (ja) 2015-06-17 2022-02-03 ダニスコ・ユーエス・インク バチルス・ギブソニイ（Ｂａｃｉｌｌｕｓ ｇｉｂｓｏｎｉｉ）クレードセリンプロテアーゼ
EP3153425B1 (de) 2015-10-06 2018-07-04 The Procter and Gamble Company Flexibler schachtelbeutel mit einem detergenspulver und schaufel
JP7364331B2 (ja) 2015-11-05 2023-10-18 ダニスコ・ユーエス・インク パエニバチルス（Ｐａｅｎｉｂａｃｉｌｌｕｓ）属種マンナナーゼ
US20180320158A1 (en) 2015-11-05 2018-11-08 Danisco Us Inc. Paenibacillus and bacillus spp. mannanases
WO2017083229A1 (en) 2015-11-13 2017-05-18 E. I. Du Pont De Nemours And Company Glucan fiber compositions for use in laundry care and fabric care
WO2017083226A1 (en) 2015-11-13 2017-05-18 E. I. Du Pont De Nemours And Company Glucan fiber compositions for use in laundry care and fabric care
JP7045313B2 (ja) 2015-11-13 2022-03-31 ニュートリション・アンド・バイオサイエンシーズ・ユーエスエー・フォー，インコーポレイテッド 洗濯ケアおよび織物ケアにおいて使用するためのグルカン繊維組成物
CN108291179B (zh) 2015-11-25 2020-07-07 荷兰联合利华有限公司 液体洗涤剂组合物
MX2018006475A (es) 2015-11-26 2018-09-28 Procter & Gamble Composiciones detergentes liquidas que comprenden proteasa y lipasa encapsulada.
BR112018011755A2 (pt) 2015-12-09 2018-12-04 Danisco Us Inc variantes combinatórias de alfa-amilase
CN108699543B (zh) 2015-12-18 2023-07-14 丹尼斯科美国公司 具有内切葡聚糖酶活性的多肽及其用途
WO2017173190A2 (en) 2016-04-01 2017-10-05 Danisco Us Inc. Alpha-amylases, compositions & methods
WO2017173324A2 (en) 2016-04-01 2017-10-05 Danisco Us Inc. Alpha-amylases, compositions & methods
EP3452569A1 (de) * 2016-05-03 2019-03-13 The Procter and Gamble Company Spülmittelzusammensetzung für geschirrspülautomat
US20190194636A1 (en) 2016-05-03 2019-06-27 Danisco Us Inc Protease variants and uses thereof
CN109072213A (zh) 2016-05-05 2018-12-21 丹尼斯科美国公司 蛋白酶变体及其用途
EP3556834B1 (de) 2016-05-09 2020-10-14 The Procter & Gamble Company Reinigungsmittelzusammensetzung umfassend eine fettsäure decarboxylase
US10689603B2 (en) 2016-05-09 2020-06-23 The Procter & Gamble Company Detergent composition
EP3511403B1 (de) 2016-05-09 2020-12-02 The Procter & Gamble Company Reinigungsmittelzusammensetzung
CA3026064A1 (en) 2016-05-31 2017-12-07 Danisco Us Inc. Protease variants and uses thereof
BR112018075933A2 (pt) 2016-06-17 2019-10-01 Danisco Us Inc variantes de protease e usos das mesmas
EP3269729B1 (de) 2016-07-14 2019-08-21 The Procter and Gamble Company Reinigungszusammensetzung
EP3301154B1 (de) 2016-10-03 2023-01-25 The Procter & Gamble Company Wäschewaschmittelzusammensetzung
WO2018067488A1 (en) 2016-10-03 2018-04-12 The Procter & Gamble Company Low ph laundry detergent composition
MX2019003845A (es) 2016-10-03 2019-06-24 Procter & Gamble Composición detergente para lavandería con un ph bajo.
RU2709518C1 (ru) 2016-10-03 2019-12-18 Дзе Проктер Энд Гэмбл Компани Композиция моющего средства для стирки с низким показателем ph
EP3301168B1 (de) 2016-10-03 2019-09-11 The Procter and Gamble Company Waschmittelzusammensetzung
EP3301157B1 (de) 2016-10-03 2019-11-20 The Procter & Gamble Company Wäschewaschmittelzusammensetzung
ES2758226T3 (es) 2016-10-03 2020-05-04 Procter & Gamble Proceso de preparación de una partícula de detergente para lavado de ropa secada por pulverización
CN109844082A (zh) 2016-10-03 2019-06-04 宝洁公司 衣物洗涤剂组合物
CN109790487A (zh) 2016-10-03 2019-05-21 宝洁公司 衣物洗涤剂组合物
WO2018085524A2 (en) 2016-11-07 2018-05-11 Danisco Us Inc Laundry detergent composition
WO2018102478A1 (en) 2016-12-02 2018-06-07 The Procter & Gamble Company Cleaning compositions including enzymes
MX2019006422A (es) 2016-12-02 2019-08-01 Procter & Gamble Composiciones de limpieza que incluyen enzimas.
CN110312794B (zh) 2016-12-21 2024-04-12 丹尼斯科美国公司 吉氏芽孢杆菌进化枝丝氨酸蛋白酶
US20200392477A1 (en) 2016-12-21 2020-12-17 Danisco Us Inc. Protease variants and uses thereof
EP3339415A1 (de) 2016-12-22 2018-06-27 The Procter & Gamble Company Wäschewaschmittelzusammensetzung
EP3339421A1 (de) 2016-12-22 2018-06-27 The Procter & Gamble Company Wäschewaschmittelzusammensetzung
EP3339422B1 (de) 2016-12-22 2020-10-21 The Procter & Gamble Company Wäschewaschmittelzusammensetzung
EP3339419A1 (de) 2016-12-22 2018-06-27 The Procter & Gamble Company Wäschewaschmittelzusammensetzung
EP3339414A1 (de) 2016-12-22 2018-06-27 The Procter & Gamble Company Wäschewaschmittelzusammensetzung
EP3339407A1 (de) 2016-12-22 2018-06-27 The Procter & Gamble Company Wäschewaschmittelzusammensetzung
EP3339416A1 (de) 2016-12-22 2018-06-27 The Procter & Gamble Company Wäschewaschmittelzusammensetzung
EP3339418A1 (de) 2016-12-22 2018-06-27 The Procter & Gamble Company Wäschewaschmittelzusammensetzung
EP3339413A1 (de) 2016-12-22 2018-06-27 The Procter & Gamble Company Wäschewaschmittelzusammensetzung
EP3339417A1 (de) 2016-12-22 2018-06-27 The Procter & Gamble Company Wäschewaschmittelzusammensetzung
JP2018104705A (ja) * 2016-12-27 2018-07-05 花王株式会社 繊維製品用粉末洗浄剤組成物
BR112019015689A2 (pt) 2017-02-01 2020-04-14 Procter & Gamble composições de limpeza compreendendo variantes de amilase
WO2018184004A1 (en) 2017-03-31 2018-10-04 Danisco Us Inc Alpha-amylase combinatorial variants
WO2018183662A1 (en) 2017-03-31 2018-10-04 Danisco Us Inc Delayed release enzyme formulations for bleach-containing detergents
BR112019027976A2 (pt) 2017-06-30 2020-07-07 Danisco Us Inc. partículas de baixa aglomeração, contendo enzimas
CN111212906B (zh) 2017-08-18 2024-02-02 丹尼斯科美国公司 α-淀粉酶变体
EP3717643A1 (de) 2017-11-29 2020-10-07 Danisco US Inc. Subtilisin-varianten mit verbesserter stabilität
CN111742041B (zh) 2017-12-21 2023-06-06 丹尼斯科美国公司 包含耐热干燥剂的含酶的热熔细粒
BR112020016068A2 (pt) 2018-02-08 2020-12-08 Danisco Us Inc. Partículas cera termicamente resistente matriz para encapsulamento de enzima
CN108334745B (zh) * 2018-03-19 2022-02-08 青岛理工大学 一种聚合酶链反应过程非线性混杂系统建模方法
JP2021516273A (ja) 2018-03-28 2021-07-01 ザ プロクター アンド ギャンブル カンパニーＴｈｅ Ｐｒｏｃｔｅｒ ＆ Ｇａｍｂｌｅ Ｃｏｍｐａｎｙ 噴霧乾燥洗濯洗剤粒子を調製するための方法
EP3546559A1 (de) 2018-03-28 2019-10-02 The Procter & Gamble Company Wäschewaschmittelzusammensetzung
EP3546554A1 (de) 2018-03-28 2019-10-02 The Procter & Gamble Company Sprühtrockenverfahren
EP3546557B1 (de) 2018-03-28 2020-10-07 The Procter & Gamble Company Katalasehemmung während eines waschvorgangs
WO2019191171A1 (en) 2018-03-28 2019-10-03 The Procter & Gamble Company Laundry detergent composition
EP3546558A1 (de) 2018-03-28 2019-10-02 The Procter & Gamble Company Waschmittelzusammensetzung
EP3546555A1 (de) 2018-03-28 2019-10-02 The Procter & Gamble Company Verfahren zur herstellung von sprühgetrocknetem waschmittelpartikel
US20210214703A1 (en) 2018-06-19 2021-07-15 Danisco Us Inc Subtilisin variants
WO2019245705A1 (en) 2018-06-19 2019-12-26 Danisco Us Inc Subtilisin variants
EP3594319B1 (de) 2018-07-12 2021-05-05 The Procter & Gamble Company Feste freifliessende partikelförmige waschmittelzusammensetzung
JP2021532795A (ja) 2018-07-31 2021-12-02 ダニスコ・ユーエス・インク 一般酸のｐｋａを低下させるアミノ酸置換を有する変異体アルファ−アミラーゼ
US20210189295A1 (en) 2018-08-30 2021-06-24 Danisco Us Inc Enzyme-containing granules
JP2022503923A (ja) 2018-09-27 2022-01-12 ダニスコ・ユーエス・インク 医療用器具を洗浄するための組成物
WO2020077331A2 (en) 2018-10-12 2020-04-16 Danisco Us Inc Alpha-amylases with mutations that improve stability in the presence of chelants
EP3887515A1 (de) 2018-11-28 2021-10-06 Danisco US Inc. Subtilisin-varianten mit verbesserter stabilität
WO2020114968A1 (en) * 2018-12-03 2020-06-11 Novozymes A/S Powder detergent compositions
WO2020210784A1 (en) 2019-04-12 2020-10-15 Ecolab Usa Inc. Antimicrobial multi-purpose cleaner and methods of making and using the same
WO2020222996A1 (en) 2019-04-29 2020-11-05 The Procter & Gamble Company A process for making a laundry detergent composition
US20220220419A1 (en) 2019-05-24 2022-07-14 Danisco Us Inc Subtilisin variants and methods of use
WO2020247582A1 (en) 2019-06-06 2020-12-10 Danisco Us Inc Methods and compositions for cleaning
EP3754010A1 (de) 2019-06-17 2020-12-23 The Procter & Gamble Company Feste, rieselfähige, teilchenförmige waschmittelzusammensetzung mit einem reinigungstensid und einem linearen polyaminsalz
WO2020264552A1 (en) 2019-06-24 2020-12-30 The Procter & Gamble Company Cleaning compositions comprising amylase variants
WO2021080948A2 (en) 2019-10-24 2021-04-29 Danisco Us Inc Variant maltopentaose/maltohexaose-forming alpha-amylases
HUE062018T2 (hu) 2020-07-06 2023-09-28 Procter & Gamble Eljárás szemcsés mosószerkészítmény elõállítására
WO2022047149A1 (en) 2020-08-27 2022-03-03 Danisco Us Inc Enzymes and enzyme compositions for cleaning
WO2022077022A1 (en) 2020-10-09 2022-04-14 The Procter & Gamble Company Packaged laundry detergent product
CN112745993B (zh) * 2020-12-28 2022-06-24 厦门琥珀日化科技股份有限公司 一种微胶囊香精及其制备方法和应用
US20240117275A1 (en) 2021-01-29 2024-04-11 Danisco Us Inc. Compositions for cleaning and methods related thereto
US20240101611A1 (en) 2021-02-22 2024-03-28 Danisco Us Inc. Methods and compositions for producing proteins of interest in pigment deficient bacillus cells
EP4108754A1 (de) 2021-06-25 2022-12-28 The Procter & Gamble Company Verfahren zur herstellung eines verpackten wäschewaschmittels
EP4108756A1 (de) 2021-06-25 2022-12-28 The Procter & Gamble Company Waschmittelpulver
WO2023278297A1 (en) 2021-06-30 2023-01-05 Danisco Us Inc Variant lipases and uses thereof
EP4123005B1 (de) 2021-07-19 2024-03-06 The Procter & Gamble Company Reinigungszusammensetzung mit bakteriensporen
CN117916354A (zh) 2021-09-03 2024-04-19 丹尼斯科美国公司 用于清洁的衣物洗涤组合物
WO2023039270A2 (en) 2021-09-13 2023-03-16 Danisco Us Inc. Bioactive-containing granules
WO2023114988A2 (en) 2021-12-16 2023-06-22 Danisco Us Inc. Variant maltopentaose/maltohexaose-forming alpha-amylases
WO2023114932A2 (en) 2021-12-16 2023-06-22 Danisco Us Inc. Subtilisin variants and methods of use
WO2023114936A2 (en) 2021-12-16 2023-06-22 Danisco Us Inc. Subtilisin variants and methods of use
WO2023114939A2 (en) 2021-12-16 2023-06-22 Danisco Us Inc. Subtilisin variants and methods of use
EP4212608A1 (de) 2022-01-14 2023-07-19 The Procter & Gamble Company Verfahren zur herstellung eines sprühgetrockneten waschmittelpartikels
WO2023150903A1 (en) 2022-02-08 2023-08-17 The Procter & Gamble Company A method of laundering fabric
WO2023150905A1 (en) 2022-02-08 2023-08-17 The Procter & Gamble Company A method of laundering fabric
EP4234672A1 (de) 2022-02-24 2023-08-30 The Procter & Gamble Company Wasserlöslicher einheitsdosisartikel mit einem faservliesstoff und einem farbstoffteilchen
EP4234666A1 (de) 2022-02-24 2023-08-30 The Procter & Gamble Company Wasserlöslicher einheitsdosisartikel, der eine faservliesbahn und ein tensidsystem umfasst
WO2023168234A1 (en) 2022-03-01 2023-09-07 Danisco Us Inc. Enzymes and enzyme compositions for cleaning
WO2023225459A2 (en) 2022-05-14 2023-11-23 Novozymes A/S Compositions and methods for preventing, treating, supressing and/or eliminating phytopathogenic infestations and infections
EP4279570A1 (de) 2022-05-19 2023-11-22 The Procter & Gamble Company Verfahren zur herstellung einer partikelförmigen wäschewaschmittelzusammensetzung
WO2023250301A1 (en) 2022-06-21 2023-12-28 Danisco Us Inc. Methods and compositions for cleaning comprising a polypeptide having thermolysin activity
EP4299701A1 (de) 2022-06-27 2024-01-03 The Procter & Gamble Company Feste freifliessende partikelförmige waschmittelzusammensetzung
EP4299704A1 (de) 2022-06-27 2024-01-03 The Procter & Gamble Company Verfahren zum waschen und trocknen von stoff
EP4299703A1 (de) 2022-06-27 2024-01-03 The Procter & Gamble Company Feste freifliessende partikelförmige waschmittelzusammensetzung
EP4299702A1 (de) 2022-06-27 2024-01-03 The Procter & Gamble Company Feste freifliessende partikelförmige waschmittelzusammensetzung
CN116286565A (zh) * 2022-07-12 2023-06-23 上海佶凯星生物科技有限公司 一株高产碱性蛋白酶的枯草芽孢杆菌菌株及其应用
WO2024050339A1 (en) 2022-09-02 2024-03-07 Danisco Us Inc. Mannanase variants and methods of use
WO2024050343A1 (en) 2022-09-02 2024-03-07 Danisco Us Inc. Subtilisin variants and methods related thereto
WO2024050346A1 (en) 2022-09-02 2024-03-07 Danisco Us Inc. Detergent compositions and methods related thereto
EP4342969A1 (de) 2022-09-21 2024-03-27 The Procter & Gamble Company Feste reinigungsmittelzusammensetzung
EP4342970A1 (de) 2022-09-21 2024-03-27 Milliken & Company Gefärbte gewebefärbende farbstoffmittelpartikel
EP4364929A1 (de) 2022-11-01 2024-05-08 The Procter & Gamble Company Siegelbacken und wasserlöslicher einheitsdosisartikel mit einer faserigen vliesstoffbahn
EP4364930A1 (de) 2022-11-01 2024-05-08 The Procter & Gamble Company Siegelbacken und wasserlöslicher einheitsdosisartikel mit einer faserigen vliesstoffbahn
WO2024102698A1 (en) 2022-11-09 2024-05-16 Danisco Us Inc. Subtilisin variants and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100192985A1 (en) * 2008-11-11 2010-08-05 Wolfgang Aehle Compositions and methods comprising serine protease variants
WO2011072099A2 (en) * 2009-12-09 2011-06-16 Danisco Us Inc. Compositions and methods comprising protease variants

Family Cites Families (186)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE680847A (de) 1963-05-27 1966-11-14
GB1296839A (de) 1969-05-29 1972-11-22
GB1372034A (en) 1970-12-31 1974-10-30 Unilever Ltd Detergent compositions
US4302544A (en) 1979-10-15 1981-11-24 University Of Rochester Asporogenous mutant of B. subtilis for use as host component of HV1 system
DK187280A (da) 1980-04-30 1981-10-31 Novo Industri As Ruhedsreducerende middel til et fuldvaskemiddel fuldvaskemiddel og fuldvaskemetode
GR76237B (de) 1981-08-08 1984-08-04 Procter & Gamble
US4450235A (en) 1982-04-21 1984-05-22 Cpc International Inc. Asporogenic mutant of bacillus subtilis useful as a host in a host-vector system
US4561998A (en) 1982-05-24 1985-12-31 The Procter & Gamble Company Near-neutral pH detergents containing anionic surfactant, cosurfactant and fatty acid
US4550862A (en) 1982-11-17 1985-11-05 The Procter & Gamble Company Liquid product pouring and measuring package with self draining feature
US4597898A (en) 1982-12-23 1986-07-01 The Proctor & Gamble Company Detergent compositions containing ethoxylated amines having clay soil removal/anti-redeposition properties
US4760025A (en) 1984-05-29 1988-07-26 Genencor, Inc. Modified enzymes and methods for making same
US4515707A (en) 1983-06-27 1985-05-07 The Chemithon Corporation Intermediate product for use in producing a detergent bar and method for producing same
DE3480411D1 (en) 1983-07-06 1989-12-14 Gist Brocades Nv Molecular cloning and expression in industrial microorganism species
US4515705A (en) 1983-11-14 1985-05-07 The Procter & Gamble Company Compositions containing odor purified proteolytic enzymes and perfumes
US4537706A (en) 1984-05-14 1985-08-27 The Procter & Gamble Company Liquid detergents containing boric acid to stabilize enzymes
US5264366A (en) 1984-05-29 1993-11-23 Genencor, Inc. Protease deficient bacillus
US5972682A (en) 1984-05-29 1999-10-26 Genencor International, Inc. Enzymatically active modified subtilisins
US5801038A (en) 1984-05-29 1998-09-01 Genencor International Inc. Modified subtilisins having amino acid alterations
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
DK171161B1 (da) 1985-03-28 1996-07-08 Hoffmann La Roche Fremgangsmåde til påvisning af forekomst eller fravær af mindst én specifik nukleinsyresekvens i en prøve eller til skelnen mellem to forskellige nukleinsyresekvenser i denne prøve
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
DK154572C (da) 1985-08-07 1989-04-24 Novo Industri As Enzymatisk detergentadditiv, detergent og fremgangsmaade til vask af tekstiler
WO1987000859A1 (en) 1985-08-09 1987-02-12 Gist-Brocades N.V. Novel lipolytic enzymes and their use in detergent compositions
US4762636A (en) 1986-02-28 1988-08-09 Ciba-Geigy Corporation Process for the preparation of granules containing an active substance and to the use thereof as speckles for treating substrates
DK122686D0 (da) 1986-03-17 1986-03-17 Novo Industri As Fremstilling af proteiner
JP2503986B2 (ja) 1986-08-08 1996-06-05 関西ペイント株式会社 無毒性防汚塗料組成物
EP0258068B1 (de) 1986-08-29 1994-08-31 Novo Nordisk A/S Enzymhaltiger Reinigungsmittelzusatz
GB8629837D0 (en) 1986-12-13 1987-01-21 Interox Chemicals Ltd Bleach activation
US4765916A (en) 1987-03-24 1988-08-23 The Clorox Company Polymer film composition for rinse release of wash additives
US4972017A (en) 1987-03-24 1990-11-20 The Clorox Company Rinse soluble polymer film composition for wash additives
DE3851875T2 (de) 1987-05-29 1995-04-13 Genencor Int Cutinase haltige reinigungsmittelzusammensetzungen.
EP0305216B1 (de) 1987-08-28 1995-08-02 Novo Nordisk A/S Rekombinante Humicola-Lipase und Verfahren zur Herstellung von rekombinanten Humicola-Lipasen
JPS6474992A (en) 1987-09-16 1989-03-20 Fuji Oil Co Ltd Dna sequence, plasmid and production of lipase
EP0471265B1 (de) 1988-01-07 1995-10-25 Novo Nordisk A/S Spezifische Protease
US5288627A (en) 1988-01-07 1994-02-22 Novo Nordisk A/S Endoprotease from Fusarium oxysporumDSM 2672 for use in detergents
PT89702B (pt) * 1988-02-11 1994-04-29 Gist Brocades Nv Processo para a preparacao de novos enzimas proteoliticos e de detergentes que os contem
JP3079276B2 (ja) 1988-02-28 2000-08-21 天野製薬株式会社 組換え体ｄｎａ、それを含むシュードモナス属菌及びそれを用いたリパーゼの製造法
US4977252A (en) 1988-03-11 1990-12-11 National Starch And Chemical Investment Holding Corporation Modified starch emulsifier characterized by shelf stability
GB8806016D0 (en) 1988-03-14 1988-04-13 Danochemo As Encapsulated photoactivator dyes for detergent use
WO1989009259A1 (en) 1988-03-24 1989-10-05 Novo-Nordisk A/S A cellulase preparation
US5648263A (en) 1988-03-24 1997-07-15 Novo Nordisk A/S Methods for reducing the harshness of a cotton-containing fabric
US4968451A (en) 1988-08-26 1990-11-06 The Procter & Gamble Company Soil release agents having allyl-derived sulfonated end caps
WO1990009446A1 (en) 1989-02-17 1990-08-23 Plant Genetic Systems N.V. Cutinase
US5665587A (en) * 1989-06-26 1997-09-09 Novo Nordisk A/S Modified subtilisins and detergent compositions containing same
DK316989D0 (da) * 1989-06-26 1989-06-26 Novo Nordisk As Enzymer
JPH04500385A (ja) * 1989-06-26 1992-01-23 ユニリーバー・ナームローゼ・ベンノートシヤープ 酵素洗剤組成物
DE69033388T2 (de) 1989-08-25 2000-05-11 Henkel Research Corp Alkalisches proteolytisches enzym und verfahren zur herstellung
US5352603A (en) 1989-08-31 1994-10-04 Kali-Chemie Ag Highly alkaline proteases
DE4023458A1 (de) * 1989-08-31 1991-03-07 Kali Chemie Ag Neue hochalkalische proteasen
KR100236540B1 (ko) 1990-04-14 2000-01-15 레클로우크스 라우에르 알카리성 바실러스-리파제, 이를 코-딩하는 dna 서열 및 리파제를 생산하는 바실러스 균주
EP0531372B2 (de) 1990-05-09 2004-04-14 Novozymes A/S Eine ein endoglucanase enzym enthaltende zellulasezubereitung
DK115890D0 (da) 1990-05-09 1990-05-09 Novo Nordisk As Enzym
US5354559A (en) 1990-05-29 1994-10-11 Grain Processing Corporation Encapsulation with starch hydrolyzate acid esters
EP0495258A1 (de) 1991-01-16 1992-07-22 The Procter & Gamble Company Waschmittelzusammensetzungen mit hochaktiven Cellulasen und Tonweichmachern
US5520838A (en) 1991-01-16 1996-05-28 The Procter & Gamble Company Compact detergent compositions with high activity cellulase
GB9108136D0 (en) 1991-04-17 1991-06-05 Unilever Plc Concentrated detergent powder compositions
US5340735A (en) 1991-05-29 1994-08-23 Cognis, Inc. Bacillus lentus alkaline protease variants with increased stability
AU682314B2 (en) * 1992-07-17 1997-10-02 Genencor International, Inc. High alkaline serine proteases
ATE444356T1 (de) 1992-07-23 2009-10-15 Novozymes As Mutierte -g(a)-amylase, waschmittel und geschirrspülmittel
WO1994007998A1 (en) 1992-10-06 1994-04-14 Novo Nordisk A/S Cellulase variants
JPH08506009A (ja) 1992-12-01 1996-07-02 ノボ ノルディスク アクティーゼルスカブ 酵素反応の増強
CA2154157C (en) 1993-01-18 1999-08-03 Fiona Susan Macbeath Machine dishwashing detergent compositions
AU682863C (en) 1993-02-11 2003-05-08 Genencor International, Inc. Oxidatively stable alpha-amylase
CA2162459A1 (en) 1993-05-08 1994-11-24 Juergen Haerer Corrosion inhibitors for silver (ii)
PL177936B1 (pl) 1993-05-08 2000-01-31 Henkel Kgaa Niskoalkaliczny środek do maszynowego zmywania naczyń
DK77393D0 (da) 1993-06-29 1993-06-29 Novo Nordisk As Aktivering af enzymer
US5698504A (en) 1993-07-01 1997-12-16 The Procter & Gamble Company Machine dishwashing composition containing oxygen bleach and paraffin oil and benzotriazole compound silver tarnishing inhibitors
US5486303A (en) 1993-08-27 1996-01-23 The Procter & Gamble Company Process for making high density detergent agglomerates using an anhydrous powder additive
US6436690B1 (en) * 1993-09-15 2002-08-20 The Procter & Gamble Company BPN′ variants having decreased adsorption and increased hydrolysis wherein one or more loop regions are substituted
ES2287931T3 (es) 1993-10-14 2007-12-16 THE PROCTER & GAMBLE COMPANY Composiciones limpiadoras que contienen proteasa.
MA23346A1 (fr) * 1993-10-14 1995-04-01 Genencor Int Variantes de la subtilisine
US5861271A (en) 1993-12-17 1999-01-19 Fowler; Timothy Cellulase enzymes and systems for their expressions
ES2364776T3 (es) 1994-02-24 2011-09-14 HENKEL AG & CO. KGAA Enzimas mejoradas y detergentes que las contienen.
ES2302330T3 (es) 1994-02-24 2008-07-01 Henkel Kommanditgesellschaft Auf Aktien Enzimas mejoradas y detergentes que las contienen.
US5691295A (en) 1995-01-17 1997-11-25 Cognis Gesellschaft Fuer Biotechnologie Mbh Detergent compositions
US6117664A (en) 1994-03-03 2000-09-12 Novo Nordisk A/S Alkaline cellulases
ES2250969T3 (es) 1994-03-29 2006-04-16 Novozymes A/S Amilasa alcalina de bacilo.
DE4411223A1 (de) * 1994-03-31 1995-10-05 Solvay Enzymes Gmbh & Co Kg Verwendung alkalischer Proteasen in gewerblichen Textilwaschverfahren
US5686014A (en) 1994-04-07 1997-11-11 The Procter & Gamble Company Bleach compositions comprising manganese-containing bleach catalysts
JP3139277B2 (ja) 1994-05-10 2001-02-26 松下電器産業株式会社 浄水器及び浄水システム
PE6995A1 (es) 1994-05-25 1995-03-20 Procter & Gamble Composicion que comprende un polimero de polialquilenoamina etoxilado propoxilado como agente de separacion de sucio
NZ289115A (en) 1994-06-17 1999-02-25 Genencor Int Laundry compositions with cellulase and pectinase enzymes suitable for degrading cell walls of vegetable origin
GB2294268A (en) 1994-07-07 1996-04-24 Procter & Gamble Bleaching composition for dishwasher use
US5879584A (en) 1994-09-10 1999-03-09 The Procter & Gamble Company Process for manufacturing aqueous compositions comprising peracids
US5516448A (en) 1994-09-20 1996-05-14 The Procter & Gamble Company Process for making a high density detergent composition which includes selected recycle streams for improved agglomerate
US5489392A (en) 1994-09-20 1996-02-06 The Procter & Gamble Company Process for making a high density detergent composition in a single mixer/densifier with selected recycle streams for improved agglomerate properties
US5691297A (en) 1994-09-20 1997-11-25 The Procter & Gamble Company Process for making a high density detergent composition by controlling agglomeration within a dispersion index
DE69535733T2 (de) 1994-10-06 2009-04-23 Novozymes A/S Ein enzympräparat mit endoglucanase aktivität
DE69515331T2 (de) 1994-12-09 2000-10-19 Procter & Gamble Diacylperoxydteilchen enthaltende zusammensetzungen für automatische geschirreinigung
US6440716B1 (en) 1995-02-03 2002-08-27 Novozymes A/S α-amylase mutants
US5534179A (en) 1995-02-03 1996-07-09 Procter & Gamble Detergent compositions comprising multiperacid-forming bleach activators
US6093562A (en) 1996-02-05 2000-07-25 Novo Nordisk A/S Amylase variants
US5574005A (en) 1995-03-07 1996-11-12 The Procter & Gamble Company Process for producing detergent agglomerates from high active surfactant pastes having non-linear viscoelastic properties
EP1683860B1 (de) 1995-03-17 2013-10-23 Novozymes A/S Neue Endoglukanasen
US5569645A (en) 1995-04-24 1996-10-29 The Procter & Gamble Company Low dosage detergent composition containing optimum proportions of agglomerates and spray dried granules for improved flow properties
JP3025627B2 (ja) 1995-06-14 2000-03-27 花王株式会社 液化型アルカリα−アミラーゼ遺伝子
US5597936A (en) 1995-06-16 1997-01-28 The Procter & Gamble Company Method for manufacturing cobalt catalysts
DE69613842T2 (de) 1995-06-16 2002-04-04 Procter & Gamble Maschinengeschirrspülmittel, die kobaltkatalysatoren enthalten
US5565422A (en) 1995-06-23 1996-10-15 The Procter & Gamble Company Process for preparing a free-flowing particulate detergent composition having improved solubility
DE19530816A1 (de) 1995-08-23 1997-02-27 Cognis Bio Umwelt Verwendung von mutierter Subtilisin-Protease in kosmetischen Produkten
US5576282A (en) 1995-09-11 1996-11-19 The Procter & Gamble Company Color-safe bleach boosters, compositions and laundry methods employing same
ES2174105T5 (es) 1995-09-18 2007-03-01 THE PROCTER & GAMBLE COMPANY Sistemas de liberacion.
MA24137A1 (fr) 1996-04-16 1997-12-31 Procter & Gamble Fabrication d'agents de surface ramifies .
US5763385A (en) 1996-05-14 1998-06-09 Genencor International, Inc. Modified α-amylases having altered calcium binding properties
US6380144B1 (en) 1996-07-31 2002-04-30 The Procter & Gamble Company Detergent composition
US5929022A (en) 1996-08-01 1999-07-27 The Procter & Gamble Company Detergent compositions containing amine and specially selected perfumes
AU3938997A (en) 1996-08-26 1998-03-19 Novo Nordisk A/S A novel endoglucanase
WO1998012307A1 (en) 1996-09-17 1998-03-26 Novo Nordisk A/S Cellulase variants
ES2201441T3 (es) 1997-03-07 2004-03-16 THE PROCTER & GAMBLE COMPANY Composiciones de blanqueantes que contienen un catalizador metalico del blanqueante, y activadores de blanqueantes y/o acidos percarboxilicos organicos.
CN1263759C (zh) 1997-03-07 2006-07-12 宝洁公司 制备交联桥大环化合物的改进方法
US6268197B1 (en) 1997-07-07 2001-07-31 Novozymes A/S Xyloglucan-specific alkaline xyloglucanase from bacillus
GB2327947A (en) 1997-08-02 1999-02-10 Procter & Gamble Detergent tablet
US6376445B1 (en) 1997-08-14 2002-04-23 Procter & Gamble Company Detergent compositions comprising a mannanase and a protease
DE19736591A1 (de) 1997-08-22 1999-02-25 Peter Prof Dr Hegemann Verfahren zum Herstellen von Nukleinsäurepolymeren
CA2745783C (en) 1997-10-13 2016-05-24 Novozymes A/S .alpha.-amylase mutants
EP0913458B1 (de) * 1997-10-22 2004-06-16 The Procter & Gamble Company Flüssige Reinigungszusammensetzungen für harte Oberflächen
AR016969A1 (es) * 1997-10-23 2001-08-01 Procter & Gamble VARIANTE DE PROTEASA, ADN, VECTOR DE EXPRESIoN, MICROORGANISMO HUESPED, COMPOSICIoN DE LIMPIEZA, ALIMENTO PARA ANIMALES Y COMPOSICIoN PARA TRATAR UN TEXTIL
ES2367505T3 (es) 1997-10-23 2011-11-04 Danisco Us Inc. Variantes de proteasa con sustituciones múltiples con carga neta alterada para usar en detergentes.
RU2269572C2 (ru) * 1997-10-23 2006-02-10 Джененкор Интернэшнл, Инк. Варианты протеазы, замещенные в нескольких положениях
AU9737398A (en) 1997-10-30 1999-05-24 Novo Nordisk A/S Alpha-amylase mutants
US5935826A (en) 1997-10-31 1999-08-10 National Starch And Chemical Investment Holding Corporation Glucoamylase converted starch derivatives and their use as emulsifying and encapsulating agents
US6287839B1 (en) 1997-11-19 2001-09-11 Genencor International, Inc. Cellulase producing actinomycetes, cellulase produced therefrom and method of producing same
CA2310454C (en) 1997-11-21 2012-01-24 Novo Nordisk A/S Protease variants and compositions
AU2207099A (en) 1997-12-24 1999-07-19 Genencor International, Inc. An improved method of assaying for a preferred enzyme and/or preferred detergentcomposition
GB9807477D0 (en) 1998-04-07 1998-06-10 Unilever Plc Coloured granular composition for use in particulate detergent compositions
DE59910042D1 (de) 1998-05-18 2004-09-02 Ciba Sc Holding Ag Wasserlösliche Granulate von Phthalocyaninverbindungen
CN101024826B (zh) 1998-06-10 2014-09-03 诺沃奇梅兹有限公司 新的甘露聚糖酶
PH11999002188B1 (en) 1998-09-01 2007-08-06 Unilever Nv Method of treating a textile
US6376450B1 (en) 1998-10-23 2002-04-23 Chanchal Kumar Ghosh Cleaning compositions containing multiply-substituted protease variants
JP2003512012A (ja) 1998-10-23 2003-04-02 ザ、プロクター、エンド、ギャンブル、カンパニー 洗剤組成物に用いられるプロテアーゼ変異体のスクリーニング法
US6294514B1 (en) 1998-11-24 2001-09-25 The Procter & Gamble Company Process for preparing mono-long chain amine oxide surfactants with low nitrite, nitrosamine and low residual peroxide
AU2026100A (en) 1998-11-30 2000-06-19 Procter & Gamble Company, The Process for preparing cross-bridged tetraaza macrocycles
US6403355B1 (en) 1998-12-21 2002-06-11 Kao Corporation Amylases
AU3420100A (en) 1999-03-31 2000-10-23 Novozymes A/S Lipase variant
GB9930697D0 (en) 1999-12-24 2000-02-16 Unilever Plc Method of treating a textile
US6815192B2 (en) 2000-02-24 2004-11-09 Novozymes A/S Family 44 xyloglucanases
US6630340B2 (en) 2000-03-01 2003-10-07 Novozymes A/S Family 5 xyloglucanases
DZ3349A1 (fr) 2000-07-28 2002-02-07 Henkel Kgaa Nouvelle enzyme amylolytique issue de bacillus sp. a 7-7 (dsm 12368) ainsi que produits de lavage et nettoyage contenant ledit enzyme amylolytique
CA2418317A1 (en) 2000-08-11 2002-02-21 Genencor International, Inc. Bacillus transformation, transformants and mutant libraries
US6440991B1 (en) 2000-10-02 2002-08-27 Wyeth Ethers of 7-desmethlrapamycin
US6582914B1 (en) 2000-10-26 2003-06-24 Genencor International, Inc. Method for generating a library of oligonucleotides comprising a controlled distribution of mutations
US6929939B2 (en) * 2001-03-23 2005-08-16 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
AU2002249102A1 (en) 2001-03-27 2002-10-08 Novozymes A/S Family 74 xyloglucanases
US7041488B2 (en) 2001-06-06 2006-05-09 Novozymes A/S Endo-beta-1,4-glucanase from bacillus
GB0114847D0 (en) 2001-06-18 2001-08-08 Unilever Plc Water soluble package and liquid contents thereof
DK200101090A (da) * 2001-07-12 2001-08-16 Novozymes As Subtilase variants
ATE319807T1 (de) 2001-08-20 2006-03-15 Unilever Nv Photobleichsprenkel und sie enthaltende waschmittel
GB0120160D0 (en) 2001-08-20 2001-10-10 Unilever Plc Photobleach speckle and laundry detergent compositions containing it
DE10162728A1 (de) 2001-12-20 2003-07-10 Henkel Kgaa Neue Alkalische Protease aus Bacillus gibsonii (DSM 14393) und Wasch-und Reinigungsmittel enthaltend diese neue Alkalische Protease
AU2003210552A1 (en) * 2002-01-16 2003-09-02 Genencor International, Inc. Multiply-substituted protease variants
WO2003089598A2 (en) 2002-04-19 2003-10-30 Novozymes Biotech, Inc Polypeptides having xyloglucanase activity and nucleic acids encoding same
US7557076B2 (en) 2002-06-06 2009-07-07 The Procter & Gamble Company Organic catalyst with enhanced enzyme compatibility
AU2003267010B2 (en) 2002-09-04 2009-10-08 Basf Se Formulations comprising water-soluble granulates
KR100554479B1 (ko) 2002-09-11 2006-03-03 씨제이라이온 주식회사 염착 얼룩 방지 세탁용 착염
TWI319007B (en) * 2002-11-06 2010-01-01 Novozymes As Subtilase variants
DE10260805A1 (de) 2002-12-23 2004-07-22 Geneart Gmbh Verfahren und Vorrichtung zum Optimieren einer Nucleotidsequenz zur Expression eines Proteins
ATE387487T1 (de) 2003-05-23 2008-03-15 Procter & Gamble Waschmittelzusammensetzung zum gebrauch in einer textilwasch- oder geschirrspülmaschine
GB0325432D0 (en) 2003-10-31 2003-12-03 Unilever Plc Ligand and complex for catalytically bleaching a substrate
WO2005046710A2 (en) 2003-11-06 2005-05-26 Genencor International, Inc. Tgf-beta binding and supported peptides
US7985569B2 (en) 2003-11-19 2011-07-26 Danisco Us Inc. Cellulomonas 69B4 serine protease variants
WO2005056782A2 (en) 2003-12-03 2005-06-23 Genencor International, Inc. Perhydrolase
DE102004027091A1 (de) * 2004-06-02 2005-12-29 Henkel Kgaa Leistungsverbesserte Alkalische Protease-Varianten und Wasch- und Reinigungsmittel, enthaltend diese leistungsverbesserten Alkalische Protease-Varianten
US7208459B2 (en) 2004-06-29 2007-04-24 The Procter & Gamble Company Laundry detergent compositions with efficient hueing dye
CN103275951A (zh) 2004-07-05 2013-09-04 诺维信公司 具有改变特性的α-淀粉酶变异体
MX2007016045A (es) * 2005-07-08 2008-03-10 Novozymes As Variantes de subtilasa.
BRPI0613471A2 (pt) * 2005-07-11 2011-01-11 Genencor Int comprimidos de enzima para os cuidados de tecidos para consumidores e processos
CA2624977C (en) 2005-10-12 2017-08-15 The Procter & Gamble Company Use and production of storage-stable neutral metalloprotease
AR059154A1 (es) 2006-01-23 2008-03-12 Procter & Gamble Una composicion que comprende una lipasa y un catalizador de blanqueador
WO2007145964A2 (en) 2006-06-05 2007-12-21 The Procter & Gamble Company Enzyme stabilizer
CN101511998A (zh) 2006-07-18 2009-08-19 丹尼斯科美国公司 在宽温度范围内具有活性的蛋白酶变体
WO2008040818A1 (en) * 2006-10-06 2008-04-10 Novozymes A/S Detergent compositions and the use of enzyme combinations therein
CN101802194B (zh) * 2007-06-06 2014-03-12 丹尼斯科美国公司 用于改良蛋白质性能的方法
MX2009013494A (es) 2007-06-11 2010-01-18 Procter & Gamble Agente benefico que contiene particulas de suministro.
DE102007038031A1 (de) 2007-08-10 2009-06-04 Henkel Ag & Co. Kgaa Mittel enthaltend Proteasen
DE102007047433A1 (de) * 2007-10-04 2009-04-09 Lanxess Deutschland Gmbh Flüssigwasch- und Flüssigreinigungsmittel
JP2011513539A (ja) 2008-02-29 2011-04-28 ザ プロクター アンド ギャンブル カンパニー リパーゼを含む洗剤組成物
EP2100947A1 (de) 2008-03-14 2009-09-16 The Procter and Gamble Company Waschmittelzusammensetzung für Spülmaschinen
WO2009120526A1 (en) 2008-03-26 2009-10-01 The Procter & Gamble Company Delivery particle
EP2947147A3 (de) * 2008-06-06 2015-12-23 Danisco US Inc. Zusammensetzungen und verfahren mit mikrobiellen proteasevarianten
EP2166092A1 (de) * 2008-09-18 2010-03-24 The Procter and Gamble Company Reinigungsmittelzusammensetzung
US8753861B2 (en) * 2008-11-11 2014-06-17 Danisco Us Inc. Protease comprising one or more combinable mutations
CA2743060C (en) * 2008-11-11 2017-03-07 Danisco Us Inc. Compositions and methods comprising a subtilisin variant
JP5882904B2 (ja) * 2009-12-09 2016-03-09 ザ プロクター アンド ギャンブルカンパニー 布地ケア製品及びホームケア製品
PL2558573T3 (pl) * 2010-04-15 2017-08-31 Danisco Us Inc. Kompozycje i sposoby obejmujące warianty proteazy
JP6448904B2 (ja) 2010-05-06 2019-01-09 ダニスコ・ユーエス・インク サブチリシン変異体を含む組成物及び方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100192985A1 (en) * 2008-11-11 2010-08-05 Wolfgang Aehle Compositions and methods comprising serine protease variants
WO2011072099A2 (en) * 2009-12-09 2011-06-16 Danisco Us Inc. Compositions and methods comprising protease variants

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A_Geneseq_201406 database Acc# AZK14016 from WO2011072099 Basler et al, 16-JUN-2011. Alignment with SEQ ID NO: 2. *
Alekseyev et al, SEQ ID NO: 1, from the sequence listing filed in 13696512 on November 6, 2012. *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140154782A1 (en) * 2011-05-05 2014-06-05 Danisco Us Inc. Compositions and Methods Comprising Serine Protease Variants
US9856466B2 (en) * 2011-05-05 2018-01-02 Danisco Us Inc. Compositions and methods comprising serine protease variants
US20130123162A1 (en) * 2011-11-10 2013-05-16 The Procter & Gamble Company Consumer products
US10626388B2 (en) 2014-07-04 2020-04-21 Novozymes A/S Subtilase variants and polynucleotides encoding same
WO2016001450A3 (en) * 2014-07-04 2016-04-14 Novozymes A/S Subtilase variants and polynucleotides encoding same
US11591586B2 (en) 2014-07-04 2023-02-28 Novozymes A/S Subtilase variants and polynucleotides encoding same
US10920209B2 (en) 2014-07-04 2021-02-16 Novozymes A/S Subtilase variants having improved storage stability
US9951301B2 (en) 2015-03-30 2018-04-24 The Procter & Gamble Company Solid free-flowing particulate laundry detergent composition
US9951296B2 (en) 2015-03-30 2018-04-24 The Procter & Gamble Company Solid free-flowing particulate laundry detergent composition
US9957470B2 (en) 2015-03-30 2018-05-01 The Procter & Gamble Company Solid free-flowing particulate laundry detergent composition
US9957466B2 (en) 2015-03-30 2018-05-01 The Procter & Gamble Company Solid free-flowing particulate laundry detergent composition
US10053654B2 (en) 2015-04-02 2018-08-21 The Procter & Gamble Company Solid free-flowing particulate laundry detergent composition
US9758286B2 (en) 2015-10-06 2017-09-12 The Procter & Gamble Company Flexible box bag comprising soluble unit dose detergent pouch
US10183087B2 (en) * 2015-11-10 2019-01-22 American Sterilizer Company Cleaning and disinfecting composition
US20170128605A1 (en) * 2015-11-10 2017-05-11 American Sterilizer Company Cleaning and disinfecting composition
US10550443B2 (en) 2016-12-02 2020-02-04 The Procter & Gamble Company Cleaning compositions including enzymes
US11453871B2 (en) * 2017-03-15 2022-09-27 Danisco Us Inc. Trypsin-like serine proteases and uses thereof
US11708542B2 (en) 2018-06-20 2023-07-25 The Procter & Gamble Company Product comprising polysaccharide derivatives
US11492571B2 (en) 2019-10-24 2022-11-08 The Procter & Gamble Company Automatic dishwashing detergent composition comprising a protease

Also Published As

Publication number Publication date
EP3575389A3 (de) 2020-03-04
EP3418382A1 (de) 2018-12-26
EP3868881A2 (de) 2021-08-25
JP2013527767A (ja) 2013-07-04
US20180216092A1 (en) 2018-08-02
US11447762B2 (en) 2022-09-20
RU2012152482A (ru) 2014-07-10
JP6567964B2 (ja) 2019-08-28
CN105925555A (zh) 2016-09-07
PL3095861T3 (pl) 2020-04-30
ES2694398T3 (es) 2018-12-20
JP2013524855A (ja) 2013-06-20
ZA201208019B (en) 2013-06-26
CN103068977A (zh) 2013-04-24
CA2798451A1 (en) 2011-11-10
DK2566960T3 (da) 2017-05-22
WO2011140364A1 (en) 2011-11-10
HUE050079T2 (hu) 2020-11-30
EP2566960A1 (de) 2013-03-13
CN105925556B (zh) 2020-11-13
CN105925556A (zh) 2016-09-07
EP2566960B1 (de) 2017-03-08
RU2598717C2 (ru) 2016-09-27
CN102933708A (zh) 2013-02-13
BR112012028467A2 (pt) 2015-09-22
BR112012028467B1 (pt) 2021-02-17
MX339810B (es) 2016-06-09
EP2566961A1 (de) 2013-03-13
ES2745011T3 (es) 2020-02-27
ES2625751T3 (es) 2017-07-20
RU2012144735A (ru) 2014-06-20
JP6448904B2 (ja) 2019-01-09
CA2798451C (en) 2020-10-06
JP7002345B2 (ja) 2022-01-20
EP3418382B1 (de) 2021-01-20
DK2566961T3 (en) 2018-12-03
JP5813753B2 (ja) 2015-11-17
HUE034524T2 (en) 2018-02-28
CN108410585A (zh) 2018-08-17
PL2566960T3 (pl) 2017-08-31
EP3868881A3 (de) 2021-11-03
BR112012028466A2 (pt) 2015-09-22
JP2018078904A (ja) 2018-05-24
MX336737B (es) 2016-01-29
EP3575389A2 (de) 2019-12-04
JP2018029592A (ja) 2018-03-01
EP3095861A1 (de) 2016-11-23
HUE045202T2 (hu) 2019-12-30
MX2012012789A (es) 2013-02-27
WO2011140316A4 (en) 2012-02-02
JP2016127822A (ja) 2016-07-14
JP2015187278A (ja) 2015-10-29
MX2012012913A (es) 2013-05-01
US20190136217A1 (en) 2019-05-09
CN105925555B (zh) 2020-12-22
RU2711984C2 (ru) 2020-01-23
DK3095861T3 (da) 2019-09-23
EP3095861B1 (de) 2019-06-26
BR112012028466B1 (pt) 2020-03-17
EP2566961B1 (de) 2018-08-22
WO2011140316A1 (en) 2011-11-10

Similar Documents

Publication Publication Date Title
US11447762B2 (en) Bacillus lentus subtilisin protease variants and compositions comprising the same
US20220204959A1 (en) Compositions and methods comprising protease variants
EP2558573B1 (de) Zusammensetzungen und verfahren mit proteasevarianten
US20140154782A1 (en) Compositions and Methods Comprising Serine Protease Variants
EP2705145A2 (de) Zusammensetzungen und verfahren mit serinproteasevarianten
AU2014206222B2 (en) Compositions and methods comprising protease variants

Legal Events

Date Code Title Description
AS Assignment

Owner name: DANISCO US INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ALEKSEYEV, VIKTOR YURYEVICH;AMIN, NEELAM S.;AUGUSTYN, KATHERINE;AND OTHERS;SIGNING DATES FROM 20120828 TO 20120910;REEL/FRAME:029273/0251

AS Assignment

Owner name: DANISCO US INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:YURYEVICH, ALEKSEYEV VIKTOR;AMIN, NEELAM S.;AUGUSTYN, KATHERINE;AND OTHERS;SIGNING DATES FROM 20121109 TO 20121213;REEL/FRAME:030589/0009

AS Assignment

Owner name: DANISCO US INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:THE PROCTER AND GAMBLE COMPANY;REEL/FRAME:031027/0881

Effective date: 20130628

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION